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ABSTRACT 
 
CLASSICAL ANTIFOLATES: SYNTHESIS OF  
5-SUBSTITUTED, 6-SUBSTITUTED AND 7-SUBSTITUTED PYRROLO[2,3-
d]PYRIMIDINES AS TARGETED ANTICANCER THERAPIES 
 
 
By 
Yiqiang Wang 
May 2013 
 
Dissertation supervised by Professor Aleem Gangjee, Ph.D. 
 This dissertation comprises an introduction, background and current research 
progress in the area of classical antifolates as the targeted anticancer therapies.  
            Mammalian cells have a sophisticated folate uptake and retention system. 
Transport into the cell is usually facilitated by one or more of three folate transporters: 
reduced folate carrier (RFC), the membrane folate receptor (FR), and the proton coupled 
folate transporter (PCFT). The expression of RFC in both normal and tumor cells 
presents a potential obstacle to antitumor selectivity. Thus, it is of interest to design 
targeted antifolates that are substrates for transporters other than RFC to restrict drug 
transport into normal tissues selectivity. This rationale provides the foundation to develop 
targeted agents that can be selectively transported into tumors by FRs and PCFT over 
RFC, with potent intracellular targets inhibition.  
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At the same time, it has been of interest not only to design potent antifolates 
against specific enzymes such as dihydrofolate reductase (DHFR), thymidylate synthase 
(TS), glycinamide- ribonucleotide formyl transferase (GARFTase) and amino-imidazole-
carboxamide-ribonuleotide formyl transferase (AICARFTase) but also to design and 
synthesize single agents that have potent multiple inhibitory activity against these 
enzymes. This strategy is particularly promising in anticancer chemotherapy against the 
multiple drug resistant cancers. Such a single agent could act at more than one active site 
and provide “combination chemotherapy” benefits. 
           In this study, twelve series of classical 5-, 6- and 7-substituted pyrrolo[2,3-
d]pyrimidines were designed and synthesized. Extensive structure modifications of the 
pyrrolo[2,3-d] pyrimidine scaffold were investigated to determine selective transport via 
FR or/and PCFT and tumor targeted antifolates with GARFTase or multiple folate 
metabolizing enzyme inhibition. 
          The design strategies employed include: variation of the side chain substitution 
position (5-,6- and 7-substituted); variation of the side chain length (n=1-6); isosteric 
replacement of the 1,4-disubstituted phenyl ring with 1,2- and 1,3- disubstituted phenyl 
ring and 2,5- disubstituted thiophenyl ring; replacement the L-glutamate with variation at 
the α and γ carboxylic acids.  
         As a part of this study, a total of one hundred and fifty six new compounds 
(including new intermediates) were synthesized and separated. Of these, twelve series 
consisting of forty two classical antifolate final compounds were submitted for biological 
evaluation. In addition, bulk synthesis of some potent final compounds (2, 2.0 g; 161, 500 
mg; 175, 1.0 g; 166, 500 mg; 194, 500 mg) was carried out to facilitate in vivo evaluation. 
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      During the synthesis of the target compounds, several synthetic improvements were 
achieved successfully including:          
1. α-Bromo ketones instead of α-chloro ketones were synthesized to react with 2,4-
diamino-6-hydroxypyrimidine to selectively afford pyrrolo[2,3-d]pyrimidines without  
side product furo[2,3-d]pyrimidines.  
2. Instead of using the reported reaction condition to get 72% yield in the hydrogenation 
of 235, a 10% Pd/C, 5 h condition was employed to get a complete transformation (100% 
yield of 236) without any partial reduction. The troublesome separation of 236 was 
avoided.               
          More importantly, a new Heck coupling of the thiophene iodide 301 and allyl 
alcohols to synthesize aldehydes in one step was discovered. The reaction condition is 
mild (45 
o
C) with a good yield (65%) and the labile ester group of 301 is tolerated at this 
condition. In addition, the reaction is fast (2 h) and easy to handle (no argon protection 
needed). Due to its potential use in analog synthesis of clinically used antifolates such as 
RTX and PMX, this mild conditioned and easy to handle Heck coupling reaction is 
highly attractive.  
          During this study, the SAR of folate transporters (RFC, FR and PCFT) and 
GARFTase inhibitors were extensively explored. The 6-substituted straight chain 
compound 166 (n=7) was extremely potent against KB tumor cells (IC50=1.3 nM, about 
80-fold more potent than clinically used PMX) without any RFC activity. The 
intracellular enzyme target of 166 was subsequently identified as GARFTase. The 5- 
substituted phenyl compound 175 (n=4) showed AICARFTase as the primary target with 
potent KB tumor cell inhibition (IC50=7.9 nM, about 8-fold more potent than PMX) and 
vii 
 
also indirectly activated AMPK cell signaling pathway via ZMP accumulation which 
transmits an inhibitory signal to the mTOR complex leading to tumor cell apoptosis. Both 
of these compounds were selected for animal study to determine the antitumor activity 
against human tumor xenograft in mice. Due to their potent antitumor activities, these 
two compounds serve as leads for future structural optimization. 
 
viii 
 
DEDICATION 
 
Dedicated To My Family For Their Love And Support 
 
 
 
 
ix 
 
ACKNOWLEDGEMENT 
 I would like to thank all of those who contributed to this work. In particular I am 
most grateful to my supervisor, Professor Dr. Aleem Gangjee, for his guidance and 
support which made this dissertation possible.  I am indebted to him not just for his 
scientific guidance but also for his encouragement, day after day, financial support 
and his friendship.  
      I would like to thank my dissertation committee: Drs. Marc W. Harrold, Patrick 
T. Flaherty, David J. Lapinsky, Lawrence H. Block and Aleem Gangjee for their 
advice and support. I wish to thank Dr. Larry H. Matherly at Barbara Ann Karmanos 
Cancer Institute, Wayne State University School of Medicine and Dr. Roy L. Kisliuk 
at Tufts University School of Medicine for evaluating all the compounds for enzyme 
inhibitory activity and antitumor activity.  I wish to express my sincere appreciation 
to Nancy Hosni and Jackie Farrer in the office of pharmacy school for their help and 
assistance. I would like to give thanks to all my colleagues in the Graduate School of 
Pharmaceutical Sciences for their help and stay with me at Duquesne University. I 
would like to thank the Graduate School of Pharmaceutical Sciences for the financial 
support.  
      Finally, I would like to express my love and gratitude to my beloved family for 
their understanding & endless love, through the duration of my studies. 
 
 
x 
 
TABLE OF CONTENTS 
Page 
Abstract .......................................................................................................................... iv 
Dedication .................................................................................................................... viii 
Acknowledgement .......................................................................................................... ix 
List of Tables ................................................................................................................. xi 
List of Figures .............................................................................................................. xiii 
List of Schemes ............................................................................................................ xvi 
List of Abbreviations .................................................................................................... xxi 
I. Biochemical Review .................................................................................................... 1 
II. Chemical Review ...................................................................................................... 68 
III. Statement of the Problem ......................................................................................... 96 
IV. Chemical Discussion ............................................................................................. 118 
V. Summary ................................................................................................................ 151 
VI. Experimental Section ............................................................................................ 158 
VII. Bibliography ........................................................................................................ 234 
Appendix 1 .................................................................................................................. 280 
Appendix 2 .................................................................................................................. 288 
Appendix 3 .................................................................................................................. 290 
Appendix 4 .................................................................................................................. 304 
Appendix 5 .................................................................................................................. 305 
 
xi 
 
LIST OF TABLES 
Page 
Table 1    Pyrrolo[2,3-d]pyrimidines and  thieno[2,3-d]pyrimidines as FR and/or          
               PCFT specific anticancer agents ...................................................................... 24 
Table 2    5,6,7,8-Tetrahydropyrido[2,3-d]pyrimidines and 7,8-dihydro-pyrimido[5,4-   
               b][1,4]thiazines as GARFTase inhibitors ......................................................... 34 
Table 3    Pyrimidines as GARFTase inhibitors ............................................................. 38 
Table 4    GARFTase inhibitory activities of Lometrexol and its straight chain  
                analogs  ........................................................................................................ 102 
Table 5    Attempted conditions for the Heck coupling of the thiophene bromide 306 .. 135 
Table 6    Attempted conditions for the Heck coupling of the thiophene iodide 301 ..... 136 
Table A1  IC50 values (nM) for compounds 6-substituted-pyrrolo[2,3-d]pyrimidines        
 with a phenyl ring in cell proliferation inhibition of RFC- and cell 
 FR-expressing lines .................................................................................... 291 
Table A2  IC50 values (nM)  for 6-substituted pyrrolo[2,3-d]pyrimidine compounds  
                  in in vitro (mouse GARFTase) and in situ GARFTase inhibition assays ..... 292 
Table A3  IC50 values (nM) for compound 164-167 (n=5-8) in cell proliferation  
 inhibition of RFC-, FR- and PCFT-expressing cell lines ............................. 293 
Table A4  IC50 values (nM) for compound 172-177 (n=1=6) in cell proliferation  
 inhibition of RFC-, FR- and PCFT-expressing cell lines ............................. 296 
Table A5  hDHFR and hTS inhibitory activity of 172-177 (n=1-6)  ............................. 298 
Table A6  Tumor cell inhibitory activity (NCI) GI50 (M) of 175 (n=4)  ........................ 299 
 
xii 
 
Table A7  IC50 values (nM) for compound 178-183  in cell proliferation  
 inhibition of RFC-, FR- and PCFT-expressing cell lines ............................. 300 
Table A8   hDHFR and hTS inhibitory activity of 178-183 .......................................... 302 
Table A9   Tumor cell inhibitory activity (NCI) GI50 values (M) of 181 (n=4)  ............ 302 
  
xiii 
 
LIST OF FIGURES 
Page 
Figure 1    Structure of folic acid illustrating the three principle moieties ......................... 1 
Figure 2    Folates and their roles in the biosynthesis of nucleic acid precursors and  
amino acids .................................................................................................... 2 
Figure 3    Thymidylate synthase (TS) catalyzed biosynthesis of dTMP from dUMP ....... 4 
Figure 4    GARFTase and AICARFTase functions in de novo synthesis of Purines ......... 7 
Figure 5    Representatives of classical antifolates and their principal target(s) .............. 10 
Figure 6    Representatives of nonclassical antifolates and their principal target(s) ......... 11 
Figure 7    Human PCFT structure ................................................................................. 19 
Figure 8    PCFT transcript expression in human normal tissues .................................... 20 
Figure 9    Structures of 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines with  
different side chain aromatic rings ................................................................ 26 
Figure 10  Structures of 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines with a  
thienoyl side chain ....................................................................................... 27 
Figure 11  A proposed mechanism of GARFTase .......................................................... 31 
Figure 12  The proposed mechanism of AICARFTase ................................................... 45 
Figure 13  Stereoview of folate cofactor and selected inhibitors binding to  
AICARFTase active site ............................................................................... 46 
Figure 14  AICARFTase inhibitors ................................................................................ 48 
Figure 15  The folate-dependent steps of de novo purine synthesis and the site of entry 
of AICA and AICAR into the pathway ......................................................... 52 
Figure 16  Effects of PMX on activation of AMPK and inhibition of mTOR ................. 53 
xiv 
 
Figure 17  The catalytic mechanism of human DHFR .................................................... 56 
Figure 18  Interaction of Glu30 with (a) dihydrofolate, and (b) MTX in the active site  
of human DHFR........................................................................................... 57 
Figure 19  The catalytic mechanism of human TS ......................................................... 62 
Figure 20  The interactions in the complex of hTS-dUMP-PMX.................................... 64 
Figure 21  Structures of classical 6-Substituted Pyrrolo[2,3-d]pyrimidine 2, 161 and 162 
(n=4-6) .......................................................................................................................... 96 
Figure 22  Design of Classical 6-Substituted Pyrrolo[2,3-d]pyrimidine 161 and 162 ...... 98 
Figure 23  Design of 163 as a hybrid of 2 and Pemetrexed (PMX). ................................ 99 
Figure 24  6-Substituted straight chain compounds design: replacement of the phenyl  
ring by methylene units .............................................................................. 101 
Figure 25  Stereoview. Overlay of the docked pose of 166 (white) with an analog of  
DDACTHF (purple) in hGARFTase (PDB ID: 1NJS) ................................ 103 
Figure 26  Design of 168 and 170 ................................................................................ 105 
Figure 27  Structures of 5-substituted pyrrolo[2,3-d]pyrimidines 172-177(n=1-6)........ 106 
Figure 28  Design of 5-substituted pyrrolo[2,3-d]pyrimidines 172-177 (n=1-6) ........... 108 
Figure 29  Stereoview. Overlay of the docked pose of 175 (blue) with  
BW2315U89 (red) in AICARFTase (PDB ID: 1PL0) ................................. 110 
Figure 30  Stereoview. Overlay of the docked pose of 175 (blue) with  
10-CF3CO-DDACTHF (red) in hGARFTase (PDB ID: 1NJS) ................... 111 
Figure 31  Design of 5-substituted pyrrolo[2,3-d]pyrimidines 178-183 (n=1-6) with   
                   a thiophene side chain   …………………………………………................113 
Figure 32  Structures of 5-substituted pyrrolo[2,3-d]pyrimidines 184-186 (n=6-8) with  
xv 
 
a straight side chain .................................................................................... 114 
Figure 33  Design of 5-substituted pyrrolo[2,3-d]pyrimidines 184-186 (n=6-8) with a  
straight side chain ...................................................................................... 114 
Figure 34  Structures of 7-substituted pyrrolo[2,3-d]pyrimidines 187-190 (n=5-8) with 
a straight side chain .................................................................................... 115 
Figure 35  Designed analogs with variations in the glutamate moiety .......................... 116 
Figure 36  Extensive structure modifications on the pyrrolo[2,3-d]pyrimidine scaffold 
to find FR and PCFT specific tumor targeted antifolates ............................ 151 
Figure A1 Structures of 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines......... 290 
Figure A2 Structures of 2-amino-4-oxo-6-substituted straight chain pyrrolo[2,3- 
d]pyrimidines ............................................................................................. 293 
Figure A3 Structures of 2-amino-4-oxo-5-substituted pyrrolo[2,3-d]pyrimidines  
172-177 (n=1-6)  ........................................................................................ 296 
Figure A4  3 and 175 KB Protections .......................................................................... 297 
Figure A5 Structures of 2-amino-4-oxo-5-substituted pyrrolo[2,3-d]pyrimidines  
178-183 (n=1-6)  ........................................................................................ 299 
Figure A6  3 and 181 KB Protections .......................................................................... 301 
Figure A7  Bulk synthesis for animal study ................................................................. 304 
Figure A8  Calculated tPSA and ClogP values of PMX and selected compounds by 
                   ChemBioDraw Ultra  12.0.2…………………………………………….... 306 
 
 
  
xvi 
 
LIST OF SCHEMES 
Page 
Scheme 1    Synthesis of 2,5,6-trisubstitutedpyrrolo[2,3-d]pyrimidines 27 ..................... 68 
Scheme 2    Synthesis of pyrrolo[2,3-d]pyrimidines 30 and 32....................................... 69 
Scheme 3    Synthesis of pyrrolo[2,3-d]pyrimidine 34 ................................................... 69 
Scheme 4    Synthesis of pyrrolo[2,3-d]pyrimidines 40 .................................................. 70 
Scheme 5    Synthesis of furo[2,3-d]pyrimidines 42 and pyrrolo[2,3-d]pyrimidines 43 .. 71 
Scheme 6    Synthesis of pyrrolo[2,3-d]pyrimidines 46 and furo[2,3-d]pyrimidines 47 .. 72 
Scheme 7    Synthesis of pyrrolo[2,3-d]pyrimidines 51 .................................................. 72 
Scheme 8    Synthesis of 2-amino-4-methyl pyrrolo[2,3-d]pyrimidine 57 ...................... 73 
Scheme 9    Synthesis of 2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-6- 
yl)acetic acid 59.......................................................................................... 74 
Scheme 10  Synthesis of 2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidine-5- 
carbonitrile 61 ............................................................................................ 74 
Scheme 11  Synthesis of 2,4-diamino-5-arylalkyl substituted pyrrolo[2,3-d]pyrimidine  
66 ............................................................................................................... 75 
Scheme 12  Synthesis of 5-substituted pyrrolo[2,3-d]pyrimidine 70 .............................. 76 
Scheme 13  Synthesis of PMX from 6-amino-5-pyrimidylacetaldehydes 74 .................. 77 
Scheme 14  Synthesis of PMX from α-bromo aldehyde 78 ............................................ 72 
Scheme 15  Synthesis of 7-substituted pyrrolo[2,3-d]pyrimidines 86 ............................. 79 
Scheme 16  Synthesis of pyrrolo[2,3-d]pyrimidines 90 .................................................. 80 
Scheme 17  Synthesis of 4-methyl pyrrolo[2,3-d]pyrimidines 93 ................................... 80 
Scheme 18  Synthesis of 2,4-dimethyl pyrrolo[2,3-d]pyrimidines 99 ............................. 81 
xvii 
 
Scheme 19  Synthesis of pyrrolo[2,3-d]pyrimidines 101 via Fischer indole cyclization .. 81 
Scheme 20  Synthesis of 4-amino-5-cyanopyrrolo[2,3-d]pyrimidine 107 ....................... 82 
Scheme 21  Synthesis of 4-amino-5-substituted pyrrolo[2,3-d]pyrimidines 112 ............. 83 
Scheme 22  Synthesis of 5,6-disubstitutedpyrrolo[2,3-d]pyrimidine 114 ........................ 83 
Scheme 23  Synthesis of 2,5,6-trimethyl pyrrolo[2,3-d]pyrimidine 118 ......................... 84 
Scheme 24  Synthesis of 2,5,-dimethyl-N
7
-substitutedpyrrolo[2,3-d]pyrimidine 125 ...... 85 
Scheme 25  Synthesis of 2,5-dimethyl pyrrolo[2,3-d]pyrimidine 130 ............................. 85 
Scheme 26  Synthesis of N
7
-substituted analogs of PMX 138 ........................................ 86 
Scheme 27  Synthesis of PMX via a guanidine cyclization ............................................ 87 
Scheme 28  Synthesis of 2-methyl-4-amino-pyrrolo[2,3-d]pyrimidine 145 .................... 88 
Scheme 29  Synthesis of 5-substituted 2-des-4-oxo-pyrrolo[2,3-d]pyrimidine 148 ......... 88 
Scheme 30  A general transformation of Sonogashira coupling ...................................... 89 
Scheme 31  Mechanism of Sonogashira cross-coupling ................................................. 90 
Scheme 32  Synthesis of N-(7-benzyl-4-methyl-5-(phenylethynyl)-7H-pyrrolo[2,3- 
d]pyrimidin-2-yl)-N-pivaloylpivalamide 151 .............................................. 90 
Scheme 33  Synthesis of classical 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]- 
pyrimidines by Sonogashira coupling ......................................................... 91 
Scheme 34  General transformation of Heck coupling ................................................... 91 
Scheme 35  Heck coupling to synthesis aldehyde 157 .................................................... 92 
Scheme 36  A proposed mechanism of Heck coupling to synthesis aldehyde 157 .......... 93 
Scheme 37  Improved Heck coupling to synthesis aldehyde 157 .................................... 93 
Scheme 38  Heck coupling with thiophenyl bromide 159............................................... 94 
Scheme 39  Synthesis of intermediates 202 and 203 .................................................... 118 
xviii 
 
Scheme 40  Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidines with the α- 
bromomethylketone .................................................................................. 119 
Scheme 41  Synthesis of intermediate α-bromomethylketones 215-217 ....................... 119 
Scheme 42  Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidine 2, 161  
and 162 ..................................................................................................... 120 
Scheme 43  Synthesis of intermediate 6-iodo-pyrrolo[2,3-d]pyrimidine 230 ................ 122 
Scheme 44  Synthesis of intermediate acetylene 234 by Sonogashira coupling ............ 122 
Scheme 45  Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidine 163 (n=2). ................ 123 
Scheme 46  Synthesis of intermediate straight chain α-bromomethyl ketones 241-244 124 
Scheme 47  Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidine 164-167 (n=5-8). ...... 124 
Scheme 48  Retro synthetic analysis of 6-substituted pyrrolo[2,3-d]pyrimidine 168 ..... 126 
Scheme 49  Synthesis of intermediate 261 ................................................................... 127 
Scheme 50  Synthesis of intermediate 263 ................................................................... 127 
Scheme 51  Synthesis of intermediate 253 ................................................................... 128 
Scheme 52  Synthesis of  169 and 170 ......................................................................... 129 
Scheme 53  Synthesis of 168 and 171 .......................................................................... 129 
Scheme 54  Retro synthesis analysis of 5-substituted pyrrolo[2,3-d]pyrimidines with  
phenyl side chain analogues 172-177 (n=1-6) ........................................... 130 
Scheme 55  Synthesis of intermediate 282-286 ............................................................ 131 
Scheme 56  Synthesis of intermediate 288-293 ............................................................ 131 
Scheme 57  Synthesis of  5-substituted pyrrolo[2,3-d]pyrimidine with phenyl side  
chain analogues 172-177 (n=1-6) .............................................................. 132 
Scheme 58  Retro synthesis analysis of intermediate 300 ............................................. 133 
xix 
 
Scheme 59  Synthesis of intermediate 306 ................................................................... 134 
Scheme 60  Improved synthesis of intermediate 306 .................................................... 134 
Scheme 61  Heck coupling of the thiophene bromide 306 ............................................ 134 
Scheme 62  Synthesis of the thiophene iodide 301 ....................................................... 135 
Scheme 63  Improved Heck coupling of 300 ............................................................... 136 
Scheme 64  Synthesis of intermediate 308-312 ............................................................ 137 
Scheme 65  Synthesis of 178-183 ................................................................................ 138 
Scheme 66  Synthesis of intermediate aldehydes 335-336............................................ 139 
Scheme 67  Synthesis of intermediate aldehyde 337 .................................................... 140 
Scheme 68  Synthesis of 184-186 (n=6-8) ................................................................... 141 
Scheme 69  Retro synthesis analysis of 7-substituted pyrrolo[2,3-d]pyrimidine 187- 
190 (n=5-8) .............................................................................................. 142 
Scheme 70  Synthesis of intermediates 353-356 .......................................................... 143 
Scheme 71  Synthesis of 7-substituted pyrrolo[2,3-d]pyrimidine 187-190  
 (n=5-8) .................................................................................................... 143 
Scheme 72  Synthesis of pteroic acid 361 .................................................................... 144 
Scheme 73  Synthesis of N-methyl compound  191...................................................... 144 
Scheme 74  Synthesis of glutmate derivatives 192 and 193 .......................................... 145 
Scheme 75  Synthesis of N-methy compound 194........................................................ 146 
Scheme 76  Synthesis of glutmate derivatives 195 and 196 .......................................... 146 
Scheme 77  Synthesis of glutmate derivative 197 ........................................................ 147 
Scheme 78  Synthesis of glutmate derivatives 198 and 199 .......................................... 148 
Scheme 79  Synthesis of glutmate derivative 200 ........................................................ 149 
xx 
 
Scheme 80  Synthesis of glutmate derivative 200a ...................................................... 150 
 
xxi 
 
LIST OF ABBREVIATIONS 
 
AICA 
AICAR 
Aminoimidazole-4-carboxamide 
Aminoimidazole-4-carboxamide ribosyl-5-phosphate 
AICARFTase Aminoimidazole-4-carboxamide ribosyl-5-phosphate Formyl 
Transferase 
AIDS Acquired immunodeficiency syndrome 
ALL 
AML 
AMP 
AMPK 
Acute lymphoblastic leukemia 
Acute myelogenous leukemia 
Adenosine monophosphate 
AMP-activated protein kinase 
AMT Aminopterin 
ARDS Acute respiratory distress syndrome 
ATIC 5-Amino-4-imidazolecarboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase 
ATP Adenosine-5‟-triphosphate 
CAM Chorioallantoic membrane 
CNS Central nervous system 
DHFR Dihydrofolate reductase 
DMAP 4-Dimethylamino pyridine 
DMF N,N-dimethyl formamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
xxii 
 
dATP 2‟-Deoxyadenosine-5‟-triphosphate 
dGTP 2‟-Deoxyguanosine-5‟-triphosphate 
dTDP 2‟-Deoxythymidine-5‟-diphosphate 
dTMP 2‟-Deoxythymidine-5‟-monophosphate 
dTTP 2‟-Deoxythymidine-5‟-triphosphate 
dUMP 2‟-Deoxyuridine-5‟-monophosphate 
dUTP 2‟-Deoxyuridine-5‟-triphosphate 
E. coli Escherichia coli  
EDX 10-Ethyl-l0-deaza aminopterin 
FA 
FGAR 
Folic acid 
Formyl glycinamide ribonucleotide 
FH2 7,8-Dihydrofolate 
FH4 5,6,7,8-Tetrahydrofolate 
FPGH Folylpolyglutamate hydrolase 
FPGS Folyl poly--glutamate synthetase 
FR Folate receptor 
FdUMP 5-Fluoro-2‟-deoxyuridine-5‟-monophosphate 
5-FU 5- Fluorouracil 
GAR Glycinamide ribosyl-5-phosphate 
GARFTase Glycinamide ribonucleotide formyl transferase 
GDP 
GPI 
Guanosine diphosphate 
Glycosylphosphatidylinositol 
GTP Guanosine triphosphate 
xxiii 
 
IMP Inositol monophosphate 
L. casei 
LMX 
Lactobacillus casei 
Lometrexol 
LV Leucovorin 
MAC 
MFS 
Mycobacterium Avium Complex 
Major facilitator superfamily 
MRP Multidrug resistance protein 
MTHFR Methylene tetrahydrofolate reductase 
MTX Methotrexate 
NADPH Nicotinamide adenine dinucleotide phosphate 
NCI National cancer institute 
NMR Nuclear magnetic resonance 
NRTI 
NSCLC 
Nucleoside reverse transcriptase inhibitors 
Non-small cell lung cancer 
PABA 
PCFT 
Para-amino benzoic acid 
Proton coupled folate transporter 
PDB Protein data bank 
PDDF N
10
-propargyl-5,8-dideazafolate 
Pgp P-glycoprotein 
Piv 
PMX 
PPRP 
Pivaloyl (trimethyl acetyl) 
Pemetrexed 
Phosphoribosylpyrophosphate 
PteGlu Pteroylglutamic Acid 
xxiv 
 
PTX Piritrexim 
Rh Recombinant human 
rl Rat liver 
RNA Ribonucleic acid 
RFC Reduced folate carriers 
RTX 
SCID 
Raltitrexed 
Severe combined immunodeficient 
SHMT Serine hydroxymethyl transferase 
T. gondii Toxoplasma gondii  
TLC Thin layer chromatography 
TMP Trimethoprim 
TMQ Trimetrexate 
TNP-351 N-[4-[3-(2,4-Diamino-7H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl]benzoyl-L-glutamic acid. 
TS Thymidylate Synthase 
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I. BIOCHEMICAL REVIEW 
Folic acid (Figure 1), a water-soluble vitamin of the B-complex group, was first 
reported by Mitchell and coworkers1 in 1941 by isolating this growth factor from spinach 
leaves and naming it folic acid. The structure of folic acid consists of three moieties: a 
hetero-bicyclic pteridine, a p-aminobenzoic acid (PABA) and a glutamic acid (Figure 1), 
and thus folic acid is also called pteroylglutamic acid. Its structure probably does not 
occur in nature as such, but it can be regarded as the parent compound of a group of 
naturally occurring folates which are designated as the B9 vitamin family. 
 
Figure 1 Structure of folic acid illustrating the three principle moieties. 
        Folic acid in its various cofactor forms plays a crucial role in the biosynthesis of 
nucleic acid precursors and resultantly in deoxyribonucleic acid (DNA) synthesis and cell 
replication.2-4 Compounds that closely resemble FA and inhibit the function of enzymes 
involved in folate metabolism are termed antifolates. These antifolates represent an 
important class of antimetabolites and are used as chemotherapeutic agents.5-9  
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Figure 2 Folates and their roles in the biosynthesis of nucleic acid precursors and amino 
acids. Note: TS: Thymidylate Synthase; DHFR: Dihydrofolate Reductase; SHMT: Serine 
Hydroxymethyltransferase; MTHFR: Methylenetetrahydrofolate Reductase; GARFTase: 
Glycinamide-ribonucleotide Formyl Transferase; AICARFTase: Amino-imidazole-
carboxamide-ribonuleotide Formyl Transferase; AICAR: Aminoimidazole-4-carboxamide 
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ribosyl-5-phosphate; dTMP: 2‟-Deoxythymidylate 5‟-monophosphate; dUMP: 2‟-
Deoxyuridylate-5‟-monophosphate; dTMP: 2‟-Deoxythymidylate 5‟-triphosphate; GAR: 
Glycinamide Ribosyl-5-phosphate; DNA: Deoxyribonucleotide; IMP: Inositol 
monophosphate. 
 
1. FOLATE METABOLISM 
Folic acid exists in several oxidative states, each of which is essential to the role 
of the cofactor in metabolism. Intracellular reduction of the pyrazine portion of the 
pteridine ring, catalyzed by a NADPH (nicotinamide adenine dinucleotide phosphate)-
specific dihydrofolate reductase (DHFR) leads to the formation of 7,8-dihydrofolate 
(FH2) followed by 5,6,7,8-tetrahydrofolate (FH4) (Figure 2).
10 Folic acid is poorly taken 
up into mammalian cells by a reduced folate carrier (RFC) system which is ubiquitously 
expressed and present on the cell surface. The principal mechanism of folic acid (FA) 
uptake is via the proton coupled folate transporter (PCFT) in the intestines.11-13 
Tetrahydrofolate functions as the coenzyme in the utilization of single-carbon units and is 
the central component of the folate metabolism. The metabolism of amino acids (glycine, 
serine, methionine, and histidine), nucleic acid synthesis (purine nucleotide and the 5-
methyl group of thymine) and formation of formylmethionyl-tRNA are all dependent on 
FH4 (Figure 2). FH4 is capable of carrying single carbon units in various oxidation states 
including methyl, methylene, and formyl groups. The oxidative levels of these single 
carbon units correspond to methanol, formaldehyde, and formic acid, respectively. These 
single carbon units may be attached to the N5- and/or N10- positions. The biologically 
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relevant cofactor forms of FA include 5-methyltetrahydrofolate (N5-CH3-FH4), 5,10-
methylenetetrahydrofolate (N5,N10-CH2-FH4), 5-formyltetrahydro-folate (N
5
-CHO-FH4), 
10-formyltetrahydrofolate (N10-CHO-FH4), and 5-formiminotetra-hydrofolate (N
5
-
CH=NH-FH4) (Figure 2). 
 
Figure 3 Thymidylate synthase (TS) catalyzed biosynthesis of dTMP from dUMP. 
A number of enzymes are involved in folate-dependent reactions by using 
different derivatives of FH4 in one-carbon transfer reactions (Figure 2). (i) 5,10-
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methylene tetrahydrofolate (N5,N10-CH2-FH4) provides one carbon for the synthesis of 
thymidylate from deoxyuridylate mediated by thymidylate synthase (TS), an initial step 
in the synthesis of precursors for DNA. (ii) N10-CHO-FH4 provides two carbons 
sequentially for the synthesis of the purine ring in reactions mediated by glycinamide- 
ribonucleotide formyl transferase (GARFTase) and amino-imidazole-carboxamide-
ribonuleotide formyl transferase (AICARFTase). (iii) N5-CH3-FH4 provides one carbon 
for the vitamin B-12 dependent synthesis of methionine from homocysteine mediated by 
methionine synthetase, which is followed by the synthesis of S-adenosylmethionine.   
TS is unique among enzymes that utilize FH4 cofactor in that N
5,N10-CH2-FH4 acts 
as the source of the methyl group as well as the reductant, by concerted transfer of its 
methylene moiety and the 6-hydrogen atom in the form of hydride to form the 5-methyl 
group of dTMP (Figure 3). This represents the sole de novo source of dTMP in dividing 
cells. Hence, inhibition of TS, in the absence of salvage, leads to “thymineless death”.14 
“Thymineless death” is observed in mammalian cells when severe deoxythymidine-
triphosphate (dTTP) depletion takes place due to 5-fluorouracil (5-FU) or methotrexate 
(MTX) treatment.15 The dTTP depleted mammalian cells irreversible lose colony-
forming ability and undergo cell death.14  This phenomenon underlies the mechanism of 
several antibacterial, antimalarial and anticancer agents, such as Sulfamethoxazole, 
Trimethoprim, Methotrexate and Fluorouracil.14, 16-18 The phenomenon was first reported 
by Barner and Cohen19, 20 in 1954 that thymine requiring mutants of the E. coli bacterium 
lost viability when grown in a medium lacking thymine but containing other essential 
nutrients. The phenomenon was commonly attributed to "unbalanced growth" when cells 
continued fundamental processes of RNA transcription, protein synthesis and metabolism 
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in the absence of DNA replication.20 This effect is unusual in that the deprivation of many 
other nutritional requirements such as amino acids or vitamins has a biostatic, but not 
lethal effect.21, 22  Studies on numerous tumor cells have indicated that thymine starvation 
has both direct and indirect effects. The direct effects include both single- and double-
strand DNA breaks.23 The former may be repaired effectively, but the latter will lead to 
cell death. Depletion of dTTP in mammalian cells induces apoptosis, although the 
mechanism underlying this process remains to be elucidated.24-26 Methotrexate and 5-FU 
cause a decrease in dTTP levels and a concomitant increase in dUTP, which is 
incorporated into DNA. This leads to extensive DNA damage as a result of the active 
process of excision repair at the many uracil-containing sites in DNA, and thus triggers a 
DNA-damage-induced apoptosis.15 
During TS catalyzed dTMP biosynthesis, N5,N10-CH2-FH4 is oxidized to FH2 and 
is converted back to FH4 by dihydrofolate reductase (DHFR) which maintains the 
intracellular reduced folate pool. Thus inhibition of DHFR leads to a partial depletion of 
the intracellular reduced folate pool and consequently limits cell growth.27 Both human 
TS and human DHFR are crucial enzymes for cell growth and both continue to represent 
attractive chemotherapeutic targets.28, 29 
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Figure 4 GARFTase and AICARFTase functions in de novo synthesis of Purines.30 
      Two other folate related enzymes in the de novo biosynthesis of purine nucleotides 
are β-Glycinamide-ribonucleotide transformylase (GARFTase) and Amino-
imidazolecarboxamide ribosyl-5-phosphate formyl transferase (AICARFTase) utilizing 
the cofactor, N10-CHO-FH4 to transfer one carbon units (Figure 4).
30 These carbons 
comprise the C-8 carbon and C-2 carbon of purine nucleotides. GARFTase catalyzes the 
third in the series of ten reactions required for purine synthesis (Figure 4), the conversion 
8 
 
 
of glycinamide ribosyl-5-phosphate (GAR) to formyl-glycinamide ribosyl-5-phosphate 
(fGAR), utilizing N10-formyl-FH4. GARFTase occurs in mammals as one enzyme in a 
trifunctional protein, which catalyzes the second and the fifth steps of this pathway in 
addition to the third step. The fGAR formed is converted further to amino-
imidazolecarboxamide ribosyl-5-phosphate (AICAR). AICARFTase is responsible for the 
catalysis of the last two steps in de novo biosynthesis of purine. AICARFTase utilizes 
N10-CHO-FH4  cofactor and converts AICAR to formyl-amino-imidazolecarboxamide 
ribosyl-5-phosphate (fAICAR). fAICAR continues along the purine biosynthetic pathway 
leading to the formation of inosine-5‟-monophosphate (IMP), the precursor of adenosine-
5‟-triphosphate (ATP) and guanosine-5‟-triphosphate (GTP) necessary for ribonucleic 
acid (RNA) synthesis and of 2‟-deoxyadenosine-5‟-triphosphate (dATP) and 2‟-
deoxyguanosine-5‟-triphosphate (dGTP) necessary for DNA synthesis.28 
Mammalian cells have been discovered to have sophisticated folate uptake and 
retention systems due to the importance of folate in the maintenance of one carbon 
metabolism.28, 31 Transport into the cell is usually facilitated by one of three carrier 
systems: reduced folate carrier (RFC), the membrane folate receptor (FR), and the proton 
coupled folate transporter (PCFT). The reduced form of FA including N5-CH3-FH4 and 
N10-CHO-FH4 are actively taken up into the cell by the RFC system.
32  FR, however, has 
a higher affinity for the oxidized form of the folate cofactor than the reduced form. PCFT 
is primarily responsible for FA uptake from the diet via the intestines at relatively low pH 
in the jejunum.11-13 
Once transported inside the cell, the cofactors are converted to the poly-γ-
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glutamyl species by the enzyme folylpoly-γ-glutamate synthetase (FPGS), which adds 
glutamic acid residues to the gamma carboxylic acid via amide bonds. Usually 4-8 
glutamate residues are added to the γ-carboxylic acid group of the cofactor or reduced 
folate. The polyglutamylated folates usually have higher binding affinity to some folate 
dependent enzymes (e.g. TS) and have increased intracellular retention time, because of 
their polyanionic nature.31, 33, 34 
Folylpolyglutamate hydrolase (FPGH)35 is an enzyme found in the lysosomes, 
which catalyzes the hydrolysis of folates polyglutamates back to their monoglutamate 
form. Through an ATP dependent process, folate monoglutamates can be effluxed from 
the cell via multidrug resistance protein (MRP) including P-glycoprotein (Pgp).36 
Folate metabolism has been recognized for a long time as an attractive target for 
cancer chemotherapy because of its crucial role in the biosynthesis of nucleic acid 
precursors.37-40  Antimetabolites that interfere with this folate metabolism pathway are 
known as antifolates and are clinically useful as antimicrobial, antifungal, antiprotozoal, 
and antitumor agents.5, 7, 41, 42 
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 Figure 5 Representatives of classical antifolates and their principal target(s). 
         Based on their mechanism of transportation and the ability to undergo 
polyglutamylation, antifolates are classified into two types: classical antifolates and 
nonclassical antifolate.43 Classical antifolates contain an intact L-glutamate side chain , 
while nonclassical antifolates contain a lipophilic side chain.44, 45 As shown in Figure 5, 
representatives of classical antifolates include methotrexate (MTX), aminopterin (AMT), 
pralatrexate, N10-propargyl-5,8-dideazafolate (PDDF), raltitrexed (RTX, ZD1694, 
Tomudex), pemetrexed (PMX, LY231514, Alimta), GW1843, plevitrexed (ZD9331) and 
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lometrexol (LMX). This group of antifolates closely resembles the structure of 
endogenous folates and their metabolites. Classical antifolates are actively taken up into 
cells by folate transporter systems.32, 33 
 
Figure 6 Representatives of nonclassical antifolates and their principal target(s). 
        The nonclassical antifolates are represented by structures shown in Figure 6: AG337 
(nolatrexed, thymitaq), AG331, pyrimethamine, trimethoprim (TMP), piritrexim (PTX) 
and trimetrexate (TMQ). Nonclassical antifolates are not taken up by the folate active 
transport systems (RFC, FR and PCFT) and are presumably taken up by passive and/or 
facilitated diffusion.32, 33 
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2. Membrane transport of folates 
 Mammalian cells are unable to synthesize folates de novo, therefore, 
internalization of extracellular folates is essential. Natural folates are hydrophilic anionic 
molecules which show only minimal capacities to cross biological membranes by passive 
diffusion alone. Accordingly, three major folate uptake systems have been discovered to 
facilitate absorbtion and membrane translocation of these essential cofactors.46-48 As 
mentioned above, the reduced folate carrier (RFC) is the major transport system for 
folates in mammalian cells and tissues at physiologic pH. Folate receptors (FRs) α and β 
are glycosylphosphatidylinositol (GPI)-anchored proteins that transport folates by 
receptor-mediated endocytosis.49 Finally, the proton-coupled folate transporter (PCFT) 
functions optimally at acidic pH.10, 50-52  
 
2.1. The Reduced Folate Carrier (RFC) 
The ubiquitously expressed RFC is the major transport system in mammalian 
cells and tissues for folates except FA. RFC is also the major transporter of antifolates 
used for cancer chemotherapy such as MTX, PMX, and RTX (Figure 5), and that the 
effectiveness of these agents is closely linked to levels and activity of this transport 
system in both tumors and normal tissues.53, 54  
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2.1.1. Structure of RFC 
Goldman and coworkers
55
 first reported the functional properties of RFC for 
murine leukemia cells in 1968. RFC (SLC19A1), a member of the major facilitator 
superfamily (MFS) of transporters, is characterized by its anion exchange property. 
Human RFC (hRFC) is comprised of 591 amino acids and is 64-66% conservation with 
rodent RFCs. RFC is an integral membrane protein characterized by 12 transmembrane 
domains (TMDs) and cytoplasmic-oriented amino and carboxyl termini.
56-59
 hRFC is N-
glycosylated at an N-glycosylation consensus site in the first extracellular loop (EL) 
connecting TMD1 and TMD2 (Asn58).
60
 A large loop domain that connects TMD6 and 
TMD7 is poorly conserved between species and can be replaced by a nonhomologous 
segment from the SLC19A2 carrier.
61
 When separate TMD1-TMD6 and TMD7-TMD12 
RFC half-molecules are coexpressed in human RFC-null cells, they are targeted to the 
cell plasma membrane surface and restore RFC transport activity. 
 
2.1.2. RFC distribution 
        RFC is the major folate cofactor transporter in mammals and transports folates into 
cells of peripheral tissues from blood.
62
 In human tissues, the highest hRFC transcript 
levels were recorded in placenta and liver, with significant hRFC levels in kidney, 
leukocytes, lung, bone marrow, intestine, and portions of the central nervous system 
(CNS) and brain.
63
  RFC is essential for tissue development since targeting both RFC 
alleles is embryonic lethal.
64
 In at least some tissues (e.g., small intestine), mouse RFC is 
responsive to dietary folates supply such that increased RFC transcripts and proteins were 
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detected under conditions of dietary folate deficiency.
65
 However, the significance of this 
result in intestine is unclear since RFC is unlikely to be active at the acid pH of the gut 
and PCFT is the major intestinal transporter for uptake of dietary folates. 
 
 2.1.3. Transport mechanism of RFC 
         RFC is a secondary active anionic exchanger that transports reduced folates via 
counter-transport with organic anions.
4
 RFC is the major transport system for reduced 
folates in mammalian cells and tissues.  Its physiologic substrate is 5-methyl THF, the 
major circulating folate form.
4
 As an integral transmembrane protein, RFC has a high 
affinity (~50-100-fold) for reduced folates (Ki ~1-5 µM) and a low affinity for FA (Ki ~ 
200 µM). Transport by RFC is characterized by a neutral pH optimum and significantly 
decreased transport activity below pH 7.
4, 48, 50
 
Only small transmembrane chemical gradients were generated by RFC. However, 
folates are negatively charged by preserve of the two glutamate carboxyl groups which 
are ionized at physiological pH. When considered within the context of the membrane 
potential, RFC actually produces a substantial electrochemical potential difference for 
folates across cell membranes.55 RFC function is not directly linked to ATP hydrolysis 
and it is neither Na+ nor H+ dependent, which is unique.66, 67 Instead, RFC-mediated 
transport is highly sensitive to the transmembrane anion gradient, in particular, the 
organic phosphate gradient. 66, 67 Organic phosphates are highly concentrated in cells 
where they are synthesized by ATP-dependent reactions and are largely retained. Their 
resulting asymmetrical distribution across cell membranes is the driving force for RFC-
mediated uphill transport of folates into cells.67 
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2.1.4. RFC in antifolate chemotherapy 
Classical antifolates such as MTX, RTX, and PMX (Figure 5) are all actively 
transported into mammalian cells by RFC as the major transporter.54, 68 Membrane 
transport of antifolates such as MTX is critical to antitumor activity since this provides 
sufficient intracellular drug to sustain maximal inhibition of targeted enzymes (e.g. 
DHFR and TS) and for synthesis of polyglutamate derivatives required for high affinity 
binding to some intracellular enzymes and for sustained drug effects as plasma antifolate 
levels decline. However, the loss of active transport of MTX in drug resistance tumors 
has been reported as early as 1962 in MTX resistant L5178 murine leukemia cells.69 
Since then, impaired transport has emerged as one of the dominant modes of tumor 
resistance to classical antifolate inhibitors such as MTX.70, 71 
Impaired transport (RFC) that results in a loss of sensitivity to standard doses of 
antifolate should be circumvented to some extent by increasing extracellular 
concentrations of drug. The increase forces the drug into tumor cells expressing mutated 
or low levels of RFC, and involves alternate uptake routes or passive diffusion, to a 
sufficient extent to inhibit intracellular enzymes and/or to support polyglutamate 
synthesis. However, the elevated extracellular antifolate concentration always results in 
severe toxicity due to the lack of selectivity of uptake into the tumor cells compared 
normal cells.  
 
2.2. The folate receptors (FRs) 
           The FRs are a family of proteins with high affinity folate binding and represent 
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another mode of folate uptake into mammalian cells. They bind folic acid, reduced 
folates, many antifolates and folate conjugates with high (low nanomolar) affinities. 
 
2.2.1. Structure of FRs 
Human FRs are encoded by three distinct genes, designated α, β and γ localized to 
chromosome 11q13.3-q13.5.72  FRs α, β and γ are homologous proteins (68-79% identical 
amino acid sequences) and contain from 229 to 236 amino acids with two (β, γ) or three 
(α) N-glycosylation sites.73 Compared to RFC, FRα and β are cell surface glycosyl 
phosphatidylinositol (GPI)-anchored glycoproteins, while FRγ lacks a signal for GPI 
anchor attachment and is a secretory protein of unknown function.49 
 
2.2.2. FRs distribution  
        FRα is predominantly expressed on the apical (luminal) surface of polarized 
mammalian epithelial cells where it is not in contact with the circulating folate.
74
 Among 
normal tissues, FRα is widely expressed at the brush-border membrane of the choroid 
plexus, retinal pigment epithelium, proximal tubules in kidney, fallopian tubes, uterus 
and placenta.
49
  The unusual polarized expression of FRα appears to protect normal 
tissues from FR-targeted cytotoxic agents in the circulation.
75
 FRβ is expressed in 
placenta, spleen, thymus and in CD34+ monocytes and hematopoeitic cells.76-79 In normal 
bone marrow and peripheral blood cells, expression of FRβ is restricted to the 
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myelomonocytic lineage (e.g. mature neutrophils) and was reported to be 
nonfunctional.
80
 
        FRα has been reported to be overexpress in malignant tissues, such as non-mucinous 
adenocarcinomas of ovary, uterus and cervix, and ependymal brain tumors.
49
  FRα levels 
positively correlate with tumor stages and grades.
81
 FRβ malignant expression has been 
reported to involve a substantial fraction of chronic myelogenous leukemia and acute 
myelogenous leukemia (AML) cells, but not Acute Lymphoblastic Leukemia (ALL).
80, 82
 
Both FRα and FRβ in malignant tissues seem to be functional, prompting the use of folic 
acid and pteroyl moieties for tumor targeting of toxins, liposomes, imaging and cytotoxic 
agents. 
75, 82, 83
 
 
2.2.3. Transport mechanism of FRs 
            Membrane-bound FRs mediate folate internalisation via a non-classical receptor-
mediated endocytosis.84-87 This process is initiated when a folate molecule binds to a 
folate receptor on the cell surface, followed by invagination of the plasma membrane at 
that site and the formation of a vesicle (endosome) that migrates along microtubules in 
the cytoplasm to the perinuclear endosomal compartment where it is acidified to a pH of 
6.0-6.5. The decrease in pH results in dissociation of the folate from the folate receptor 
complex.88 Folate ligand is then exported into the cytoplasm by a process requiring a 
transendosomal pH gradient.86, 87, 89, 90 
FRs offer a potential means of selective tumor targeting, given their restricted 
pattern of tissue expression and function as discussed above. Importantly, FRα is reported 
to be overexpressed in a number of carcinomas including up to 90% of ovarian cancers.81, 
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91 FRα in normal tissues (unlike tumors) is reported to be inaccessible to the circulation, 
which ensured the targeting safety without toxicity to normal tissues. FRβ is expressed in 
a wide range of myeloid leukemia cells, while FRβ in normal hematopoetic cells differs 
from that in leukemia cells in its inability to bind folate ligand.80 
 
2.3. The proton-coupled folate transporter (PCFT) 
PCFT, a new folate carrier (SLC46A1) was discovered in 2006.10  Two other 
members of this family (SLC46A2 and SLC46A3) were also reported recently.51, 52 
PCFT as a high-affinity folate transporter is a proton-folate symporter that functions 
optimally at acidic pH by coupling the flow of protons down an electrochemical 
concentration gradient to the uptake of folates into cells.
10, 50-52
  Like RFC, PCFT is major 
facilitator superfamily (MFS) protein. However, human PCFT (hPCFT) shares only ~14% 
amino acid identity with hRFC.
48, 50
 Although PCFT can transport heme, its primary role 
appears to be intestinal absorption of dietary folates and plays a major role in in vivo 
folate homeostasis.
92, 93
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2.3.1. Structure of PCFT 
 
Figure 7 Human PCFT structure.
56
 
The gene that encodes human PCFT (SLC46A1) is located on chromosome 
17q11.2. and consists of five exons. hPCFT is comprised of 459 amino acids with a 
molecular mass of 49.8 kDa. It is predicted to include 12 TMDs with N- and C-termini 
oriented to the cytoplasm (Figure 7). This structure has been validated by 
immunofluorescence analysis of hemagglutin (HA)-tagged hPCFT molecules.94, 95 The 
loop domain between the first and second TMDs must be extracellular because the two 
putative N-glycosylation consensus sites in this region are glycosylated. N-glycosylation 
does not appear to be required for either PCFT trafficking or function.94  
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2.3.2. PCFT expression patterns in human tissue 
          PCFT is expressed in many normal tissues including small intestine, colon, liver, 
kidney, placenta, retina and brain. Within the intestine and colon, high levels of PCFT are 
expressed in apical brush-border membranes in the proximal jejunum and duodenum. 
However, PCFT levels decrease sharply in other segments of the intestine and colon.
10
  
PCFT is also found in the choroid plexus.
96
 
 
Figure 8 PCFT transcript expression in human normal tissues.
56
 
          In normal human tissues, elevated hPCFT levels were measured in kidney, liver, 
placenta, and spleen, with modest levels in most tissues and undetectable levels in bone 
marrow and colon (Figure 8).
56
 For a number of human tissues, hPCFT proteins were 
detected by immunohistochemistry with hPCFT-specific antibody. These results 
substantiate and demonstrate that while hPCFT is expressed in normal human tissues, its 
levels are more limited than for hRFC.56 While PCFT in the upper gastrointestinal tract is 
involved in absorption of dietary folates, the physiologic role of PCFT in tissues not 
normally associated with low pH microenvironments is not clear yet. PCFT may still 
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conceivably contribute to folate internalization in such tissues by virtue of localized 
acidification or at sufficiently elevated levels to transport 5-methyl THF and related 
folates.
48
 However, at comparatively neutral pHs characterizing most tissues, RFC is 
much more efficient at delivering reduced folates than PCFT.
97
 
 
2.3.3. Transport mechanism of PCFT 
Folate transport mediated by human, mouse and rat PCFTs is electrogenic 
indicating there is a net translocation of positive charges as each folate molecule is 
transported.51, 98-100 PCFT functions as a folate-proton symporter: the downhill flow of 
protons via PCFT is coupled with the uphill flow of folates into cells. A transvesicular pH 
gradient results in increased unidirectional folate transport and substantial transmembrane 
folate concentration gradients from the low-pH to the high-pH compartment, which is 
consistent with a proton-coupled process.101 A distinguishing characteristic of PCFT 
involves its acidic pH optimum: for PCFT, transport is maximal at pH 5-5.5. As the pH 
increases above pH 5.5, transport decreases dramatically; above pH 7, activity is not 
detectable.
48, 50 
This leads to an important cancer chemotherapy hypothesis that selective 
transport via PCFT could afford targeted therapy access solid tumors. The internal pH of 
solid tumors is often acidic,102, 103 which favors PCFT transport. Actually,   PCFT was 
identified in 29 of 32 solid human tumor cell lines104 and high levels of human PCFT 
(hPCFT) transcripts were reported in a broad range of human tumors. Whereas the role of 
hPCFT in antifolate activity and tumor selectivity is still under investigation, transport of 
classic antifolates by PCFT has been described previously.97 
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2.3.4. FRs and PCFT specific anticancer chemotherapy  
          The expression of RFC in both normal and tumor cells presents a potential obstacle 
to antitumor selectivity. Further, loss of RFC is frequently associated with antifolate 
resistance. Thus, it is of interest to design targeted antifolates that are substrates for 
transporters other than RFC with limited expression and/or transport into normal tissues 
compared with tumors. This rationale provided the impetus to develop targeted agents 
that are selectively transported into tumors by FRs and PCFT over RFC, with potent 
intracellular targets inhibition.56  
 
a. Folate-conjugated cytotoxins 
Folate-conjugated cytotoxins, liposomes, radionuclides, or cytotoxic antifolates 
have been used to target FRs.105-108 Unfortunately, for most folate-based anticancer agents 
such as classical antifolates (including MTX, RTX and PMX), tumor selectivity is lost, 
since substrates are shared between FRs and the ubiquitously expressed RFC. One 
strategy for selectively tumor cell targeting via FRs involves prodrug conjugates in which 
folate or pteroate is covalently linked to cytotoxins such as mitomycin C18 that, upon 
internalization, are selectively cleaved to release cytotoxic drug. While these drug 
conjugates are not likely to be RFC substrates, the success of this tumor targeting 
approach could be significantly compromised by inefficient cleavage and release of the 
cytotoxic moiety, resulting in decreased chemotherapeutic activity. Alternatively, 
premature cleavage of the drug conjugates (prior to tumor internalization) could decrease 
selectivity and increase toxicity to normal proliferative tissues. Additionally, use of folic 
acid conjugates could ultimately release free folic acid within the tumor which could 
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function as a nutrient for the tumor. However, if a FR targeted ligand were itself cytotoxic 
without RFC activity, selective tumor targeting would ensue.109 
 
b. FRα-targeted TS inhibitor BGC638 and BGC945 
             Jackman and colleagues
110, 111
 introduced a new generation of TS-targeted 
therapeutics to include the FRα-targeted agents BGC638 and BGC945, both 
cyclopenta[g]quinazoline analogs, neither of which are RFC or FPGS substrates. 
BGC945 demonstrated superior in vitro efficacy over BGC638 with FRα-expressing 
tumors. BGC945 was tested in vivo in mice with human KB tumor xenografts and treated 
with 5-[125I]-iodo-2‟-deoxyuridine. 110, 111 It was established that BGC945 was a 
selective TS inhibitor toward FRα-expressing tumors. BGC945 was licensed by Onyx 
Pharmaceuticals with the name ONX 0801 and in 2009, a phase I clinical trial was 
initiated in the UK. No further information on these compounds is currently available. 
 
c. FRα- and PCFT-targeted Garftase inhibitors 
Gangjee and coworkers109, 112, 113 recently reported novel 6-substituted classical 
pyrrolo[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine as cytotoxic antifolates with 
varying lengths of the carbon bridge region (Table 1 shows only the three- and four-
carbon bridge analogs), that are characterized by selective FR and/or PCFT transport over 
RFC transport. 
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Pyrrolo[2,3-d]pyrimidines and  thieno[2,3-d]pyrimidines as FR and/or PCFT 
specific anticancer agents (Table 1) 
Structure Compound Biological Activity (IC50) Ref. 
 
 
1  n = 3 
 
 
2  n = 4 
hGARFTase          2.44 µM 
KB                           1.7 nM 
IGROV1                  2.2 nM 
hGARFTase          0.15 µM 
KB                           1.9 nM 
IGROV1                  3.6 nM 
101
 
 
3  n = 4 
 
 
4  n = 5 
 
hGARFTase          0.06 µM 
KB                         0.55 nM 
IGROV1                0.97 nM 
hGARFTase          3.31 µM 
KB                         3.17 nM 
IGROV1                 176 nM 
105
 
 
5  n = 3 
 
 
6  n = 4 
 
hGARFTase          8.52 µM 
KB                            23 nM 
IGROV1                  4.7 nM 
hGARFTase          5.51 µM 
KB                           4.9 nM 
IGROV1                  5.9 nM 
104
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1. SAR of 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines and thieno[2,3-
d]pyrimidine with different side chain aromatic rings in whole cell assay as 
GARFTase inhibitors with selectivity for FRs and/or PCFT over RFC.101,104,105 
For all these series, the three- and four-carbon bridge analogs were discovered the 
most active toward FR and PCFT-expressing human tumors (KB and IGROV1) and the 
cytotoxicity was primarily due to potent inhibition of GARFTase, although for the  
thieno[2,3-d]pyrimidine antifolates, a secondary target, most likely AICARFTase, was 
also implied at higher concentration.109, 112-114  
            The biological results for these analogs establish the remarkable potency against 
tumor cell proliferation, resulting from FR- and/or PCFT-mediated cellular uptake, and 
inhibition of GARFTase. Significant in vivo antitumor activity was recorded for the 
thieno[2,3-d]pyrimidine compound 6 with severe combined immunodeficient (SCID) 
mice bearing both early and more importantly advanced stage KB tumors. 
 
2.  SAR of 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines with different 
side chain aromatic rings in whole cell assay as GARFTase inhibitors with selectivity 
for FRs and/or PCFT over RFC.115 (Figure 9) 
          None of the isomers (2-3 and 7-10) are substrates for RFC. For FRα, replacement 
of the side chain phenyl (2, IC50 of 6.3 nM for FRα-expressing RT16 cells) with a 
thiophene (3, IC50 of 1.8 nM for FRα-expressing RT16 cells) or furan ring (7, IC50 of 0.16 
nM for FRα-expressing RT16 cells) favors binding and transport by FRα. 
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Figure 9 Structures of 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines with 
different side chain aromatic rings.115  
          The relative position of the carbon bridge and L-glutamate is important for the 
pyridine side chain (8, 9 and 10, IC50 of 8.5 nM, 1.27 nM and 215 nM for FRα-
expressing RT16 cells, respectively). For FRβ, replacement of the side chain phenyl (2, 
IC50 of 10 nM for FRβ-expressing D4 cells) with a thiophene (3, IC50 of 0.57 nM for 
FRβ-expressing D4 cells) or furan ring (7, IC50 of 0.92 nM for FRβ-expressing D4 cells) 
favors binding and transport by FRβ as well. For PCFT, replacement of the side chain 
phenyl (2, IC50 of 213 nM for hPCFT-expressing R2/hPCFT4 cells) with a thiophene (3, 
IC50 of 43.4 nM for hPCFT-expressing R2/hPCFT4 cells) favors binding and transport by 
PCFT, whereas, a furan side chain (7, IC50 of 439 nM for hPCFT-expressing R2/hPCFT4 
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cells) decreases the binding and transport by PCFT. The relative position of the carbon 
bridge and L-glutamate is also important for the pyridine side chain (9, IC50 of 66.8 nM 
for hPCFT-expressing R2/hPCFT4 cells; 8 and 10 are not transported by PCFT), hence, 
the position of the pyridine nitrogen is important in the regioisomers.  
 
3. SAR of 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines with a thienoyl 
side chain in whole cell assay as GARFTase inhibitors with selectivity for FRs 
and/or PCFT over RFC.116 (Figure 10) 
 
Figure 10 Structures of 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines with a 
thienoyl side chain.116 
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None of the regioisomers (11-15) are substrates for RFC. Analogs with a 1,3-
disubstituted relationship (14 and 15) of the 4-carbon bridge and the L-glutamate 
demonstrate better activity toward KB tumor cells (IC50 of 0.14 nM and 0.13 nM, 
respectively), which is about 2-fold more potent than 3. Analogs with a 1,2-disubstituted 
relationship (11, 12 and 13) of the 4-carbon bridge and the L-glutamate show 
substantially decreased yet moderate activity toward KB (IC50 of 171 nM, 267 nM and 
25nM, respectively). Compounds 14 and 15 also showed a significantly high level of FRα 
and PCFT activity (IC50 of 2.53 nM and 2.56 nM for FRα-expressing RT16 cells; IC50 of 
35 nM and 64 nM for hPCFT-expressing R2/hPCFT4 cells), which is equipotent to 3 
(IC50 of 2 nM for FRα-expressing RT16 cells; IC50 of 43.4 nM for hPCFT-expressing 
R2/hPCFT4 cells). In contrast, compounds 11 and 12 are inactive toward FRα-expressing 
RT16 cells and hPCFT-expressing R2/hPCFT4 cells. Compound 13, however, shows 
weak inhibitory activity of FRα (IC50 of 147 nM for FRα-expressing RT16 cells). Hence, 
for both FRα and PCFT transport, 1,3-disubstituted relationship between the carbon 
bridge domain and L-glutamate moiety is important to maintain binding and transport of 
this series. 
         Although the 6-substituted pyrrolo[2,3-d]pyrimidine antifolates exhibit near 
exclusive selectivity for FR and hPCFT over hRFC, it is important to better identify 
structure-activity relationships for substrate binding and transport for each of these 
carriers. Indeed, while it has been possible to identify cytotoxic folate analogs with 
selective membrane transport by FRs over RFC, to date no compounds have been 
identified with hPCFT transport selectivity without substantial FR uptake. Furthermore, it 
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is not yet certain whether it might be beneficial to develop exclusive hPCFT-selective 
substrates without FR transport, as long as hRFC transport is limited.
56
 
  
3. Glycinamide-ribonucleotide transformylase (GARFTase) 
 GARFTase (EC 2.1.2.2) was first discovered and partially characterized from 
pigeon liver by pioneer investigators Warren and Buchanan.117 GARFTase catalyzes the 
transfer of the formyl group from N10-CHO-FH4 to the primary, side-chain amino group 
of glycinamide ribonucleotide (GAR) to yield formylglycinamide ribonucleotide (FGAR) 
and tetrahydrofolate (Figure 4), ultimately resulting in the incorporation of C-8 into 
inosinic acid (IMP) as summarized above in the folate metabolism section. It is the third 
step and the first of two folate-dependent formyl transfers in the de novo purine 
biosynthetic pathway. The critical role that purine nucleotides play as precursors to RNA 
and DNA led to that inhibition of de novo purine biosynthesis might be a viable approach 
for cancer chemotherapy.5, 118 The validation of this hypothesis was demonstrated when 
5,10-dideazatetrahydrofolate (DDATHF), a potent antitumor agent, was determined to be 
the  inhibition of GARFTase and consequently of de novo purine biosynthesis.119 
GARFTase continues to be of interest because of its function in catalyzing the formyl 
transfer,120, 121 its role in the synthesis of DNA precursor purines,122 its key mechanistic 
features of the reaction,123-126 and as an important target for chemotherapeutic drug 
design.127-137 
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3.1. Structure of GARFTase 
hGARFTase is located at the C-terminus of a trifunctional enzyme with a 
molecular mass of more than 110 kDa, which is also responsible for catalyzing the 
second (glycinamide ribonucleotide synthetase) and fifth (aminoimidazole ribonucleotide 
synthetase) reactions of de novo purine biosynthesis.138 The crystal structure of 
hGARFTase has been reported at pH 4.2 (1.7 Å), at pH 8.5 (2 Å), at pH 8.5 in the binary 
complex with the substrate β-GAR (2.2 Å)126 and at pH 7 in a binary complex with the 
co-substrate analog inhibitor 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-
tetrahydrofolic acid (10-CF3CO-DDACTHF) (2 Å)
139 and a series of other folate 
inhibitors.133 
 
3.2. Catalytic Mechanism of GARFTase 
Kinetic studies of the E. coli GARFTase120 and of the human GARFTase140 and 
murine GARFTase141 domains suggest a sequential mechanism in which the formyl 
group is transferred by a direct nucleophilic attack of the GAR amino group on the 
formyl carbon of the co-substrate, leading to the formation of a tetrahedral intermediate. 
Formation of this intermediate and its transformation to product require proton transfers. 
It has been proposed that a “ fixed” water molecule, rather than the invariant amino acids 
in the active site, mediates the proton transfer between substrate and cofactor, but this has 
not been verified by experiments. 
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Figure 11 A proposed mechanism of GARFTase.121  
A proposed GARFTase mechanism is shown in Figure 11.121 As the cofactor N10-
CHO-FH4 binds to the active site, Asp144 forms a salt bridge to the imidazolium of 
His108 and the formyl group is positioned to form hydrogen bonds to Asn106 and the 
protonated imidazolium group of His108. The nucleophilic amino group of GAR then 
attacks the activated formyl group to form a tetrahedral intermediate. A proton transfer 
from GAR to the N10 of folate is mediated by a catalytic water molecule, followed by the 
breakdown of the tetrahedral intermediate to form products. The positioning of this water 
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molecule may be assisted by a hydrogen bond to the carboxylic acid group of Asp144. 
(To simplify the figure, Asp144 is shown twice in Figure 7; it actually spans from the N1 
of His108 to the bound H2O molecule.) 
 
3.3. Binding of Inhibitors 
 An X-ray crystal structure (1.98 Å) of hGARFTase was reported by Zhang et 
al.139 in a binary complex with the co-substrate analog inhibitor 10-CF3CO-DDACTHF 
(Table 2) at pH 7 (PDB ID 1NJS). The cofactor binding pocket of hGARFTase is located 
at the interface between the N-terminal mononucleotide binding domain and the C-
terminal half of the structure and consists of three parts:  the pteridine binding cleft, the 
benzoylglutamate region, and the formyl transfer region.  
Pteridine Binding Cleft. The diaminopyrimidinone ring of 10-CF3CO-DDACTHF 
is deeply buried in the active site cleft at the same location as the quinazoline ring of 10-
formyl-5,8,10-trideazafolic acid (10-formyl-TDAF) in the E. coli GARFTase complex 
(PDB entry 1C2T). The connecting chain from the diaminopyrimidinone ring to the L-
glutamate, composed of single carbon bonds, is longer than its counterpart in 10-formyl-
TDAF, due to the removal of the fused benzene ring, which makes it more flexible when 
adapting to the binding site to optimize the gem-diol interactions with the protein. The 
diaminopyrimidinone ring of 10-CF3CO-DDACTHF is tilted about 15 ° relative to the 
quinazoline ring of 10-formyl-TDAF, facilitating N2 within hydrogen bonding range (3.1 
Å) of the backbone carbonyl oxygen of Glu141. The diaminopyrimidinone ring conserves 
all of the key interactions observed with the quinazoline ring of 10-formyl-TDAF, and 
33 
 
 
provides additional key hydrogen bonds with the enzyme. Several hydrophobic residues 
(Leu85, Ile91, Leu92, Phe96, and Val97) encircle a deep cavity holding the heterocycle. 
The diaminopyrimidinone ring forms six hydrogen bonds to the main chain amides and 
carbonyls of Arg90, Leu92, Ala140, Glu141, and Asp144, and two hydrogen bonds to 
ordered waters (W18 and W70). In the quinazoline ring of 10-formyl-TDAF, the N8 
nitrogen has been proposed to play a key role in recognition and interaction with folate-
binding enzymes and forms one end of an H-bond donor−acceptor−donor array. While its 
replacement with carbon does not preclude its binding to GARFTase, its presence appears 
to contribute to substrate recognition by the folate transport system and/or FPGS. The 
diaminopyrimidinone ring of 10-CF3CO-DDACTHF, however, preserves this N
8 nitrogen 
and forms hydrogen bonds to the carbonyl oxygen of Arg90 (2.8 Å) and an ordered 
solvent molecule W70 (2.7 Å).  
 Glutamate Tail. In the 10-CF3CO-DDACTHF complex, the PABA moiety is 
located in a hydrophobic pocket sandwiched between the side chains of Ser118 and Ile91. 
The carbonyl group is in the same plane as the phenyl ring. The glutamate tail is almost 
perpendicular to the PABA plane and parallel to the aliphatic stem of the 
diaminopyrimidinone ring. In contrast to its flexibility in E. coli GARFTase complex 
structures, the glutamate moiety is solvent-exposed, but exhibits a remarkably well-
ordered structure in the complex structure of 10-CF3CO-DDACTHF with human 
GARFTase. A salt bridge (2.7 Å) is formed between the α-carboxylate and Arg64 so that 
the γ-carboxylate points to the solvent. Additional interactions observed include a 
hydrogen bond between the Ile91 backbone amide and the α-glutamate carboxylate (2.8 
Å).  
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Formyl Transfer Region and the Gem-Diol Structure. Key interactions for tight 
binding of 10-CF3CO-DDACTHF to hGARFTase are found in the formyl transfer region. 
Strong electron density next to the ketone oxygen indicates that the ketone is hydrated to 
a gem-diol, similar to the 10-formyl-TDAF and β-GAR complex with the E. coli 
GARFTase (PDB ID 1C2T). The gem-diol forms extensive interactions with the formyl 
transfer region, especially with two essential residues Asp144 and His108. The Asp144 
carboxylate forms hydrogen bonds (2.5 and 2.7 Å) to each of the hydroxyl groups of the 
gem-diol. N3 in the imidazole ring of His108 also forms hydrogen bonds with both 
hydroxyl groups of the gem-diol [OA1 (2.7 Å) and OA2 (3.1 Å)]. Additionally, OA2 also 
forms a potential hydrogen bond (3.0 Å) with the backbone carbonyl oxygen of Gly117.  
 
3.4. GARFTase Inhibitors 
Three classes of GARFTase inhibitors are reviewed and listed in Table 2, Table 3 
and Table 4. 
 
3.4.1. 5,6,7,8-Tetrahydropyrido[2,3-d]pyrimidines and 7,8-dihydro-pyrimido[5,4-
b][1,4]thiazines as GARFTase inhibitors (Table 2) 
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Structure Compound Biological 
Activity 
Ref. 
 
 
 
Lometrexol 
(DDATHF) 
 
hGARFTase (Ki) 
6 nM 
 
142 
    
 
 
LY-222306 
(6-R,S) 
 
hGARFTase (Ki) 
0.77 nM 
 
CCRF-CEM (IC50) 
27 nM 
 
143 
    
 
 
LY-254155 
(6-R,S) 
LY-309887 
(6-R) 
 
hGARFTase (Ki) 
2.1 nM 
 
CCRF-CEM (IC50) 
27 nM 
 
144 
    
 
 
AG-2034 
 
hGARFTase (Ki) 
28 nM 
 
CCRF-CEM (IC50) 
2.9 nM 
 
145 
    
 
 
AG-2037 
(pelitrexol) 
 
hGARFTase (Ki) 
0.5 nM 
 
 
 
146 
 
  
Lometrexol. The first GARFTase inhibitor in clinical trials, the 6-(R)-isomer (the same 
configuration found in natural tetrahydrofolates of 5,10-dideazatetrahydrofolic acid) of 
DDATHF, termed lometrexol (LMTX, Table 1), was synthesized by E.C. Taylor at 
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Princeton and Chuan (Joe) Shih at Eli Lilly in 1985.147 This discovery established 
GARFTase and the purine de novo biosynthetic pathway as valid targets for 
antineoplastic intervention. LMX is structurally analogous to THF except that the 5- and 
10- nitrogens of THF are replaced by carbons. LMTX is a poor inhibitor of both TS and 
DHFR, but a potent inhibitor of GARFTase (Ki = 6 nM) and a substrate for FPGS.
148 In 
CCRF-CEM cells with impaired RFC function, polyglutamylation of LMTX by FPGS is 
so extensive as to effectively negate the impact of the loss of RFC and the resistant 
phenotype.
149
 In phase I clinical trials, patients treated with LMTX without folic acid 
coadminstration developed severe and cumulative dose-limiting  myelosuppression and 
mucositis.150 The cumulative toxicity of LMTX is believed to be due in part to its ability 
to be transported by both the RFC and FRs, resulting in toxic cellular levels.151 When 
LMTX was administered with folic acid, there was a reduction in clinical toxicity, 
permitting a 10-fold dose escalation over that without folate supplementation.
152
 
       While LMTX is an excellent substrate for FRs,
32
 it is primarily transported into 
tumors  and normal tissues by RFC, whereupon it is extensively polyglutamylated by 
FPGS and inhibits GARFTase, leading to ATP and GTP depletion and potent antitumor 
activity with preclinical models in vitro and in vivo.
119, 153
  
 
          LY-309887. Unexpected cumulative toxicity with LMTX led to a search for a 
second-generation antimetabolite with a more favorable toxicological, biochemical and 
pharmacological profile. Habeck et al.143 reported a novel class of classical antifolates 
that replaced the 1‟,4‟-phenyl group of LMTX with a 2‟,5‟-furan (LY-222306) and a 
2‟,5‟-thiophene (LY-254155) (Table 1) in 1994. Both LY-222306 and LY-254155 
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(mixtures of diastereomers) were found to be potent inhibitors of CCRF-CEM cell 
growth (IC50 = 27 and 2.3 nM, respectively) and human GARFTase (Ki = 0.77 and 2.1 
nM, respectively). Further resolution of LY-254155 into its two diastereomers provided 
LY-309887 (6R-2‟,5‟-thienyl-5,10-dideazatetrahydrofolic acid, Table 1), which was more 
potent than LMTX at inhibiting tumor growth in the murine C3H mammary tumor model 
and several tumor xenografts.144, 153  LY-309887 displayed a 9-fold more inhibitory 
potency against GARFTase compared to LMTX. In preclinical models, LY-309887 was 
more potent than LMTX against two pancreatic xenografts and in the human LX-1 lung 
carcinoma model. However, in two preliminary reports of phase I studies with LY-
309887, all patients received concurrent folic acid but still suffered from cumulative 
toxicity, suggesting that, like LMTX, cumulative toxicity and lack of selective transport 
into tumors remains a toxic property of LY-309887 as well.154, 155 
 
 AG-2037. AG-2037 (pelitrexol) is in phase II clinical development (Table 1)  for 
patients with metastatic adenocarcinoma of the colon or rectum that failed prior 
fluorouracil and leucovorin calcium therapy.156 Its configuration at C-6 is reversed 
compared to LMTX and the thiophene is methylated at the 4-position of AG-2037. AG-
2037 is a potent inhibitor of GARFTase (Ki = 0.5 nM) and exhibits significant 
antiproliferative effects against tumor cells both in vitro and in vivo.157 Several phase I 
studies have been completed that indicate that AG-2037 is well tolerated and its 
maximum tolerated dose in phase II studies have been determined.158  
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3.4.2. Pyrimidines as GARFTase inhibitors (Table 3) 
Structure Compound Biological 
Activities 
Ref. 
 
 
7-DM-
DDATHF 
X = CH2  
 
5-DACTHF 
X = NH 
CCRF-CEM (IC50) 
0.13 µM 
 
 
hog liver  
GARFTase (IC50) 
2.6 µM 
 
159 
 
 
 
160 
    
 
 X = CH 
 
 
 
 X = N 
 
hog liver  
GARFTase (IC50) 
2.06 µM 
 
hog liver  
GARFTase (IC50) 
0.14 µM 
161 
 
 
 
161 
    
 
10-CHO-
DDACTHF 
R = H 
 
 
10-CF3CO-
DDACTHF 
R = CF3 
hGARFTase (Ki) 
14 nM 
CCRF-CEM (IC50) 
60 nM 
 
rhGARFTase (Ki) 
15 nM 
CCRF-CEM (IC50) 
16 nM 
134 
 
 
 
 
162 
    
 
(10R)-CH3S-
DDACTHF 
 
 
 
(10S)-CH3S-
DDACTHF 
 
rhGARFTase (Ki) 
210 nM 
CCRF-CEM (IC50) 
80 nM 
 
rhGARFTase (Ki) 
180 nM 
CCRF-CEM (IC50) 
50 nM 
163 
 
 
 
 
163 
    
 
α-CH2-10-
CF3CO-
DDACTHF 
R1=COONH2 
R2=COOH 
hGARFTase (Ki) 
4.8 µM 
CCRF-CEM (IC50) 
inactive 
 
164 
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γ-CH2-10-
CF3CO-
DDACTHF 
R1=COOH 
R2=COONH2 
 
γ -Tetrazole-
10-CF3CO-
DDACTHF 
R1=COOH 
R2=tetrazole 
 
 
hGARFTase (Ki) 
56 nM 
CCRF-CEM (IC50) 
300 nM 
 
 
hGARFTase (Ki) 
130 nM 
CCRF-CEM (IC50) 
40 nM 
 
164 
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7-DM-DDATHF. During the development of GARFTase inhibitors, open-chain 
analogs of LMTX were synthesized and evaluated by Boger et al..159, 166 These analogs 
avoided the C-6 stereocenter of LMTX and were therefore less challenging to synthesize. 
7-Desmethylene-DDATHF (7-DM-DDATHF) (Table 2) is approximately 8-fold less 
potent than LMTX against human leukemia CCRF-CEM cells (IC50 = 130 nM vs. 16 
nM). 7-DM-DDATHF is also a FPGS substrate and its polyglutamated conjugates are 
more potent inhibitors of GARFTase than the parent compound. These results 
demonstrated the removal of the annulated tetrahydropyridine ring of LMTX had 
minimal effect on binding to GARFTase. A similar compound 5-DACTHF (Table 2) was 
reported by Kelley et al.167 in 1990. 5-DACTHF showed an IC50 of 2.6 μM against hog 
liver GARFTase and slight inhibition of AICARFTase (IC50 = 200 μM in L1210 cells). 
  
10-CF3CO-DDACTHF. The synthesis and evaluation of 10-formyl-5,10-dideaza-
acyclic-5,6,7,8-tetrahydrofolic acid (10-CHO-DDACTHF, Table 2), an acyclic analog of 
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LMTX bearing a nontransferable C-10 formyl group, was also reported.168 10-CHO-
DDACTHF showed potent inhibition against cell growth (IC50 = 60 nM, CCRF-CEM) 
and hGARFTase (Ki = 14 nM), but suffered from instability due to a facile oxidative 
deformylation. By combining the 2,4-diaminopyrimidone core of 10-CHO-DDACTHF 
with a more stable trifluoromethyl ketone moiety, 10-(Trifluoroacetyl)-5,10-dideaza-
acyclic-5,6,7,8-tetrahydrofolic acid (10-CF3CO-DDACTHF, Table 2) was discovered.
139 
It is a potent inhibitor of tumor cell proliferation, with an IC50 of 16 nM against CCRF-
CEM cells, which represents a 10-fold improvement over LMTX. This compound 
specifically inhibits recombinant hGARFTase (Ki = 15 nM), and is stable, displaying no 
competitive oxidative deacylation. 
 
10-CH3S-DDACTHF. 10-CH3S-DDACTHF was also reported to be potent, 
exhibiting an IC50 of 100 nM against CCRF-CEM cells.
169 A follow-up asymmetric 
synthesis of (10R)- and (10S)- diastereomers of 10-CH3S-DDACTHF was reported in 
2008.170  Both diastereomers are potent and selective inhibitors of rhGARFTase (10R, Ki 
= 210; 10S,  Ki = 180 nM) and effective inhibitors of cell growth (IC50 = 80 and 50 nM, 
respectively, against CCRF-CEM cells), which is dependent on intracellular 
polyglutamation by FPGS but not transported by the RFC. 
 
γ-CONH2-10-CF3CO-DDACTHF and γ-tetrazole-10-CF3CO-DDACTHF (Table 
2).  The glutamic acid portion of 10-CF3CO-DDACTHF was further explored in the 
development of GARFTase inhibitors. As summaried previously, folates and many 
41 
 
 
antifolates are polyglutamylated by FPGS after entering cells. FPGS attaches additional 
glutamates to the γ-carboxylic acid of folates and antifolates. Polyglutamation of folates 
and antifolates increases their affinity to target enzymes (e.g. TS and GARFTase) and 
makes them less susceptible to cellular efflux, providing a long-lived cellular supply of 
the molecules. However, this long-term enhanced intracellular accumulation of 
antifolates, which results from their polyglutamation, contributes to their cumulative 
toxicity. Therefore, GARFTase inhibitors that do not undergo polyglutamylation while 
maintaining potent enzyme binding is considered to be attractive. Amide analog γ-
CONH2-10-CF3CO-DDACTHF (Table 2) exhibited potent inhibitory activity against 
rhGARFTase (Ki = 56 nM) and purine-sensitive cytotoxic activity (IC50 = 300 nM, 
CCRF-CEM), whereas α-CONH2-10-CF3CO-DDACTHF showed decreased affinity (Ki 
= 4.8 μM) and was inactive in cellular functional assays.17148 Another potent 
nonpolyglutamatable analog γ-tetrazole-10-CF3CO-DDACTHF (Table 2) exhibited 
purine-sensitive cytotoxic activity (IC50 = 40 nM) and was a selective inhibitor of 
hGARFTase (Ki = 130 nM).
172 As anticipated, both γ-CONH2-10-CF3CO-DDACTHF and 
γ-tetrazole-10-CF3CO-DDACTHF are not dependent on FPGS for activity, and hence not 
susceptible to resistance caused by FPGS. 
 
3.4.3. Pyrrolo[2,3-d]pyrimidines and  thieno[2,3-d]pyrimidines  
Gangjee and coworkers109, 112, 113 recently described novel 6-substituted classical 
pyrrolo[2,3-d]pyrimidine  and thieno[2,3-d]pyrimidine  as cytotoxic antifolates with 
varying lengths of the carbon bridge region (Table 1), that are characterized by selective 
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FR and PCFT transport over RFC transport. For every series, the three- and four-carbon 
bridge analogs were the most active toward FR-expressing human tumors (KB and 
IGROV1) and the cytotoxicity was primarily due to potent inhibition of GARFTase, 
although for the thieno[2,3-d]pyrimidine antifolates, a secondary target, most likely 
AICARFTase, was also implied at higher concentration. 50-51  
The 6-substituted classical pyrrolo[2,3-d]pyrimidine with a thiophene side chain, 
compound 3 is much more potent in vitro compared with the most potent of the 
previously published pyrrolo[2,3-d]pyrimidine 2 and the thieno[2,3-d]pyrimidine 6, both 
of which contain a benzoyl ring in the side chain (Table 1). Significant in vivo antitumor 
activity was demonstrated for compound 3 with severe combined immunodeficient 
(SCID) mice bearing both early and more importantly advanced stage KB tumors. 
 
4. Aminoimidazole-4-carboxamide ribonucleotide transformylase (AICARFTase) 
          Aminoimidazole-4-carboxamide ribonucleotide transformylase (AICARFTase) 
catalyzes the penultimate reaction in the de novo purine biosynthetic pathway, producing 
formyl-AICAR (FAICAR) from AICAR using N10-formyltetrahydrofolate (N10-CHO-
FH4) as the formyl donor. It exists as one domain of a bifunctional enzyme that also 
contains IMP cyclohydrolase (IMP CHase) that catalyzes the final reaction of the 
pathway (Figure 4). Because of the large demand for purines by cancer cells, 
AICARFTase has been targeted by antifolate inhibitors in chemotherapy along with 
GARFTase.173, 174 
 
43 
 
 
4.1. Structure of AICARFTase 
          AICARFTase is highly conserved from E. coli to human but has no sequence 
homology with other folate-dependent enzymes, such as GARFTase.175 Thus, folate-
based inhibitors of GARFTase do not usually inhibit AICARFTase because of differential 
interactions within the two active sites.176 For example, lometrexol potently inhibits 
GARFTase but not AICARFTase.119, 177 
          Ian A. Wilson and coworkers174, 176, 178-180 have previously reported several crystal 
structures of human and avian ATIC (the bifunctional enzyme, aminoimidazole-4-
carboxamide ribonucleotide (AICAR) transformylase (AICARFTase)/IMP 
cyclohydrolase (IMPCH)) in both unliganded and complexed forms. The ATIC forms an 
intertwined symmetrical homodimer (each monomer being composed of 393 residues) 
with the IMPCH domain at the N terminus (residues 1–199) and the AICARFTase 
domain at the C terminus (residues 200–593). The IMPCH active sites are contained 
within each monomer of the dimer, but the AICARFTase active site is located at the 
dimer interface with key active-site residues being contributed from both monomers.  
 
4.2. AICARFTase catalytic mechanism  
          Because both transformylases (GARFTase and AICARFTase ) catalyze a similar 
chemical reaction, that is a transfer of a formyl group from the same cofactor, they were 
anticipated to have similar catalytic mechanisms. However, evidences implied that two 
enzymes might operate differently.173 (1) The amino acid sequence homology between 
the two transformylases is quite low. Although a similar grouping of amino acids (His, 
Asp, and Asn) that acts as a catalytic triad in GARFTase was also found in AICARFTase, 
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these amino acids are not the catalytic residues as revealed by mutation analysis.181 (2) 
The transformylation of AICAR by N10-formyldihydrofolate (N10-CHO-FH2; kinetically 
equivalent to N10-CHO-FH4) is an unfavorable reaction with a Keq of 0.024.
182 
AICARFTase is found as a domain of the bifunctional enzyme throughout all species 
characterized to date from E. coli to human, an arrangement that couples the unfavorable 
formation of FAICAR with the highly favorable cyclization reaction catalyzed by IMP 
CHase.173 (3) Previous studies on substrate analogues revealed that the amide moiety in 
AICAR is essential for formyl transfer, and its conformation is important in the binding 
to the enzyme active site. Wilson and coworkers182  proposed that the amide assists in the 
required proton shuttling from the 5-amino group to the N10 of the folate in the 
tetrahedral transition state. (4) A partially refined crystallographic structure of the 
bifunctional enzyme has indicated that Lys266 and His267 are two potentially important 
catalytic residues in the active site.173 Site-directed mutation of these residues to alanine 
were found to abolish the transformylase activity of the mutants, although they still retain 
binding affinity for AICAR.183 
            The catalytic mechanism of AICARFTase was evaluated with pH dependent 
kinetics, site-directed mutagenesis, and quantum chemical calculations.173 The result 
indicated that the amide-assisted mechanism is concerted such that the proton transfers 
from the 5-amino group to the formamide are simultaneous with nucleophilic attack by 
the 5-amino group. Because this process does not lead to a kinetically stable intermediate, 
the intramolecular proton transfer from the 5-amino group through the 4-carboxamide to 
the formamide proceeds in the same transition state. Collectively, these experimental and 
theoretical analyses lead to a proposed mechanism for AICARFTase catalysis shown in 
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Figure 12.  
 
   Figure 12 A proposed mechanism of AICARFTase.173 
          In this proposed mechanism, Lys266, with the aid of His267, acts as a general acid 
catalyst to interact with the N3 of the imidazole ring of AICAR. His267 aids Lys266 to 
be in the right position for a hydrogen-bonding interaction. The 4-carboxamide mediates 
proton shuttling from the 5-amino to 4-carboxamide and then to the nitrogen of the 
leaving group with simultaneous nucleophilic attack of the 5-amino group on the formyl 
group of folate cofactor. The first proton transfer is facilitated by the intramolecular 
hydrogen bond in the ground-state AICAR and the protonated 4-carboxamide species is 
only present transiently. The theoretical results suggest that protonation of the nitrogen of 
the leaving group is critical in the aminolysis reaction between AICAR and the formyl 
group rather than the nucleophilic attack on the carbonyl group. The central role assigned 
to proton transfer compensates for the weak nucleophilicity of the AICAR 5-amino group.  
 
4.3. Binding of AICARFTase inhibitors 
          AICARFTase is unique among folate-binding enzymes for several reasons:184 (1) 
Its most striking features are its “oxyanion hole” consisting of Lys266, Arg451, and its 
backbone amide in the center of the active-site cleft, and an additional helix dipole 
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consisting of residues 450-468 with its N-terminus pointing toward the “oxyanion hole”.  
      A.  
 B.  
Figure 13 Stereoview of folate cofactor and selected inhibitors binding to AICARFTase 
active site (PDB 1P4R).184 (A) AICARFTase active site. The lower ligand is the native 
AICAR substrate identified by X-ray crystallography. The upper ligand is the folate 
cofactor docked via AutoDock. (B) NSC37173 binds to the active site. The lower ball-
and-stick ligand is the crystallographic AICAR binding position. The upper ball-and-stick 
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ligand is the docked position of NSC37173 with AICAR present. The green stick model 
is the docked position of  NSC37173 without AICAR present (empty active site). 
 
          Considering the weak nucleophilicity of the 5-amino group of AICAR and the 
overall reaction direction favoring the reactants, this “oxyanion hole” is very likely to be 
particularly important for the stabilization of the transition state during the formyl 
transfer. Some AICARFTase inhibitors found in the virtual screening have either an 
“electron-rich” linker [-(O=)S(=O)-NH-, -(O=)S(=O)-O-, -C(=O)-NH-, or -C(=O)-O-] or 
an “electron-rich” terminal group (-SO3-) or both.184 This feature appears to be the most 
critical “hot spot” for future inhibitor design and is consistent with the crystal structures 
of ATIC complexed with the sulfonyl-containing antifolates.175 (2) The second important 
feature of the AICARFTase active site is its aromatic system composed of residues 
Phe316, Phe591, Phe544, and Phe541, which play a critical role in anchoring and 
orienting the substrate AICAR and folate cofactor for binding and catalysis.  
           As shown in the crystal structures and docking studies of the folate cofactor and 
NSC37173 (PDB 1P4R) (Figure 13), the aromatic stacking of Phe591, the imidazole of 
AICAR, the benzene of the folate, and Phe316 essentially “locate and orient” the 
enzyme-substrate-cofactor ternary complex for catalysis. Again, all of the inhibitors 
identified contain at least one aromatic moiety that mostly binds into the pterin binding 
pocket and stacks with Phe544, or more frequently, have two aromatic moieties linked by 
an “electron rich” linker. The second aromatic moiety interacts with Phe316 or Phe541 
depending on the “perturbation” from the rest of the inhibitors. Effective utilization of an 
aromatic system seems the second principle for AICARFTase inhibitor design. The above 
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two features may play a defining role in developing useful pharmacophores and in 
selecting useful novel scaffolds.184 (3) Unlike TS, DHFR, or GARFTase, AICARFTase 
does not undergo significant conformational change upon ligand binding.184 The most 
noticeable changes are for Arg207 side chain moving in for phosphate/sulfate binding, 
the Phe544/Phe316 side-chain rotations for aromatic modulation, and a slight “closing-
in” of the Pro543-Phe544-Arg545-Asp546 loop for a more constricted pterin pocket. 
From a drug designer‟s view, a more predictive behavior of the designed ligands and a 
more reliable free energy assessment should be expected with this type of “pre-formed” 
active site. However, the role of sequestered structural waters is difficult to predict. 
 
4.4. AICARFTase inhibitors 
 
a. BW1540 and BW2315 
 
Figure 14 AICARFTase inhibitors. 
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         Compared with the number of relatively potent inhibitors of GARFTase 
summarized before, specific inhibitors of AICARFTase have been scarce. However, 
Burroughs Wellcome (Research Triangle Park, NC) had designed and synthesized two 
antifolates that are specific (nM) for human AICARFTase, as compared with other folate-
dependent enzymes, GARFTase, DHFR, and TS.175 These compounds are both 
sulfamido-bridged 5,8-dideazafolate analogs identified as BW1540U88UD (BW1540) 
and BW2315U89UC (BW2315) (Fig. 14) that differ only in the disposition of the imido 
and sulfonyl groups within the bridge region. BW1540 and BW2315 have approximate Ki 
values against human ATIC of 8 and 6 nM, respectively, whereas the Ki values against 
GARFTase, DHFR and TS are within the micromolar range, except for BW1540, which 
showed low nanomolar inhibition against DHFR.
175
 Cytotoxicity assays against human 
colon cell lines yielded an approximate IC50 of 0.7–3 µM for BW1540 and 1–5 µM for 
BW2315 respectively. BW1540 and BW2315 were co-crystallized at 2.55 and 2.60 Å 
with human ATIC in the presence of substrate AICAR to elucidate their mechanism of 
inhibition. It was found both of these compounds bound to the AICARFTase  active site 
of ATIC and the sulfonyl groups dominate inhibitor binding and orientation through 
interaction with the proposed oxyanion hole. These agents then appear to mimic the 
anionic transition state and now implicate Asn431 in the reaction mechanism along with 
previously identified key catalytic residues Lys266 and His267. Moreover, interaction of 
the sulfonyl oxygens with the oxyanion hole of the AICARFTase active site suggests that 
it is the driving force behind the high affinity for these sulfonyl-containing antifolates 
(The Km of 10-f-THF is 100 µM
185
, whereas the Ki values for BW1540 and BW2315 are 
8 and 6 nM, respectively.
175
 Thus, these two antifolates bind more strongly to the 
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AICARFTase active site, by at least 1000-fold, than the natural co-factor N10-
formyltetrahydrofolate. This effect is probably due to the sulfonyl groups mimicking the 
oxyanion of the transition state perhaps with a stronger interaction.  
 
b. NSC37173 and NSC30171  
          Virtual screening of the human AICAR transformylase active site by use of 
AutoDock against the NCI diversity set, a library of compounds with nonredundant 
pharmacophore profiles, has revealed NSC30171, which had nanomolar inhibition (Ki = 
154 nM, IC50 = 600 nM), and NSC37173 (IC50 = 4.1 µM) against human 
AICARFTase.184 The human AICARFTase /BW1540 complex (PDB 1P4R) was selected 
as the docking template. NSC30171 was picked out via NSC37173 similarity searching. 
Enzymatic testing revealed that it is the most potent inhibitor found through virtual 
screening of this series of compounds (Ki = 154 nM and IC50 = 600 nM). Docking with 
and without AICAR substrate in the active site strongly indicates that this nonfolate 
competes with AICAR substrate for the AICAR binding site. Key interactions with the 
AICARFTase active site residues appear to be the electrostatic and H-bonding 
interactions between its sulfate and the enzyme “oxyanion hole”, and the aromatic 
stacking of the NSC30171 naphthalene ring with the Phe590 benzyl ring.  
 
c. TNP-351  
          TNP-351, characterized by a pyrrolo[2,3-d]pyrimidine ring, exhibits potent 
antitumor activities against mammalian solid tumors.186 The mechanism of action of 
TNP-351 was evaluated using methotrexate-resistant CCRF-CEM human lymphoblastic 
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leukemia cell lines as well as partially purified FPGS, AICARFTase, and GARFTase 
from parent CCRF-CEM cells. TNP-351 was found to significantly inhibit the growth of 
L1210 and CCRF-CEM cells in culture, with the doses effective against 50% of the cells 
(ED50 values) being 0.79 and 2.7 nM, respectively. The methotrexate-resistant CCRF-
CEM cell line, which has an impaired methotrexate transport, showed less resistance to 
TNP-351 than to methotrexate. Inhibitory activities of TNP-351 and its polyglutamates-
Gn (n=1–6) for AICARFTase were found to be significantly enhanced with increasing 
glutamyl chain length (inhibition constants (Ki): G1, 52 μM; G6, 0.07 μM). Neither TNP-
351 nor its polyglutamates were very potent GARFTase inhibitors.  
 
d. Pemetrexed (PMX, Alimta) 
          Pemetrexed (PMX) is currently in widespread clinical use as the first line therapy 
of mesothelioma and non–small cell lung cancer (NSCLC) and is also currently being 
evaluated for the treatment of a variety of other solid tumors in the US.187, 188  In 2009, 
PMX was approved in combination with cisplatin as a first-line treatment of patients with 
locally advanced or metastatic NSCLC, the first drug ever approved for this purpose.188   
Thymidylate synthase (TS) was identified originally as the primary intercellular target
189 
of PMX. However, it was clear from the start that PMX is a multitargeted antifolate that 
inhibit DHFR, GARFTase and AICARFTase in addition to TS.188  
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Figure 15  The folate-dependent steps of de novo purine synthesis and the site of entry of 
AICAR into the pathway.
190
   
 
        Although GARFTase was originally suggested to be an important secondary target 
of PMX, R.G. Moran and colleagues
190, 191
 suggested that AICARFTase (pemetrexed, Ki 
= 3 µM; polyglutamate pemetrexed, Ki = 0.26 µM against human AICARFTase) was 
likely a more important target for PMX than originally envisaged in the absence of TS. 
The substrate of the AICARFTase reaction, ZMP, accumulated in intact pemetrexed-
inhibited tumor cells (ZMP is an AMP mimetic and activator of AMPK) by 
AICARFTase inhibition. The ZMP accumulation causes an activation of AMP-activated 
protein kinase, which causes phosphorylation of AMPK target proteins and the 
subsequent inhibition of the mammalian target of rapamycin (mTOR) and 
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hypophosphorylation of the downstream targets of mTOR that control initiation of 
protein synthesis and cell growth. (Figure 15) 
 
Figure 16 Effects of PMX on activation of AMPK and inhibition of mTOR. Schematic 
diagram showing activation of AMPK by either AMP or ZMP that result in inhibition of 
mTOR and its downstream targets.
190
 
 
        It was also suggested that the activity of pemetrexed against human cancers is a 
reflection of its direct inhibition of folate dependent target proteins combined with 
prolonged inhibition of the mTOR pathway secondary to accumulation of ZMP. (Figure 
15)
190, 191
 Pharmacologic inhibition of mTOR with direct inhibitors is currently of 
substantial interest for cancer therapy, and current mTOR inhibitors have shown activity 
against human lung cancers.
192, 193
 Perhaps this indirect inhibition of pemetrexed to the 
mTOR pathway explains the activity of pemetrexed in lung cancers, an unusual pattern 
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for classical antifolates. However, whether AMPK activation offers a therapeutic 
advantage over direct mTOR inhibitors remains an open question. Although downstream 
effects on mTORC1 are involved in pemetrexed action, the spectrum of effects is not 
confined to mTORC1-dependent processes, and AICARFTase inhibitors represent a 
unique class of anticancer agents different from the rapamycin analogs. 
 
5. Dihydrofolate reductase (DHFR) 
Dihydrofolate reductase (DHFR) (EC 1.5.1.3) is a universal enzyme found in 
almost all organisms including: Pneumocystis jirovecii (P. jirovecii), Toxoplasma gondii 
(T. gondii), Mycobacterium avium complex (MAC) and cancer. DHFR inhibitors play a 
very important role in the treatment of cancer, as exemplified by MTX (Figure 5) in 
neoplastic diseases. 
Aminopterin (AMT) (Figure 5), is the first 2,4-diamino antifolate in the treatment 
of acute lymphoblastic leukemia (ALL). MTX, the N10-methyl analog of AMT, is widely 
used in clinical alone and in combination in the treatment of various forms of cancer, 
such as lymphoma, germ cell tumors, breast cancer and head and neck cancer.194 Both 
AMT and MTX differ from FA by the substitution of a 4-amino group for the 4-oxo 
group of the pteridine ring. This minor modification transforms the normal substrate into 
a very tight-binding inhibitor of DHFR. AMT and MTX have a highly basic 2,4-
diaminopyrimidine moiety in vitro and in vivo in the pteridine ring which is protonated 
and forms an ionic bond with the active site of the DHFR enzyme at the Glu30 and 
accounts, in part, for the high affinity of these compounds for DHFR.195 X-ray crystal 
structure demonstrates a different binding mode for MTX compared to the normal 
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substrate. While MTX was successful in cancer treatment, tumor resistance to MTX has 
developed. Two of the most common MTX resistance mechanisms are identified: 
decreased MTX transport (RFC) into tumor cells196-198 and an increase in DHFR due to 
gene amplification.198, 199 Other mechanisms include: decreased retention due to defective 
polyglutamylation (FPGS),200-202 decreased binding of MTX to DHFR because of DHFR 
mutation, increased translational of DHFR and increased breakdown of MTX 
polyglutamates.203, 204  
 
5.1. Structure of DHFR 
The first crystal structure of a DHFR enzyme was reported by Matthews in 
1977.205 Since then, X-ray crystal structures have been reported for complexes of the 
protein from various species (bacteria, avian and mammalian). The homology among 
vertebrate DHFR is 75-90% while only 25-40% in bacterial DHFR.206, 207 
DHFR is a monomeric protein containing 159-250 amino acids with a molecular 
weight in the range of 18000-22000 Daltons. It has a / structure with the core made up 
of eight-stranded -sheet consisting of seven parallel strands, and one antiparallel strand 
present at the C-terminal. It contains at least four -helices. Vertebrate DHFRs usually 
contain longer sequences (30 amino acid residues) with the additional amino acid 
residues accommodated in eight insertions into the loop regions connecting the elements 
of the secondary structure. The DHFR active site is located in a hydrophobic pocket (with 
the exception of Asp27 (E. coli DHFR) for bacterial enzyme or Glu30 in vertebrate 
DHFR) is 15 Å deep, which cuts across one face of the enzyme. The hydrophobic nature 
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of the active site indicates that hydrophobic and van der Walls interactions play an 
important role in cofactor or inhibitor binding. This hydrophobic pocket serves as a 
binding site for the substrate or the antifolates and the nicotinamide portion of NADPH. 
The polarity of the substrate binding site is complementary to the folate or inhibitors.208 
The pteridine ring and the glutamate side chain portions of the folate/antifolate are 
surrounded by backbone carbonyls and polar side chains, while the benzoyl moiety of the 
folate forms hydrophobic interactions with the side-chains of surrounding non-polar 
hydrophobic residues.208 
 
5.2. Catalytic mechanism of DHFR 
 
Figure 17 The catalytic mechanism of human DHFR.209, 210 
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As shown in Figure 17, there is an indirect proton transfer from Glu30 residue to 
the N5 atom of the substrate.209 In addition, W206 stabilizes Glu30 whereas W228 and 
W206 serve as a hydrogen atom channel from the Glu30 to the N5 of the pterin ring.209 
 
5.3. Ligand (inhibitor or cofactor) binding to DHFR 
 
Figure 18 Interaction of Glu30 with (a) dihydrofolate  and (b) MTX in the active site of 
human DHFR.208, 211 
 
MTX binds to DHFR in a conformation that the para-aminobenzoyl moiety is 
almost perpendicular to the pteridine moiety as observed in various crystal structures.208, 
211 A variety of evidence (spectroscopic,212, 213 calorimetric,213 theoretical and NMR214) 
strongly identified that N1 of MTX is protonated in the crystal structures. The Glu30 in 
human DHFR is ionized and forms an ionic bond with the protonated N1 of MTX (Figure 
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18). In addition to the ionic bond, the two oxygen atoms of Glu30 form hydrogen bonds 
with the 2-amino group and N1. This ionic (or salt bridge) bonding has been noted as a 
hallmark of all known potent DHFR inhibitors. It should also be noted that all DHFR 
inhibitors with a 2,4-diamino pyrimidine moiety such as pteridines, pyridopyrimidines, 
and quinazolines are bound in the similar mode as MTX. In contrast to the pyrimidine 
portion of the pteridine ring of MTX, the pyrazine portion is not directly bonded to 
DHFR. The para-aminobenzoyl moiety of MTX is surrounded by hydrophobic residues 
in the DHFR active site. The -carboxylate of the L-glutamate is involved in a reinforced 
ionic bond with the protonated guanidinium moiety of a conserved Arg57, while the -
carboxylate is nonspecific in its binding to the enzyme.208, 211  
Nonclassical antifolates also bind to DHFR using the same type of ionic bond as 
classical antifolate MTX. Lipophilic nonclassical antifolates have limited success as 
anticancer agents because of their low therapeutic selectivity and difficulty in 
pharmaceutical formulation related to solubility.215, 216 
 
5.4. DHFR inhibitors  
MTX217 (Figure 5) was first synthesized in 1949 and is still, together with the 
antibacterial drug TMP, the DHFR inhibitor most often used in clinic. The most common 
use of MTX is as an anticancer drug, but the drug is widely used as an anti-inflammatory 
and immunosuppressive agent with activity against autoimmune disorders.218 
The drug exists as a highly polar anion at physiological pH and enters the cells by 
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the energy-dependent RFC. Inside the cell the molecule is polyglutamylated, which leads 
to altered properties.  
Intrinsic and acquired resistance to MTX limits its efficacy in clinic. Resistance 
has been attributed to several different mechanisms including a reduced level of cellular 
uptake of the drug,219 and an increase in DHFR levels involved in folic acid metabolism. 
As mentioned, MTX is transported into cells by RFC. Consequently, the poor ability to 
transport the drug into the cell can be a source of natural resistance.220, 221 Major 
limitations, besides the resistance with MTX treatment, are bone marrow toxicity, 
gastrointestinal ulceration, and kidney and liver damage. In high doses, given 
intermittently, the adverse effect on the bone-marrow can be relieved by the periodic 
administration of leucovorin (LV), circumventing the MTX mediated blockade of 
tetrahydrofolic acid production (LV „rescue‟ procedure).222, 223  
Pralatrexate (Figure 5) was identified in 1990s.224 It was of interest in developing 
antifolates with greater therapeutic selectivity that could be more effectively internalized 
into tumors (transported into the cells through RFC) and would be more toxic to cancer 
cells than normal cells. This led to the discovery of pralatrexate, which was approved as a 
treatment for relapsed or refractory peripheral T-cell lymphoma by FDA in 2009.225 
Lipophilic nonclassical antifolates have been developed in an attempt to 
circumvent the mechanisms of resistance, such as decreased active transport, decreased 
polyglutamylation, DHFR mutations. These nonclassical antifolates differ from the 
traditional classical analogs by increased potency, greater lipid solubility, or improved 
cellular uptake. Although they are effective inhibitors, problems still remain with respect 
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to the toxicity due to the lack of selectivity for tumors. 
6. Thymidylate synthase (TS) 
           Thymidylate synthase (TS) is present in almost all living organisms including 
bacteria, DNA viruses and protozoa.226 TS is a macromolecular homodimeric enzyme that 
catalyzes the reductive methylation of dUMP to dTMP which is further phosphorylated to 
thymidine-5‟-diphosphate (dTDP) and thymidine-5‟-triphosphate (dTTP). The dTTP 
formed is utilized by DNA polymerase and is incorporated into DNA. The TS catalyzed 
reaction is a key step in DNA biosynthesis and the only de novo biosynthetic pathway to 
dTMP. TS inhibition results in a thymineless state, which prevents the growth of actively 
dividing cells.227-229 This effect is probably due to increased DNA fragmentation resulting 
from dTTP depletion, which increases misincorporation of 2‟-deoxyuridine-5‟-
triphosphate (dUTP). TS has long been regarded as an important target in cancer 
chemotherapy, and antimetabolites have been developed that inhibit at both the dUMP as 
well as the folate cofactor (antifolates) binding site.  
 
6.1. Structure of TS 
Thymidylate synthase (TS) enzymes are highly conserved evolutionary both in 
terms of structure and mechanism.226 The active Thymidylate synthase (TS) enzyme is a 
homodimer consisting of two identical subunits of about 35000 Dalton each, and contains 
about 316 amino acids. The primary structure of TS from thirty species is highly 
conserved: approximately 27 amino acids are completely conserved.226 The crystal 
structures of PMX and RTX with human TS have also been obtained.230, 231 Several 
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crystal structures of TS complexed with substrates and inhibitors have also been 
reported.232-236 These crystal structures are important in understanding both the 
mechanism and inhibition of TS and provide useful insights for structure based rational 
drug design. 
    
6.2. Catalytic mechanism of TS 
          Binding of substrate and cofactor to Thymidylate synthase (TS) proceeds in an 
ordered fashion with sequential binding of substrate (dUMP) followed by cofactor 
(N5,N10-CH2-THF), which induces a conformational change to form a noncovalent 
ternary complex (TS-dUMP-cofactor).237 The substrate dUMP is activated at the C5 
position by a nucleophilic attack on the C6 of the uracil ring of dUMP by a catalytic 
sulfhydryl moiety Cys195 of human TS which results in the formation of a Michael-type 
adduct 16 (Figure 19). 
62 
 
 
 
Figure 19 The catalytic mechanism of human TS.237 
 
               N10 protonation changes the cofactor from an inactive tricyclic form to the 
active bicyclic form 17 in which the cofactor N5,N10-CH2-FH4 is in the iminium ion form 
at N5. This results in the transformation of the noncovalent ternary complex into an 
unstable covalent ternary complex. The activated C5 of Michael-type adduct is then 
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trapped by the N5-iminium ion of the reduced cofactor to form intermediate 18. The 
proton at the C5-position of dUMP is abstracted by a yet unidentified base in the active 
site. The enzymatic reaction is completed by the reduction of the methylene of 20 via 
hydride transfer from C6 of the reduced cofactor 21, which is simultaneously oxidized at 
the N5C6 bond to form FH2. At the same time -elimination of the sulfhydryl anion 
from C6 in 22 occurs to reform the double bond affording the product, dTMP which is 
then released from the active site. 
 
6.3. Binding of TS inhibitors. 
The crystal structure of the ternary complex of human TS with dUMP and PMX 
has been solved at 1.9 Å resolution. PMX is a 6-5 fused TS inhibitor with the 
pyrrolo[2,3-d]pyrimidine instead of  6-6 fused pteridine or quinazoline rings of other 
antifolates (Figure 20).231  The ternary structure of human TS-dUMP- PMX reveals that 
PMX is anchored in the active site by aromatic stacking between the fused pyrrolo[2,3-
d]pyrimidine ring system and the dUMP pyrimidine ring. In addition to the hydrogen 
bond between the donor exocyclic amino group (N10) of PMX to Ala312 O, there is 
another between the donor amino group (N3) of PMX and the O of Asp218.  
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Figure 20 The interactions in the complex of hTS-dUMP-PMX.231  
 
A conserved water molecule (Wat330) donates a hydrogen bond to the acceptor 
N1 of the pyrrolo[2,3-d]pyrimidine ring, and donates another to either the Ala312 O atom 
or to Val313 O. Wat330 is surrounded in a tetrahedral arrangement by these two acceptors 
and two hydrogen bond donors (Arg50 -NH, and Asn112 -NH), enabling the water 
molecule to completely satisfy its hydrogen bonding potential. An additional specific 
hydrogen bond is also observed between the donor N7 H of PMX and O atom of Asn112.  
 The PABA ring of PMX is surrounded by hydrophobic side-chains: Ile108, 
Leu221, Phe225 and Met311. This hydrophobic environment provides several favorable 
interactions important to the tight binding of folate-based inhibitors. The negatively 
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charged glutamic acid tail occupies a shallow, positively charged groove on the enzyme 
surface. The Glu carboxyl group interacts with the highly conserved Lys77 –N atom, and 
may form water-mediated hydrogen bonds to this group, as in other TS inhibitors.  
 
6.4. TS inhibitors  
PDDF238, 239 (Figure 5) was the first quinazoline TS inhibitor to be tested 
clinically. Although PDDF was active in phase I, it resulted unpredictable and 
unacceptable renaltoxicity and hepatotoxicity which resulted in a discontinuation of any 
further clinical studies. The poor solubility, largely attributed to the presence of the 2-
amino group in PDDF, probably caused the drug to precipitate within the renal tubules.  
RTX240 (Figure 5), the third generation analog of PDDF, was found to be more 
water soluble at low pH and has no significant renal toxicity. RTX is a TS inhibitor and is 
a good substrate for FPGS. Once polyglutamylated, RTX is more than 100-fold more 
potent as an inhibitor of TS than the monoglutamylated drug. RTX is currently approved 
for clinical use in Europe and Japan.  
PMX241 (Figure 5), an antifolate originally developed as a TS inhibitor, is a 
multitargeted agent, which possesses a 6-5 fused pyrrolo[2,3-d]pyrimidine instead of the 
more common 6-6 fused pteridine or quinazoline ring structure. Preliminary studies187, 242 
revealed that PMX polyglutamates are not only potent inhibitors of TS but also of 
AICARFTase , DHFR and GARFTase. PMX has been approved by FDA for the 
treatment of malignant pleural mesothelioma in combination with cisplatin and recently 
in non small lung cancer in the United States and has provided a renewed interest in the 
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development of classical antifolates as antitumor agents.  
Plevitrexed243 (Figure 5) is classical compound that does not depend on FPGS for 
its activity, however it uses the RFC system for its entry into the cell. This compound 
resulted from a series of studies aimed at developing water-soluble, 
nonpolyglutamylatable TS inhibitors.  
 
7. Multiple targeted antifolates in combinational anticancer chemotherapy 
            It has been of interest not only to design potent antifolates against specific 
enzymes of DHFR, TS, GARFTase and AICARFTase but also to design and synthesize 
single agents that have potent multiple inhibitory activity against these enzymes.244, 245 
This strategy is particularly promising in anticancer chemotherapy against the multiple 
drug resistant cancers. Such a single agent could act at more than one active site and 
provide “combination chemotherapy” benefits including: circumvent the pharmacokinetic 
problems of multiple agents, avoid of drug-drug interactions, used at lower doses to 
alleviate toxicity, devoid of overlapping toxicities, and most importantly delay or prevent 
cancer drug resistance.246-248 Other advantages of such single agents are in the reduced 
cost and increased patient compliance. In addition, the clinical success of pemetrexed 
provides a good example of multiple targeted antifolates used in combinational anticancer 
chemotherapy. 244, 245, 249, 250 
        As summarized before, PMX is a multitargeted antifolate (MTA) that inhibit DHFR, 
GARFTase and AICARFTase in addition to TS, which is the primary intracellular target.  
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The clinical success of pemetrexed has generated renewed interest in the design of single 
agents that function as multitargeted inhibitors against more than one target. 
It has been our long-standing goal to design and synthesize single agents that are potent 
multitargeted inhibitors against folate metabolism enzymes.  
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II. CHEMICAL REVIEW 
The chemistry related to the present work is reviewed and includes synthetic 
approaches to the following heterocyclic systems and relevant reactions: 
1. Synthesis of pyrrolo[2,3-d]pyrimidines 
2. Sonogashira coupling in antifolate synthesis 
3. Heck coupling reaction in one-step aldehyde synthesis 
 
1. Synthesis of pyrrolo[2,3-d]pyrimidines 
A large quantity of literature has been disclosed for the synthesis of pyrrolo[2,3-
d]pyrimidines because of their application as deazapurine analogs. The synthetic 
strategies to this 6-5 bicyclic ring system have three general classifications from: 
1. furan precursors  
2. pyrimidine precursors 
3. pyrrole precursors 
 
1.1. From furan precursors  
 
Scheme 1 Synthesis of 2,5,6-trisubstitutedpyrrolo[2,3-d]pyrimidines 27. 
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        Taylor and coworkers251 reported a general method to 2,5,6-trisubstituted-4-amino-
pyrrolo[2,3-d]pyrimidines 27 in 1995 (Scheme 1). Condensation of appropriate -
hydroxyketones 23 with malonodinitrile 24 afforded the corresponding 2-amino-3-
cyanofurans 25 which on cyclization with amidines 26 afforded the corresponding 2,4-
diamino-pyrrolo[2,3-d]pyrimidines 27 by an unexpected ring transformation/ring 
annulation sequence. 
 
1.2. From pyrimidines precursors 
 
Scheme 2 Synthesis of pyrrolo[2,3-d]pyrimidines 30 and 32. 
Noell and Robins252 first reported in 1964 the synthesis of pyrrolo[2,3-
d]pyrimidines 30 and 32 by the reaction of chloroacetaldehyde 29 with 2-amino-6-
alkylamino-4-hydroxypyrimidines 28 and 6-amino-1,3-dimethyluracil, 31 respectively 
(Scheme 2).  
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Scheme 3 Synthesis of pyrrolo[2,3-d]pyrimidine 34. 
In the same report, Noell and coworkers252 also reported the synthesis of 
pyrrolo[2,3-d]pyrimidine 34 from 2-methylthio-6-amino-4-pyrimidone 33 and 
chloroacetaldehyde 29 (Scheme 3). 
Scheme 4 Synthesis of pyrrolo[2,3-d]pyrimidines 40. 
Gibson et al.253 reported in 1998 a synthetic approach to prepare 2-amino-4-oxo-
pyrrolo[2,3-d]pyrimidines 40 (Scheme 4). In this report, 2,6-diamino-4-
hydroxypyrimidine 35 was reacted with a biselectrophile, an oxime 36, in the presence of 
a weak base (sodium carbonate, sodium acetate, or triethylamine) to afford the C-5 
alkylated pyrimidine derivatives 38. No side products resulting from substitution at any 
other position were isolated. Cyclization of pyrimidine derivatives 38 at 120 C under 
acid-catalyzed transoximation with benzaldehyde or acetaldehyde 39 afforded substituted 
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pyrrolo[2,3-d]pyrimidines 40. 
 
Scheme 5 Synthesis of furo[2,3-d]pyrimidines 42 and pyrrolo[2,3-d]pyrimidines 43. 
Fumio et al.254 reported in 1973 that the reaction of 6-amino-1,3-dimethyluracil 
31 with phenacyl bromides 41 in DMF afforded 1,3-dimethyl-6-phenylpyrrolo[2,3-
d]pyrimidines 43 in 69-74% yields (Scheme 5). The reaction of 31 and 41 in acetic acid 
afforded 1,3-dimethyl-5-phenylfuro[2,3-d]pyrimidine-2,4(1H,3H)-diones 42 as a by-
product.   
         Secrist and Liu255 provided a detailed study of the reaction of 2,6-diamino-4-
hydroxypyrimidine 35 with various -halo aldehydes and ketones (Scheme 6) in 1978. 
They reported that the cyclization occurred via two different modes to produce either the 
pyrrolo[2,3-d]pyrimidine and/or the furo[2,3-d]pyrimidine. Thus -halo ketones, 
chloroacetone 44 and 3-bromo-2-butanone 45, afforded both the furo[2,3-d]pyrimidine 47 
and the pyrrolo[2,3-d]pyrimidine 46, whereas 45 afforded only the pyrrolo[2,3-
d]pyrimidine 46 on reaction with 35. It was concluded that a critical electron density is 
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necessary at the C5 of the pyrimidine nucleus for it to react with the -carbon atom of the 
-halo aldehydes or ketones to afford exclusively pyrrolo[2,3-d]pyrimidines.  
 
Scheme 6 Synthesis of pyrrolo[2,3-d]pyrimidines 46 and furo[2,3-d]pyrimidines 47. 
 
 
Scheme 7 Synthesis of pyrrolo[2,3-d]pyrimidines 51. 
Davoll and coworker256 reported in 1960 the synthesis of various pyrrolo[2,3-
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d]pyrimidines 51 (Scheme 7) by an acid mediated cyclization of suitable pyrimidine 5-
acetone or acetaldehyde side-chains onto the neighboring amino group. The pyrimidines 
were obtained from the acetals ethyl(2,2-diethoxyethyl)acetate 48, or 2,2-
diethoxyethylmalonodinitrile, or their ketal derivatives respectively and cyclization with 
guanidine, urea or thiourea 49. 
 
Scheme 8 Synthesis of 2-amino-4-methyl pyrrolo[2,3-d]pyrimidine 57. 
Gangjee and coworkers257 reported in 2000 the synthesis of 2-amino-4-methyl-
pyrrolo[2,3-d]pyrimidine 57 (Scheme 8) via a novel ring closure method. The synthesis 
started with condensation of 2-acetylbutyrolactone 52 with guanidine carbonate 26 to 
afford the substituted pyrimidine 53. Chlorination with POCl3 provided the dichloro 
compound 54 which was in turn condensed with benzylamine to afford 2-amino-4-
methyl-7-(N-benzyl)piperidinyl[2,3-d]pyrimidine 55. Oxidative aromatization of this 
compound with MnO2 provided the N
7
-benzylated compound 56. Compound 57 was 
afforded following debenzylation of 56 with metallic sodium in ammonia. 
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Scheme 9 Synthesis of 2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-6-
yl)acetic acid 59. 
Gangjee and coworkers258 reported in 2001 the synthesis of 2-(2-amino-4-oxo-
4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-6-yl)acetic acid 59 from the condensation of 
2,6-diaminopyrimidin-4(1H)-one 35 with ethyl 4-chloro-3-oxobutanoate 58 in the 
presence of sodium acetate (Scheme 9). 
 
Scheme 10 Synthesis of 2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidine-5-
carbonitrile 61. 
In another report of 2001, Gangjee and coworkers259 also reported the synthesis of 
2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 61 (Scheme 10) 
from the condensation of compound 35 with 2-chloro-3-oxopropanenitrile 60 under basic 
conditions. 
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Scheme 11 Synthesis of 2,4-diamino-5-arylalkyl substituted pyrrolo[2,3-d]pyrimidine 66. 
Miwa and coworkers260 reported in 1991 the synthesi of a series of 2,4-diamino-5-
arylalkyl substituted classical pyrrolo[2,3-d]pyrimidine antifolates (Scheme 11).  In this 
report, the ring system was constructed by the condensation of guanidine 26 and the 
malonodinitrile derivative 63. The resulting lactam 64 was subjected to borane reduction 
to provide the pyrrolo[2,3-d]pyrimidine intermediate 66 along with its 5,6-dihydro analog 
65, which were separated by flash chromatography in 45% and 46% yields, respectively.  
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Scheme 12 Synthesis of 5-substituted pyrrolo[2,3-d]pyrimidine 70. 
          Miwa and coworkers260 reported in 1993 a synthesis of pemetrexed utilizing the 
spontaneous cyclization of 6-amino-5-pyrimidylacetaldehyde for the synthesis of 
pemetrexed (Scheme 12). The synthesis of the acetal protected aldehyde 68 was a photo-
initiated free radical addition of ethyl bromocyanoacetate to the corresponding enol ether 
67. The reaction of the enol ether 67 with ethyl bromocyanoacetate in methanol under 
UV irradiation regioselectively afforded the acetal functionalized ethyl cyanoacetate 68. 
Condensation of 68 and guanidine at reflux provided the acetal protected 6-amino-5-
pyrimidylacetaldehyde 69. Acid catalyzed deprotection of the dimethyl acetal and t-butyl 
moieties of 69 afforded 4-[2-(2-amino-4-oxo-pyrrolo[2,3-d]pyrimidin-5-yl)-ethyl]-
benzoic acid 70. Conversion of acid 70 to pemetrexed involved a standard peptide 
coupling with diethyl L-glutamate and final saponification.    
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Scheme 13 Synthesis of PMX from 6-amino-5-pyrimidylacetaldehydes 74. 
Taylor and coworker261 reported in 1999 a concise synthesis of PMX (Scheme 13) 
which involved the spontaneous cyclization of 6-amino-5-pyrimidylacetaldehydes 74 
which was generated utilizing the Nef reaction with compound 73 onto the adjacent 
amino group. 2,4-Diamino-6-oxo-pyrimidine, 35 was known to form Michael adducts at 
its unsubstituted C-5 position.262-266 The synthesis of 60 thus involved a Michael addition 
reaction between 35 and the Michael acceptor 72, which was synthesized in three steps 
that involved a palladium-catalyzed cross-coupling267 between methyl 4-iodobenzoate 71 
and allyl alcohol, aldol condensation with nitromethane followed by dehydration with 
methanesulfonyl chloride in the presence of triethylamine.268 As expected, the 
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condensation afforded the nitro derivative 73 in high yield. Compound 73 was then 
converted to 4-[2-(2-amino-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl]ethylbenzoic acid 70 
by the Nef reaction in a one-pot, five-step procedure. Conversion of acid 70 to 
pemetrexed involved a standard peptide coupling with diethyl L-glutamate using 2-
chloro-4,6-dimethoxy-1,3,5-triazine as the activating agent in presence of N-
methylmorpholine and final saponification.    
Scheme 14 Synthesis of PMX from α-bromo aldehyde 78. 
        Barnett and coworker  also reported269 in 1999 a practical synthesis of PMX 
(Scheme 14) which involved the cyclization of 2-bromo-4-arylbutanal 78 with 2,4-
diamino-6-oxo-pyrimidine 35 regioselectively provided 5-substituted pyrrolo[2,3-
d]pyrimidine 79 as shown in Scheme 14. The key intermediate α-bromo aldehyde 78 was 
synthesized from aryl bromide 75 and alkyne 76 with Sonogashira coupling followed by 
reduction of the triple bond, oxidation to aldehyde and corresponding bromination of the 
aldehyde 78. 
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Scheme 15 Synthesis of 7-substituted pyrrolo[2,3-d]pyrimidines 86. 
Legraverend and coworkers270 reported in 1985 the synthesis of pyrrolo[2,3-
d]pyrimidines 86 from 2-amino-4,6-dichloro-5-(2,2-diethoxyethyl)pyrimidine 83 
(Scheme 15). Thus, 5-allyl-2-amino-4,6-dihydroxypyrimidine 80, prepared by the 
reaction of guanidine hydrochloride with diethyl allylmalonate, was converted to the 4,6-
dichloro derivative 81 by reacted with POCl3, and diethylaniline in the presence of PCl5. 
The (2-amino-4,6-dichloropyrimidin-5-yl)acetaldehyde 82 was afforded from 81 by 
ozonolysis of the allyl group (Scheme 15). The diethylacetal 83 was prepared from its 
aldehyde 82 by using standard methods. The acetal 83 was cyclized to 2-amino-4-chloro-
7-alkyl-7H-pyrrolo-[2,3-d]pyrimidine 85 by reacted with dilute aqueous HCl at room 
temperature.  Final compound 86 was then obtained by hydrolysis of the 4-chloro group 
of 85 using 1 N HCl at 100 C. 
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Scheme 16 Synthesis of pyrrolo[2,3-d]pyrimidines 90. 
Sakamoto and coworkers271 reported in 1993 the synthesis of pyrrolo[2,3-
d]pyrimidines 90 by utilizing an intramolecular cyclization of protected 5-acetaldehyde 
pyrimidines 89 (Scheme 16). Compounds 89 were synthesized by palladium (0) catalyzed 
coupling of the appropriate 2,4-disubstituted-5-bromo-6-acetamido pyrimidine 87 with 
(Z)-1-ethoxy-2-(tributylstannyl)ethane 88. The same methodology was also applicable for 
the synthesis of pyrrolo[3,2-d]pyrimidines, except that, 5-acetylamino-4-iodopyrimidine 
was used as the starting material. 
 
Scheme 17 Synthesis of 4-methyl pyrrolo[2,3-d]pyrimidines 93. 
Kondo et al.272 reported the synthesis of 4-methyl pyrrolo[2,3-d]pyrimidine 93 via 
a palladium(0) catalyzed cross-coupling of terminal acetylenes 92 with N-(5-halo-4-
pyrimidinyl)methane sulfonamides 91 (Scheme 17).  
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Scheme 18 Synthesis of 2,4-dimethyl pyrrolo[2,3-d]pyrimidines 99. 
In the same report, Kondo and coworkers272 also reported the synthesis of 2,4-
dimethyl pyrrolo[2,3-d]pyrimidine 99 via a photoinduced or thermal cyclization of 4-
azidopyrimidines 98 containing an olefinic functionality at the 5-position (Scheme 18). 
Intermediates 98 were obtained by a palladium catalyzed cross-coupling between the 5-
iodopyrimidine 94 and appropriate stannanes 95, followed by nucleophilic displacement 
of the 4-chloro in pyrimidine 97 in the presence of sodium azide.  
 
Scheme 19 Synthesis of pyrrolo[2,3-d]pyrimidines 101 via Fischer indole cyclization. 
Another report employed the Fischer indole cyclization of 4-
pyrimidinylhydrazones 100 (Scheme 19) to afford the pyrrolo[2,3-d]pyrimidine ring 
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system 101.273-277 The applicability of the Fischer-indole cyclization to the synthesis of 
pyrrolo[2,3-d]pyrimidines, however,  is limited by the high reaction temperature and the 
steric constraints for the [3,3] sigmatropic rearrangement involved in the mechanism.  
 
1.3. From Pyrroles 
 
Scheme 20 Synthesis of 4-amino-5-cyanopyrrolo[2,3-d]pyrimidine 107. 
Taylor and coworkers278 reported in 1965 the synthesis of 4-amino-5-cyano-
pyrrolo[2,3-d]pyrimidine 107 (Scheme 20) starting from the tetracyanoethylene 102 via 
2-mercapto-3,4-dicyano-5-aminopyrrole 104.279 Reaction of 104 with 
triethylorthoformate followed by ammonia (as shown in route A) resulted in the 
formation of a formamidine intermediate which then cyclized to 106. The mercapto group 
of 106 could be removed by Raney nickel to afford 107. Formamidine acetate 105 also 
condensed with 104 to give 106 but in lower yields as shown in route B. 
83 
 
 
 
Scheme 21 Synthesis of 4-amino-5-substituted pyrrolo[2,3-d]pyrimidines 112. 
     In the same report, Taylor and coworkers278 also reported synthesized 4-amino-
5-methyl-pyrrolo[2,3-d]pyrimidine 112 (R = CH3, C6H5) (Scheme 21) from 2-amino-3-
cyano-5-substituted pyrroles 111 which were obtained from malonodinitrile 109 and the 
appropriate -aminoketones 108. Treatment of pyrrole 110 with triethylorthoformate 
followed by ammonia resulted in a failure to afford the desired pyrrolo[2,3-d]pyrimidine 
110. The fact that pyrroles 110 did not cyclize to pyrrolo[2,3-d]pyrimidine 112 in 
ethanolic ammonia was attributed to the absence of the second nitrile.    
 
Scheme 22 Synthesis of 5,6-disubstitutedpyrrolo[2,3-d]pyrimidine 114. 
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Tolman and coworkers280 reported in 1968 the synthesis of pyrrolo[2,3-
d]pyrimidine 114 by cyclization of 2-amino-5-bromo-3,4-dicyanopyrrole 113 with 
formamidine acetate 91a (Scheme 22). Ramasamy and coworkers281 also utilized the 
pyrrole 105 to form the pyrrolo[2,3-d]pyrimidine ring system for use in nucleoside 
synthesis. Swayze and coworkers 282 reported the synthesis of the versatile pyrrole 113 in 
an efficient one-step reaction from tetracyanoethylene 102. On controlled addition of HBr 
in acetic acid, 113 undergoes an intramolecular self-condensation to afford 114.  
 
Scheme 23 Synthesis of 2,5,6-trimethyl pyrrolo[2,3-d]pyrimidine 118. 
Eger and coworkers283, 284 reported in 1987 the synthesis of 2,5,6-trimethyl 
pyrrolo[2,3-d]pyrimidine 118 (Scheme 23) from 1-(1-phenylethyl)-2-amino-3-cyano-4,5-
dimethylpyrrole 117 by heating with a mixture of acetonitrile and sodium methoxide. The 
pyrrole 117 was obtained by cyclocondensation of 3-hydroxy-2-butanone 115, 1-phenyl-
ethylamine 116 and malonodinitrile 109. 
Chen and coworkers285 reported an efficient synthesis of pyrrolo[2,3-d]pyrimidine 
125 (Scheme 24): Acetone 119 was condensed with malonodinitrile 109 to afford 120. 
Bromination of 120 by NBS and benzoyl peroxide in chloroform afforded 121; 
Cyclization of 121 with aryl amine 122 afforded the substituted pyrrole intermediate 123. 
Compound 123 was then elaborated to the pyrrolo[2,3-d]pyrimidine 125. 
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Scheme 24 Synthesis of 2,5,-dimethyl-N7-substitutedpyrrolo[2,3-d]pyrimidine 125. 
 
Scheme 25 Synthesis of 2,5-dimethyl pyrrolo[2,3-d]pyrimidine 130. 
Girgis and coworkers286 reported in 1985 the synthesis of 2,5-dimethyl 
pyrrolo[2,3-d]pyrimidine 130 (Scheme 25) from 2-acetylamino-3-cyano-4-methylpyrrole 
129 by heating with 85% phosphoric acid. The pyrrole 129 was obtained by acetylation 
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of 2-amino-3-cyano-4-methylpyrrole 128 with acetic anhydride. Cyclocondensation of 
126 or 127 with malonodinitrile 109 by sodium hydroxide afforded the precursor pyrrole 
128.287, 288 
Scheme 26 Synthesis of N7-substituted analogs of PMX 138.  
Taylor and coworkers289 reported in 2001 the synthesis of a pyrrolo[2,3-
d]pyrimidine analog of PMX 138 by a novel route (Scheme 26). A manganic triacetate 
dihydrate catalized radical cyclization of racemic methyl N-crotyl-N-[1-(3,4-phenyl)-eth-
1-yl)malonamide 135, afforded a diastereomeric mixture of the 3-carbomethoxy-2-
pyrrolidinone 136.290 Compound 135 was afforded by alkylation of racemic 1-(3,4-
dimethoxy-phenyl)-ethylamine 131 with crotyl bromide 132 followed by a DMAP 
catalyzed acylation with methyl malonyl chloride 134. The pyrrolidinone 136 was 
converted to the thiolactam 137 with P2S5 followed by cyclocondensation with guanidine 
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to afford the N7-protected 5,6-dihydro-5-allyl-pyrrolo[2,3-d]pyrimidine 138 successfully. 
This compound was then elaborated to afford analogs of PMX. 
 
Scheme 27 Synthesis of PMX via a guanidine cyclization. 
Barnett and coworkers291 reported in 1993 the synthesis of a 2-amino-4-oxo-5,6-
dihydropyrrolo[2,3-d]pyrimidine 142 via a guanidine cyclization of a preformed 3-
carbethoxy-2-thiopyrrolidine intermediate 141 as the key step (Scheme 27). This 
intermediate 141 was prepared in several steps from 4-propionaldehyde benzoic acid tert-
butyl ester 139. Compound 142 was oxidized to the pyrrolo[2,3-d]pyrimidine 
intermediate 143, which was then elaborated to PMX in several steps. 
88 
 
 
 
Scheme 28 Synthesis of 2-methyl-4-amino-pyrrolo[2,3-d]pyrimidine 145. 
Dave and coworkers292 reported in 1980 a general procedure for the synthesis of 
condensed pyrimidines. The condensation between acetonitrile and substituted pyrrole 
144 (scheme 28) under HCl (g) condition afforded 2-methyl pyrrolo[2,3-d]pyrimidine 
145 in 60% yield. 
 
Scheme 29 Synthesis of 5-substituted 2-des-4-oxo-pyrrolo[2,3-d]pyrimidine 148. 
Bookser and coworkers293 reported in 2005 the synthesis of pyrrolo[2,3-
d]pyrimidine 148 (scheme 29) via the condensation between substituted pyrrole 146 and 
triethylorthoformate 147 under acidic conditions.  
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2. Sonogashira coupling in antifolate synthesis 
 
 
Scheme 30 A general transformation of Sonogashira coupling.294, 295 
 
Sonogashira and coworkers296  reported in 1975 the synthesis of symmetrically 
substituted alkynes via a coupling reaction between acetylene gas and aryl iodides or 
vinyl bromides in the presence of catalytic amounts of Pd(PPh3)Cl2 and CuI under mild 
conditions (Scheme 30). Thus, the copper-palladium catalyzed coupling of terminal 
alkynes with aryl and vinyl halides to give enynes is named the Sonogashira cross-
coupling. Typically, two catalysts, a zerovalent palladium complex and a halide salt of 
copper (I), are necessary for the reaction. Copper (I) salts, such as copper (I) iodide, react 
with the terminal alkyne and produce a copper (I) acetylide, which acts as an activated 
species to increase the rate of the coupling reactions.294 However, the copper-free 
Sonogashira coupling of aryl iodides with terminal acetylenes has been developed 
recently.297-300 The Sonogashira coupling reaction also requires a base to neutralize the 
hydrogen halide produced as the byproduct of this coupling reaction. The reactivity order 
of the aryl and vinyl halides is as: I ≈ OTf > Br >> Cl.294, 295 
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Scheme 31 Mechanism of Sonogashira cross-coupling.301 
Sonogashira coupling is believed to involve oxidative addition-reductive 
elimination pathway (Scheme 31), although the mechanism is not clearly understood. 
  
Scheme 32 Synthesis of N-(7-benzyl-4-methyl-5-(phenylethynyl)-7H-pyrrolo[2,3-
d]pyrimidin-2-yl)-N-pivaloylpivalamide 151. 
 
Gangjee coworkers reported302 in 2007 the synthesis of N-(7-benzyl-4-methyl-5-
(phenylethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-N-pivaloylpivalamide 151 from N-(7-
benzyl-5-iodo-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-N-pivaloylpivalamide 149 and 
phenylacetylene 150 via a Sonogashira cross-coupling in the presence of 
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tetrakis(triphenylphosphine)palladium(0) and CuI as catalysts in dichloromethane 
(Scheme 32).
 
Scheme 33 Synthesis of classical 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]-
pyrimidines by Sonogashira coupling.113 
 
In 2010, Wang and Gangjee et al. 113 reported the synthesis of classical 2-amino-4-
oxo-6-substituted-pyrrolo[2,3-d]-pyrimidines 154a-c (Scheme 33) from terminal alkynes 
152a-c and thiophenyl bromide 153 via a Sonogashira cross-coupling in the presence of 
tetrakis(triphenylphosphine)palladium(0) and CuI as catalysts in DMF (Scheme 33). 
 
3. Heck coupling reaction in one-step aldehyde synthesis 
 
 
Scheme 34 General transformation of Heck coupling. 
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          The Heck coupling reaction (also called the Mizoroki-Heck reaction) is the 
chemical reaction of an aryl or vinyl halide (or triflate) with an alkene and a base and 
palladium catalyst to form a substituted alkene.
303, 304
 Together with the other palladium-
catalyzed cross-coupling reactions, this reaction is of great importance in modern organic 
synthesis as reviewed.
305-307
 Richard F. Heck was awarded the 2010 Nobel Prize in 
Chemistry for the discovery and development of this reaction. A General transformation 
of Heck coupling is shown in Scheme 34. 
 
Scheme 35 Heck coupling to synthesis aldehyde 157. 
 
          From the very beginning of Heck coupling, Heck disclosed in 1968 the formation 
of 3-aryl aldehydes and ketones by the reaction of primary and secondary allylic alcohols 
with aryl palladium complexes prepared in situ from arylmercuric chlorides or acetates 
and either an equimolecular amount of a palladium (II) salt, or a catalytic amount of this 
salt with an equimolecular amount of copper (II) chloride to regenerate the palladium 
after each reaction cycle.
308
 The teams of Heck and Chalk reported in 1976 
simultaneously, but independently, a strong improvement in these couplings by 
disclosing that such compounds are also obtained using aryl iodides or bromides and, 
furthermore, with a catalytic amount of a palladium catalyst (Scheme 35).
309, 310
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As shown in Scheme 35, this reaction was carried out with catalytic amount of palladium 
acetate at 100 C in MeCN for 0.5 hour to afford aldehydes 157 with good yield (60%) 
from phenyl iodide 155 and allyl alcohol 156.309, 310 This kind of Heck coupling reactions 
with unsaturated alcohols has been widely used to synthesize aldehydes from aryl halides 
in one step reaction.
305-307
  
 
Scheme 36 A proposed mechanism of Heck coupling to synthesis aldehyde 157. 
 
        A possible mechanism of this Heck coupling to synthesize aldehydes 157 from 
phenyl iodide and allyl alcohol was proposed in Scheme 36. 
 
Scheme 37 Improved Heck coupling to synthesis aldehyde 157. 
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        Larock and coworkers reported311 reported in 1989 an improved Heck coupling to 
synthesis aldehyde 157 with much better yield (90%) and lower temperature (70 C). 
(Scheme 37) This reaction between phenyl iodide 155 and allyl alcohol 156 is carried out 
successfully with assistance of palladium acetate as the key catalyst, Bu4NCl as the phase 
transfer catalyst and lithium acetate as the base. The easy availability of the reactants and 
catalysts plused the excellent yield and pretty mild condition made this reaction very 
attractive to synthesize aldehydes as versatile intermediates.112, 312-314 However, the 
applications of this condition to heterocycle (such as thiophene and furan) halides other 
than phenyl halides were not reported, which highly limited the application of this 
reaction.311 
 
Scheme 38 Heck coupling with thiophenyl bromide 159. 
 
         Yoshida and coworkers reported315, 316 in 1977 an improved Heck coupling with 
thiophenyl bromides as shown in Scheme 38. 2-Bromothiophene 159 was alkylated in the 
2 position by reaction with allylic alcohol 156 in the presence of Pd(OAc)2, NaI, 
NaHCO3 at 90 C under Ar2 for 4 h gave 76% 3-(thiophen-2-yl)propanal 160. Although 
this is a successful example of Heck coupling with thiophenyl bromides, the drawbacks 
of this reaction are very obvious: Only thiophenyl bromide without any substitutions on 
the thiophenyl ring was demonstrated; the reaction tolerance of different functional 
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groups (e.g. –COOMe, -C=O) on the thiophene ring is not known; the reaction condition 
is pretty hash: high temperature (90 C) and argon protection needed. 
         Due to its potential use in synthesis of classical antifolates and analogs such as RTX 
and PMX,269, 317 the mild conditioned and wide functional group tolerant Heck coupling 
of thiophenyl halides with allyl alcohols to afford aldehydes in one step is highly 
attractive. 
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III. STATEMENT OF THE PROBLEM 
1. Synthesis of classical 6-Substituted pyrrolo[2,3-d]pyrimidine 2, 161 and 162 (n=4-
6) analogues as folate receptor specific GARFTase inhibitors and as targeted 
anticancer agents109 
  
Figure 21 Structures of classical 6-Substituted Pyrrolo[2,3-d]pyrimidine 2, 161and 162 
(n=4-6).
109
 
 
        The high affinity FRs offer a potential means of selective tumor targeting, given 
their restricted pattern of tissue expression and function.
73
  For instance, FRα is expressed 
on the apical membrane surface of normal tissues such as kidney, placenta, and choroid 
plexus, whereas FRβ is expressed in placenta, spleen, and thymus. Importantly, FRα is 
overexpressed in a number of carcinomas including up to 90% of ovarian cancers.
81, 91
  
        Close associations were reported between FRα expression levels with grade and 
differentiation status of ovarian tumors. FRα in normal tissues (unlike tumors) is reported 
to be inaccessible to the circulation. 
73
 FRβ is expressed in a wide range of myeloid 
leukemia cells.
80
 FRβ in normal hematopoetic cells differs from that in leukemia cells in 
its inability to bind folate ligand.
78
 
        The concept of targeting FRs in cancer is not new. Folate-conjugated cytotoxins, 
liposomes, radionuclides, or cytotoxic antifolates
73, 107, 318, 319
 have all been used to target 
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FRs. Unfortunately, for most folate-based therapeutics such as classical antifolates 
[including RTX, PMX, and lometrexol (LMX)], tumor selectivity is lost, since substrates 
are shared between FRs and the ubiquitously expressed RFC. Indeed, this likely explains 
the severe myelosuppression encountered in phase 1 study with LMX.
150
 
        One strategy for selectively targeting tumor cells via FRs involves prodrug 
conjugates in which folate or pteroate is covalently linked to cytotoxins such as 
mitomycin 
18
C that, upon internalization, are selectively cleaved to release the cytotoxic 
drug. While these folate drug conjugates are unlikely to be RFC substrates, the success of 
this tumor targeting approach could be significantly compromised by inefficient cleavage 
and lack of release of the cytotoxic moiety, resulting in decreased chemotherapeutic 
activity. Alternatively, premature cleavage of the conjugates (prior to tumor 
internalization) could decrease selectivity and increase toxicity to normal proliferative 
tissues. In addition, the use of folic acid conjugates could ultimately release free folic 
acid within the tumor which could function as a nutrient for the tumor. If, however, a FR- 
targeted ligand were itself cytotoxic without RFC activity, selective tumor targeting 
would ensue. Antifolates that selectively target FRs over RFC have been described
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and, more recently, cyclopenta[g]quinazoline antifolates,
111, 320
 all of which potently 
inhibit thymidylate synthase (TS) within cells. When tested in mice,
320
 a 
cyclopenta[g]quinazoline antifolate had no toxicity to normal tissues, as reflected in lack 
of weight loss, nor were there any macroscopic signs of toxicity to major organs, 
consistent with the premise that FR targeting is highly selective. 
        On the basis of the clinical success of PMX,
321
 Gangjee et al.
322, 323
 designed and 
synthesized classical 6-substituted 2-amino- 4-oxopyrrolo[2,3-d]pyrimidine antifolates 
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with three- and four carbon bridges as inhibitors of dihydrofolate reductase (DHFR) 
and/or TS. Both 1 and 2, (Figure 22) were poor inhibitors of purified human DHFR and 
TS and were only modest inhibitors of tumor CCRF-CEM leukemia cell growth in the 
presence of supraphysiologic folate. This inhibition was largely protected by 
hypoxanthine (but not thymidine), indicating the inhibition of the purine biosynthesis 
pathway rather than the pyrimidine by 1 and 2.
322, 323
 
  
Figure 22  Design of Classical 6-Substituted Pyrrolo[2,3-d]pyrimidine 161 and 162.109 
 
        It was proposed that compounds 1 and 2, along with their five and six-carbon bridge 
homologues 161 and 162 (Figure 22), could be selective high affinity ligands for FRs 
with potent inhibitory activity against FR-expressing Chinese hamster ovary (CHO) cells 
and human tumor cells.
109
 In addition, the folate-dependent purine biosynthetic enzyme, 
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glycinamide ribonucleotide formyltransferase (GARFTase), was proposed as the major 
intracellular target responsible for the cytotoxic activity of this class of agents. While 
antifolates that target GARFTase including LMX have been described
324
 and are under 
continued development, to our knowledge, this is the first report
109
 of GARFTase 
inhibitors that are selectively transported into tumor cells by FRs but not RFC and that 
exhibit potent inhibitory activities against FR-expressing tumor cells.
109
 
 
2. Synthesis of classical 6-substituted pyrrolo[2,3-d]pyrimidine 163 (n=2) as folate 
receptor specific GARFTase inhibitors and as targeted anticancer agents114  
                                
Figure 23  Design of 163 as a hybrid of 2 and Pemetrexed (PMX).114  
 
 
         We reported a series of 6-substituted pyrrolo[2,3-d]pyrimidine classical antifolates 
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2, 161 and 162 (Figure 22) described above that are specifically taken up by the folate 
receptor (FR) and inhibit FR expressing tumor cells (KB and IGROV1) at nanomolar 
IC50 values.
109 These compounds are the 6-regioisomers of the well known antifolate 
PMX, in that the bridge is substituted in the 6- rather than 5-position of the pyrrolo[2,3-
d]pyrimidine ring.  
              In addition, these analogs are not transported via RFC into normal cells. 
GARFTase was confirmed as the target enzyme for these compounds. The 3- and 4-
bridge carbon analogs were most inhibitory toward FR-expressing cells, primarily due to 
the potent inhibition of GARFTase. The 3- and 4-bridge carbon analogs did not inhibit 
human DHFR or TS. 
        Pemetrexed(PMX)  is clinically used for the treatment of mesothelioma and non–
small cell lung cancer(NSCLC) and is currently being evaluated for the treatment of a 
variety of other solid tumors in the US.187 More recently, PMX has been approved in 
combination with cisplatin for the first-line treatment of patients with locally advanced or 
metastatic NSCLC other than squamous cell histology.188 PMX is a reported to be 
multitargeted antifolate that inhibits several folate metabolizing enzymes: TS, DHFR, 
AICARFTase and GARFTase.188 However, PMX suffers from dose-limiting toxicity due 
to its transport by RFC which is ubiquitously expressed in normal cells. To determine if 
transposing the side chain from the 5-position of PMX to the 6-position would maintain 
the multitarget attributes of PMX and perhaps provide selectivity for FR over RFC, the 6-
regioisomer of PMX, 163 was synthesized and evaluated as a hybrid of 2 and pemetrexed 
(PMX) in Figure 23.  
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3. Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidines  with a straight chain for 
folate receptor transport and GARFTase enzyme inhibition SAR study 
        A highly active compound of the previous series (Figure 22) included a 4 carbon 
bridge analog 2 that was a targeted agent, selectively transported into tumor cells by 
folate receptors (FRs) and the proton-coupled folate transporter (PCFT) (but not RFC) 
whereupon it inhibited de novo purine biosynthesis at the level of GARFTase. Compound 
2 was highly active toward both KB and IGROV1 tumor cells in culture.109 
 
Figure 24  6-Substituted straight chain compounds design: replacement of the phenyl 
ring  by methylene units.
325
      
  
        To further explore the SAR of the GARFTase inhibition and non-RFC targeted 
specificity of these compounds, several series of analogs were designed and synthesized 
as summaried above. 
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       At the same time, it was of interest to inspect the disclosed SAR of the known 
GARFTase inhibitor in clinical trial, lometrexol (LMX), to facilitate our study. A series 
of lometrexol analogs were reported in which the phenyl ring in the bridge was replaced 
by a methylene bridge of variable length.
324, 326
 (Figure 24) 
 
Table 4 GARFTase inhibitory activities of Lometrexol and its straight chain analogs324 
Compound Lometrexol (n=2) L1 (n=4) L2 (n=5) L3 (n=6) 
Ki (µM) 0.10 0.049 0.028 0.018 
 
        Replacement of the phenyl ring of lometrexol by either two, three, or four more 
methylene units did not abrogate activity against GARFTase.  In fact, there was an 
increase in binding affinity of analogs to GARFTase as the methylene chain was 
extended in the bridge region between the heterocycle and the glutamate (Table 4).
324
  A 
similar design strategy was employed with our 6-substituted pyrrolo[2,3-d]pyrimidines 
(Figure 24).  Straight chain compounds 164-167 (n=5-8) were designed with replacement 
of the phenyl ring of lead compound 2 by methylene bridges of variable length (Figure 
24). 
325
  These analogs served as probes for the binding of the central portion of the 
molecule to FR and/or PCFT transport as well as to GARFTase. 
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Figure 25 Stereoview. Overlay of the docked pose of 166 (white) with an analog of 
DDACTHF (purple) in hGARFTase (PDB ID: 1NJS)325 
           
            The docked pose of 166 (n=7) in the hGARFTase active site is shown in Figure 
25.325 The cofactor binding pocket of hGARFTase is located at the interface between the 
N-terminal mononucleotide binding domain and the C-terminal half of the structure. The 
binding site for the folate cofactor moiety consists of three parts:  the pteridine binding 
cleft, the benzoylglutamate region, and the formyl transfer region.139 The docked pose 
shows the pyrrolo[2,3-d]pyrimidine scaffold of 166 (n=7)  to be buried deep in the active 
site and occupies the same location as the diaminopyrimidone ring in the native crystal 
structure ligand (10-CF3CO-DDACTHF, purple). This orientation of the scaffold permits 
the 2-amino moiety to form hydrogen bonds to Glu141 and the backbone of Leu92. The 
N1 nitrogen interacts with the backbone of Leu92 to form a hydrogen bond. The 4-oxo 
moiety forms a hydrogen bond with Asp144 and forms water-mediated hydrogen bonds 
with Asp142 and Ala140. The molecule is oriented in a manner which aids the N7 
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nitrogen to form a hydrogen bond with Arg90. As is shown with an analog of DDACTHF 
(purple), several hydrophobic residues flank the pocket which holds the pyrrolo[2,3-
d]pyrimidine scaffold. The hydrophobic pocket consists of Leu85, Ile91, Leu92, Val97 
(not shown), and the folate binding loop residues 141-146. The amide NH of the 
glutamate side chain forms a hydrogen bond with Met89. The 7-carbon side chain of 166 
(n=7) shifts the glutamate side chain away from the corresponding glutamate side chain 
of the analog of DDACTHF. The carbonyl group of the glutamate side chain interacts 
with Arg64, which is not seen with the corresponding carbonyl group of the side chain of 
the analog of DDACTHF. The γ-carboxylic acid interacts with Arg64. The α-carboxylic 
acid of the glutamate side chain interacts with Arg90. Thus, the interaction pattern of the 
α- and γ-carboxylic acid moieties of 166 (n=7) are reversed compared to the 
corresponding α- and γ-carboxylic acids of the analog of DDACTHF and could represent 
an alternate conformation for the side chain. These interactions could account, in part, for 
the potent activity observed for 166 (n=7) against hGARFTase.  
 
 
 
 
 
 
 
 
 
105 
 
 
4. Synthesis of isosteric isomers of compound 2 as folate receptor specific GARFTase 
inhibitors of selectively targeted anticancer agents  
 
Figure 26 Design of 168 and 170.  
 
           Gangjee and coworkers109 described 6-substituted classical pyrrolo[2,3-
d]pyrimidines, 1 and 2  as potent GARFTase inhibitors with selective transport by FR and 
PCFT over RFC, providing tumor targeting capability. Interestingly, the four carbon chian 
compound 2 was not a substrate of RFC, whereas the three carbon chain compound 1 
showed significant growth inhibitory activity (IC50 of 304 nM) toward RFC-expressing 
PC43-10 cells. This result demonstrated the impact of the length of the bridge domain of 
6-substituted classical pyrrolo[2,3-d]pyrimidines on selective transport by FRs and/or by 
PCFT versus RFC. Compound 1 with a 3-carbon bridge was the most potent compound 
toward cells expressing FRs and PCFT, but was also transported by RFC; whereas the 4-
carbon bridge analog 2 was selectively transported by FRs and by PCFT but not by RFC, 
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but was less potent than 1 as an inhibitor of tumor cells in culture, suggesting that the 
chain length of the carbon bridge for optimum potency and transport selectivity is in 
between 3- and 4-atoms.  
        Thus, in an attempt to determine the optimum length of carbon bridge for 
GARFTase inhibitory activity and selective transport by FRs and/or PCFT over RFC, 168 
and 170 with 1,3-  and 1,2- substituted phenyl rings (Figure 26) were designed as analogs 
with chain lengths between three and four carbons. The bond angle of the 1,4-
disubstituted compound 2 is 180o , which is greater than that of the 1,2-disubstituted 
compound 170 as 60o and the 1,3-disubstituted compound 168 as 120o. Thus, the total 
lengths of the carbon bridge of 168 and 170 would be in between 3 and 4 atoms. These 
compounds are proposed to have similar or possible  more potent activities than 1without 
RFC transport providing targeted therapy for tumors that express FR and/or PCFT. 
 
5. Synthesis of classical 5-substituted pyrrolo[2,3-d]pyrimidines (n=1-6) with a 
phenyl ring in the chain as folate receptor specific TS, DHFR, GARFTase and/or 
AICARFTase multiple enzyme inhibitors (MTI) against tumors327 
 
 
Figure 27 Structures of 5-substituted pyrrolo[2,3-d]pyrimidines 172-177 (n=1-6).327 
 
107 
 
 
       Folate-dependent biosynthetic pathways serve as important therapeutic targets for 
cancer chemotherapy. Antifolate drugs for cancer include potent inhibitors of 
dihydrofolate reductase (DHFR) [methotrexate (MTX)], thymidylate synthase (TS) 
[raltitrexed (RTX), GW1843U, pemetrexed (PMX)], and both of the purine biosynthetic 
enzymes, β-glycinamide ribonucleotide formyl transferase (GARFTase) [lometrexol 
(LMX), PMX] and 5-aminoimidazole-4-carboxamide ribonucleotide formyl transferase 
(AICARFTase) [PMX]. While all these agents are transported by RFC, the expression of 
RFC in both normal and tumor cells presents a potential obstacle to antitumor selectivity. 
Further, loss of RFC is frequently associated with antifolate resistance. Thus, it is of 
interest to design targeted antifolates that are substrates for transporters other than RFC 
with limited expression and/or transport into normal tissues compared with tumors. If 
these drugs also inhibited targets other than or in addition to DHFR and TS, this would 
afford further benefit by circumventing MTX, 5-FU (5-fluorouracil), PMX and RTX 
tumor resistance due to increased DHFR or TS. This rationale provided the impetus to 
develop targeted agents that are selectively transported into tumors by FRs over RFC, 
with intracellular targets other than or in addition to DHFR and TS.  
         We recently reported109 a series of 6-substituted pyrrolo[2,3-d]pyrimidine classical 
antifolates 1 and 2 that are specifically taken up by the folate receptor (FR) and inhibit 
FR expressing tumor cells (KB and IGROV1) at nanomolar IC50 values. These 
compounds are 6-regioisomers of the well known antifolate PMX in that the bridge is 
substituted in 6- rather than 5-position of the pyrrolo[2,3-d]pyrimidine ring.                        
        In addition, these analogs are not transported via RFC into normal cells. GARFTase 
was confirmed as the target enzyme for these compounds. The 3- and 4-bridge carbon 
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analogs (compounds 1 and 2, respectively) were most inhibitory toward FR-expressing 
cells, primarily due to the potent inhibition of GARFTase. Compounds 1 and 2 did not 
inhibit human DHFR or TS. 
 
 
Figure 28 Design of 5-substituted pyrrolo[2,3-d]pyrimidines 172-177 (n=1-6).327 
        As mentioned above, pemetrexed(PMX)  is clinically used for the treatment of 
mesothelioma and non–small cell lung cancer(NSCLC) and is currently being evaluated 
for the treatment of a variety of other solid tumors in the US.187 More recently, PMX has 
been approved in combination with cisplatin for the first-line treatment of patients with 
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locally advanced or metastatic NSCLC other than squamous cell histology.188 PMX is a 
multitargeted antifolate that inhibits several folate metabolism enzymes: TS, DHFR, 
AICARFTase and GARFTase. 188 However, PMX suffers from dose-limiting toxicity due 
to its transport by RFC which is ubiquitously expressed in normal cells.328 To determine 
if altering the length of the side chain of PMX would maintain the multitarget attributes 
of PMX and perhaps provide selectivity for FR over RFC, we synthesized and evaluated 
the one to six carbon chain homologs of PMX (n=2) 172-177 (n=1-6, except n=2). 
(Figure 28) 
 
Molecular Modeling Studies327: 
 
          Molecular modeling studies were performed using LeadIT 1.3.0 and visualized 
using MOE 2011.10.327  Redocking the native crystal structure ligands (BW2315U89 for 
AICARFTase (PDB ID: 1PL0), 10-CF3CO-DDACTHF for hGARFTase (PDB ID: 
1NJS)4, and PMX for FRb) into their respective crystal structures afforded docked poses 
with RMSD ~ 1Å. 
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Docking studies with AICARFTase (PDB ID: 1PL0) 327 
 
 
 
Figure 29 Stereoview. Overlay of the docked pose of 175 (blue) with BW2315U89 (red) 
in AICARFTase (PDB ID: 1PL0). 327 
 
          Figure 29 shows the overlay of the docked poses of 175 (red) with the crystal 
structure ligand BW2315U89 (blue) (a potent inhibitor) in AICARFTase (PDB ID: 
1PL039). The pyrrolo[2,3-d]pyrimidine scaffold of 175 occupies the same location as the 
dihydroquinazoline scaffold of BW2315U89. Analogous to BW2315U89, the 2-NH2 and 
N3 nitrogens of 175 interact with Asp546 while the 4-oxo moiety forms a hydrogen bond 
with the side chain of Asn547. The N7-nitrogen of 175 forms a hydrogen bond with the 
backbone of Met312. The pyrrolo[2,3-d]pyrimidine scaffold of 175 forms hydrophobic 
interactions with Met312, Phe315, Ile452, Pro543 and Phe544. The aryl glutamate 
section of 175 is oriented similar to the phenyl glutamate side chain of BW2315U89. 
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Docking studies with hGARFTase (PDB ID: 1NJS) 327        
 
Figure 30 Stereoview. Overlay of the docked pose of 175 (blue) with 10-CF3CO-
DDACTHF (red) in hGARFTase (PDB ID: 1NJS). 327 
 
           Figure 30 shows the docked pose of 175 in the hGARFTase  active site. The 
cofactor binding pocket of hGARFTase is located at the interface between the N-terminal 
mononucleotide binding domain and the C-terminal half of the structure. The binding site 
for the folate cofactor moiety consists of three parts:  the pteridine binding cleft, the 
benzoylglutamate region, and the formyl transfer region.1 The docked pose shows the 
pyrrolo[2,3-d]pyrimidine scaffold of 175 to be buried deep in the active site and occupies 
the same location as the diaminopyrimidone ring in the native crystal structure ligand 
(10-CF3CO-DDACTHF, not shown). This orientation of the scaffold permits the 2-amino 
moiety to form hydrogen bonds to the backbone of Glu141 and Ser93. The N1 nitrogen 
interacts with the backbone of Leu92 to form a hydrogen bond. The 4-oxo moiety forms a 
hydrogen bond with Asp144 and forms water-mediated hydrogen bonds with Asp142 and 
Ala140 (not shown). 
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            The molecule is oriented in a manner which aids the N7 nitrogen to form a 
hydrogen bond with Arg90. The pyrrolo[2,3-d]pyrimidine scaffold resided in a 
hydrophobic pocket formed by Leu85, Ile91 (not shown), Leu92, Val97, and the folate 
binding loop residues 141-146. The flexible 4-atom side chain helps to orient the 
thiophene moiety into the benzoylglutamate region of the protein. The amide NH of the 
glutamate side chain forms a hydrogen bond with Met89. The α-carboxylic acid of the 
glutamate side chain interacts with Arg64 and additionally interacts with the backbone of 
Ile91. The γ-carboxylic acid can form a water-mediated hydrogen bond with Arg90. The 
interaction of the flexible glutamate side chain is very similar to the interaction network 
observed for the glutamate side chain of 10-CF3CO-DDACTHF. These docking results 
suggest that 175 should bind and inhibit the two folate dependent puring biosynthetic 
enzymes (GARFTase and AICARFTase). 
 
6. Synthesis of classical 5-substituted pyrrolo[2,3-d]pyrimidines (n=1-6) with a 
thiophenyl ring in the chain as folate receptor specific TS, DHFR, GARFTase and 
AICARFTase multiple enzyme inhibitors (MTI) against tumors 
       Gangjee and coworkers113, 329 recently reported a series of 6-substituted pyrrolo[2,3-
d]pyrimidine thienoyl antifolates. (Figure 31) The best characterized of this series 
compound 3 included a 4 carbon bridge and was selectively transported into cells by 
folate receptors (FRs) and the proton-coupled folate transporter (PCFT) (but not RFC) 
whereupon it inhibited de novo purine biosynthesis at the level of GARFTase. Compound 
3 was highly active toward both KB and IGROV1 tumors. In vivo in SCID mice with KB 
tumor xenograft, Compound 3 was highly active against both early and advanced stage 
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tumors. Based on the 5-substituted pyrrolo[2,3-d]pyrimidine structure of PMX and our 
results with the 6-substituted compound 3, it was of interest to synthesize 5-substituted 
 
 
  Figure 31 Design of 5-substituted pyrrolo[2,3-d]pyrimidines 178-183. (n=1-6) 
 
pyrrolo[2,3-d]pyrimidine thienoyl analogs with 1 to 6 carbon atoms in the bridge (178-
183) as hybrid molecules of PMX and 3. These analogs could be envisaged to afford 
multi-targeted attributes of PMX, while preserving FRα and/or PCFT specificity of 6-
substituted analogs previously reported62b (Figure 31).  
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7. Synthesis of classical 5-substituted pyrrolo[2,3-d]pyrimidines with a straight side 
chain as folate receptor specific anticancer agents 
 
Figure 32 Structures of 5-substituted pyrrolo[2,3-d]pyrimidines 184-186 (n=6-8) with a 
straight side chain. 
        A similar design strategy was employed with the 5-substituted pyrrolo[2,3-
d]pyrimidines 184-186 (n=6-8) (Figure 32) as with 6-substituted analogs described 
above.  
 
Figure 33 Design of 5-substituted pyrrolo[2,3-d]pyrimidines 184-186 (n=6-8) with a 
straight side chain. 
 
        Straight chain 184-186 (n=6-8) were designed with replacement of the phenyl ring 
of the lead compound 175 by methylene bridges of variable length (Figure 33).
325
  These 
analogs served as probes for the binding of the central portion of the molecule to 
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GARFTase as well as to FR and/or PCFT transport and to other folate metabolizing 
enzmes: TS, DHFR and AICARFTase. 
 
8. Synthesis of classical 7-Substituted pyrrolo[2,3-d]pyrimidines with a straight side 
chain as folate receptor specific anticancer agents 
 
Figure 34 Structures of 7-substituted pyrrolo[2,3-d]pyrimidines 187-190 (n=5-8) with a 
straight side chain. 
        As indicated above, both the 6-substituted and 5-substituted pyrrolo[2,3-
d]pyrimidines  with straight chains in place of the aryl group in the side chain were 
designed to achieve folate receptor specific anticancer agents. The biological activities of 
these straight chain analogs demonatrated that different regio positions (5-, or 6-) of the 
pyrrolo[2,3-d]pyrimidine is critical for both folate transport specificity as well as folate 
enzyme inhibition.  
        Thus, it was of interest to synthesize 7-substituted pyrrolo[2,3-d]pyrimidine analogs 
187-190 (n=5-8) to explore the effects of side chain orientation for both the folate 
transport specificity and folate enzyme inhibition. (Figure 34)  In addition, it could serve 
as an excellent comparision with both of our 6-substituted and 5-substituted pyrrolo[2,3-
d]pyrimidines to make a more completed SAR. It was speculated that the flexibility of 
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the straight chain analogs would have the opportunity to orient an appropriate 
confirmation critical to binding to FR as well as folate metabolizing enzymes. 
 
9. Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidine glutmate derivatives as folate 
receptor specific anticancer agents  
 
Figure 35  Designed analogs with variations in the glutamate moiety.  
 
             As part of a continuing effort to develop novel classical antifolates as antitumor 
agents, Gangjee and coworkers330 recently reported a series of classical 2,4-diamino-5-
substituted-furo[2,3-d]pyrimidines with either an α- or γ-carboxylic acid in the glutamate 
moiety. The structure-activity relationship indicated that for these compounds the α-
carboxylic acid is more important than the γ-carboxylic acid both for DHFR inhibitory 
activity and human RFC binding affinity. To investigate the structural requirements of the 
glutamate carboxlic acids of antifolates with respect to FR substrate activity, a series of 
analogs 197-199 (Figure 35) with and without carboxylic acids in the glutamate portion 
of 2 were designed and synthesized as the first series in a broader program to determine 
the structure –activity relationship for FR and the importance of the α- and the γ-
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carboxylic acid groups to biological activity.  
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IV. CHEMICAL DISCUSSION 
1: Synthesis of classical 6-substituted pyrrolo[2,3-d]pyrimidine 2, 161 and 162 (n=4-
6)  
Scheme 39  Synthesis of intermediates 202 and 203. 322, 323 
 
        Compounds 2 , 161 and 162 (n=4-6) were obtained via a nine-step synthesis from 
the commercially available methyl 4-formylbenzoate 205 using an α-bromomethyl ketone 
condensation with pyrimidine as the key step as outlined in Scheme 1.109 In the 
previously reported synthesis,322, 323 the α-chloromethylketones were used to afford both 
the 6-substituted pyrrolo[2,3-d]pyrimidine, as well as the 5-substituted furo[2,3-
d]pyrimidine and involved a separation of the two compounds. (Scheme 39) 
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Scheme 40  Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidines with the α-
bromomethylketone. 
        In this study, the α-bromomethylketones were selected to afford regiospecifically the 
6-substituted pyrrolo[2,3-d]pyrimidines without the furo[2,3-d]pyrimidines and 
circumvent the separation step.
109
 
Scheme 41  Synthesis of intermediate α-bromomethylketones 215-217. 
 
        Thus, a Wittig reaction331 of 205 with triphenylphosphonium bromides 206-208 in 
1:1 DMSO/THF with 2 equiv of NaH afforded the unsaturated acids 209-211 as a mixture 
120 
 
 
of E- and Z-isomers. (Scheme 41) Hydrogenation of 209-211 afforded the saturated acids 
212-214, which was converted to the acid chloride and immediately reacted with 
diazomethane followed by 48% HBr to give the desired α-bromomethylketones 215-
217.332  
 
  Scheme 42  Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidine 2, 161 and 162. 
 
           With the desired α-bromomethylketones 215-217 in hand, the next step was the 
condensation of 2,4-diamino-6-hydroxypyrimidine with 215-217 (Scheme 42). Optimal 
reaction yields were obtained at room temperature for 3 days and only the pyrrolo[2,3-
d]pyrimidines 218-220 were  obtained. No side product furo[2,3-d]pyrimidines were 
found in this reaction compared with condensation with α-chloromethylketones that 
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afford both pyrrolo[2,3-d]pyrimidines and furo[2,3-d]pyrimidines. Hydrolysis of 218-220 
afforded the corresponding free acids 221-223. Subsequent coupling with L-glutamate 
diethyl ester using N-methyl morpholine and 2,4-dimethoxy-6-chloro-triazine as the 
activating agents afforded the diesters 224-226. Final saponification of the diesters gave 
the target compounds 2, 161 and 162.109 
        Synthetic improvements compared with the known methods322 323: 
1. α-Bromomethyl ketones 215-217 was reacted with 2,4-diamino-6-hydroxypyrimidine 
35 to afford only pyrrolo[2,3-d]pyrimidines 218-220.  No side product furo[2,3-
d]pyrimidines were found in this reaction compared with condensation with α-
chloromethylketones to afford both pyrrolo[2,3-d]pyrimidines and furo[2,3-
d]pyrimidines, which facilitate a much easier separation of the product. 
2. Methanol instead of methanol and DMSO (1:1) mixture was used as the solvent for the 
hydrolysis of 218-220 to afford 221-223.  DMSO is difficult to remove. 
3. Better peptide coupling reagents: N-methyl morphorine and 2,4-dimethoxy-6-chloro-
triazine instead of the triethylamine and isobutyl chloroformate were used as peptide 
coupling reagents for the synthesis of 224-226. Isobutyl chloroformate is flammable and 
very toxic. N-methyl morphorine and 2,4-dimethoxy-6-chloro-triazine are safer and more 
convenient as the activating agents for the synthesis of diesters 224-226 in this study. 
 
2. Synthesis of classical 6-substituted pyrrolo[2,3-d]pyrimidine 163 (n=2)  
            Compound 163 was obtained via a Sonogashira coupling reaction between the 
intermediates 230 (Scheme 43) and 234 (Scheme 44) as the key step.114, 333 The 
intermediate 230 was obtained by a four-step synthesis from the commercially available 
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2,4-diamino-6-hydroxy primidine 35 (Scheme 43). Compound 28 was condensed with α-
chloro acetaldehyde 227 to afford the pyrrolo[2,3-d]pyrimidine 228.334 Protection of 228 
with a pivaloy group provided compound 229, which was converted to the 6-substituted 
mercury salt  and immediately reacted with iodine  to give the desired 6-iodo pyrrolo[2,3-
d]pyrimidine 230. 
   
  Scheme 43  Synthesis of intermediate 6-iodo-pyrrolo[2,3-d]pyrimidine 230.  
          The synthesis of intermediate 234 began with the coupling of commercially 
available 4-iodobenzoic acid 231(Scheme 44) and diethyl-L-glutamate hydrochloride to 
afford diethyl 4-iodobenzoyl-L-glutamate 232.  The yield of 232 was 95 %, which was 
better than that reported by Taylor and co-workers (75%).114, 333 
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Scheme 44  Synthesis of intermediate acetylene 234 by Sonogashira coupling. 
        Palladium catalyzed coupling of 232 with trimethylsilyl acetylene, in the presence of 
tetrakis-(triphenylphosphine) palladium (0) (Pd(PPh4)3), copper (I) iodide (CuI) and 
triethylamine, gave 233 as a reddish oil, which was immediately desilyated using n-
Bu4NF to afford the acetylene 234 (74% over two steps).  
        With the 6-iodo pyrrolo[2,3-d]pyrimidine 230  in hand,  a palladium catalyzed 
carbon-carbon coupling reaction with the aryl iodide  230 and  the acetylene 234 (Scheme 
45) led to the 6-substituted compound 235. Instead of using the reaction condition of 5% 
Pd/C, 48 h described by Taylor and co-workers114, 333 to get 72% yield of the 
hydrogenation of 235, a 10% Pd/C, 5 hour-condition was employed to get a complete 
transformation (100% yield of 236) without any partial reduction. No separation is 
needed for 236 because of the complete transformation of this reduction. Compound 236 
was then converted to the target compound 163 by a convenient deprotection with 1N 
sodium hydroxide solution. 
 
Scheme 45  Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidine 163 (n=2). 
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3. Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidine 164-167 (n=5-8) with a 
straight side chain  
        Compounds 164-167 (n=5-8) were obtained via a seven-step synthesis from the 
commercially available alkyl carboxylic acid esters237-240 using an α-bromomethyl 
ketone condensation with pyrimidine as the key step as outlined in Scheme 47.  
  
Scheme 46  Synthesis of intermediate straight chain α-bromomethyl ketones 241-244. 
        Commercially available carboxylic acids 237-240 were converted to the acid 
chlorides and immediately reacted with diazomethane followed by 48% HBr to give the 
desired α-bromomethylketones 241-244. (Scheme 46) 
 
Scheme 47  Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidine 164-167 (n=5-8). 
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         With the desired α- bromomethylketones 241-244 in hand, the next step was the 
condensation of 2,4-diamino-6-hydroxypyrimidine 35 with 241-244 (Scheme 47). 
Optimal yields were obtained at room temperature for 3 days and only pyrrolo[2,3-
d]pyrimidines 245-248 were  obtained. No side product furo[2,3-d]pyrimidines were 
found in this reaction compared with condensation with α-chloromethylketones to afford 
both pyrrolo[2,3-d]pyrimidines and furo[2, 3-d]pyrimidines. Hydrolysis of 245-248 
afforded the corresponding free acids. Subsequent coupling with L-glutamate diethyl 
ester using N-methyl morpholine and 2,4-dimethoxy-6-chloro-triazine as the activating 
agents afforded the diesters 249-252. Final saponification of the diesters gave the target 
compounds 164-167. 
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4.Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidine 168 and 170 as isosteric 
isomers of compound 2  
Scheme 48 Retro synthetic analysis of 6-substituted pyrrolo[2,3-d]pyrimidine 168.  
 
        Two retro synthetic routes were proposed as shown in Scheme 48.115  From route A, 
it was anticipated that a Sonogashira coupling of the iodide 259 with commercially 
available terminal acetylene alcohols, 258, followed by hydrogenation, Jones oxidation 
and homologation would afford the α-bromomethylketone 257.  Sequential coupling with 
2,6-diamino-3H-pyrimidin-4-one 35, hydrolysis, L-glutamate peptide coupling and 
saponification would afford the target compound 168. The target compound could also be 
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synthesized from route B. The commercially available terminal acetylene carboxylic acid 
256 would first be converted to the α-bromomethylketone 255, which could undergo 
coupling reaction with 35 to give the key intermediate 2-amino-4-oxo-6-alkynl-
pyrrolo[2,3-d]pyrimidine, 253. Sequential Sonogashira coupling with iodide, 254, 
hydrogenation and sponification would afford the target compounds. 
          From a retro-synthetic stand point of view, route B would be better than route A for  
compounds with the isosteric replacement of 1,4-disubstituted phenyl ring on the side 
chain , since the common intermediate 253 generated from route B could be used to 
synthsize several other analogs for SAR studies.  
         Thus, compound 168 was obtained via a Sonogashira coupling reaction between the 
intermediates 253 and 263 as the key step.
 
Scheme 49  Synthesis of intermediate 261. 
 
 
Scheme 50  Synthesis of intermediate 263. 
 
        The synthesis of intermediate 261 (Scheme 49) began with the coupling of 
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commercially available 2-iodobenzoic acid 260 and diethyl-L-glutamate hydrochloride to 
afford diethyl 2-iodobenzoyl-L-glutamate 261. The diethyl 3-iodobenzoyl-L-glutamate 
263 was synthesized by the same procedure as shown (Scheme 50). 
 
 
Scheme 51  Synthesis of intermediate 253. 
 
        The other key intermediate 253 was obtained by a five-step synthesis from the 
commercially available pent-4-ynoic acid 256. (Scheme 51) Carboxylic acid 256 was 
converted to the acid chloride and immediately reacted with diazomethane followed by 
48% HBr to give the desired α-bromomethylketone 255. Condensation of 2,6-diamino-
3H-pyrimidin-4-one, 35 with α-bromomethylketone 255 at room temperature for 3 days 
afforded the desired terminal alkyne 253.   
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Scheme 52 Synthesis of 169 and 170. 
 
 
Scheme 53 Synthesis of 168 and 171. 
 
          Compounds 264 and 266 were obtained by a Sonogashira coupling of 253 with 
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iodide 261  and 263 in the presence of tetrakis-(triphenylphosphine) palladium (0) 
(Pd(PPh4)3), copper(I) iodide (CuI) and triethylamine. Hydrogenation and saponification 
of 264 and 266 afforded 170 and 168, respectively. (Scheme 52, Scheme 53) 
 
5. Synthesis of classical 5-substituted pyrrolo[2,3-d]pyrimidines with a phenyl side 
chain 172-177 (n=1-6) 
 
Scheme 54  Retro synthesis analysis of 5-substituted pyrrolo[2,3-d]pyrimidines with 
phenyl side chain analogues 172-177 (n=1-6). 
 
        A retro synthesis analysis of 5-substituted pyrrolo[2,3-d]pyrimidines with phenyl 
side chain analogues 172-177 (n=1-6) was shown. (Scheme 54) The 5-substituted 
pyrrolo[2,3-d]pyrimidine ring could be synthesized from the cyclolization between 2,4-
diamino-4-oxo-pyrimidine 35 and α-bromo aldehydes 281-286, which could be obtained 
by α-bromonation of the corresponding aldehydes 275-280. The aldehydes 275-280 could 
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be easily obtained by a one step Heck coupling from benzyl iodide 268 and allyl alcohols 
269-274. 
 
Scheme 55  Synthesis of intermediate 281-286. 
 
        Thus, a Heck coupling reaction335 of 268 with alcohols 269-274 in DMF at 70 oC 
afforded the aldehydes 275-280 (yields: 83-92%). α-Bromonation of 275-280 with 5,5-
dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 287336 at room temperature afforded the 
corresponding α-bromo aldehydes 281-286 (yields: 74-78%). (Scheme 55) 
 
Scheme 56 Synthesis of intermediate 288-293. 
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        The 5-substituted pyrrolo[2,3-d]pyrimidines 288-293were synthesized by 
condensation of 281-286 with 2,4-diamino-6-hydroxypyrimidine 35 at 45 oC in the 
presence of sodium acetate (yields: 45-50%). (Scheme 56) 
 
Scheme 57  Synthesis of  5-substituted pyrrolo[2,3-d]pyrimidine with phenyl side chain 
analogues 172-177 (n=1-6). 
 
        Subsequent hydrolysis with 3N NaOH followed by coupling with diethyl L-
glutamate using N-methyl morpholine and 2,4-dimethoxy-6-chlorotriazine as the 
activating agents afforded the diesters 294-299 (yields: 51-78% over two steps). Final 
saponification of the diesters with 1N NaOH gave the target compounds 5-substituted 
pyrrolo[2,3-d]pyrimidines 172-177 (yields: 88-97%). (Scheme 57) 
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6. Synthesis of 5-substituted pyrrolo[2,3-d]pyrimidines with a thiophenyl side chain 
analogues 178-183 (n=1-6) 
        The thiophenyl side chain analogues 178-183 (n=1-6) were proposed to be 
synthesized by the similar procedure as their phenyl analogs. The only synthetic 
challenge of this series is synthesis of the intermediate aldehyde with a thiophenyl side 
chain 300. 
 
Scheme 58  Retro synthesis analysis of intermediate 300. 
  
        A retro synthesis analysis of intermediate 300 was shown. (Scheme 58) By route A, 
the aldehyde 300 could be obtained in a three step reaction from a Sonogashira coupling 
of iodide 301 and alkyne 304 followed by the reduction of the triple bond and oxidization 
of the alcohol 302 to aldehyde 300. By route B, the aldehyde 300 could be obtained by a 
one step Heck coupling of thiophenyl iodide 301 with allyl alcohol 270 as the synthesis 
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of its phenyl analogs described above. 
        It is obvious that the better way to synthesize it is by a one step Heck coupling. 
However, this Heck coupling of the thiophene iodide (with an ester group) and the allyl 
alcohol has not been reported in the literature.  
       To investigate the heterocycle Heck coupling, the key intermediate thiophene 
bromide 306 was proposed first because of the ease of its synthesis from commercially 
available carboxylic acid 305 by esterification.  
 
Scheme 59  Synthesis of intermediate 306.  
 
        The intermediate 306 was successfully obtained by reflux of the carboxylic acid 305 
with H2SO4 and methanol in 54% yield as shown. (Scheme 59) 
 Scheme 60  Improved synthesis of intermediate 306. 
 
        A significantly improved yield of 93% was achieved by reaction of 305 with oxaly 
chloride with the assistance of DMF followed by esterification with methanol and 
DMAP. (Scheme 60) 
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Scheme 61 Heck coupling of the thiophene bromide 306. 
 
        Unfortunately, the Heck coupling of the thiophene bromide 306 and allyl alcohol 
270 under the previous condition335 was unsuccessful. (Scheme 61) 
        Several different reaction conditions were further explored to precede this Heck 
coupling. The different conditions attempted are listed in Table 5.   
 
Table 5 Attempted conditions for Heck coupling of the thiophene bromide 306. 
Entry Pd(OAc)2 Temperature (
oC) Time (h) Yield 
a 0.05 eq 70 12 Decomposeda 
b 0.05 eq 70 1 Decomposeda 
c 0.05 eq r.t. 12 No reactionb 
d 0.05 eq 45 12 No reactionb 
e 0.5 eq 45 12 No reactionb 
a. No starting material or product found on TLC 
b. No convertion from starting material found on TLC 
 
            The most probable reason for the unsuccess of this reaction is the low reactivity of 
the bromide in the Heck coupling. The more reactive thiophene iodide 301 was proposed 
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to provide a better Heck coupling reactant. 
 
Scheme 62  Synthesis of the thiophene iodide 301. 
 
        The thiophene iodide 301 was successfully synthesized by iodination of 308 with 
PhI(OCOCF3)2 and iodine at room temperature with 90% yield. (Scheme 62) 
 
Scheme 63  Improved Heck coupling of 300 
 
       Further exploration of Heck coupling of this thiophene iodide 301 with ally alcohol 
270 is shown in Scheme 63. 
        Unfortunately, the Heck coupling of the thiophene iodide 301 and allyl alcohol 270 
under the previous condition335 was unsuccessful as the thiophene bromide 306.   
      
Table 6 Attempted conditions for the Heck coupling of the thiophene iodide. 
Entry Pd(OAc)2 Temperature (
oC) Time (h) Yield 
a 0.05 eq 70 12 Decomposeda 
b 0.05 eq 70 1 Decomposeda 
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c 0.05 eq r.t. 12 No reactionb 
d 0.5 eq r.t. 12 No reactionb 
e 0.5 eq 45 2h 65% 
a. No starting material or product found on TLC 
b. No convertion from starting material found on TLC 
 
         Several different reaction conditions were further explored to precede this Heck 
coupling. The different conditions attempted are listed in Table 6.  The condition tried 
first (Entry a) is 0.05eq Pd(OAc)2 at 70 
oC for 12h as reported with the phenyl iodide 
before.335 The reactant 301 was found to be decomposed due to the high temperature. The 
same result was found when the reaction time was reduced to 1h (Entry b). The reaction 
was tried at room temperature with different equivalents of Pd(OAc)2 (0.05eq, Entry c; 
0.5eq, Entry d) for 12h. No reaction was found under these conditions. A sucessful 
reaction condition was found with a good yield of 65% when the reaction temperature 
increased to 45 oC for 2h and the equivalent of Pd(OAc)2 increased to 0.5eq (Entry e). 
Thus, a successful Heck coupling of the thiophene iodide 301 and allyl alcohol 270 to 
synthesize the aldehyde 300 in one step was discovered. The reaction condition is mild 
(45 oC) and the yield is good (65%). In addition, the reaction is fast (2h) and easy to 
handle (no argon protection needed).  
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Scheme 64  Synthesis of intermediate 308-312. 
 
Scheme 65 Synthesis of 178-183. 
 
       With the desired of Heck coupling of thiophene iodide 300, other aldehydes of the 
series (n=1-6) were successfully synthesized at the same reaction condition in 60-70% 
yields as shown in Scheme 64. 
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        Compounds 178-183 were obtained starting from the methyl 5-iodothiophene-2-
carboxylate 301 using an α-bromo aldehyde condensation with 2,4-diamino-4-oxo- 
pyrimidine 35 as the key step as outlined in Scheme 65. Thus, a Heck coupling reaction 
of 301 with alcohols 269-274 in DMF at 45 oC afforded the aldehydes 308-312 (yields: 
60-70%). (Scheme 64) 
        α-Bromonation of 308-312 with 5,5-dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 
287 at room temperature afforded the corresponding α-bromo aldehydes 313-318 (yields: 
70-75%). (Scheme 65) The 5-substituted pyrrolo[2,3-d]pyrimidines 319-324  were 
synthesized by condensation of 313-318 with 2,4-diamino-6-hydroxypyrimidine 35 at 45 
oC in the presence of sodium acetate. Subsequent hydrolysis with 3N NaOH and then 
coupling with diethyl L-glutamate using N-methyl morpholine and 2,4-dimethoxy-6-
chlorotriazine as the activating agents afforded the diesters 325-330 (yields: 60-70% over 
two steps). Final saponification of the diesters with 1N NaOH gave the target compounds 
5-substituted pyrrolo[2,3-d]pyrimidines 178-183 (yields: 88-97%).   
 
7. Synthesis of classical 5-substituted pyrrolo[2,3-d]pyrimidine with straight side 
chain analogues 184-186 (n=6-8)  
        Compounds 184-186 (n=6-8) were obtained using an α-bromo aldehyde 
condensation with 2,4-diamino-4-oxo- pyrimidine 35 as the key step as outlined in 
Scheme 68.  These analogs were proposed to be synthesized by the same procedure as 
their phenyl  and thiophenyl analogs. The only synthetic challenge of this series is the 
intermediate aldehyde with a straight side chain which is not commercially available.  
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Scheme 66  Synthesis of intermediate aldehydes 335-336. 
 
        The intermediate aldehydes 335-336 were obtained successfully by reduction of the 
commercially available carboxylic acid 331-332 to the corresponding alcohols 333-334 
by BH3 in THF at -18 
oC followed by PCC oxidation. (Scheme 66) 
 
Scheme 67  Synthesis of intermediate aldehyde 337. 
 
        The intermediate aldehyde 337 was afforded successfully in 88% yield by reaction of 
the commercially available bromide 338 with DMSO and NaHCO3 at 165 
oC. (Scheme 
67) 
       With the desired intermediate straight chain aldehydes 335-337 in hand, the synthesis 
of compounds 184-186 (n=6-8) is pretty straight forward as shown in Scheme 68: 
141 
 
 
 
Scheme 68  Synthesis of 184-186 (n=6-8).  
  
        α-Bromonation of 335-337 with 5,5-dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 
287 at room temperature afforded the corresponding α-bromo aldehydes 339-341 (yields: 
60-70%). The 5-substituted pyrrolo[2,3-d]pyrimidines 342-344  were synthesized by 
condensation of 339-341 with 2,4-diamino-6-hydroxypyrimidine 35 at 45 oC in the 
presence of sodium acetate (yields: 45-50%).  Subsequent hydrolysis with 1N NaOH and 
then coupling with diethyl L-glutamate using N-methyl morpholine and 2,4-dimethoxy-6-
chlorotriazine as the activating agents afforded the diesters 345-347 (yields: 60-70% over 
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two steps).  Final saponification of the diesters with 1N NaOH gave the target compounds 
5-substituted pyrrolo[2,3-d]pyrimidines 184-186  (n=6-8) (yields: 90-95%). 
   
8. Synthesis of classical 7-substituted pyrrolo[2,3-d]pyrimidines with a straight side 
chain 187-190 (n=5-8) 
 
Scheme 69  Retro synthesis analysis of 7-substituted pyrrolo[2,3-d]pyrimidine 187-190 
(n=5-8). 
 
          The retro synthesis analysis of 7-substituted pyrrolo[2,3-d]pyrimidine 187-190  
(n=5-8) is shown in Scheme 69. These analogs could be obtained by the reaction of the 
bromide 348-351 with the known intermediate 229, which could be obtained from the 
cyclolization of 2,4-diamino-6-hydroxypyrimidine 28 with α-chloro aldehyde 227. The 
alkylation of the 7-N of 229 is the key step in this synthesis. 
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Scheme 70  Synthesis of intermediates 353-356. 
 
        The 7-substituted pyrrolo[2,3-d]pyrimidines 353-356 were obtained by N7- 
alkylation of the common intermediate 229 by bromides 348-351 with NaH in DMF. The 
intermediate 229 has a pivaloyl group protected at the N2- position to ensure the 
exclusive alkylation at the N7- position. (Scheme 70) 
 
Scheme 71  Synthesis of 7-substituted pyrrolo[2,3-d]pyrimidine 187-190  (n=5-8). 
 
        With the desired intermediate 7-substituted pyrrolo[2,3-d]pyrimidines 353-356 in 
hand, the synthesis of compounds 187-190  (n=5-8) was carried out as shown in Scheme 
71. Subsequent hydrolysis 353-356 with 1N NaOH and then coupling with diethyl L-
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glutamate using N-methyl morpholine and 2,4-dimethoxy-6-chlorotriazine as the 
activating agents afforded the diesters 357-360 (yields: 60-70% over two steps). Final 
saponification of the diesters with 1N NaOH gave the target compounds 7-substituted 
pyrrolo[2,3-d]pyrimidines 187-190  (n=5-8) (yields: 90-95%).   
 
9. Synthesis of 175 glutmate derivatives  
 
Scheme 72  Synthesis of pteroic acid 361. 
 
         The 175 glutmate derivatives were synthesized by coupling with its pteroic acid 361 
and the corresponding glutamate derivatives. As shown in Scheme 72, the pteroic acid 
361 was synthesized from the previously described intermediate 291 by hydrolysis with 
3N NaOH at 45 oC (yield: 82%).    
Scheme 73  Synthesis of N-methyl compound  191. 
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        With the desired intermediate pteroic acid 361 in hand,   191 was obtained by peptide 
coupling of 361 with the N-methyl L-glutamate 362 using N-methyl morpholine and 2,4-
dimethoxy-6-chlorotriazine as the activating agents (yields: 65%).  Final saponification of 
the diesters with 1N NaOH gave the target compound 5-substituted pyrrolo[2,3-
d]pyrimidine with a N-methylated L-glutamate 191 (yield: 89%). (Scheme 73)  
 
Scheme 74  Synthesis of glutmate derivatives 192 and 193. 
 
           The other two derivatives with a aspartic acid 192 and a homoglutamic acid 193 
were synthesized similiarly by coupling reactions of the pteroic acid 361 with the 
glutamate derivatives 364-365  using N-methyl morpholine and 2,4-dimethoxy-6-
chlorotriazine as the activating agents (yields: 74-75%).  Final saponification of the 
diesters with 1N NaOH gave the target compounds 5-substituted pyrrolo[2,3-
d]pyrimidines with aspartic acid 192 and homoglutamate  193 as shown in Scheme 74 
(yields: 93-95%).   
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10. Synthesis of compound 166 glutmate derivatives  
Scheme 75  Synthesis of N-methy compound 194. 
 
         The 166 glutmate derivatives were synthesized by coupling with its pteroic acid 368 
and the corresponding glutamate derivatives. As shown in Scheme 75, 194 was obtained 
by peptide coupling of 368 with the N-methyl L-glutamate 362 using N-methyl 
morpholine and 2,4-dimethoxy-6-chlorotriazine as the activating agents (yields: 56%).  
Final saponification of the diesters with 1N NaOH gave the target compounds 6-
substituted straight side chain pyrrolo[2,3-d]pyrimidines with a N-methylated L-
glutamate 194 (yield: 82%). (Scheme 75) 
 
Scheme 76  Synthesis of  glutmate derivatives 195 and 196. 
 
         The other two derivatives with a aspartic acid 195  and a homoglutamic acid 196 
were synthesized similiarly by coupling reactions of  the pteroic acid 368 with the 
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glutamate derivatives 364-365  using N-methyl morpholine and 2,4-dimethoxy-6-
chlorotriazine as the activating agents (yields: 68-71%).  Final saponification of the 
diesters with 1N NaOH gave the target compounds 6-substituted straighy side chain 
pyrrolo[2,3-d]pyrimidines with aspartic acid 195 and homoglutamate  196 as shown in 
Scheme 76 (yields: 92-94%).   
 
11. Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidines as compound 2 glutmate 
derivatives  
        The compound 2 glutmate derivative 197 was synthesized by coupling with 
glutamate derivative 372 using N-methyl morpholine and 2,4-dimethoxy-6-chlorotriazine 
as the activating agents in Scheme 77 (yields: 64%).  
 
Scheme 77  Synthesis of  glutmate derivative 197. 
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Scheme 78  Synthesis of  glutmate derivatives 198 and 199. 
 
        The compound 2 glutmate derivatives were synthesized by coupling with glutamate 
derivative  using N-methyl morpholine and 2,4-dimethoxy-6-chlorotriazine as the 
activating agents (yields: 46-54%).  Final saponification of the diesters with 1N NaOH 
gave the target compounds gave the target compounds 6-substituted pyrrolo[2,3-
d]pyrimidines with glutmate derivatives 198 and 199 as shown in Scheme 78 (yields: 89-
90%). 
 
 
 
 
 
 
 
149 
 
 
12. Synthesis of 6-substituted pyrrolo[2,3-d]pyrimidines as compound 161 glutmate 
derivatives  
 
Scheme 79  Synthesis of  glutmate derivative 200. 
 
        Similarly, the 5 carbon chain 161 glutmate derivative 200 was synthesized by the 
peptide coupling of pteroic acid 222 with the corresponding glutamate derivative 372 in 
67% yield as shown in Scheme 79. 
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Scheme 80 Synthesis of glutmate derivative 200a. 
 
              Similarly, the 5 carbon chain 161 glutmate derivative 200a was synthesized by 
the peptide coupling of pteroic acid 222 with the corresponding glutamate derivative 374 
followed by hydrolysis with 1N NaOH as shown in Scheme 80. 
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V. SUMMARY 
         Twelve series of classical 5-, 6- and 7-substituted pyrrolo[2,3-d]pyrimidines were 
designed and synthesized. Extensive structure modifications of the pyrrolo[2,3-d] 
pyrimidine scaffold were investigated to determine selective transport via FR or/and 
PCFT and tumor targeted antifolates with GARFTase or multiple folate metabolizing 
enzyme inhibition. 
 
 
 Figure 36 Extensive structure modifications on the pyrrolo[2,3-d]pyrimidine scaffold to   
find FR and PCFT specific tumor targeted antifolates. 
        The design strategies employed included (Figure 36): 
1. Variation of the side chain substitution position (5-,6- and 7-substituted) 
2. Variation of the side chain length (n=1-6) 
3. Isosteric replacement of the 1,4-disubstituted phenyl ring with 1,2- and 1,3- 
disubstituted phenyl ring and 2,5- disubstituted thiophenyl ring 
4. Replacement the L-glutamate with variation at the α and γ carboxylic acids  
        As a part of this study, a total of one hundred and fifty six new compounds 
(including new intermediates) were synthesized and separated. Of these, twelve series 
consisting of forty two classical antifolate final compounds were submitted for biological 
evaluation. In addition, bulk synthesis of some potent final compounds (2, 2.0g; 161, 
500mg; 175, 1.0g; 166, 500mg; 194, 500mg) was carried out to facilitate in vivo 
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evaluation. 
        During the synthesis of the target compounds, several synthetic improvements were 
achieved successfully including:          
1. α-Bromo ketones instead of α-chloro ketones were synthesized to react with 2,4-
diamino-6-hydroxypyrimidine to selectively afford pyrrolo[2,3-d]pyrimidines without  
side product furo[2,3-d]pyrimidines.  
2. Instead of using the reported reaction condition to get 72% yield in the hydrogenation 
of 235, a 10% Pd/C, 5 h condition was employed to get a complete transformation (100% 
yield of 236) without any partial reduction. The troublesome separation of 236 was 
avoided.          
        More importantly, a new Heck coupling of the thiophene iodide 301 and allyl 
alcohols to synthesize aldehydes in one step was discovered. The reaction condition is 
mild (45 
o
C) with a good yield (65%) and the labile ester group of 301 is tolerated at this 
condition. In addition, the reaction is fast (2h) and easy to handle (no argon protection 
needed). Due to its potential use in analog synthesis of clinically used antifolates such as 
RTX and PMX, this mild conditioned and easy to handle Heck coupling reaction is 
highly attractive.  
         During this study, the SAR of folate transporters (RFC, FR and PCFT) and 
GARFTase inhibitors were extensively explored. The 6-substituted straight chain 
compound 166 (n=7) was extremely potent against KB tumor cells (IC50=1.3 nM, about 
80-fold more potent than clinically used PMX) without any RFC activity. The 
intracellular enzyme target of 166 was subsequently identified as GARFTase. The 5- 
substituted phenyl compound 175 (n=4) showed AICARFTase as the primary target with 
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potent KB tumor cell inhibition (IC50=7.9 nM, about 8-fold more potent than PMX) and 
also indirectly activated AMPK cell signaling pathway via ZMP accumulation which 
transmits an inhibitory signal to the mTOR complex leading to tumor cell apoptosis. Both 
of these compounds were selected for animal study to determine the antitumor activity 
against human tumor xenograft in mice. Due to their potent antitumor activities, these 
two compounds serve as leads for future structural optimization. 
 
The target compounds synthesized as part of this study are all classical antifolates 
and listed below: 
1. (S)-2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-6-yl)butyl)benzamido)pentanedioic acid (2) 
2. (S)-2-(4-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-6-yl)pentyl)benzamido)pentanedioic acid (161) 
3. (S)-2-(4-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-6-yl)hexyl)benzamido)pentanedioic acid (162) 
4. (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-6-yl)ethyl)benzamido)pentanedioic acid (163) 
5. (S)-2-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)hexanamido)pentanedioic acid (164) 
6. (S)-2-(7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)heptanamido)pentanedioic acid (165) 
7. (S)-2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)octanamido)pentanedioic acid (166) 
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8. (S)-2-(9-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)nonanamido)pentanedioic acid (167) 
9. (S)-2-(3-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-6-yl)butyl)benzamido)pentanedioic acid (168)  
10. (S)-2-(2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-6-yl)but-1-yn-1-yl)benzamido)pentanedioic acid (169) 
11. (S)-2-(2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-6-yl)butyl)benzamido)pentanedioic acid (170) 
12. (S)-2-(3-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-6-yl)but-1-yn-1-yl)benzamido)pentanedioic acid (171) 
13.  (S)-2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-
5-yl)methyl)benzamido)pentanedioic acid (172)  
14. (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid (173)  
15. (S)-2-(4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)propyl)benzamido)pentanedioic acid (174) 
16. (S)-2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)butyl)benzamido)pentanedioic acid (175)  
17. (S)-2-(4-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)pentyl)benzamido)pentanedioic acid (176) 
18. (S)-2-(4-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)hexyl)benzamido)pentanedioic acid (177)  
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19. (S)-2-(5-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-
5-yl)methyl)thiophene-2-carboxamido)pentanedioic acid (178)  
20. (S)-2-(5-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)ethyl)thiophene-2-carboxamido)pentanedioic acid 
(179)  
21. (S)-2-(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)propyl)thiophene-2-carboxamido)pentanedioic 
acid (180) 
22. (S)-2-(5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)butyl)thiophene-2-carboxamido)pentanedioic acid 
(181) 
23. (S)-2-(5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)pentyl)thiophene-2-carboxamido)pentanedioic 
acid (182) 
24. (S)-2-(5-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)hexyl)thiophene-2-carboxamido)pentanedioic acid 
(183) 
25. (S)-2-(7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)heptanamido)pentanedioic acid (184) 
26. (S)-2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)octanamido)pentanedioic acid (185) 
27. (S)-2-(9-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)nonanamido)pentanedioic acid (186) 
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28. (S)-2-(6-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-
yl)hexanamido)pentanedioic acid (187) 
29. (S)-2-(7-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-
yl)heptanamido)pentanedioic acid (188) 
30. (S)-2-(8-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-
yl)octanamido)pentanedioic acid (189) 
31. (S)-2-(9-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-
yl)nonanamido)pentanedioic acid (190) 
32. (S)-2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)butyl)-N-methylbenzamido)pentanedioic acid 
(191) 
33. (S)-2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)butyl)benzamido)succinic acid (192) 
34. (S)-2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)butyl)benzamido)hexanedioic acid (193) 
35. (S)-2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)-N-methyloctanamido)pentanedioic acid (194) 
36. (S)-2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)octanamido)succinic acid (195) 
37. (S)-2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)octanamido)hexanedioic acid (196) 
38. 4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)-N-propylbenzamide (197) 
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39. 2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)benzamido)butanoic acid (198) 
40. 4-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)benzamido)butanoic acid (199) 
41. 4-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)pentyl)-N-propylbenzamide (200) 
42. 4-(4-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)pentyl)benzamido)butanoic acid (200a) 
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VI. EXPERIMENTAL SECTION 
 All evaporations were carried out in vacuo with a rotary evaporator. Analytical 
samples were dried in vacuo (0.2 mmHg) in a CHEM-DRY drying apparatus over P2O5 at 
80 oC.  Melting points were determined on a MEL-TEMP II melting point apparatus with 
a FLUKE 51 K/J electronic thermometer and are uncorrected.   Nuclear magnetic 
resonance spectra for proton (1H NMR) were recorded on either a Bruker WH-400 (400 
MHz) spectrometer or a Bruker WH-500 (500 MHz) spectrometer.  The chemical shift 
values are expressed in ppm (parts per million) relative to tetramethylsilane as an internal 
standard: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad singlet. Mass 
spectra were recorded on a VG-7070 double-focusingmass spectrometer or in a LKB-
9000 instrument in the electron ionization (EI) mode. Chemical names follow IUPAC 
nomenclature. Thin-layer chromatography (TLC) was performed on Whatman Sil 
G/UV254 silica gel plates with a fluorescent indicator, and the spots were visualized 
under 254 and 365 nm illumination. All analytical samples were homogeneous on TLC in 
three different solvent systems. Proportions of solvents used for TLC are by volume. 
Column chromatography was performed on a 230-400 mesh silica gel (Fisher, 
Somerville, NJ) column.  Elemental analyses were performed by Atlantic Microlab, Inc., 
Norcross, GA. Element compositions are within 0.4% of the calculated values.  
Fractional moles of water frequently found in the analytical sample of antifolates could 
not be prevented in spite of 24-48 h of drying in vacuo and was confirmed where possible 
by the presence in the 1H NMR spectra. All solvents and chemicals were purchased from 
Aldrich Chemical Co. or Fisher Scientific and were used as received. For all the 
compounds submitted for biological evaluation, a single spot in three different solvent 
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systems with three different Rf values confirmed >95% purity. 
(4E/Z)-5-[4-(Methoxycarbonyl)phenyl]pent-4-enoic acid (209): Compound 209 was 
synthesized as reported previously:22  To a suspension of methyl 4-formylbenzoate (205) 
(3.2 g, 20mmol) and (3-carboxypropyl)triphenylphosphonium bromide 206 (8.6 g, 20 
mmol) in 80 mL DMSO/THF (1:1) was added 2 equiv of NaH (92%) (1.0 g, 40 mmol) in 
one portion in an ice bath and N2 atmosphere. The resulting suspension was stirred in an 
ice bath for an additional 30 min and slowly warmed to room temperature for another 6 h. 
TLC indicated the disappearance of the aldehyde spot and formation of two spots 
centered at Rf ) 0.19 (hexane/EtOAc, 3:1). To the reaction mixture cooled in an ice bath 
was added ice/water (100 g) followed by concentrated HCl (10 mL). The resulting 
solution was extracted with ether (100 mL X 3) and dried over Na2SO4. After evaporation 
of solvent, the residue was loaded on a silica gel column (4 X 20 cm) and flash-
chromatographed with hexane/EtOAc (2:1) and the desired fractions were pooled. After 
evaporation of solvent the residue was recrystallized from ethyl ether to afford 4.4 g, 
yield 94% as white crystals, mp 121-123 °C (lit.22 mp 118-121 °C), Rf  = 0.20 
(Hexane/EtOAc, 3:1 ). 1H NMR (DMSO-d6) δ 2.40-2.46 (m, 4 H, 2 CH2), 3.84(s, 3H, 
OCH3), 6.47-6.52 (m, 2 H, CH=CH), 7.52 (d, 2 H, C6H4, J = 4.1 Hz), 7.89 (d, 2 H, C6H4, 
J = 4.2 Hz), 12.18 (br, 1H, COOH).  
     (5E/Z)-6-[4-(Methoxycarbonyl)phenyl]hex-5-enoic acid (210): Compound 210 was 
synthesized as described for 209: yield 90% as white crystals, mp 77-81 °C, Rf  = 0.22 
(Hexane/EtOAc, 3:1 ). 1H NMR (DMSO-d6) δ 1.60-1.76 (m, 2 H, CH2), 2.20-2.35 (m, 4 
H, 2 CH2), 3.84(s, 3H, OCH3), 6.45-6.55 (m, 2 H, CH=CH), 7.53 (d, 2 H, C6H4,  J = 4.0 
Hz), 7.89 (d, 2 H, C6H4,  J = 4.0 Hz), 12.06 (br, 1H, COOH). Anal. calcd. for (C14H16O4): 
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C, 67.74; H, 6.45; found: C, 67.94; H, 6.66.  
     (6E/Z)-7-[4-(Methoxycarbonyl)phenyl]hept-6-enoic acid (211): Compound 211 was 
synthesized as described for 209: yield 92% as white crystals, mp 72-73 °C, Rf  = 0.26 
(Hexane/EtOAc, 3:1 ). 1H NMR (CDCl3) δ 1.48-1.76 (m, 4 H, 2 CH2), 2.23-2.44 (m, 4 H, 
2 CH2), 3.91(s, 3H, OCH3), 6.30-6.50 (m, 2 H, CH=CH), 7.32 (d, 2 H, C6H4, J = 4.0 Hz), 
7.97 (d, 2 H, C6H4,  J = 4.0 Hz ).  Anal. calcd. for (C15H18O4): C, 68.70; H, 6.87; found: 
C, 68.43; H, 7.10.  
       5-[4-(Methoxycarbonyl)phenyl]pentanoic acid (212): Compound 212 was 
synthesized as reported previously:22  To a solution of 209 (3.0 g, 15 mmol) in 
EtOAc/CHCl3 (2:1, 50 mL) was added 10% Pd/C (500 mg). The resulting suspension 
was hydrogenated in a Parr apparatus overnight at 45-50 psi hydrogen pressure. TLC 
indicated the disappearance of the starting material and the formation of one major spot at 
Rf ) 0.29 (hexane/EtOAc, 3:1). The reaction mixture was filtered through Celite and 
washed with methanol (30 mL). After evaporation of the solvent, the residue was loaded 
on to a silica gel column (4 x 20 cm) and flash-chromatographed with hexane/EtOAc 
(3:1) and the desired fractions were pooled. After evaporation of the solvent and 
recrystallization from Et2O/EtOAc (2:1), 3.0 g (100%) of 212 was obtained as white 
crystals, mp 85-86 °C (lit.22 mp 86.9-88.5 °C), Rf  = 0.25 (Hexane/EtOAc, 3:1 ). 
1H NMR 
(DMSO-d6) δ 1.40-1.70 (m, 4 H, 2 CH2), 2.23 (t, 2 H, CH2), 2.66 (t, 2 H, CH2), 3.83 (s, 3 
H, OCH3), 7.34 (d, 2 H, C6H4, J = 3.9 Hz), 7.88 (d, 2 H, C6H4, J = 3.9 Hz), 12.04 (s, 1H, 
COOH). 
      6-[4-(Methoxycarbonyl)phenyl]hexanoic acid (213): Compound 213 was 
synthesized as described for 212: yield 99% as white crystals, mp 49-51 °C, Rf  = 0.26 
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(Hexane/EtOAc, 3:1 ). 1H NMR (CDCl3) δ 1.34-1.43 (m, 2 H, CH2), 1.58-1.72 (m, 4 H, 2 
CH2), 2.35 (t, 2 H, CH2), 2.66 (t, 2 H, CH2), 3.89(s, 3H, OCH3), 7.23 (d, 2 H, C6H4, J = 
4.0 Hz), 7.94 (d, 2 H, C6H4, J = 4.0 Hz). Anal. calcd. for (C14H18O4): C, 67.20; H, 7.20; 
found: C, 67.45; H, 7.30. 
     7-[4-(Methoxycarbonyl)phenyl]heptanoic acid (214): Compound 214 was 
synthesized as described for 212: yield 94% as white crystals, mp 66-67 °C, Rf  = 0.26 
(Hexane/EtOAc, 3:1 ). 1H NMR (CDCl3) δ 1.27-1.42 (m, 4 H, 2 CH2), 1.50-1.71 (m, 4 H, 
2 CH2), 2.33 (t, 2 H, CH2), 2.64 (t, 2 H, CH2), 3.89(s, 3H, OCH3), 7.20 (d, 2 H, C6H4, J = 
4.0 Hz), 7.94 (d, 2 H, C6H4, J = 4.0 Hz). Anal. calcd. for (C15H20O4  · 0.1CH3COOC2H5): 
C, 67.72; H, 7.68; found: C, 67.69; H, 7.60. 
      Methyl 4-(6-bromo-5-oxohexyl)benzoate (215): To a solution of  5-[4-
(methoxycarbonyl)phenyl]pentanoic acid (212) (0.36 g, 1.5 mmol) in a 50 mL flask was 
added oxalyl chloride (1.5 mL) and anhydrous CH2Cl2 (10 mL). The resulting solution 
was refluxed for 1 h and then cooled to room temperature. After evaporation of solvent 
under reduced pressure, the residue was dissolved in ethyl ether (20 mL). The resulting 
solution was added dropwise to an ice-cooled ether solution of diazomethane (generated 
in situ from 1.4 g N-nitroso-N-methylurea) over 10 min. To this solution was added 48% 
HBr (1.5 mL). The resulting mixture was refluxed for 1.5 h. After the mixture was cooled 
to room temperature, the organic layer was separated and the aqueous layer was extracted 
with ether (20 mL x 3). The combined organic layers were washed with two portions of 
10% Na2CO3 solution and dried over Na2SO4. The solvent was evaporated to afford 0.44 
g (90%) of 215 as yellow needles: mp 65-66 °C, Rf  = 0.45 (Hexane/EtOAc, 3:1 ). 
1H 
NMR (DMSO-d6) δ 1.43-1.65 (m, 4 H, 2 CH2), 2.54-2.74 (m, 4 H, 2 CH2), 3.83 (s, 3 H, 
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OCH3), 4.32(s, 2H, CH2Br), 7.34 (d, 2 H, C6H4, J = 4.0 Hz), 7.87 (d, 2 H, C6H4, J = 4.0 
Hz). 
     Methyl 4-(7-bromo-6-oxoheptyl)benzoate (216): Compound 216 was synthesized as 
described for 215: yield 80% as white crystals, mp 55-56 °C, Rf  = 0.52 (Hexane/EtOAc, 
3:1 ). 1H NMR (CDCl3) δ 1.30-1.42 (m, 2 H, CH2), 1.59-1.72 (m, 4 H, 2 CH2), 2.61-2.70 
(m, 4 H, 2 CH2), 3.87 (s, 2H, CH2Br), 3.90 (s, 3 H, OCH3), 7.23 (d, 2 H, C6H4, J = 4.0 
Hz), 7.95 (d, 2 H, C6H4, J = 4.0 Hz). HRMS calcd. for C15H19BrO3 326.0518, found 
326.0524. 
     Methyl 4-(8-bromo-7-oxooctyl)benzoate (217): Compound 217 was synthesized as 
described for 215: yield 85% as yellow crystals, mp 47-48 °C, Rf  = 0.53 
(Hexane/EtOAc, 3:1 ). 1H NMR (CDCl3) δ 1.30-1.39 (m, 4 H, 2 CH2), 1.60-1.71 (m, 4 H, 
2 CH2), 2.58-2.69 (m, 4 H, 2 CH2), 3.87 (s, 2H, CH2Br), 3.90 (s, 3 H, OCH3), 7.23 (d, 2 
H, C6H4, J = 4.0 Hz), 7.95 (d, 2 H, C6H4, J = 4.0 Hz). HRMS calcd. for C16H21BrO3 
340.0674, found 340.0683.  
      Methyl 4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl]benzoate (218):  To a suspension of  2,4-diamino-6-hydroxypyrimidine 35 (1.53 
g, 12.2 mmol) in anhydrous DMF (40 mL) was added 215 (3.82 g, 12.2 mmol). The 
resulting mixture was stirred under N2 at room temperature for 3 days. TLC showed the 
disappearance of starting materials and the formation of one major spot at  Rf  = 0.28 
(CHCl3/MeOH, 6:1). After evaporation of solvent, CH3OH (20 mL) was added followed 
by silica gel (5 g). Evaporation of the solvent afforded a plug, which was loaded onto a 
silica gel column (3.5 cm x 15 cm) and eluted initially with CHCl3 followed by 10% 
MeOH in CHCl3 and then 15% MeOH in CHCl3. Fractions showing Rf  = 0.28 were 
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pooled and evaporated, and the resulting solid was recrystallized from MeOH to afford 
1.53 g (37%) of 218 as yellow crystals: mp 240-241 °C (lit.22 mp 241.9-243.7 °C). This 
compound was identical in all respects to that reported in the literature.22  1H NMR 
(DMSO-d6) δ 1.52-1.62 (m, 4 H, 2 CH2),  2.49-2.71 (m, 4 H, 2 CH2), 3.83 (s, 3 H, 
OCH3), 5.84 (s, 1 H, CH), 5.95 (s, 2 H, 2-NH2), 7.34 (d, 2 H, C6H4, J = 4.0 Hz), 7.87 (d, 
2 H, C6H4, J = 4.0 Hz) 10.12 (s, 1 H, 3-NH), 10.80 (s, 1H, 7-NH). 
      Methyl 4-[5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)pentyl]benzoate (219): Compound 219 was synthesized as described for 218: yield 
35% as yellow crystals, mp 229-230 °C, Rf  = 0.31 (CHCl3/MeOH, 6:1).  
1H NMR 
(DMSO-d6) δ 1.26-1.36 (m, 2 H, CH2), 1.52-1.66 (m, 4 H, 2 CH2),  2.48-2.68 (m, 4 H, 2 
CH2), 3.82 (s, 3 H, OCH3), 5.84 (s, 1 H, CH), 5.95 (s, 2 H, 2-NH2), 7.33 (d, 2 H, C6H4, J 
= 4.0 Hz), 7.86 (d, 2 H, C6H4, J = 4.0 Hz) 10.12 (s, 1 H, 3-NH), 10.79 (s, 1H, 7-NH). 
Anal. calcd. for (C19H22 N4O3 · 0.2 H2O): C, 63.74; H, 6.31; N, 15.65; found: C, 63.78; H, 
6.26; N, 15.44. 
     Methyl 4-[6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)hexyl]benzoate (220): Compound 220 was synthesized as described for 218: yield 
35% as yellow crystals, mp 219-221 °C, Rf  = 0.35 (CHCl3/MeOH, 6:1).  
1H NMR 
(DMSO-d6) δ 1.25-1.35 (m, 4 H, 2 CH2), 1.47-1.65 (m, 4 H, 2 CH2),  2.49-2.67 (m, 4 H, 
2 CH2), 3.82 (s, 3 H, OCH3), 5.83 (s, 1 H, CH), 5.95 (s, 2 H, 2-NH2), 7.33 (d, 2 H, C6H4, 
J = 4.0 Hz), 7.86 (d, 2 H, C6H4, J = 4.0 Hz) 10.11 (s, 1 H, 3-NH), 10.76 (s, 1H, 7-NH). 
Anal. calcd. for (C20H24 N4O3 · 0.67 H2O): C, 63.13; H, 6.71; N, 14.72; found: C, 63.16; 
H, 6.65; N, 14.58. 
      4-[4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]benzoic 
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acid (221):  To a suspension of 218 (178 mg, 0.5 mmol) in 10 mL CH3OH was added 3 N 
NaOH (10 mL). The resulting mixture was stirred under N2 at 40-50 °C for 24 h. 
TLC indicated the disappearance of starting material and the formation of one major spot 
at the origin. The resulting solution was passed through Celite and washed with a 
minimum amount of CH3OH. The combined filtrate was evaporated under reduced 
pressure to dryness. To this residue was added distilled water (10 mL). The solution was 
cooled in an ice bath, and the pH was adjusted 3 to 4 using 3 N HCl. The resulting 
suspension was chilled in a dry ice/acetone bath and thawed to 4 °C overnight in a 
refrigerator. The precipitate was filtered, washed with cold water, and dried in a 
desiccator under reduced pressure using P2O5 to afford 120 mg (74%) of 221 as a brown 
powder:  mp >262 °C (dec) (lit.22 mp >266 °C ), Rf  = 0.20 (CHCl3/MeOH, 5:1). This 
compound was identical in all respects to that reported in the literature.22 
     4-[5-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)pentyl]benzoic 
acid (222): Compound 222 was synthesized as described for 221: yield 90% as a brown 
powder,  mp >271 °C (dec), Rf  = 0.18 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ 
1.26-1.36 (m, 2 H, CH2), 1.55-1.67 (m, 4 H, 2 CH2),  2.48-2.69 (m, 4 H, 2 CH2), 5.85 (s, 
1 H, CH), 5.96 (s, 2 H, 2-NH2), 7.31 (d, 2 H, C6H4, J = 4.0 Hz), 7.84 (d, 2 H, C6H4, J = 
4.0 Hz) , 10.12 (s, 1 H, 3-NH), 10.80 (s, 1H, 7-NH). Anal. calcd. for (C18H20 N4O3 · 0.75 
CH3OH): C, 61.80; H, 6.36; N, 15.37; found: C, 62.05; H, 6.05; N, 15.08. 
      4-[6-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexyl]benzoic 
acid (223): Compound 223 was synthesized as described for 221: yield 98% as a brown 
powder,  mp >276 °C (dec), Rf  = 0.18 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ 
1.24-1.35 (m, 4 H, 2 CH2),  1.48-1.64 (m, 4 H, 2 CH2),  2.49-2.66 (m, 4 H, 2 CH2), 5.84 
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(s, 1 H, CH), 5.97 (s, 2 H, 2-NH2), 7.29 (d, 2 H, C6H4, J = 4.0 Hz), 7.84 (d, 2 H, C6H4, J 
= 4.0 Hz), 10.13 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH). Anal. calcd. for (C19H22 N4O3 · 1.4 
H2O): C, 60.11; H, 6.58; N, 14.76; found: C, 60.13; H, 6.38; N, 14.38. 
      (S)-diethyl 2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)benzamido)pentanedioate (224): To a solution of 221 (290 mg, 0.89 mmol) in 
anhydrous DMF (40 mL) was added 6-chloro-2,4-dimethoxy-1,3,5-triazine (180 mg, 1.07 
mmol) and N-methylmorpholine (105 mg, 1.07 mmol). After the mixture was stirred at 
r.t. for 2 h, N-methylmorpholine (105 mg, 1.07 mmol) and dimethyl L-glutamate 
hydrochloride (423 mg, 1.78 mmol) were added all at once. The mixture was stirred at r.t. 
for 4 h. TLC showed the formation of one major spot at Rf  = 0.55 (CHCl3/MeOH, 5:1). 
The reaction mixture was evaporated to dryness under reduced pressure. The residue was 
dissolved in a minimum amount of CHCl3/MeOH, 5:1, and chromatographed on a silica 
gel column (2 cm x 15 cm) with 4% MeOH in CHCl3 as the eluent. Fractions that showed 
the desired single spot at Rf  = 0.55 were pooled and evaporated to dryness to afford 224 
307mg, yield 68% as a yellow syrup, which was used directly for the next step. 1H NMR 
(DMSO-d6) δ  1.08-1.28 (m, 6 H, 2 CH3),  1.52-1.68 (m, 4 H, 2 CH2),  1.88-2.15 (m, 2 H, 
CH2), 2.40-2.68 (m, 6 H, 3 CH2), 3.98-4.12 (m, 4 H, 2 CH2),   4.36-4.46 (m, 1 H, CH), 
5.84 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 7.28 (d, 2 H, C6H4, J = 4.0 Hz), 7.78 (d, 2 H, 
C6H4, J = 4.0 Hz), 8.63 (d, 1 H, CONH, , J = 4.4 Hz), 10.11 (s, 1 H, 3-NH), 10.78 (s, 1H, 
7-NH). 
        (S)-diethyl 2-(4-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)pentyl)benzamido)pentanedioate (225): Compound 225 was synthesized as 
described for 224: yield 88% as a yellow syrup, Rf  = 0.57 (CHCl3/MeOH, 5:1).  
1H NMR 
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(DMSO-d6) δ  1.14-1.23 (m, 6 H, 2 CH3),  1.28-1.38 (m, 2 H, CH2), 1.55-1.67 (m, 4 H, 2 
CH2),  1.90-2.20 (m, 2 H, CH2), 2.40-2.68 (m, 6 H, 3 CH2), 4.02-4.12 (m, 4 H, 2 CH2),   
4.38-4.46 (m, 1 H, CH), 5.85 (s, 1 H, CH), 5.96 (s, 2 H, 2-NH2), 7.30 (d, 2 H, C6H4, J = 
4.0 Hz), 7.79 (d, 2 H, C6H4, J = 4.0 Hz), 8.64 (d, 1 H, CONH, , J = 4.4 Hz), 10.12 (s, 1 H, 
3-NH), 10.80 (s, 1H, 7-NH). Anal. calcd. for (C27H35N5O6 · 0.75 H2O): C, 60.15; H, 6.82; 
N, 12.99; found: C, 60.30; H, 6.86; N, 12.66. 
       (S)-diethyl 2-(4-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)hexyl)benzamido)pentanedioate (226): Compound 226 was synthesized as described 
for 224: yield 77% as a yellow syrup, Rf  = 0.60 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-
d6) δ  1.11-1.21 (m, 6 H, 2 CH3),  1.25-1.34 (m, 4 H, 2 CH2), 1.48-1.64 (m, 4 H, 2 CH2),  
1.92-2.16 (m, 2 H, CH2), 2.39-2.46 (m, 2 H, CH2), 2.49-2.66 (m, 4 H, 2 CH2), 4.01-4.14 
(m, 4 H, 2 CH2),   4.37-4.47 (m, 1 H, CH), 5.82 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 7.28 
(d, 2 H, C6H4, J = 4.0 Hz), 7.78 (d, 2 H, C6H4, J = 4.0 Hz), 8.63 (d, 1 H, CONH, , J = 3.8 
Hz), 10.10 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH). Anal. calcd. for (C28H37N5O6 · 1.0 H2O): 
C, 60.31; H, 7.05; N, 12.56; found: C, 60.18; H, 7.02; N, 12.48. 
(S)-2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)benzamido)pentanedioic acid (2): To a solution of the diester 224 (580 mg, 
1.14 mmol) was added 1 N NaOH (15 mL), and the mixture was stirred under N2 at room 
temperature for 1 h. Add one or two drops of methanol to help the dissolution of the 
reactant if necessary.  The TLC showed the disappearance of the starting material (Rf  = 
0.55) and formation of one major spot at the origin (CHCl3/MeOH, 5:1). The reaction 
mixture was evaporated to dryness under reduced pressure. The residue was dissolved in 
water (10 mL), the resulting solution was cooled in an ice bath, and the pH was adjusted 
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to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was frozen in a dry 
ice/acetone bath, thawed in a refrigerator to 4-5 °C, and filtered. The residue was washed 
with a small amount of cold water and ethyl acetate and dried in vacuo using P2O5 to 
afford 380 mg (73%) 2 as a yellow powder: mp 172-173 °C (lit.22 mp 171-173 °C), Rf  = 
0.05 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ  1.58 (br, 4 H, 2 CH2),  1.88-2.10 (m, 
2 H, CH2), 2.29-2.37 (t, 2 H, CH2), 2.52-2.70 (m, 4 H,  2 CH2), 4.32-4.42 (m, 1 H, CH), 
5.83 (s, 1 H, CH), 5.97 (s, 2 H, 2-NH2), 7.26 (d, 2 H, C6H4, J = 4.0 Hz), 7.78 (d, 2 H, 
C6H4, J = 4.0 Hz), 8.50 (d, 1 H, CONH, , J = 3.0 Hz), 10.14 (s, 1 H, 3-NH), 10.78 (s, 1H, 
7-NH), 12.21 (br, 2 H, 2 COOH). Anal. calcd. for (C22H25N5O6 · 1.5 H2O): C, 54.76; H, 
5.85; N, 14.52; found: C, 54.88; H, 5.73; N, 14.29. 
(S)-2-(4-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)pentyl)benzamido)pentanedioic acid (161): Compound 161 was synthesized as 
described for 2, yield 60% as a yellow powder,  mp 208-209 °C, Rf  = 0.05 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  1.26-1.36 (m, 2 H, CH2), 1.54-1.66 (m, 4 
H, 2 CH2),  1.88-2.20 (m, 2 H, CH2), 2.31-2.39 (t, 2 H, CH2), 2.52-2.68 (m, 4 H, 2 CH2), 
4.32-4.42 (m, 1 H, CH), 5.85 (s, 1 H, CH), 5.99 (s, 2 H, 2-NH2), 7.29 (d, 2 H, C6H4, J = 
4.0 Hz), 7.79 (d, 2 H, C6H4, J = 4.0 Hz), 8.52 (d, 1 H, CONH, , J = 3.9 Hz), 10.14 (s, 1 H, 
3-NH), 10.80 (s, 1H, 7-NH), 12.24 (br, 2 H, 2 COOH). Anal. calcd. for (C23H27N5O6  · 1.0 
H2O): C, 56.66; H, 6.00; N, 14.36; found: C, 56.69; H, 5.90; N, 14.11. 
(S)-2-(4-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)hexyl)benzamido)pentanedioic acid (162): Compound 162 was synthesized as 
described for 2, yield 83% as a yellow powder,  mp 220-221 °C, Rf  = 0.05 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  1.25-1.35 (m, 4 H, 2 CH2), 1.48-1.65 (m, 4 
168 
 
 
H, 2 CH2),  1.88-2.15 (m, 2 H, CH2), 2.30-2.38 (t, 2 H, CH2), 2.49-2.68 (m, 4 H, 2 CH2), 
4.33-4.43 (m, 1 H, CH), 5.83 (s, 1 H, CH), 5.96 (s, 2 H, 2-NH2), 7.28 (d, 2 H, C6H4, J = 
4.0 Hz), 7.90 (d, 2 H, C6H4, J = 4.0 Hz), 8.52 (d, 1 H, CONH, , J = 3.8 Hz), 10.12 (s, 1 H, 
3-NH), 10.78 (s, 1H, 7-NH), 12.21 (br, 2 H, 2 COOH). Anal. calcd. for (C24H29N5O6 · 2.5 
H2O): C, 54.54; H, 6.48; N, 13.25; found: C, 54.74; H, 6.12; N, 13.12. 
(S)-diethyl 2-(4-iodobenzamido)pentanedioate(232): To a solution 4-iodobenzoic acid 
231 (1.24 g, 5 mmol) in anhydrous DMF (40 mL) was added 6-chloro-2,4-dimethoxy-
1,3,5-triazine (1.05 g, 6 mmol) and N-methylmorpholine (0.65 mL, 6 mmol). After the 
mixture was stirred at r.t. for 2 h, N-methylmorpholine (0.65 mL, 6 mmol) and dimethyl 
L-glutamate hydrochloride (1.44 g, 6 mmol) were added all at once. The mixture was 
stirred at r.t. for 4 h. TLC showed the formation of one major spot at Rf  = 0.42 
(Hexane/EtOAc, 2:1 ). The reaction mixture was evaporated to dryness under reduced 
pressure. The residue was chromatographed on a silica gel column (2 cm x 15 cm) with 
Hexane/EtOAc, 3:1 as the eluent. Fractions were pooled and evaporated to dryness to 
afford 232 2.05 g, yield 95% as white crystals, mp 105-106 °C (lit.2 mp 105-106 °C), Rf  
= 0.42 (Hexane/EtOAc, 2:1 ). 1H NMR (CDCl3) δ 1.18-1.26(t, 3 H, J = 7.2 Hz, γ-
COOCH2CH3), 1.27-1.33 (t, 3 H, J = 7.2 Hz, α-COOCH2CH3), 2.10-2.35 (m, 2 H, β-
CH2), 2.38-2.56 (m, 2 H, γ-CH2), 4.06-4.16 (m, 2 H, γ-COOCH2CH3), 4.20-4.28 (m, 2 H, 
α-COOCH2CH3), 4.72-4.77 (m, 1 H, α-CH), 7.10 (d, 1 H, J = 6.7 Hz, CONH, exch), 7.55 
(d, 2 H, J = 8.6 Hz, C6H4), 7.80 (d, 2 H, J = 8.6 Hz, C6H4). 
(S)-diethyl 2-(4-((trimethylsilyl)ethynyl)benzamido)pentanedioate (233): A mixture 
of 232 (1.30 g, 3 mmol), trimethylsilyl acetylene (0.87 g, 9 mmol), 
tetrakis(triphenylphosphine)palladium (0.35 g, 0.3 mmol), copper iodide (0.114 g, 0.6 
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mmol), and triethylamine (0.6 mL) in 1,2-dichloroethane (15 mL) was stirred at room 
temperature under nitrogen in the dark overnight. Methylene chloride (20 mL) was added 
to the reaction mixture, and the mixture was washed with brine (20 mL x 2). The organic 
layer was separated and the solvent evaporated. The residue obtained was loaded onto a 
silica gel column and eluted with 4:1 hexanes/ethyl acetate. Fractions containing the 
product (TLC, Rf  = 0.44, Hexane/EtOAc, 2:1 ) were pooled and the solvent evaporated to 
afford 1.22 g (100%) of 233 as a red oil. 
1
H NMR (CDCl3) δ 0.26 (s, 9H, -Si(CH3)3), 
1.20-1.24 (t, 3 H, J = 7.2 Hz, γ-COOCH2CH3), 1.28-1.32 (t, 3 H, J = 7.2 Hz, α-
COOCH2CH3), 2.10-2.36 (m, 2 H, β-CH2), 2.38-2.56 (m, 2 H, γ-CH2), 4.06-4.15 (m, 2 H, 
γ-COOCH2CH3), 4.20-4.28 (m, 2 H, α-COOCH2CH3), 4.74-4.81 (m, 1 H, α-CH), 7.06 (d, 
1 H, J = 7.4 Hz, CONH, exch), 7.52 (d, 2 H, J = 8.5 Hz, C6H4), 7.76 (d, 2 H, J = 8.5 Hz, 
C6H4). 
 (S)-diethyl 2-(4-ethynylbenzamido)pentanedioate (234): Compound 233 (1.21 g, 
3mmol) was dissolved in THF (15 mL), to which tetrabutylammonium fluoride (3 mL of 
a 1 M solution in THF) was added, and the solution stirred at room temperature for 2 h. 
Methylene chloride (20 mL) was added to the reaction mixture and washed with brine (20 
mL x 2), then the organic layer separated and dried over Na2SO4 and the solvent was 
evaporated. The crude residue was flash chromatographed on silica gel and eluted with 
2:1 hexanes/ethyl acetate. Fractions containing the desired product (TLC) were pooled 
and evaporated to afford 0.72 g (72%) of 234 as a red oil : TLC Rf 0.25 (hexanes/ethyl 
acetate, 2:1); 
1
H NMR (CDCl3) δ 1.20-1.24 (t, 3 H, J = 7.2 Hz, γ-COOCH2CH3), 1.28-
1.32 (t, 3 H, J = 7.2 Hz, α-COOCH2CH3), 2.09-2.37 (m, 2 H, β-CH2), 2.38-2.56 (m, 2 H, 
γ-CH2), 3.20 (s, 1H, -CH), 4.06-4.15 (m, 2 H, γ-COOCH2CH3), 4.20-4.28 (m, 2 H, α-
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COOCH2CH3), 4.74-4.81 (m, 1 H, α-CH), 7.13 (d, 1 H, J = 7.4 Hz, CONH, exch), 7.55 
(d, 2 H, J = 8.5 Hz, C6H4), 7.78 (d, 2 H, J = 8.5 Hz, C6H4). 
2-amino-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (228): To a solution of 2,4-diamino-6-
hydroxypyrimidine 28 (5.0 g, 40 mmol) and sodium acetate (4.88 g, 60 mmol) in water 
(200 mL) at 100 °C was added a 50% solution of chloroacetaldehyde in water 227 (5.0 
mL, 40 mmol), dropwise, over a period of 15 min. The reaction mixture was stirred under 
reflux for a further 5 h. The resulting suspension was refrigerated overnight, and the 
precipitate obtained was filtered, washed with cold water (25 mL x 2), then with cold 
acetone (20 mL x 2) and dried to afford 4.15 g (69%) of 228 as a grey solid: TLC Rf 0.45 
(CHCl3/MeOH, 3:1); mp 322 °C (lit
2
 mp 323-324 °C); 
1
H NMR (DMSO-d6) δ 6.04 (bs, 2 
H, 2-NH2, exch), 6.18 (q, 1 H, 5-H), 6.60 (q, 1 H, 6-H), 10.22 (bs, 1 H, 3-NH, exch), 
10.96 (bs, 1 H, 7-NH, exch). 
      N-(4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide (229): A 
mixture of 228 (3.67 g, 24.5 mmol), pyridine (40 mL) and pivaloyl chloride (10.5 mL) 
was heated at 80-90 °C for 2 h. Volatiles were stripped under vacuum, and the residue 
was dissolved in methanol (20 mL), silica gel (5 g) was added, and the solvent was 
evaporated to form a plug which was dried, loaded on top of a silica gel column and 
eluted with 2:1 ethyl acetate/hexanes. Fractions containing the product (TLC) were 
pooled and the solvent evaporated to afford 2.07 g (36%) of 229 as an yellow solid: TLC 
Rf  0.50 (acetate/hexanes, 5:1); mp 293 °C (lit
300 
295 °C); 
1
H NMR (DMSO-d6) δ 1.24 (s, 
9 H, -C(CH3)3), 6.40 (q, 1 H, 5-H), 6.95 (q, 1 H, 6-H), 10.80 (bs, 1 H, 2-NHPiv or 3-NH, 
exch), 11.58 (bs, 1 H, 2-NHPiv or 3-NH, exch), 11.84 (bs, 1 H, 7-NH, exch). 
      N-(6-iodo-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide (230): 
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To a solution of 229 (150 mg, 0.64 mmol) in glacial acetic acid (5 mL) was added 
mercuric acetate (239 mg, 0.75 mmol) that was completely dissolved in glacial acetic 
acid (15 mL). The mixture was stirred at room temperature for 10 min, poured into 
saturated NaCl (10 mL), and stirred for 30 min. The precipitate was filtered, washed with 
water (3 mL), followed by MeOH (3 mL), and dried. The precipitate was combined with 
MeOH (5 mL) and stirred at room temperature for 1 h to remove starting material and 
filtrated to afford the crude. A mixture of this crude, iodine (0.19 g, 0.75 mmol) and 
CH2Cl2 (5 mL) was stirred at room temperature overnight. The solvent was removed 
under reduced pressure. The residue was washed with 3 M Na2S2O3 (5 mL x 2), followed 
by water (5 mL x 2), and dried in vacuo. The crude product was purified by column 
chromatography on silica gel and eluted with 1:1 ethyl acetate/hexanes.  The fractions 
containing the desired product (TLC) were pooled and evaporated to afford 175 mg 
(78%) of 230 as a white solid: TLC Rf 0.60 (ethyl acetate/hexanes, 2:1); mp 210 °C dec 
(lit.
2
 mp 211 °C dec); 
1
H NMR (DMSO-d6) δ 1.23 (s, 9 H, -C(CH3)3), 6.61 (s, 1 H, 5-H), 
10.88 (s, 1 H, 2-NHPiv or 3-NH, exch), 11.88 (s, 1 H, 2-NHPiv or 3-NH, exch), 12.10 (s, 
1 H, 7-NH, exch). 
      (S)-diethyl 2-(4-((4-oxo-2-pivalamido-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)ethynyl)benzamido)pentanedioate (235): To a 50-mL round-bottom flask covered 
with aluminum foil were added 230 (180 mg, 0.5 mmol) and acetylene 234 (248 mg, 0.75 
mmol), copper(I) iodide (25 mg, 0.1 mmol)  and tetrakis(triphenyl phosphine)palladium 
(0) (30 mg, 0.025 mmol)dissolved in anhydrous DMF (10 mL), followed by the addition 
of triethylamine (0.25 mL). The dark brown solution was stirred at 60 °C under nitrogen 
for 4h. The volatiles were removed in vacuo and the crude residue was flash 
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chromatographed on silica gel and eluted with 3% MeOH in CH2Cl2 to afford the 
compound 235 135 mg (48%) as a yellow solid: TLC Rf  0.65 (MeOH/CH2Cl2, 1:9); mp 
260 °C dec; 
1
H NMR (DMSO-d6) δ 1.15-1.22 (m, 6H, -2CH3), 1.25 (s, 9 H, -C(CH3)3), 
1.99-2.15 (m, 2 H, β-CH2), 2.43-2.45 (m, 2 H, γ-CH2), 4.02-4.15 (m, 4 H, α, γ-
COOCH2CH3), 4.42-4.48 (m, 1 H, α-CH),  6.85 (s, 1 H, 5-H), 7.65 (d, 2 H, C6H4, J = 8.5 
Hz), 7.94 (d, 2 H, C6H4, J = 8.5 Hz), 8.85 (d, 1 H, CONH, , J = 7.5 Hz), 10.98 (s, 1 H, 2-
NHPiv or 3-NH, exch), 11.97 (s, 1 H, 2-NHPiv or 3-NH, exch), 12.27 (s, 1 H, 7-NH, 
exch). 
 (S)-diethyl 2-(4-(2-(4-oxo-2-pivalamido-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)ethyl)benzamido)pentanedioate (236): To a solution of 235 (50 mg) in 
MeOH/CH2Cl2 (1:1, 30 mL) was added 10% Pd/C (50 mg). The resulting suspension was 
hydrogenated in a Parr apparatus for 5h at 50 psi hydrogen pressure. The reaction mixture 
was filtered through Celite and washed with methanol (30 mL). After evaporation of the 
solvent, 50 mg (100%) of 236 was obtained as a grey solid: mp 142 °C, Rf  0.65 
(MeOH/CH2Cl2, 1:9). 
1H NMR (DMSO-d6) δ 1.13-1.21 (m, 6H, -2CH3), 1.24 (s, 9 H, -
C(CH3)3), 1.96-2.13 (m, 2 H, β-CH2), 2.41-2.45 (t, 2 H, γ-CH2, J = 7.6 Hz), 2.91-3.04 (m, 
4H, -CH2CH2-), 4.00-4.14 (m, 4 H, α, γ-COOCH2CH3), 4.38-4.45 (m, 1 H, α-CH),  6.10 
(s, 1 H, 5-H), 7.33 (d, 2 H, C6H4, J = 8.2 Hz), 7.79 (d, 2 H, C6H4, J = 8.2 Hz), 8.65 (d, 1 
H, CONH, , J = 7.5 Hz), 10.76 (s, 1 H, 2-NHPiv or 3-NH, exch), 11.40 (s, 1 H, 2-NHPiv 
or 3-NH, exch), 11.82 (s, 1 H, 7-NH, exch). 
     (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)ethyl)benzamido)pentanedioic acid (163): To a solution of the diester 236 (50 mg) 
was added 1 N NaOH (4 mL), and the mixture was stirred under N2 at room temperature 
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for 3 days. TLC (CH2Cl2/MeOH, 9:1) showed the disappearance of the starting material 
(Rf  = 0.65) and formation of one major spot at the origin. The reaction mixture was 
evaporated to dryness under reduced pressure. The residue was dissolved in water (3 
mL), the resulting solution was cooled in an ice bath, and the pH was adjusted to 3-4 with 
dropwise addition of 1 N HCl. The resulting suspension was frozen in a dry ice/acetone 
bath, thawed in a refrigerator to 4-5 °C, and filtered. The residue was washed with a 
small amount of cold water and ethyl acetate and dried in vacuo using P2O5 to afford 30 
mg (80%) of 163 as a pale white powder: mp 209 °C (lit.2 mp 210-213 °C), Rf  = 0.05 
(CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ  1.90-2.11 (m, 2 H, CH2), 2.31-2.37 (t, 2 H, 
CH2), 2.77-2.84 (t, 2 H,  CH2), 2.92-2.98 (t, 2 H,  CH2), 4.34-4.41 (m, 1 H, CH), 5.86 (s, 
1 H, CH), 5.97 (s, 2 H, 2-NH2), 7.31 (d, 2 H, C6H4, J = 8.0 Hz), 7.79 (d, 2 H, C6H4, J = 
8.0 Hz), 8.51 (d, 1 H, CONH, , J = 8.0 Hz), 10.12 (s, 1 H, 3-NH), 10.89 (s, 1H, 7-NH), 
12.60 (br, 2 H, 2 COOH). Anal. (C20H21N5O6 · 0.75 H2O) Cal. C: 54.48, H: 5.14, N: 
15.88. Found C: 54.49, H: 5.04, N: 15.53. 
Ethyl 8-bromo-7-oxooctanoate (241): To a solution of 7-methoxy-7-oxoheptanoic acid 
(237) (0.32 g, 1.5 mmol) in a 50 mL flask was added oxalyl chloride (1.5 mL) and 
anhydrous CH2Cl2 (10 mL). The resulting solution was refluxed for 1 h and then cooled 
to room temperature. After evaporation of solvent under reduced pressure, the residue 
was dissolved in ethyl ether (20 mL). The resulting solution was added dropwise to an 
ice-cooled ether solution of diazomethane (generated in situ from 1.4 g N-nitroso-N-
methylurea) over 10 min. To this solution was added 48% HBr (1.5 mL). The resulting 
mixture was refluxed for 1.5 h. After the mixture was cooled to room temperature, the 
organic layer was separated and the aqueous layer was extracted with ethyl ether (20 mL 
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x 3). The combined organic layers were washed with two portions of 10% Na2CO3 
solution and dried over Na2SO4. The solvent was evaporated to afford 0.38 g 241: yield 
79% as white crystals, mp 68-69 °C, Rf  = 0.50 (Hexane/EtOAc, 5:1 ). 
1H NMR (CDCl3) 
δ 1.24-1,27 (t, 3 H, CH3, J = 7.5 Hz ), 1.32-1.37 (m, 2 H,  CH2), 1.62-1.65 (m, 4 H, 2 
CH2), 2.28-2.31 (t, 2 H, CH2, J = 7.5 Hz ), 2.65-2.69 (m, 2 H, CH2), 3.87 (s, 2H, CH2Br), 
4.10-4.14 (q, 2 H, CH2, J = 7.5 Hz ). 
Methyl 9-bromo-8-oxononanoate (242): Compound 242 was synthesized as described 
for 241: yield 83% as light yellow crystals, mp 70-71 °C, Rf  = 0.51 (Hexane/EtOAc, 5:1 
). 1H NMR (CDCl3) δ 1.32-1.33 (m, 4 H, 2 CH2), 1.60-1.63 (m, 4 H, 2 CH2), 2.28-2.31 (t, 
2 H, CH2, J = 7.5 Hz ), 2.63-2.66 (t, 2 H, CH2, J = 7.5 Hz ), 3.66 (s, 3H, CH3), 3.87 (s, 2H, 
CH2Br). 
Methyl 10-bromo-9-oxodecanoate (243): Compound 243 was synthesized as described 
for 241: yield 78% as yellow crystals, mp 123-124 °C, Rf  = 0.51 (Hexane/EtOAc, 5:1 ). 
1H NMR (CDCl3) δ 1.31-1.33 (m, 6 H, 3 CH2), 1.60-1.62 (m, 4 H, 2 CH2), 2.28-2.31 (t, 2 
H, CH2, J = 7.5 Hz ), 2.63-2.66 (t, 2 H, CH2, J = 7.5 Hz ), 3.66 (s, 3H, CH3), 3.87 (s, 2H, 
CH2Br). 
Methyl 11-bromo-10-oxoundecanoate (244): Compound 244 was synthesized as 
described for 241: yield 72% as yellow crystals, mp 92-93 °C, Rf  = 0.52 (Hexane/EtOAc, 
3:1 ). 1H NMR (CDCl3) δ 1.31-1.33 (m, 8 H, 4 CH2), 1.59-1.62 (m, 4 H, 2 CH2), 2.28-
2.31 (t, 2 H, CH2, J = 7.5 Hz ), 2.62-2.65 (t, 2 H, CH2, J = 7.5 Hz ), 3.66 (s, 3H, CH3), 3.87 
(s, 2H, CH2Br). 
Ethyl 6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexanoate 
(245): To a suspension of 2,4-diamino-6-hydroxypyrimidine 35 (1.26 g, 10.0 mmol) in 
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anhydrous DMF (40 mL) was added 241 (2.64 g, 10.0 mmol). The resulting mixture was 
stirred under N2 at room temperature for 3 days. TLC showed the disappearance of 
starting materials and the formation of one major spot. After evaporation of solvent, 
CH3OH (20 mL) was added followed by silica gel (5 g). Evaporation of the solvent 
afforded a plug, which was loaded onto a silica gel column (3.5 cm x 15 cm) and eluted 
initially with CHCl3 followed by 10% MeOH in CHCl3 and then 15% MeOH in CHCl3. 
Fractions showing Rf  = 0.39 were pooled and evaporated to afford 1.20 g 245: yield 41% 
as a yellow solid, mp 189-190 °C, Rf  = 0.39 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) 
δ 1.15-1.17 (t, 3 H, CH3,  J = 7.5 Hz), 1.26-1.31 (m, 2 H, CH2), 1.52-1.57 (m, 4 H, 2 
CH2), 2.25-2.28 (t, 2 H, CH2,  J = 7.5 Hz), 2.44-2.47 (t, 2 H, CH2,  J = 7.5 Hz), 4.01-4.06 
(m, 2 H, OCH2), 5.84 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 10.10 (s, 1 H, 3-NH), 10.77 (s, 
1H, 7-NH).  
Methyl 7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)heptanoate 
(246): Compound 246 was synthesized as described for 245: yield 39% as a yellow solid, 
mp 178-179 °C, Rf  = 0.39 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ 1.24-1.29 (m, 4 
H, 2 CH2), 1.49-1.56 (m, 4 H, 2 CH2), 2.27-2.30 (t, 2 H, CH2,  J = 7.5 Hz), 2.44-2.47 (m, 
2 H, CH2), 3.57 (s, 3 H, OCH3), 5.83 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 10.11 (s, 1 H, 3-
NH), 10.77 (s, 1H, 7-NH).  
Methyl 8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)octanoate 
(247): Compound 247 was synthesized as described for 245: yield 43% as a yellow solid, 
mp 162-163 °C, Rf  = 0.41 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ 1.21-1.30 (m, 6 
H, 3 CH2), 1.49-1.56 (m, 4 H, 2 CH2), 2.27-2.29 (t, 2 H, CH2,  J = 7.5 Hz), 2.43-2.47 (t, 2 
H, CH2,  J = 7.5 Hz), 3.57 (s, 3 H, OCH3), 5.84 (s, 1 H, CH), 6.00 (s, 2 H, 2-NH2), 10.16 
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(s, 1 H, 3-NH), 10.79 (s, 1H, 7-NH).  
Methyl 9-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)nonanoate 
(248): Compound 248 was synthesized as described for 245: yield 42% as a yellow solid, 
mp 165-166 °C, Rf  = 0.41 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ 1.21-1.30 (m, 8 
H, 4 CH2), 1.49-1.56 (m, 4 H, 2 CH2), 2.26-2.29 (t, 2 H, CH2,  J = 7.5 Hz), 2.44-2.47 (t, 2 
H, CH2,  J = 7.5 Hz), 3.57 (s, 3 H, OCH3), 5.85 (s, 1 H, CH), 6.03 (s, 2 H, 2-NH2), 10.20 
(s, 1 H, 3-NH), 10.81 (s, 1H, 7-NH).  
(S)-diethyl 2-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)hexanamido)pentanedioate (249): To a suspension of 245 (100 mg, 0.34 mmol) in 10 
mL CH3OH was added 1 N NaOH (10 mL). The resulting mixture was stirred under N2 at 
r.t. for 24 h. TLC indicated the disappearance of starting material and the formation of 
one major spot at the origin. The resulting solution was cooled in an ice bath, and the pH 
was adjusted 3 to 4 using 3 N HCl. The resulting suspension was chilled in a dry 
ice/acetone bath and thawed to 4 °C overnight in a refrigerator. The precipitate was 
filtered, washed with cold water, and dried in a desiccator under reduced pressure using 
P2O5 to a brown powder, which was used directly for the next step. 
To a solution of this brown powder in anhydrous DMF (5 mL) was added 6-chloro-2,4-
dimethoxy-1,3,5-triazine (72 mg, 0.42 mmol) and N-methylmorpholine (43 mg, 0.42 
mmol). After the mixture was stirred at r.t. for 2 h, N-methylmorpholine (43 mg, 0.42 
mmol) and dimethyl L-glutamate hydrochloride (120 mg, 0.51 mmol) were added all at 
once. The mixture was stirred at r.t. for 4 h. TLC showed the formation of one major spot 
at Rf  = 0.62 (CHCl3/MeOH, 5:1). The reaction mixture was evaporated to dryness under 
reduced pressure. The residue was dissolved in a minimum amount of CHCl3/MeOH, 5:1, 
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and chromatographed on a silica gel column (2 cm x 15 cm) with 4% MeOH in CHCl3 as 
the eluent. Fractions that showed the desired single spot at Rf  = 0.62 were pooled and 
evaporated to dryness to afford 249 102 mg: yield 67% as a yellow syrup, Rf  = 0.62 
(CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ  1.15-1.18 (t, 6 H, 2 CH3, J = 7.0 Hz),  1.23-
1.29 (m, 2 H,  CH2), 1.48-1.58 (m, 4 H, 2 CH2), 1.76-1.82 (m, 1 H,  CH),  1.92-1.98 (m, 1 
H,  CH),   2.09-2.12 (t, 2 H, CH2, J = 7.0 Hz), 2.33-2.37 (m, 2 H, CH2), 2.44-2.47 (m, 2 
H,  CH2), 4.02-4.07 (m, 4 H, 2 CH2),   4.19-4.24 (m, 1 H, CH), 5.84 (s, 1 H, CH), 5.94 (s, 
2 H, 2-NH2), 8.16 (d, 1 H, CONH, , J = 3.8 Hz), 10.10 (s, 1 H, 3-NH), 10.76 (s, 1H, 7-
NH).  
(S)-diethyl 2-(7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)heptanamido)pentanedioate (250): Compound 250 was synthesized as described for 
249: yield 70% as a yellow syrup, Rf  = 0.62 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) 
δ  1.15-1.18 (m, 6 H, 2 CH3),  1.23-1.30 (m, 4 H,  2 CH2), 1.48-1.58 (m, 4 H, 2 CH2), 
1.76-1.82 (m, 1 H,  CH),  1.92-1.99 (m, 1 H,  CH),   2.09-2.12 (t, 2 H, CH2, J = 7.0 Hz), 
2.33-2.37 (m, 2 H, CH2), 2.44-2.47 (m, 2 H,  CH2), 4.02-4.08 (m, 4 H, 2 CH2),   4.20-4.24 
(m, 1 H, CH), 5.83 (s, 1 H, CH), 5.93 (s, 2 H, 2-NH2), 8.15 (d, 1 H, CONH, , J = 3.8 Hz), 
10.10 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH).  
(S)-diethyl 2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)octanamido)pentanedioate (251): Compound 251 was synthesized as described for 
249: yield 68% as a yellow syrup, Rf  = 0.64 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) 
δ  1.16-1.19 (t, 6 H, 2 CH3, J = 7.0 Hz), 1.22-1.32 (m, 6 H,  3 CH2), 1.47-1.57 (m, 4 H, 2 
CH2), 1.76-1.82 (m, 1 H,  CH),  1.92-1.99 (m, 1 H,  CH),   2.09-2.12 (t, 2 H, CH2, J = 7.0 
Hz), 2.34-2.37 (m, 2 H, CH2), 2.45-2.48 (m, 2 H,  CH2), 4.02-4.08 (m, 4 H, 2 CH2),   
178 
 
 
4.20-4.24 (m, 1 H, CH), 5.84 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 8.15 (d, 1 H, CONH, , J 
= 3.8 Hz), 10.10 (s, 1 H, 3-NH), 10.76 (s, 1H, 7-NH).  
(S)-diethyl 2-(9-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)nonanamido)pentanedioate (252): Compound 252 was synthesized as described for 
249: yield 66% as a yellow syrup, Rf  = 0.64 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) 
δ  1.15-1.18 (t, 6 H, 2 CH3, J = 7.0 Hz), 1.22-1.32 (m, 8 H,  4 CH2), 1.47-1.57 (m, 4 H, 2 
CH2), 1.76-1.82 (m, 1 H,  CH),  1.92-1.99 (m, 1 H,  CH),   2.09-2.12 (t, 2 H, CH2, J = 7.0 
Hz), 2.34-2.37 (m, 2 H, CH2), 2.45-2.48 (m, 2 H,  CH2), 4.02-4.08 (m, 4 H, 2 CH2),   
4.20-4.24 (m, 1 H, CH), 5.83 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 8.15 (d, 1 H, CONH, , J 
= 3.8 Hz), 10.10 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH).  
(S)-2-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)hexanamido)pentanedioic acid (164): To a solution of the diester 249 (100 mg, 0.22 
mmol) was added 1 N NaOH (5 mL), and the mixture was stirred under N2 at room 
temperature for 1 h. TLC showed the disappearance of the starting material and formation 
of one major spot at the origin (CHCl3/MeOH, 5:1). The resulting solution was cooled in 
an ice bath, and the pH was adjusted to 3-4 with dropwise addition of 1 N HCl. The 
resulting suspension was frozen in a dry ice/acetone bath, thawed in a refrigerator to 4-5 
°C, and filtered. The residue was washed with a small amount of cold water and ethyl 
acetate and dried in vacuo using P2O5 to afford 78 mg 164: yield 90% as a white powder, 
mp 145-146 °C decomposed, Rf  = 0.08 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ  
1.24-1.30 (m, 2 H,  CH2), 1.48-1.58 (m, 4 H, 2 CH2), 1.71-1.79 (m, 1 H,  CH),  1.88-1.95 
(m, 1 H,  CH),   2.09-2.12 (t, 2 H, CH2, J = 7.5 Hz), 2.24-2.27 (m, 2 H, CH2, J = 7.5 Hz), 
2.44-2.47 (m, 2 H,  CH2), 4.16-4.21 (m, 1 H, CH), 5.84 (s, 1 H, CH), 5.95 (s, 2 H, 2-
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NH2), 7.99 (d, 1 H, CONH, , J = 4.0 Hz), 10.10 (s, 1 H, 3-NH), 10.76 (s, 1H, 7-NH), 
12.50 (br, 2 H, 2 COOH). Anal. (C17H23N5O6 · 2.0 H2O) Cal. C: 47.55, H: 6.34, N: 16.31. 
Found C: 47.88, H: 6.01, N: 15.98. 
(S)-2-(7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)heptanamido)pentanedioic acid (165): Compound 165 was synthesized as described 
for 164: yield 91% as a pale yellow powder, mp 116-117 °C decomposed, Rf  = 0.08 
(CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ  1.22-1.32 (m, 4 H,  2 CH2), 1.45-1.58 (m, 
4 H, 2 CH2), 1.71-1.79 (m, 1 H,  CH),  1.91-1.98 (m, 1 H,  CH),   2.09-2.12 (t, 2 H, CH2, J 
= 7.5 Hz), 2.24-2.28 (m, 2 H, CH2, J = 7.5 Hz), 2.44-2.47 (m, 2 H,  CH2), 4.16-4.21 (m, 1 
H, CH), 5.84 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 8.02 (d, 1 H, CONH, , J = 4.0 Hz), 10.10 
(s, 1 H, 3-NH), 10.76 (s, 1H, 7-NH), 12.12 (br, 1 H, 1 COOH), 12.52 (br, 1 H, 1 COOH). 
Anal. (C18H25N5O6 · 0.5 H2O) Cal. C: 51.92, H: 6.29, N: 16.82. Found C: 51.92, H: 6.43, 
N: 16.59. 
(S)-2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)octanamido)pentanedioic acid (166): Compound 166 was synthesized as described 
for 164: yield 95% as a yellow powder, mp 135-136 °C decomposed, Rf  = 0.08 
(CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ  1.20-1.32 (m, 6 H,  3 CH2), 1.45-1.58 (m, 
4 H, 2 CH2), 1.71-1.79 (m, 1 H,  CH),  1.90-1.98 (m, 1 H,  CH),   2.08-2.12 (t, 2 H, CH2, J 
= 7.5 Hz), 2.24-2.28 (m, 2 H, CH2, J = 7.5 Hz), 2.44-2.47 (t, 2 H,  CH2, J = 7.5 Hz), 4.16-
4.21 (m, 1 H, CH), 5.84 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 8.02 (d, 1 H, CONH, J = 3.8 
Hz), 10.11 (s, 1 H, 3-NH), 10.76 (s, 1H, 7-NH). Anal. (C19H27N5O6 · 0.5 H2O) Cal. C: 
53.01, H: 6.56, N: 16.27. Found C: 53.29, H: 6.76, N: 16.19. 
(S)-2-(9-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
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yl)nonanamido)pentanedioic acid (167): Compound 167 was synthesized as described 
for 164: yield 90% as a pale yellow powder, mp 123-124 °C decomposed, Rf  = 0.08 
(CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ  1.20-1.32 (m, 8 H,  4 CH2), 1.42-1.58 (m, 
4 H, 2 CH2), 1.71-1.79 (m, 1 H,  CH),  1.90-1.98 (m, 1 H,  CH),   2.08-2.11 (t, 2 H, CH2, J 
= 7.5 Hz), 2.24-2.28 (m, 2 H, CH2, J = 7.5 Hz), 2.44-2.47 (t, 2 H,  CH2, J = 7.5 Hz), 4.16-
4.21 (m, 1 H, CH), 5.84 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 8.01 (d, 1 H, CONH, J = 3.8 
Hz), 10.11 (s, 1 H, 3-NH), 10.76 (s, 1H, 7-NH). Anal. (C20H29N5O6 · 0.5 H2O) Cal. C: 
54.04, H: 6.80, N: 15.76. Found C: 54.17, H: 6.85, N: 15.67. 
(S)-diethyl 2-(2-iodobenzamido)pentanedioate (261): To a solution 2-iodobenzoic acid 
260 (2.48 g, 10 mmol) in anhydrous DMF (40 mL) was added 6-chloro-2,4-dimethoxy-
1,3,5-triazine (2.10 g, 12 mmol) and N-methylmorpholine (1.30 mL, 12 mmol). After the 
mixture was stirred at r.t. for 2 h, N-methylmorpholine (1.30 mL, 12 mmol) and dimethyl 
L-glutamate hydrochloride (2.88 g, 12 mmol) were added all at once. The mixture was 
stirred at r.t. for 4 h. TLC showed the formation of one major spot at Rf  = 0.38 
(Hexane/EtOAc, 2:1 ). The reaction mixture was evaporated to dryness under reduced 
pressure. The residue was chromatographed on a silica gel column (2 cm x 15 cm) with 
Hexane/EtOAc, 3:1 as the eluent. Fractions were pooled and evaporated to dryness to 
afford 261 4.32 g, yield 99% as white crystals, mp 111 °C, Rf  = 0.38 (Hexane/EtOAc, 
2:1 ). 1H NMR (CDCl3) δ 1.23-1.26(t, 3 H, J = 7.2 Hz, γ-COOCH2CH3), 1.30-1.33 (t, 3 
H, J = 7.0 Hz, α-COOCH2CH3), 2.09-2.16 (m, 1 H, β-CH2), 2.31-2.39 (m, 1 H, β-CH2), 
2.46-2.60 (m, 2 H, γ-CH2), 4.11-4.15 (m, 2 H, γ-COOCH2CH3), 4.22-4.27 (m, 2 H, α-
COOCH2CH3), 4.79-4.83 (m, 1 H, α-CH), 6.53-6.54 (d, 1 H, J = 4.0 Hz, CONH, exch), 
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7.09-7.13 (t, 1 H, C6H4 ,  J = 8.6 Hz), 7.37-7.42 (m, 2 H, C6H4), 7.86-7.88 (d, 1 H, C6H4,  
J = 4.0 Hz,). 
(S)-diethyl 2-(3-iodobenzamido)pentanedioate (263): Compound 263 was synthesized 
as described for 261: yield 98% as white crystals: mp 103 °C, Rf  = 0.40 (Hexane/EtOAc, 
2:1 ). 1H NMR (CDCl3) δ 1.23-1.25(t, 3 H, J = 7.2 Hz, γ-COOCH2CH3), 1.30-1.32 (t, 3 
H, J = 7.0 Hz, α-COOCH2CH3), 2.11-2.18 (m, 1 H, β-CH2), 2.28-2.34 (m, 1 H, β-CH2), 
2.40-2.53 (m, 2 H, γ-CH2), 4.12-4.16 (m, 2 H, γ-COOCH2CH3), 4.24-4.26 (m, 2 H, α-
COOCH2CH3), 4.74-4.77 (m, 1 H, α-CH), 7.02-7.04 (d, 1 H, J = 4.0 Hz, CONH, exch), 
7.17-7.20 (t, 1 H,  J = 4.0 Hz, C6H4), 7.76-7.78 (d, 1 H, J = 1.0 Hz, C6H4), 7.84-7.85 (d, 1 
H, J = 1.0 Hz, C6H4), 8.16-8.17 (t, 1 H, J = 1.0 Hz, C6H4). 
1-bromohex-5-yn-2-one (255): To a solution of pent-4-ynoic acid 256 (1.96 g, 20 mmol) 
in a 50 mL flask was added oxalyl chloride (8.0 mL) and anhydrous CH2Cl2 (10 mL). The 
resulting solution was refluxed for 1 h and then cooled to room temperature. After 
evaporation of solvent under reduced pressure, the residue was dissolved in ethyl ether 
(20 mL). The resulting solution was added dropwise to an ice-cooled ether solution of 
diazomethane (generated in situ from 14 g N-nitroso-N-methylurea) over 10 min. To this 
solution was added 48% HBr (15 mL). The resulting mixture was refluxed for 1.5 h. 
After the mixture was cooled to room temperature, the organic layer was separated and 
the aqueous layer was extracted with ether (20 mL x 3). The combined organic layers 
were washed with two portions of 10% Na2CO3 solution and dried over Na2SO4. The 
solvent was evaporated to afford 3.25 g (93%) of 255 as a yellow oil, Rf  = 0.52 
(Hexane/EtOAc, 3:1 ). 1H NMR (CDCl3) δ 1.97-1.98 (t, 1 H, CH, J = 2.0 Hz), 2.48-2.51 
(t, 2 H, CH2, J = 7.0 Hz), 2.90-2.93 (t, 2 H, CH2, J = 7.0 Hz), 3.83 (s, 3 H, OCH3), 3.91 
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(s, 2H, CH2Br). 
2-amino-6-(but-3-yn-1-yl)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (253): To a 
suspension of 2,4-diamino-6-hydroxypyrimidine 35 (2.20 g, 17.4 mmol) in anhydrous 
DMF (40 mL) was added 255 (3.05 g, 17.4 mmol). The resulting mixture was stirred 
under N2 at room temperature for 3 days. TLC showed the disappearance of starting 
materials and the formation of one major spot at  Rf  = 0.32 (CHCl3/MeOH, 4:1). After 
evaporation of solvent, CH3OH (20 mL) was added followed by silica gel (5 g). 
Evaporation of the solvent afforded a plug, which was loaded onto a silica gel column 
(3.5 cm x 15 cm) and eluted initially with CHCl3 followed by 10% MeOH in CHCl3 and 
then 15% MeOH in CHCl3. Fractions showing Rf  = 0.32 were pooled and evaporated to 
afford 2.67 g (76%) of 253 as a yellow powder: mp 230-231 °C (lit.22 mp 230-231 °C). 
1H NMR (DMSO-d6) δ 2.43-2.47 (m, 2 H, CH2), 2.66-2.69 (t, 2 H, CH2, J = 7.0 Hz), 
2.78-2.79 (t, 1 H, CH, J = 2.5 Hz), 5.97 (s, 1 H, CH), 6.14 (s, 2 H, 2-NH2), 10.30 (s, 1 H, 
3-NH), 10.90 (s, 1H, 7-NH). 
(S)-diethyl 2-(2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-
1-yn-1-yl)benzamido)pentanedioate (264): To a 25-mL round-bottomed flask, equipped 
with a magnetic stirrer and gas inlet, was added a mixture of 
tetrakis(triphenylphosphine)palladium(0) (23.2 mg, 0.02 mmol), triethylamine (10 mL), 
253 (87 mg, 0.2 mmol) and anhydrous DMF (10 mL). To the stirred mixture, under N2, 
was added copper(I) iodide (7.6 mg, 0.04 mmol) and 261 (40 mg, 0.2 mmol), and the 
reaction mixture was stirred at room temperature overnight (17-18 h). Silica gel (0.5 g) 
was then added, and the solvent was evaporated under reduced pressure. The resulting 
plug was loaded on to a silica gel column (3.5 × 12 cm) and eluted with CHCl3 followed 
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by 3% MeOH in CHCl3 and then 5% MeOH in CHCl3. Fractions with desired Rf (TLC) 
were pooled and evaporated to afford 264 as a yellow syrup 50 mg, yield: 50%, Rf = 0.32 
(CHCl3/MeOH, 10:1). 
1H NMR (DMSO-d6) δ 1.12-1.14 (t, 3H, -CH3, J = 7.0 Hz), 1.19-
1.22 (t, 3H, -CH3, J = 7.0 Hz), 1.90-2.11 (m, 2 H, β-CH2), 2.46-2.48 (m, 2 H, γ-CH2), 
2.67-2.70 (t, 2 H, CH2, J = 7.0 Hz), 2.76-2.79 (t, 2 H, CH2, J = 7.0 Hz), 4.01-4.15 (m, 4 
H, α, γ-COOCH2CH3), 4.44-4.48 (m, 1 H, α-CH),  5.99 (s, 1 H, 5-H), ), 6.06 (s, 2 H, 2-
NH2), 7.40-7.50 (m, 4 H, C6H4), 8.69-8.71 (d, 1 H, CONH, , J = 4.0 Hz), 10.21 (s, 1 H, 3-
NH, exch), 10.85 (s, 1 H, 7-NH, exch). 
(S)-diethyl 2-(2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)benzamido)pentanedioate (265): To a solution of 264 (120 mg) in 
MeOH/CH2Cl2 (1:1, 30 mL) was added 10% Pd/C (240 mg). The resulting suspension 
was hydrogenated in a Parr apparatus for 5h at 55 psi hydrogen pressure. The reaction 
mixture was filtered through Celite and washed with methanol (30 mL). After 
evaporation of the solvent, 120 mg (100%) of 265 was obtained as a white syrup, Rf = 
0.32 (CHCl3/MeOH, 10:1). 
1H NMR (DMSO-d6) δ 1.12-1.14 (t, 3H, -CH3, J = 7.0 Hz), 
1.19-1.22 (t, 3H, -CH3, J = 7.0 Hz), 1.53-1.58 (m, 4 H, 2 CH2), 1.90-2.11 (m, 2 H, β-
CH2), 2.46-2.48 (m, 2 H, γ-CH2), 2.73 (s, 2 H, CH2), 2.89 (s, 2 H, CH2), 4.03-4.14 (m, 4 
H, α, γ-COOCH2CH3), 4.39-4.43 (m, 1 H, α-CH), 5.83 (s, 1 H, 5-H), 5.93 (s, 2 H, 2-
NH2), 7.24-7.26 (m, 1 H, C6H4), 7.30-7.31 (m, 1 H, C6H4), 7.34-7.37 (m, 1 H, C6H4), 
8.65-8.67 (d, 1 H, CONH, , J = 4.0 Hz), 10.09 (s, 1 H, 3-NH, exch), 10.75 (s, 1 H, 7-NH, 
exch).   
 (S)-2-(2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-1-yn-
1-yl)benzamido)pentanedioic acid (169): Compound 169 was synthesized as described 
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for 2: yield 98% as a pale powder: mp 167 °C decomposed, Rf  = 0.05 (CHCl3/MeOH, 
5:1). 1H NMR (DMSO-d6) δ 1.81-2.11 (m, 2 H, β-CH2), 2.38-2.41 (t, 2 H, γ-CH2, J = 7.0 
Hz), 2.68-2.70 (t, 2 H, CH2, J = 7.0 Hz), 2.76-2.79 (t, 2 H, CH2, J = 7.0 Hz), 4.43-4.47 
(m, 1 H, α-CH), 5.98 (s, 2 H, 2-NH2), 6.00 (s, 1 H, 5-H), 7.39-7.45 (m, 1 H, C6H4), 7.48-
7.50 (m, 1 H, C6H4), 8.69-8.71 (d, 1 H, CONH, J = 4.0 Hz), 10.14 (s, 1 H, 3-NH, exch), 
10.84 (s, 1 H, 7-NH, exch). 
(S)-2-(2-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)benzamido)pentanedioic acid (170): Compound 170 was synthesized as 
described for 2: yield 90% as a pink powder: mp 177-178 °C decomposed, Rf  = 0.05 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ 1.50-1.62 (m, 4 H, 2 CH2), 1.90-2.11 (m, 2 
H, β-CH2), 2.36-2.38 (m, 2 H, γ-CH2), 2.73 (s, 2 H, CH2), 2.89 (s, 2 H, CH2), 4.34-4.39 
(m, 1 H, α-CH), 5.85 (s, 1 H, 5-H), ), 6.05 (s, 2 H, 2-NH2), 7.23-7.25 (m, 2 H, C6H4), 
7.30-7.34 (m, 2 H, C6H4), 8.54-8.56 (d, 1 H, CONH,  J = 5.0 Hz), 10.21 (s, 1 H, 3-NH, 
exch), 10.79 (s, 1 H, 7-NH, exch).  Anal. (C22H25N5O6 · 1.1 H2O) Cal. C: 55.60, H: 5.77, 
N: 14.74. Found C: 55.32, H: 5.58, N: 14.40. 
(S)-diethyl 2-(3-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-
1-yn-1-yl)benzamido)pentanedioate (266): Compound 266 was synthesized as 
described for 264: yield 73% as a yellow powder: mp 178-179 °C decomposed, Rf  = 0.32 
(CHCl3/MeOH, 10:1). 
1H NMR (DMSO-d6) δ 1.15-1.16 (t, 3H, -CH3, J = 7.0 Hz), 1.19-
1.20 (t, 3H, -CH3, J = 7.0 Hz), 1.98-2.14 (m, 2 H, β-CH2), 2.42-2.45 (m, 2 H, γ-CH2), 
2.73-2.76 (t, 2 H, CH2, J = 7.0 Hz), 2.78-2.81 (t, 2 H, CH2, J = 7.0 Hz), 4.03-4.13 (m, 4 
H, α, γ-COOCH2CH3), 4.41-4.45 (m, 1 H, α-CH),  5.99 (s, 2 H, 2-NH2),  6.01 (s, 1 H, 5-
H), 7.44-7.47 (t, 1 H, C6H4, J = 4.0 Hz), 7.53-7.54 (d, 1 H, C6H4, J = 4.0 Hz), 7.80-7.82 
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(d, 1 H, C6H4, J = 4.0 Hz), 7.90 (s, 1 H, C6H4), 8.79-8.80 (d, 1 H, CONH, , J = 4.0 Hz), 
10.14 (s, 1 H, 3-NH, exch), 10.88 (s, 1 H, 7-NH, exch). 
(S)-diethyl 2-(3-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)benzamido)pentanedioate (267): Compound 267 was synthesized as described 
for 265: yield 100% as a white syrup, Rf  = 0.32 (CHCl3/MeOH, 10:1). 
1H NMR (DMSO-
d6) δ 1.15-1.16 (t, 3H, -CH3, J = 7.0 Hz), 1.19-1.20 (t, 3H, -CH3, J = 7.0 Hz), 1.58-1.64 
(m, 4 H, 2 CH2), 1.98-2.14 (m, 2 H, β-CH2), 2.63-2.65 (m, 2 H, γ-CH2), 2.73-2.76 (t, 2 H, 
CH2, J = 7.0 Hz), 2.78-2.81 (t, 2 H, CH2, J = 7.0 Hz), 4.03-4.13 (m, 4 H, α, γ-
COOCH2CH3), 4.41-4.45 (m, 1 H, α-CH),  5.85 (s, 1 H, 5-H), 5.93 (s, 2 H, 2-NH2),  7.36-
7.37 (m, 2 H, C6H4), 7.70 (s, 1 H, C6H4), 7.95 (s, 1 H, C6H4), 8.65-8.67 (d, 1 H, CONH, , 
J = 4.0 Hz), 10.10 (s, 1 H, 3-NH, exch), 10.78 (s, 1 H, 7-NH, exch). 
(S)-2-(3-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-1-yn-1-
yl)benzamido)pentanedioic acid (171): Compound 171 was synthesized as described 
for 2: yield 60% as a blue powder: mp 140-141 °C decomposed,Rf  = 0.05 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ 1.81-2.11 (m, 2 H, β-CH2), 2.33-2.36 (t, 2 
H, γ-CH2, J = 7.0 Hz), 2.73-2.76 (t, 2 H, CH2, J = 7.0 Hz), 2.79-2.81 (t, 2 H, CH2, J = 7.0 
Hz), 4.43-4.47 (m, 1 H, α-CH), 5.99 (s, 2 H, 2-NH2), 6.01 (s, 1 H, 5-H), 7.36-7.37 (m, 2 
H, C6H4), 7.70 (s, 1 H, C6H4), 7.95 (s, 1 H, C6H4), 8.65-8.66 (d, 1 H, CONH, J = 4.0 Hz), 
10.15 (s, 1 H, 3-NH, exch), 10.88 (s, 1 H, 7-NH, exch). 
(S)-2-(3-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)benzamido)pentanedioic acid (168): Compound 168 was synthesized as 
described for 2: yield 90% as a pale powder: mp 190-191 °C decomposed, Rf  = 0.05 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ 1.55-1.65 (m, 4 H, 2 CH2), 1.81-2.11 (m, 2 
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H, β-CH2), 2.34-2.37 (t, 2 H, γ-CH2, J = 7.0 Hz), 2.53-2.56 (m, 2 H, CH2), 2.64-2.65 (m, 
2 H, CH2), 4.38-4.42 (m, 1 H, α-CH), 5.85 (s, 1 H, 5-H), 5.96 (s, 2 H, 2-NH2), 7.36-7.37 
(m, 2 H, C6H4), 7.68-7.69 (m, 1 H, C6H4), 7.71 (s, 1 H, C6H4), 8.53-8.54 (d, 1 H, CONH, 
J = 4.0 Hz), 10.13 (s, 1 H, 3-NH, exch), 10.78 (s, 1 H, 7-NH, exch). Anal. (C22H25N5O6 · 
1.0 H2O) Cal. C: 55.81, H: 5.75, N: 14.79. Found C: 55.47, H: 5.43, N: 14.40. 
Ethyl 4-(3-oxopropyl)benzoate (275 ): To a solution of ethyl 4-iodobenzoate (268) (5 
mmol, 1.38 g) in 20 mL anhydrous DMF was added prop-2-en-1-ol 269 (6 mmol, 348 
mg), LiCl (5 mmol, 210 mg), LiOAc (12.5 mmol, 850 mg), Bu4NCl (2.5 mmol, 840 mg), 
Pd(OAc)2 (0.3 mmol, 60 mg) and the mixture was stirred at 70 °C for 3 hours. TLC 
(hexane/EtOAc, 3:1) showed the disappearance of the starting material (Rf  = 0.70) and 
formation of one major spot at Rf  = 0.60. To the reaction mixture cooled to room 
temperature was added ethyl acetate (30 mL). The resulting solution was extracted with 
H2O (10 mL X 3) and dried over Na2SO4. After evaporation of solvent, the residue was 
loaded on a silica gel column (4 X 20 cm) and flash-chromatographed with 
hexane/EtOAc (2:1) and the desired fractions were pooled. After evaporation of solvent 
the residue was dried in vacuo using P2O5 to afford 275 0.83 g, yield 83% as colorless 
liquid, Rf  = 0.60 (hexane/EtOAc, 3:1 ). 
1H NMR (CDCl3) δ  1.37-1.40 (t, 3 H, CH3, J = 
7.0 Hz), 2.80-2.83 (t, 2 H, CH2, J = 7.5 Hz),   3.00-3.03 (t, 2 H, CH2, J = 7.5 Hz),  4.34-
4.39 (q, 2 H, CH2, J = 7.0 Hz), 7.25-7.27 (d, 2 H, 2 CH, J = 4.0 Hz), 7.96-7.98 (d, 2 H, 2 
CH, J = 4.3 Hz), 9.82-9.83 (t, 1 H, CHO,  J = 1.5 Hz). 
Ethyl 4-(4-oxobutyl)benzoate (276): Compound 276 was synthesized as described for 
275: yield 88% as colorless liquid, Rf  = 0.62 (hexane/EtOAc, 3:1 ). 
1H NMR (CDCl3) δ  
1.38-1.40 (t, 3 H, CH3, J = 7.0 Hz), 1.95-2.01 (m, 2 H, CH2),  2.45-2.48 (t, 2 H, CH2, J = 
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7.5 Hz),   2.70-2.73 (t, 2 H, CH2, J = 7.5 Hz),  4.35-4.39 (q, 2 H, CH2, J = 7.0 Hz), 7.23-
7.25 (d, 2 H, 2 CH, J = 4.3 Hz), 7.96-7.98 (d, 2 H, 2 CH, J = 4.3 Hz), 9.76-9.77 (t, 1 H, 
CHO,  J = 1.5 Hz). 
Ethyl 4-(5-oxopentyl)benzoate (277): Compound 277 was synthesized as described for 
275: yield 84% as colorless liquid, Rf  = 0.62 (hexane/EtOAc, 3:1 ). 
1H NMR (CDCl3) δ  
1.37-1.40 (t, 3 H, CH3, J = 7.0 Hz), 1.66-1.70 (m, 4 H, 2 CH2),  2.45-2.47 (t, 2 H, CH2, J 
= 7.0 Hz), 2.68-2.70 (t, 2 H, CH2, J = 7.0 Hz),  4.34-4.38 (q, 2 H, CH2, J = 7.0 Hz), 7.22-
7.24 (d, 2 H, 2 CH, J = 4.0 Hz), 7.95-7.97 (d, 2 H, 2 CH, J = 4.0 Hz), 9.75-9.76 (t, 1 H, 
CHO,  J = 1.5 Hz). 
Ethyl 4-(6-oxohexyl)benzoate (278): Compound 278 was synthesized as described for 
275: yield 86% as colorless liquid, Rf  = 0.62 (hexane/EtOAc, 3:1 ). 
1H NMR (CDCl3) δ  
1.25-1.27 (m, 2 H, CH2), 1.37-1.40 (t, 3 H, CH3, J = 7.0 Hz), 1.64-1.68 (m, 4 H,  2 CH2),  
2.41-2.44 (t, 2 H, CH2, J = 7.5 Hz),   2.65-2.68 (t, 2 H, CH2, J = 7.5 Hz),  4.34-4.38 (q, 2 
H, CH2, J = 7.0 Hz), 7.22-7.24 (d, 2 H, 2 CH, J = 4.3 Hz), 7.95-7.96 (d, 2 H, 2 CH, J = 4.3 
Hz), 9.75-9.76 (t, 1 H, CHO,  J = 2.0 Hz). 
Ethyl 4-(7-oxoheptyl)benzoate (279): Compound 279 was synthesized as described for 
275: yield 92% as colorless liquid, Rf  = 0.63 (hexane/EtOAc, 3:1 ). 
1H NMR (CDCl3) δ  
1.34-1.36 (m, 4 H,  2 CH2), 1.37-1.40 (t, 3 H, CH3, J = 7.0 Hz), 1.58-1.65 (m, 4 H,  2 
CH2),  2.40-2.43 (t, 2 H, CH2, J = 7.5 Hz),   2.64-2.67 (t, 2 H, CH2, J = 7.5 Hz),  4.34-
4.38 (q, 2 H, CH2, J = 7.0 Hz), 7.22-7.24 (d, 2 H, 2 CH, J = 4.3 Hz), 7.94-7.96 (d, 2 H, 2 
CH, J = 4.3 Hz), 9.75-9.76 (t, 1 H, CHO,  J = 2.0 Hz). 
Ethyl 4-(8-oxooctyl)benzoate (280): Compound 280 was synthesized as described for 
275: yield 87% as colorless liquid, Rf  = 0.63 (hexane/EtOAc, 3:1 ). 
1H NMR (CDCl3) δ  
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1.28-1.34 (m, 6 H, 3 CH2), 1.37-1.40 (t, 3 H, CH3, J = 7.0 Hz), 1.60-1.63 (m, 4 H,  2 
CH2),  2.40-2.43 (t, 2 H, CH2, J = 7.5 Hz),   2.63-2.66 (t, 2 H, CH2, J = 7.5 Hz),  4.34-
4.38 (q, 2 H, CH2, J = 7.0 Hz), 7.22-7.24 (d, 2 H, 2 CH, J = 4.3 Hz), 7.94-7.96 (d, 2 H, 2 
CH, J = 4.3 Hz), 9.75-9.76 (t, 1 H, CHO,  J = 2.0 Hz). 
Ethyl 4-(3-bromo-4-oxobutyl)benzoate (282):To a solution of aldehyde 276 (1 mmol, 
220 mg) in 5 mL anhydrous Et2O was added 287 (0.5 mmol, 150 mg), 2N HCl in Et2O 
solution (0.1 mmol, 50 µL) and the mixture was stirred at room temperature for 24 hours. 
TLC (hexane/EtOAc, 3:1) showed the disappearance of the starting material (Rf  = 0.62) 
and formation of one major spot at Rf  = 0.50. The reaction solution was washed with 5% 
NaHCO3 solution and extracted with H2O (10 mL X 3) and dried over Na2SO4. After 
evaporation of solvent, the residue was loaded on a silica gel column (4 X 20 cm) and 
flash-chromatographed with hexane/EtOAc (2:1) and the desired fractions were pooled. 
After evaporation of solvent the residue was dried in vacuo using P2O5 to afford 282 235 
mg : yield 78% as colorless oil, Rf  = 0.50 (hexane/EtOAc, 3:1 ). 
1H NMR (CDCl3) δ  
1.38-1.41 (t, 3 H, CH3, J = 7.0 Hz), 2.19-2.27 (m, 1 H, CH2), 2.34-2.42 (m, 1 H, CH2), 
2.79-2.85 (m, 1 H, CH2), 2.91-2.97 (m, 1 H, CH2),    4.16-4.18 (m, 1 H, CHBr),  4.35-
4.39 (q, 2 H, CH2, J = 7.0 Hz), 7.27-7.29 (d, 2 H, 2 CH, J = 4.3 Hz), 7.98-8.00 (d, 2 H, 2 
CH, J = 4.3 Hz), 9.46-9.47 (d, 1 H, CHO,  J = 1.0 Hz). 
Ethyl 4-(2-bromo-3-oxopropyl)benzoate (281): Compound 281 was synthesized as 
described for 282. 281 is not stable. Use directly to next step without purification. 
Ethyl 4-(4-bromo-5-oxopentyl)benzoate (283): Compound 283 was synthesized as 
described for 282: yield 77% as colorless oil, Rf  = 0.52 (hexane/EtOAc, 3:1 ). 
1H NMR 
(CDCl3) δ  1.38-1.41 (t, 3 H, CH3, J = 7.0 Hz), 1.73-1.82 (m, 2 H, CH2), 1.86-1.96 (m, 1 
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H, CH2), 2.03-2.10 (m, 1 H, CH2), 2.71-2.75 (m, 2 H, CH2),    4.21-4.25 (m, 1 H, CHBr),  
4.35-4.39 (q, 2 H, CH2, J = 7.0 Hz), 7.23-7.25 (d, 2 H, 2 CH, J = 4.3 Hz), 7.96-7.98 (d, 2 
H, 2 CH, J = 4.3 Hz), 9.42-9.43 (d, 1 H, CHO,  J = 1.3 Hz). 
Ethyl 4-(5-bromo-6-oxohexyl)benzoate (284): Compound 284 was synthesized as 
described for 282: yield 75% as colorless oil, Rf  = 0.52 (hexane/EtOAc, 3:1 ). 
1H NMR 
(CDCl3) δ  1.37-1.41 (t, 3 H, CH3, J = 7.0 Hz), 1.63-1.75 (m, 4 H, 2 CH2), 1.87-1.99 (m, 
1 H, CH2), 2.03-2.12 (m, 1 H, CH2), 2.67-2.71 (t, 2 H, CH2, J = 7.0 Hz), 4.19-4.22 (m, 1 
H, CHBr),  4.34-4.39 (q, 2 H, CH2, J = 7.0 Hz), 7.22-7.24 (d, 2 H, 2 CH, J = 4.0 Hz), 
7.95-7.97 (d, 2 H, 2 CH, J = 4.0 Hz), 9.42-9.43 (d, 1 H, CHO,  J = 1.2 Hz). 
Ethyl 4-(6-bromo-7-oxoheptyl)benzoate (285): Compound 285 was synthesized as 
described for 282: yield 77% as colorless oil, Rf  = 0.54 (hexane/EtOAc, 3:1 ). 
1H NMR 
(CDCl3) δ 1.30-1.40 (m, 2 H, CH2), 1.37-1.40 (t, 3 H, CH3, J = 7.0 Hz), 1.62-1.70 (m, 4 
H,  2 CH2),  1.86-1.94 (m, 1 H, CH2), 2.00-2.07 (m, 1 H, CH2), 2.65-2.68 (t, 2 H, CH2, J 
= 7.5 Hz), 4.18-4.22 (m, 1 H, CHBr), 4.34-4.38 (q, 2 H, CH2, J = 7.0 Hz), 7.22-7.24 (d, 2 
H, 2 CH, J = 4.3 Hz), 7.95-7.96 (d, 2 H, 2 CH, J = 4.0 Hz), 9.42-9.43 (d, 1 H, CHO,  J = 
1.5 Hz). 
Ethyl 4-(7-bromo-8-oxooctyl)benzoate (286): Compound 286 was synthesized as 
described for 282: yield 74% as colorless oil, Rf  = 0.56 (hexane/EtOAc, 3:1 ). 
1H NMR 
(CDCl3) δ 1.30-1.40 (m, 4 H, 2 CH2), 1.37-1.40 (t, 3 H, CH3, J = 7.0 Hz), 1.62-1.64 (m, 4 
H,  2 CH2),  1.86-1.94 (m, 1 H, CH2), 2.00-2.07 (m, 1 H, CH2), 2.64-2.67 (t, 2 H, CH2, J 
= 7.5 Hz), 4.19-4.22 (m, 1 H, CHBr), 4.34-4.38 (q, 2 H, CH2, J = 7.0 Hz), 7.22-7.24 (d, 2 
H, 2 CH, J = 4.0 Hz), 7.95-7.96 (d, 2 H, 2 CH, J = 4.0 Hz), 9.42-9.43 (d, 1 H, CHO,  J = 
1.5 Hz). 
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Ethyl 4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl)benzoate (289): To a solution of 2,4-diamino-6-hydroxypyrimidine 35 (151 mg, 
1.2 mmol) and sodium acetate (180 mg, 2.2 mmol) in water (3 mL) and methanol (3 mL) 
was added α-bromo aldehyde 282 (330 mg, 1.1 mmol)  The reaction mixture was stirred 
at 45 °C for 3 hours. TLC showed the disappearance of starting materials and the 
formation of one major spot at Rf  = 0.38 (CHCl3/MeOH, 5:1). After evaporation of 
solvent, CH3OH (10 mL) was added followed by silica gel (3 g). Evaporation of the 
solvent afforded a plug, which was loaded onto a silica gel column (3.5 cm x 15 cm) and 
eluted initially with CHCl3 followed by 10% MeOH in CHCl3 and then 15% MeOH in 
CHCl3. Fractions showing Rf  = 0.38 were pooled and evaporated to afford 289 230 mg, 
yield 70%  as a pink solid: mp > 250  °C decomposed.  1H NMR (DMSO-d6) δ  1.29-1.32 
(t, 3 H, CH3, J = 7.5 Hz), 2.83-2.86 (t, 2 H, CH2, J = 7.0 Hz), 2.98-3.01 (t, 2 H, CH2, J = 
7.0 Hz), 4.27-4.31 (q, 2 H, CH2, J = 7.5 Hz), 6.03 (s, 2 H, 2-NH2), 6.29-6.30 (d, 1 H, CH,  
J = 1.0 Hz), 7.33-7.34 (d, 2 H, CH,  J = 4.0 Hz), 7.85-7.86 (d, 2 H, CH,  J = 4.0 Hz), 
10.21 (s, 1 H, 3-NH), 10.60 (s, 1H, 7-NH). 
Ethyl 4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)methyl)benzoate (288): Compound 288 was synthesized as described for 289: yield 
35% over two steps as a yellow solid: mp > 232 °C decomposed, Rf  = 0.42 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  1.28-1.31 (t, 3 H, CH3, J = 7.5 Hz), 4.00 (s, 
2 H, CH2), 4.26-4.30 (q, 2 H, CH2, J = 7.5 Hz), 6.00 (s, 2 H, 2-NH2), 6.34-6.35 (d, 1 H, 
CH,  J = 1.0 Hz), 7.40-7.42 (d, 2 H, CH,  J = 4.0 Hz), 7.82-7.84 (d, 2 H, CH,  J = 4.0 Hz), 
10.12 (s, 1 H, 3-NH), 10.74 (s, 1H, 7-NH). 
Ethyl 4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
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yl)propyl)benzoate (290): Compound 290 was synthesized as described for 289: yield 
68% as a purple solid: mp > 264 °C decomposed, Rf  = 0.42 (CHCl3/MeOH, 5:1). 
1H 
NMR (DMSO-d6) δ  1.29-1.32 (t, 3 H, CH3, J = 7.5 Hz), 1.89-1.95 (m, 2 H, CH2), 2.56-
2.59 (t, 2 H, CH2, J = 7.5 Hz), 2.65-2.68 (t, 2 H, CH2, J = 7.5 Hz), 4.27-4.31 (q, 2 H, CH2, 
J = 7.5 Hz), 5.96 (s, 2 H, 2-NH2), 6.35-6.36 (d, 1 H, CH,  J = 1.0 Hz), 7.33-7.35 (d, 2 H, 
CH,  J = 4.0 Hz), 7.85-7.87 (d, 2 H, CH,  J = 4.0 Hz), 10.08 (s, 1 H, 3-NH), 10.63 (s, 1H, 
7-NH). 
Ethyl 4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)benzoate (291): Compound 291 was synthesized as described for 289: yield 
53% as a blue solid: mp > 256 °C decomposed, Rf  = 0.44 (CHCl3/MeOH, 5:1). 
1H NMR 
(DMSO-d6) δ  1.29-1.32 (t, 3 H, CH3, J = 7.5 Hz), 1.56-1.62 (m, 4 H, 2 CH2), 2.57-2.59 
(t, 2 H, CH2, J = 7.5 Hz), 2.64-2.67 (t, 2 H, CH2, J = 7.5 Hz), 4.27-4.31 (q, 2 H, CH2, J = 
7.5 Hz), 5.94 (s, 2 H, 2-NH2), 6.31-6.32 (d, 1 H, CH,  J = 1.0 Hz), 7.32-7.34 (d, 2 H, CH,  
J = 4.0 Hz), 7.84-7.86 (d, 2 H, CH,  J = 4.0 Hz), 10.08 (s, 1 H, 3-NH), 10.59 (s, 1H, 7-
NH). 
Ethyl 4-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)pentyl)benzoate (292): Compound 292 was synthesized as described for 289: yield 
60% as a pink solid: mp > 212 °C decomposed,  Rf  = 0.45 (CHCl3/MeOH, 5:1). 
1H NMR 
(DMSO-d6) δ  1.29-1.32 (m, 5 H, CH3, CH2), 1.58-1.62 (m, 4 H, 2 CH2), 2.52-2.55 (t, 2 
H, CH2, J = 7.5 Hz), 2.62-2.65 (t, 2 H, CH2, J = 7.5 Hz), 4.27-4.31 (q, 2 H, CH2, J = 7.5 
Hz), 5.94 (s, 2 H, 2-NH2), 6.30-6.31 (d, 1 H, CH,  J = 1.0 Hz), 7.32-7.34 (d, 2 H, CH,  J = 
4.0 Hz), 7.85-7.86 (d, 2 H, CH,  J = 4.0 Hz), 10.08 (s, 1 H, 3-NH), 10.58 (s, 1H, 7-NH). 
Ethyl 4-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
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yl)hexyl)benzoate (293): Compound 293 was synthesized as described for 289: yield 
52% as a pink solid: mp > 208 °C decomposed,  Rf  = 0.45 (CHCl3/MeOH, 5:1). 
1H NMR 
(DMSO-d6) δ  1.27-1.33 (m, 7 H, CH3, 2 CH2), 1.53-1.60 (m, 4 H, 2 CH2), 2.52-2.55 (t, 2 
H, CH2, J = 7.5 Hz), 2.61-2.64 (t, 2 H, CH2, J = 7.5 Hz), 4.27-4.31 (q, 2 H, CH2, J = 7.5 
Hz), 5.94 (s, 2 H, 2-NH2), 6.30-6.31 (d, 1 H, CH,  J = 1.0 Hz), 7.32-7.34 (d, 2 H, CH,  J = 
4.0 Hz), 7.85-7.87 (d, 2 H, CH,  J = 4.0 Hz), 10.06 (s, 1 H, 3-NH), 10.57 (s, 1H, 7-NH). 
(S)-diethyl 2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)methyl)benzamido)pentanedioate (294): To a suspension of 288 (100 mg, 0.35 
mmol) in 10 mL CH3OH was added 3 N NaOH (10 mL). The resulting mixture was 
stirred under N2 at 40-50 °C for 24 h. TLC indicated the disappearance of starting 
material and the formation of one major spot at the origin. The resulting solution was 
passed through Celite and washed with a minimum amount of CH3OH. The combined 
filtrate was evaporated under reduced pressure to dryness. To this residue was added 
distilled water (10 mL). The solution was cooled in an ice bath, and the pH was adjusted 
3 to 4 using 3 N HCl. The resulting suspension was chilled in a dry ice/acetone bath and 
thawed to 4 °C overnight in a refrigerator. The precipitate was filtered, washed with cold 
water, and dried in a desiccator under reduced pressure using P2O5 to a brown powder, 
which was used directly for the next step. 
To a solution of this brown powder in anhydrous DMF (10 mL) was added 6-chloro-2,4-
dimethoxy-1,3,5-triazine (72 mg, 0.42 mmol) and N-methylmorpholine (43 mg, 0.42 
mmol). After the mixture was stirred at r.t. for 2 h, N-methylmorpholine (43 mg, 0.42 
mmol) and dimethyl L-glutamate hydrochloride (126 mg, 0.53 mmol) were added all at 
once. The mixture was stirred at r.t. for 4 h. TLC showed the formation of one major spot 
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at Rf  = 0.38 (CHCl3/MeOH, 5:1). The reaction mixture was evaporated to dryness under 
reduced pressure. The residue was dissolved in a minimum amount of CHCl3/MeOH, 5:1, 
and chromatographed on a silica gel column (2 cm x 15 cm) with 4% MeOH in CHCl3 as 
the eluent. Fractions that showed the desired single spot at Rf  = 0.38 were pooled and 
evaporated to dryness to afford 294 100 mg, yield 61% as a yellow syrup. 1H NMR 
(DMSO-d6) δ  1.14-1.19 (m, 6 H, 2 CH3), 1.88-2.15 (m, 2 H, CH2), 2.42-2.45 (m, 2 H, 
CH2), 3.98 (s, 2 H, CH2),  4.03-4.12 (m, 4 H, 2 CH2), 4.36-4.46 (m, 1 H, CH), 6.00 (s, 2 
H, 2-NH2), 6.32-6.33 (d, 1 H, CH, J = 1.0 Hz), 7.36-7.38 (d, 2 H, C6H4, J = 4.0 Hz), 7.73-
7.75 (d, 2 H, C6H4, J = 4.0 Hz), 8.59-8.61 (d, 1 H, CONH, , J = 4.0 Hz), 10.13 (s, 1 H, 3-
NH), 10.74 (s, 1H, 7-NH). 
 (S)-diethyl 2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl)benzamido)pentanedioate (295): Compound 295 was synthesized as described 
for 294: yield 51% as a colorless syrup, Rf  = 0.40 (CHCl3/MeOH, 5:1). 
1H NMR 
(DMSO-d6) δ  1.15-1.20 (m, 6 H, 2 CH3), 1.97-2.03 (m, 1 H, CH2), 2.06-2.13 (m, 1 H, 
CH2), 2.42-2.45 (m, 2 H, CH2), 2.84-2.87 (t, 2 H, CH2, J = 7.0 Hz), 2.96-2.99 (t, 2 H, 
CH2, J = 7.0 Hz), 4.02-4.13 (m, 4 H, 2 CH2), 4.40-4.44 (m, 1 H, CH), 5.99 (s, 2 H, 2-
NH2), 6.30-6.31 (d, 1 H, CH, J = 1.0 Hz), 7.28-7.30 (d, 2 H, C6H4, J = 4.0 Hz), 7.77-7.78 
(d, 2 H, C6H4, J = 4.0 Hz), 8.61-8.62 (d, 1 H, CONH, , J = 4.0 Hz), 10.13 (s, 1 H, 3-NH), 
10.60 (s, 1H, 7-NH). 
(S)-diethyl 2-(4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)benzamido)pentanedioate (296): Compound 296 was synthesized as 
described for 294: yield 65% as a colorless syrup, Rf  = 0.40 (CHCl3/MeOH, 5:1). 
1H 
NMR (DMSO-d6) δ  1.15-1.20 (m, 6 H, 2 CH3), 1.91-1.94 (m, 2 H, CH2), 1.97-2.03 (m, 1 
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H, CH2), 2.06-2.13 (m, 1 H, CH2), 2.42-2.45 (m, 2 H, CH2), 2.57-2.60 (t, 2 H, CH2, J = 
7.0 Hz), 2.63-2.66 (t, 2 H, CH2, J = 7.0 Hz), 4.02-4.13 (m, 4 H, 2 CH2), 4.42-4.45 (m, 1 
H, CH), 5.95 (s, 2 H, 2-NH2), 6.35-6.36 (d, 1 H, CH, J = 1.0 Hz), 7.29-7.30 (d, 2 H, 
C6H4, J = 4.0 Hz), 7.78-7.80 (d, 2 H, C6H4, J = 4.0 Hz), 8.62-8.64 (d, 1 H, CONH, , J = 
4.0 Hz), 10.08 (s, 1 H, 3-NH), 10.62 (s, 1H, 7-NH). 
(S)-diethyl 2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)benzamido)pentanedioate (297): Compound 297 was synthesized as described 
for 294: yield 70% as a light blue syrup,  Rf  = 0.40 (CHCl3/MeOH, 5:1). 
1H NMR 
(DMSO-d6) δ  1.15-1.20 (m, 6 H, 2 CH3), 1.55-1.64 (m, 4 H, 2 CH2), 1.97-2.03 (m, 1 H, 
CH2), 2.06-2.13 (m, 1 H, CH2), 2.42-2.45 (m, 2 H, CH2), 2.57-2.59 (t, 2 H, CH2, J = 7.5 
Hz), 2.64-2.67 (t, 2 H, CH2, J = 7.5 Hz), 4.02-4.13 (m, 4 H, 2 CH2), 4.42-4.45 (m, 1 H, 
CH), 5.94 (s, 2 H, 2-NH2), 6.31-6.32 (d, 1 H, CH, J = 1.0 Hz), 7.28-7.29 (d, 2 H, C6H4, J 
= 4.0 Hz), 7.76-7.78 (d, 2 H, C6H4, J = 4.0 Hz), 8.61-8.62 (d, 1 H, CONH, , J = 4.0 Hz), 
10.08 (s, 1 H, 3-NH), 10.59 (s, 1H, 7-NH). 
(S)-diethyl 2-(4-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)pentyl)benzamido)pentanedioate (298): Compound 298 was synthesized as 
described for 294: yield 67% as a light blue syrup, Rf  = 0.40 (CHCl3/MeOH, 5:1). 
1H 
NMR (DMSO-d6) δ  1.15-1.20 (m, 6 H, 2 CH3), 1.29-1.33 (m, 2 H, CH2),  1.55-1.62 (m, 
4 H, 2 CH2), 1.97-2.03 (m, 1 H, CH2), 2.06-2.13 (m, 1 H, CH2), 2.42-2.45 (m, 2 H, CH2), 
2.51-2.53 (m, 2 H, CH2), 2.61-2.64 (t, 2 H, CH2, J = 7.5 Hz), 4.02-4.12 (m, 4 H, 2 CH2), 
4.41-4.45 (m, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 6.31-6.32 (d, 1 H, CH, J = 1.0 Hz), 7.28-
7.29 (d, 2 H, C6H4, J = 4.0 Hz), 7.77-7.79 (d, 2 H, C6H4, J = 4.0 Hz), 8.62-8.63 (d, 1 H, 
CONH, , J = 4.0 Hz), 10.07 (s, 1 H, 3-NH), 10.58 (s, 1H, 7-NH). 
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(S)-diethyl 2-(4-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)hexyl)benzamido)pentanedioate (299): Compound 299 was synthesized as described 
for 294: yield 78% as a colorless syrup, Rf  = 0.42 (CHCl3/MeOH, 5:1). 
1H NMR 
(DMSO-d6) δ  1.15-1.20 (m, 6 H, 2 CH3), 1.27-1.34 (m, 4 H, 2 CH2),  1.53-1.62 (m, 4 H, 
2 CH2), 1.97-2.03 (m, 1 H, CH2), 2.06-2.13 (m, 1 H, CH2), 2.42-2.45 (m, 2 H, CH2), 
2.51-2.53 (m, 2 H, CH2), 2.60-2.63 (t, 2 H, CH2, J = 7.5 Hz), 4.02-4.12 (m, 4 H, 2 CH2), 
4.41-4.44 (m, 1 H, CH), 5.93 (s, 2 H, 2-NH2), 6.30-6.31 (d, 1 H, CH, J = 1.0 Hz), 7.28-
7.29 (d, 2 H, C6H4, J = 4.0 Hz), 7.77-7.79 (d, 2 H, C6H4, J = 4.0 Hz), 8.62-8.63 (d, 1 H, 
CONH, , J = 4.0 Hz), 10.06 (s, 1 H, 3-NH), 10.57 (s, 1H, 7-NH). 
(S)-2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)methyl)benzamido)pentanedioic acid (172): Compound 172 was synthesized as 
described for 2: yield 94% as a yellow powder: mp > 264 °C decomposed, Rf  = 0.05 
(CHCl3/MeOH, 5:1). 
1H NMR 400M (DMSO-d6) δ 1.88-2.15 (m, 2 H, CH2), 2.42-2.45 
(m, 2 H, CH2), 3.98 (s, 2 H, CH2), 4.37-4.39 (m, 1 H, CH), 6.00 (s, 2 H, 2-NH2), 6.32 (s, 
1 H, CH), 7.36-7.38 (d, 2 H, C6H4, J = 4.0 Hz), 7.74-7.76 (d, 2 H, C6H4, J = 4.0 Hz), 
8.46-8.48 (d, 1 H, CONH, , J = 4.0 Hz), 10.13 (s, 1 H, 3-NH), 10.73 (s, 1H, 7-NH). Anal. 
(C19H19N5O6 · 1.5 H2O) Cal. C: 51.82, H: 5.04, N: 15.90. Found C: 51.93, H: 5.14, N: 
15.56. 
(S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl)benzamido)pentanedioic acid (173): Compound 173 was synthesized as 
described for 2: yield 96% as a pink powder: mp > 250 °C decomposed, identical in all 
respects (NMR, mp) reported ed by the method of Taylor et al.,
189
 Rf  = 0.07 
(CHCl3/MeOH, 5:1).  
1H NMR 400M (DMSO-d6) δ 1.97-2.03 (m, 1 H, CH2), 2.06-2.13 
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(m, 1 H, CH2), 2.42-2.45 (m, 2 H, CH2), 2.84-2.87 (t, 2 H, CH2, J = 7.0 Hz), 2.96-2.99 (t, 
2 H, CH2, J = 7.0 Hz), 4.36-4.40 (m, 1 H, CH), 6.00 (s, 2 H, 2-NH2), 6.30 (s, 1 H, CH), 
7.27-7.29 (d, 2 H, C6H4, J = 4.0 Hz), 7.77-7.79 (d, 2 H, C6H4, J = 4.0 Hz), 8.50-8.52 (d, 1 
H, CONH, , J = 4.0 Hz), 10.15 (s, 1 H, 3-NH), 10.61 (s, 1H, 7-NH).Anal. (C20H21N5O6 · 
1.2 H2O) Cal. C: 53.45, H: 5.26, N: 15.58. Found C: 53.49, H: 5.38, N: 15.48. 
(S)-2-(4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)benzamido)pentanedioic acid (174): Compound 174 was synthesized as 
described for 2: yield 97% as a pale blue powder: mp > 189 °C decomposed,Rf  = 0.07 
(CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ 1.90-1.94 (m, 2 H, CH2), 1.94-2.00 (m, 1 
H, CH2), 2.06-2.13 (m, 1 H, CH2), 2.33-2.36 (m, 2 H, CH2), 2.57-2.60 (t, 2 H, CH2, J = 
7.0 Hz), 2.63-2.66 (t, 2 H, CH2, J = 7.0 Hz), 4.36-4.40 (m, 1 H, CH), 5.96 (s, 2 H, 2-
NH2), 6.35-6.36 (d, 1 H, CH, J = 1.0 Hz), 7.28-7.30 (d, 2 H, C6H4, J = 4.0 Hz), 7.78-7.80 
(d, 2 H, C6H4, J = 4.0 Hz), 8.50-8.52 (d, 1 H, CONH, , J = 4.0 Hz), 10.08 (s, 1 H, 3-NH), 
10.62 (s, 1H, 7-NH). Anal. (C21H23N5O6 · 0.70 H2O) Cal. C: 55.52, H: 5.42, N: 15.42. 
Found C: 55.62, H: 5.41, N: 15.03. 
(S)-2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)benzamido)pentanedioic acid (175): Compound 175 was synthesized as 
described for 2: yield 88% as a blue powder: mp > 153 °C decomposed, Rf  = 0.07 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  1.55-1.63 (m, 4 H, 2 CH2), 1.92-2.00 (m, 1 
H, CH2), 2.03-2.13 (m, 1 H, CH2), 2.33-2.36 (t, 2 H, CH2, J = 7.5 Hz), 2.57-2.60 (t, 2 H, 
CH2, J = 7.5 Hz), 2.62-2.65 (t, 2 H, CH2, J = 7.5 Hz), 4.37-4.39 (m, 1 H, CH), 5.95 (s, 2 
H, 2-NH2), 6.31-6.32 (d, 1 H, CH, J = 1.0 Hz), 7.27-7.29 (d, 2 H, C6H4, J = 4.0 Hz), 7.77-
7.79 (d, 2 H, C6H4, J = 4.0 Hz), 8.49-8.50 (d, 1 H, CONH, , J = 4.0 Hz), 10.09 (s, 1 H, 3-
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NH), 10.58 (s, 1H, 7-NH). Anal. (C22H25N5O6 · 1.2 H2O) Cal. C: 55.38, H: 5.79, N: 
14.68. Found C: 55.08, H: 5.57, N: 14.37. 
(S)-2-(4-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)pentyl)benzamido)pentanedioic acid (176): Compound 176 was synthesized as 
described for 2: yield 93% as a blue powder: mp > 167 °C decomposed, Rf  = 0.08 
(CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ  1.29-1.32 (m, 2 H, CH2), 1.58-1.62 (m, 4 
H, 2 CH2), 1.92-2.00 (m, 1 H, CH2), 2.03-2.13 (m, 1 H, CH2), 2.33-2.36 (t, 2 H, CH2, J = 
7.5 Hz), 2.53-2.55 (m, 2 H, CH2), 2.61-2.64 (t, 2 H, CH2, J = 7.5 Hz), 4.37-4.40 (m, 1 H, 
CH), 5.94 (s, 2 H, 2-NH2), 6.31-6.32 (d, 1 H, CH, J = 1.0 Hz), 7.27-7.29 (d, 2 H, C6H4, J 
= 4.0 Hz), 7.77-7.79 (d, 2 H, C6H4, J = 4.0 Hz), 8.50-8.51 (d, 1 H, CONH, , J = 4.0 Hz), 
10.08 (s, 1 H, 3-NH), 10.58 (s, 1H, 7-NH). Anal. (C23H27N5O6 · 1.0 H2O) Cal. C: 56.66, 
H: 6.00, N: 14.36. Found C: 56.73, H: 6.09, N: 14.13. 
(S)-2-(4-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)hexyl)benzamido)pentanedioic acid (177): Compound 177 was synthesized as 
described for 2: yield 93% as a blue powder: mp > 178 °C decomposed, Rf  = 0.10 
(CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ  1.27-1.32 (m, 4 H, 2 CH2), 1.53-1.62 (m, 4 
H, 2 CH2), 1.92-2.00 (m, 1 H, CH2), 2.03-2.13 (m, 1 H, CH2), 2.33-2.36 (t, 2 H, CH2, J = 
7.5 Hz), 2.52-2.54 (m, 2 H, CH2), 2.59-2.62 (t, 2 H, CH2, J = 7.5 Hz), 4.36-4.41 (m, 1 H, 
CH), 5.94 (s, 2 H, 2-NH2), 6.31-6.32 (d, 1 H, CH, J = 1.0 Hz), 7.27-7.29 (d, 2 H, C6H4, J 
= 4.0 Hz), 7.77-7.79 (d, 2 H, C6H4, J = 4.0 Hz), 8.49-8.51 (d, 1 H, CONH, , J = 4.0 Hz), 
10.07 (s, 1 H, 3-NH), 10.57 (s, 1H, 7-NH). Anal. (C24H29N5O6 · 1.77CH3OH · 0.1HCl) 
Cal. C: 56.91, Cl: 0.65, H: 6.70, N: 12.88. Found C: 56.58, Cl: 0.62, H: 6.19, N: 12.85. 
 Methyl 5-(3-oxopropyl)thiophene-2-carboxylate (308): To a solution of 5-
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iodothiophene-2-carboxylate 301 (5 mmol, 1.34 g) in 20 mL anhydrous DMF was added 
prop-2-en-1-ol 269 (15 mmol, 900 mg), LiCl (5 mmol, 210 mg), LiOAc (12.5 mmol, 850 
mg), Bu4NCl (5 mmol, 2.78 g), Pd(OAc)2 (2.5 mmol, 500 mg) and the mixture was 
stirred at 45 °C for 2 hours. TLC (hexane/EtOAc, 3:1) showed the disappearance of the 
starting material and formation of one major spot at Rf  = 0.50. To the reaction mixture 
cooled to room temperature was added ethyl acetate (30 mL). The resulting solution was 
extracted with H2O (10 mL X 3) and dried over Na2SO4. After evaporation of solvent, the 
residue was loaded on a silica gel column (4 X 20 cm) and flash-chromatographed with 
hexane/EtOAc (5:1) and the desired fractions were pooled. After evaporation of solvent 
the residue was dried in vacuo using P2O5 to afford 308 0.48 g, yield 52% as yellow 
liquid, Rf  = 0.50 (hexane/EtOAc, 3:1 ). 
1H NMR (CDCl3) δ  2.86-2.89 (t, 2 H, CH2, J = 
7.5 Hz),   3.16-3.19 (t, 2 H, CH2, J = 7.5 Hz),  3.86 (s, 3 H, CH3), 6.82-6.83 (d, 1 H, 1 
CH, J = 2.0 Hz), 7.62-7.63 (d, 1 H,  CH, J = 2.0 Hz), 9.83 (s, 1 H, CHO). 
Methyl 5-(4-oxobutyl)thiophene-2-carboxylate (300): Compound 300 was synthesized 
as described for 308: yield 65% as yellow liquid, Rf  = 0.53 (hexane/EtOAc, 3:1 ). 
1H 
NMR (CDCl3) δ  2.00-2.05 (m, 2 H, CH2), 2.51-2.54 (t, 2 H, CH2, J = 7.5 Hz),   2.88-
2.91 (t, 2 H, CH2, J = 7.5 Hz), 3.86 (s, 3 H, CH3), 6.80-6.81 (d, 1 H, 1 CH, J = 2.0 Hz), 
7.63-7.64 (d, 1 H,  CH, J = 2.0 Hz), 9.78 (s, 1 H, CHO). 
Methyl 5-(5-oxopentyl)thiophene-2-carboxylate (309): Compound 309 was 
synthesized as described for 308: yield 54% as yellow liquid, Rf  = 0.54 (hexane/EtOAc, 
3:1 ). 1H NMR (CDCl3) δ  1.70-1.75 (m, 4 H, 2 CH2), 2.46-2.49 (t, 2 H, CH2, J = 7.5 Hz),   
2.85-2.88 (t, 2 H, CH2, J = 7.5 Hz), 3.86 (s, 3 H, CH3), 6.79-6.80 (d, 1 H, 1 CH, J = 2.0 
Hz), 7.62-7.63 (d, 1 H,  CH, J = 2.0 Hz), 9.76-9.77 (t, 1 H, CHO, J = 1.5 Hz). 
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Methyl 5-(6-oxohexyl)thiophene-2-carboxylate (310): Compound 310 was synthesized 
as described for 308:  yield 65% as yellow liquid, Rf  = 0.54 (hexane/EtOAc, 3:1 ). 
1H 
NMR (CDCl3) δ  1.38-1.44 (m, 2 H, CH2), 1.64-1.75 (m, 4 H, 2 CH2), 2.42-2.46 (t, 2 H, 
CH2, J = 7.5 Hz),   2.83-2.86 (t, 2 H, CH2, J = 7.5 Hz), 3.86 (s, 3 H, CH3), 6.77-6.78 (d, 1 
H, 1 CH, J = 2.0 Hz), 7.62-7.63 (d, 1 H,  CH, J = 2.0 Hz), 9.76-9.77 (t, 1 H, CHO, J = 1.5 
Hz). 
Methyl 5-(7-oxoheptyl)thiophene-2-carboxylate (311): Compound 311 was synthesized 
as described for 308: yield 70% as yellow liquid, Rf  = 0.55 (hexane/EtOAc, 3:1 ). 
1H 
NMR (CDCl3) δ  1.35-1.40 (m, 4 H, 2 CH2), 1.60-1.73 (m, 4 H, 2 CH2), 2.41-2.44 (t, 2 H, 
CH2, J = 7.5 Hz),   2.81-2.84 (t, 2 H, CH2, J = 7.5 Hz), 3.86 (s, 3 H, CH3), 6.77-6.78 (d, 1 
H, 1 CH, J = 2.0 Hz), 7.62-7.63 (d, 1 H,  CH, J = 2.0 Hz), 9.76-9.77 (t, 1 H, CHO, J = 1.5 
Hz). 
Methyl 5-(8-oxooctyl)thiophene-2-carboxylate (312): Compound 312 was synthesized 
as described for 308:  yield 61% as brown liquid, Rf  = 0.57 (hexane/EtOAc, 3:1 ). 
1H 
NMR (CDCl3) δ  1.30-1.40 (m, 6 H, 3 CH2), 1.54-1.60 (m, 4 H, 2 CH2), 2.40-2.44 (t, 2 H, 
CH2, J = 7.5 Hz),   2.81-2.84 (t, 2 H, CH2, J = 7.5 Hz), 3.86 (s, 3 H, CH3), 6.77-6.78 (d, 1 
H, 1 CH, J = 2.0 Hz), 7.62-7.63 (d, 1 H,  CH, J = 2.0 Hz), 9.76-9.77 (t, 1 H, CHO, J = 1.5 
Hz). 
Methyl 5-(2-bromo-3-oxopropyl)thiophene-2-carboxylate (313): To a solution of 
aldehyde 308 (2.9 mmol, 540 mg) in 5 mL anhydrous Et2O was added 287 (1.45 mmol, 
435 mg), 2N HCl in Et2O solution (0.29 mmol, 150 µL) and the mixture was stirred at 
room temperature for 24 hours. TLC (hexane/EtOAc, 3:1) showed the disappearance of 
the starting material and formation of one major spot at Rf  = 0.43. The reaction solution 
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was washed with 5% NaHCO3 solution and extracted with H2O (10 mL X 3) and dried 
over Na2SO4. After evaporation of solvent, the residue was loaded on a silica gel column 
(4 X 20 cm) and flash-chromatographed with hexane/EtOAc (5:1) and the desired 
fractions were pooled. After evaporation of solvent the residue was dried in vacuo using 
P2O5 to afford 313 440 mg : yield 57% as yellow oil, Rf  = 0.43 (hexane/EtOAc, 3:1 ). 
1H 
NMR (CDCl3) δ 3.16-3.19 (m, 2 H, CH2),  3.92 (s, 3 H, CH3), 4.35-4.40 (m, 1 H, CHBr),  
6.92-6.93 (d, 1 H, 1 CH, J = 2.0 Hz), 7.75-7.76 (d, 1 H,  CH, J = 2.0 Hz), 9.51-9.52 (d, 1 
H, CHO, J = 1.0 Hz). 
Methyl 5-(3-bromo-4-oxobutyl)thiophene-2-carboxylate (314): Compound 314 was 
synthesized as described for 313: yield 65% as yellow oil, Rf  = 0.45 (hexane/EtOAc, 3:1 
). 1H NMR (CDCl3) δ 2.88-2.89 (m, 2 H, CH2), 2.95-2.96 (m, 2 H, CH2),  3.87 (s, 3 H, 
CH3), 4.23-4.26 (m, 1 H, CHBr),  6.86-6.87 (d, 1 H, 1 CH, J = 2.0 Hz), 7.64-7.65 (d, 1 H,  
CH, J = 2.0 Hz), 9.48-9.49 (d, 1 H, CHO, J = 1.0 Hz). 
Methyl 5-(4-bromo-5-oxopentyl)thiophene-2-carboxylate (315): Compound 315 was 
synthesized as described for 313: yield 68% as yellow oil, Rf  = 0.45 (hexane/EtOAc, 3:1 
). 1H NMR (CDCl3) δ 1.71-1.72 (m, 2 H, CH2), 1.93-2.00 (m, 1 H, CH2), 2.08-2.13 (m, 1 
H, CH2), 2.85-2.90 (m, 2 H, CH2),  3.86 (s, 3 H, CH3), 4.23-4.25 (m, 1 H, CHBr),  6.79-
6.80 (d, 1 H, 1 CH, J = 2.0 Hz), 7.62-7.63 (d, 1 H,  CH, J = 2.0 Hz), 9.44-9.45 (d, 1 H, 
CHO, J = 1.0 Hz). 
Methyl 5-(5-bromo-6-oxohexyl)thiophene-2-carboxylate (316): Compound 316 was 
synthesized as described for 313.  316 is not stable. Use directly to next step without 
purification. 
Methyl 5-(6-bromo-7-oxoheptyl)thiophene-2-carboxylate (317): Compound 317 was 
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synthesized as described for 313: yield 60% as yellow oil, Rf  = 0.47 (hexane/EtOAc, 3:1 
). 1H NMR (CDCl3) δ 1.37-1.42 (m, 2 H, CH2), 1.56-1.59 (m, 4 H, 2 CH2), 2.04-2.08 (m, 
2 H, CH2), 2.82-2.85 (t, 2 H, CH2, J = 7.5 Hz),  3.85 (s, 3 H, CH3), 4.19-4.22 (m, 1 H, 
CHBr),  6.77-6.78 (d, 1 H, 1 CH, J = 2.0 Hz), 7.62-7.63 (d, 1 H,  CH, J = 2.0 Hz), 9.42-
9.43 (d, 1 H, CHO, J = 1.0 Hz). 
Methyl 5-(7-bromo-8-oxooctyl)thiophene-2-carboxylate (318): Compound 318 was 
synthesized as described for 313: yield 65% as yellow oil, Rf  = 0.50 (hexane/EtOAc, 3:1 
). 1H NMR (CDCl3) δ 1.34-1.39 (m, 4 H, 2 CH2), 1.57-1.61 (m, 4 H, 2 CH2), 2.00-2.06 
(m, 2 H, CH2), 2.81-2.84 (t, 2 H, CH2, J = 7.5 Hz),  3.86 (s, 3 H, CH3), 4.19-4.26 (m, 1 H, 
CHBr),  6.77-6.78 (d, 1 H, 1 CH, J = 2.0 Hz), 7.62-7.63 (d, 1 H,  CH, J = 2.0 Hz), 9.42-
9.43 (d, 1 H, CHO, J = 1.0 Hz). 
Methyl 5-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)methyl)thiophene-2-carboxylate (319): To a solution of 2,4-diamino-6-
hydroxypyrimidine 35 (171 mg, 1.36 mmol) and sodium acetate (223 mg, 2.72 mmol) in 
water (3 mL) and methanol (3 mL) was added α-bromo aldehyde 313 (360 mg, 1.36 
mmol)  The reaction mixture was stirred at 45 °C for 3 hours. TLC showed the 
disappearance of starting materials and the formation of one major spot at Rf  = 0.40 
(CHCl3/MeOH, 5:1). After evaporation of solvent, CH3OH (10 mL) was added followed 
by silica gel (3 g). Evaporation of the solvent afforded a plug, which was loaded onto a 
silica gel column (3.5 cm x 15 cm) and eluted initially with CHCl3 followed by 10% 
MeOH in CHCl3 and then 15% MeOH in CHCl3. Fractions showing Rf  = 0.40 were 
pooled and evaporated to afford 319 245 mg, yield 59%  as a white solid: mp 220-221 °C 
decomposed.  1H NMR (DMSO-d6) δ  3.76 (s, 3 H, CH3), 4.16 (s, 2 H, CH2), 6.02 (s, 2 H, 
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2-NH2), 6.47-6.48 (d, 1 H, CH,  J = 1.3 Hz), 6.97-6.98 (d, 1 H, CH,  J = 1.8 Hz), 7.59-
7.60 (d, 1 H, CH,  J = 1.8 Hz), 10.15 (s, 1 H, 3-NH), 10.80 (s, 1H, 7-NH). 
Methyl 5-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl)thiophene-2-carboxylate (320): Compound 320 was synthesized as described 
for 319:  yield 50% as a yellow solid: mp 185-186 °C decomposed, Rf  = 0.40 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  2.88-2.91 (t, 2 H, CH2, J = 7.5 Hz), 3.20-
3.23 (t, 2 H, CH2, J = 7.5 Hz),  3.77 (s, 3 H, CH3), 5.99 (s, 2 H, 2-NH2), 6.35-6.36 (d, 1 H, 
CH,  J = 1.0 Hz), 6.90-6.91 (d, 1 H, CH,  J = 1.8 Hz), 7.60-7.61 (d, 1 H, CH,  J = 1.8 Hz), 
10.15 (s, 1 H, 3-NH), 10.64 (s, 1H, 7-NH). 
Methyl 5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)thiophene-2-carboxylate (321): Compound 321 was synthesized as described 
for 319: yield 64% as a clear syrup, Rf  = 0.42 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) 
δ 1.94-2.00 (m, 2 H, CH2),  2.59-2.62 (t, 2 H, CH2, J = 7.5 Hz), 2.81-2.84 (t, 2 H, CH2, J = 
7.5 Hz),  3.79 (s, 3 H, CH3), 5.97 (s, 2 H, 2-NH2), 6.36-6.37 (d, 1 H, CH,  J = 1.0 Hz), 
6.97-6.98 (d, 1 H, CH,  J = 2.0 Hz), 7.63-7.64 (d, 1 H, CH,  J = 2.0 Hz), 10.10 (s, 1 H, 3-
NH), 10.65 (s, 1H, 7-NH). 
Methyl 5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)thiophene-2-carboxylate 37d (322): Compound 322 was synthesized as 
described for 319: yield 46% as a light yellow solid: mp 150-151 °C decomposed, Rf  = 
0.44 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ 1.62-1.64 (m, 4 H, 2 CH2),  2.57-2.60 
(t, 2 H, CH2, J = 7.5 Hz), 2.83-2.86 (t, 2 H, CH2, J = 7.5 Hz),  3.78 (s, 3 H, CH3), 5.95 (s, 
2 H, 2-NH2), 6.33-6.34 (d, 1 H, CH,  J = 1.0 Hz), 6.94-6.95 (d, 1 H, CH,  J = 1.8 Hz), 
7.62-7.63 (d, 1 H, CH,  J = 1.8 Hz), 10.09 (s, 1 H, 3-NH), 10.60 (s, 1H, 7-NH). 
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Methyl 5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)pentyl)thiophene-2-carboxylate (323): Compound 323 was synthesized as described 
for 319: yield 47% as a pink solid: mp 139-140 °C decomposed,Rf  = 0.46 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ 1.32-1.34 (m, 2 H, CH2),  1.58-1.66 (m, 4 
H, 2 CH2),  2.51-2.54 (m, 2 H, CH2), 2.82-2.85 (t, 2 H, CH2, J = 7.5 Hz),  3.78 (s, 3 H, 
CH3), 5.94 (s, 2 H, 2-NH2), 6.31-6.32 (d, 1 H, CH,  J = 1.0 Hz), 6.94-6.95 (d, 1 H, CH,  J 
= 1.8 Hz), 7.62-7.63 (d, 1 H, CH,  J = 1.8 Hz), 10.08 (s, 1 H, 3-NH), 10.59 (s, 1H, 7-NH). 
Methyl 5-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)hexyl)thiophene-2-carboxylate (324): Compound 324 was synthesized as described 
for 319: yield 50% as a pink solid: mp 168-169 °C decomposed, Rf  = 0.45 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ 1.30-1.33 (m, 4 H, 2 CH2),  1.55-1.64 (m, 4 
H, 2 CH2),  2.51-2.54 (m, 2 H, CH2), 2.80-2.83 (t, 2 H, CH2, J = 7.5 Hz),  3.78 (s, 3 H, 
CH3), 5.94 (s, 2 H, 2-NH2), 6.31-6.32 (d, 1 H, CH,  J = 1.0 Hz), 6.94-6.95 (d, 1 H, CH,  J 
= 1.8 Hz), 7.60-7.61 (d, 1 H, CH,  J = 1.8 Hz), 10.07 (s, 1 H, 3-NH), 10.58 (s, 1H, 7-NH). 
(S)-diethyl 2-(5-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)methyl)thiophene-2-carboxamido)pentanedioate (325): To a suspension of 319 (75 
mg, 0.26 mmol) in 3 mL CH3OH was added 3 N NaOH (3 mL). The resulting mixture 
was stirred under N2 at 40-50 °C for 24 h. TLC indicated the disappearance of starting 
material and the formation of one major spot at the origin. The resulting solution was 
passed through Celite and washed with a minimum amount of CH3OH. The combined 
filtrate was evaporated under reduced pressure to dryness. To this residue was added 
distilled water (10 mL). The solution was cooled in an ice bath, and the pH was adjusted 
3 to 4 using 3 N HCl. The resulting suspension was chilled in a dry ice/acetone bath and 
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thawed to 4 °C overnight in a refrigerator. The precipitate was filtered, washed with cold 
water, and dried in a desiccator under reduced pressure using P2O5 to a brown powder, 
which was used directly for the next step. 
To a solution of this brown powder in anhydrous DMF (5 mL) was added 6-chloro-2,4-
dimethoxy-1,3,5-triazine (55 mg, 0.31 mmol) and N-methylmorpholine (32 mg, 0.31 
mmol). After the mixture was stirred at r.t. for 2 h, N-methylmorpholine (32 mg, 0.31 
mmol) and dimethyl L-glutamate hydrochloride (75 mg, 0.31 mmol) were added all at 
once. The mixture was stirred at r.t. for 4 h. TLC showed the formation of one major spot 
at Rf  = 0.42 (CHCl3/MeOH, 5:1). The reaction mixture was evaporated to dryness under 
reduced pressure. The residue was dissolved in a minimum amount of CHCl3/MeOH, 5:1, 
and chromatographed on a silica gel column (2 cm x 15 cm) with 4% MeOH in CHCl3 as 
the eluent. Fractions that showed the desired single spot at Rf  = 0.42 were pooled and 
evaporated to dryness to afford 325 85 mg, yield 70% as a yellow syrup.  
1H NMR (DMSO-d6) δ  1.14-1.19 (m, 6 H, 2 CH3), 1.92-1.97 (m, 1 H, CH2), 2.04-2.11 
(m, 1 H, CH2), 2.38-2.41 (m, 2 H, CH2), 4.03-4.10 (m, 4 H, 2 CH2), 4.13 (s, 2 H, CH2), 
4.34-4.38 (m, 1 H, CH), 6.01 (s, 2 H, 2-NH2), 6.44-6.45 (d, 1 H, CH,  J = 1.0 Hz), 6.90-
6.91 (d, 1 H, CH,  J = 1.8 Hz), 7.62-7.63 (d, 1 H, CH,  J = 1.8 Hz), 8.52-8.53 (d, 1 H, 
CONH, , J = 4.0 Hz), 10.13 (s, 1 H, 3-NH), 10.78 (s, 1H, 7-NH). 
(S)-diethyl 2-(5-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl)thiophene-2-carboxamido)pentanedioate (326): Compound 326 was 
synthesized as described for 325: yield 72% as a yellow syrup, Rf  = 0.42 (CHCl3/MeOH, 
5:1). 1H NMR (DMSO-d6) δ  1.15-1.20 (m, 6 H, 2 CH3), 1.92-1.99 (m, 1 H, CH2), 2.05-
2.12 (m, 1 H, CH2), 2.40-2.43 (t, 2 H, CH2, J = 7.5 Hz), 2.87-2.90 (t, 2 H, CH2, J = 7.5 
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Hz), 3.15-3.18 (t, 2 H, CH2, J = 7.5 Hz), 4.02-4.13 (m, 4 H, 2 CH2), 4.35-4.39 (m, 1 H, 
CH), 5.98 (s, 2 H, 2-NH2), 6.35-6.36 (d, 1 H, CH,  J = 1.0 Hz), 6.84-6.85 (d, 1 H, CH,  J 
= 2.0 Hz), 7.64-7.65 (d, 1 H, CH,  J = 2.0 Hz), 8.55-8.56 (d, 1 H, CONH, , J = 4.0 Hz), 
10.14 (s, 1 H, 3-NH), 10.63 (s, 1H, 7-NH). 
(S)-diethyl 2-(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)thiophene-2-carboxamido)pentanedioate (327): Compound 327 was 
synthesized as described for 325: yield 60% as a colorless syrup, Rf  = 0.44 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  1.15-1.20 (m, 6 H, 2 CH3), 1.92-1.99 (m, 3 
H, CH2), 2.05-2.12 (m, 1 H, CH2), 2.40-2.43 (t, 2 H, CH2, J = 7.5 Hz), 2.59-2.62 (t, 2 H, 
CH2, J = 7.5 Hz), 2.77-2.80 (t, 2 H, CH2, J = 7.5 Hz), 4.02-4.13 (m, 4 H, 2 CH2), 4.35-
4.39 (m, 1 H, CH), 5.97 (s, 2 H, 2-NH2), 6.36-6.37 (d, 1 H, CH,  J = 1.0 Hz), 6.89-6.90 
(d, 1 H, CH,  J = 2.0 Hz), 7.67-7.68 (d, 1 H, CH,  J = 2.0 Hz), 8.60-8.61 (d, 1 H, CONH, , 
J = 4.0 Hz), 10.10 (s, 1 H, 3-NH), 10.65 (s, 1H, 7-NH). 
(S)-diethyl 2-(5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)thiophene-2-carboxamido)pentanedioate (328): Compound 328 was 
synthesized as described for 325: yield 52% as a colorless syrup,  Rf  = 0.45 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  1.15-1.20 (m, 6 H, 2 CH3), 1.58-1.66 (m, 4 
H, 2 CH2), 1.92-1.99 (m, 3 H, CH2), 2.05-2.12 (m, 1 H, CH2), 2.40-2.43 (t, 2 H, CH2, J = 
7.5 Hz), 2.57-2.60 (t, 2 H, CH2, J = 7.5 Hz), 2.79-2.81 (t, 2 H, CH2, J = 7.5 Hz), 4.02-4.12 
(m, 4 H, 2 CH2), 4.35-4.39 (m, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 6.33-6.34 (d, 1 H, CH,  J 
= 1.0 Hz), 6.87-6.88 (d, 1 H, CH,  J = 2.0 Hz), 7.66-7.67 (d, 1 H, CH,  J = 2.0 Hz), 8.58-
8.60 (d, 1 H, CONH, , J = 4.0 Hz), 10.09 (s, 1 H, 3-NH), 10.60 (s, 1H, 7-NH). 
(S)-diethyl 2-(5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
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yl)pentyl)thiophene-2-carboxamido)pentanedioate (329): Compound 329 was 
synthesized as described for 325: yield 65% as a colorless syrup, Rf  = 0.44 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  1.15-1.20 (m, 6 H, 2 CH3), 1.30-1.36 (m, 2 
H, CH2), 1.58-1.66 (m, 4 H, 2 CH2), 1.92-1.99 (m, 3 H, CH2), 2.05-2.12 (m, 1 H, CH2), 
2.40-2.43 (t, 2 H, CH2, J = 7.5 Hz), 2.52-2.55 (t, 2 H, CH2, J = 7.5 Hz), 2.78-2.81 (t, 2 H, 
CH2, J = 7.5 Hz), 4.02-4.12 (m, 4 H, 2 CH2), 4.35-4.39 (m, 1 H, CH), 5.94 (s, 2 H, 2-
NH2), 6.32-6.33 (d, 1 H, CH,  J = 1.0 Hz), 6.87-6.88 (d, 1 H, CH,  J = 2.0 Hz), 7.66-7.67 
(d, 1 H, CH,  J = 2.0 Hz), 8.59-8.61 (d, 1 H, CONH, , J = 4.0 Hz), 10.08 (s, 1 H, 3-NH), 
10.59 (s, 1H, 7-NH). 
(S)-diethyl 2-(5-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)hexyl)thiophene-2-carboxamido)pentanedioate (330): Compound 330 was 
synthesized as described for 325: yield 61% as a colorless syrup, Rf  = 0.42 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  1.15-1.20 (m, 6 H, 2 CH3), 1.29-1.35 (m, 4 
H, 2 CH2), 1.54-1.63 (m, 4 H, 2 CH2), 1.92-1.99 (m, 3 H, CH2), 2.05-2.12 (m, 1 H, CH2), 
2.40-2.43 (t, 2 H, CH2, J = 7.5 Hz), 2.52-2.54 (t, 2 H, CH2, J = 7.5 Hz), 2.76-2.79 (t, 2 H, 
CH2, J = 7.5 Hz), 4.02-4.12 (m, 4 H, 2 CH2), 4.35-4.40 (m, 1 H, CH), 5.94 (s, 2 H, 2-
NH2), 6.31-6.32 (d, 1 H, CH,  J = 1.0 Hz), 6.87-6.88 (d, 1 H, CH,  J = 2.0 Hz), 7.67-7.68 
(d, 1 H, CH,  J = 2.0 Hz), 8.59-8.61 (d, 1 H, CONH, , J = 4.0 Hz), 10.07 (s, 1 H, 3-NH), 
10.58 (s, 1H, 7-NH). 
(S)-2-(5-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)methyl)thiophene-2-carboxamido)pentanedioic acid (178): Compound 178 was 
synthesized as described for 2: yield 93% as a yellow powder: mp 188 °C decomposed, 
Rf  = 0.05 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  1.87-1.92 (m, 1 H, CH2), 2.00-
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2.07 (m, 1 H, CH2), 2.30-2.33 (t, 2 H, CH2,  J = 7.5 Hz), 4.12 (s, 2 H, CH2), 4.29-4.33 (m, 
1 H, CH), 6.02 (s, 2 H, 2-NH2), 6.43-6.44 (d, 1 H, CH,  J = 1.0 Hz), 6.90-6.91 (d, 1 H, 
CH,  J = 1.8 Hz), 7.63-7.64 (d, 1 H, CH,  J = 1.8 Hz), 8.42-8.44 (d, 1 H, CONH, , J = 4.0 
Hz), 10.15 (s, 1 H, 3-NH), 10.79 (s, 1H, 7-NH). Anal. (C17H17N5O6S · 0.83CH3OH) Cal. 
C: 48.01, H: 4.59, N: 15.70, S: 7.19. Found C: 47.90, H: 4.26, N: 15.58, S: 7.22. 
(S)-2-(5-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl)thiophene-2-carboxamido)pentanedioic acid (179): Compound 179 was 
synthesized as described for 2: yield 90% as a pink powder: mp 181 °C decomposed, Rf  
= 0.05 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ 1.88-1.93 (m, 1 H, CH2), 2.02-2.08 
(m, 1 H, CH2), 2.31-2.34 (t, 2 H, CH2, J = 7.5 Hz), 2.86-2.89 (t, 2 H, CH2, J = 7.5 Hz), 
3.14-3.17 (t, 2 H, CH2, J = 7.5 Hz), 4.30-4.35 (m, 1 H, CH), 6.00 (s, 2 H, 2-NH2), 6.35-
6.36 (d, 1 H, CH,  J = 1.0 Hz), 6.83-6.84 (d, 1 H, CH,  J = 2.0 Hz), 7.64-7.65 (d, 1 H, 
CH,  J = 2.0 Hz), 8.45-8.47 (d, 1 H, CONH, , J = 4.0 Hz), 10.16 (s, 1 H, 3-NH), 10.64 (s, 
1H, 7-NH). Anal. (C18H19N5O6S · 1.1H2O) Cal. C: 47.70, H: 4.71, N: 15.45, S: 7.07. 
Found C: 47.95, H: 4.71, N: 15.09, S: 6.95. 
 (S)-2-(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)thiophene-2-carboxamido)pentanedioic acid (180): Compound 180 was 
synthesized as described for 2: yield 90% as a pale blue powder: mp 159 °C decomposed, 
Rf  = 0.06 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ 1.88-1.97 (m, 3 H, CH2), 2.01-
2.08 (m, 1 H, CH2), 2.31-2.34 (t, 2 H, CH2, J = 7.5 Hz), 2.59-2.62 (t, 2 H, CH2, J = 7.5 
Hz), 2.77-2.80 (t, 2 H, CH2, J = 7.5 Hz), 4.30-4.35 (m, 1 H, CH), 5.97 (s, 2 H, 2-NH2), 
6.36-6.37 (d, 1 H, CH,  J = 1.0 Hz), 6.88-6.89 (d, 1 H, CH,  J = 2.0 Hz), 7.67-7.68 (d, 1 
H, CH,  J = 2.0 Hz), 8.46-8.48 (d, 1 H, CONH, , J = 4.0 Hz), 10.11 (s, 1 H, 3-NH), 10.64 
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(s, 1H, 7-NH). Anal. (C19H21N5O6S · 0.95 CH3OH) Cal. C: 50.14, H: 5.23, N: 14.65, S: 
6.71. Found C: 50.52, H: 5.07, N: 14.29, S: 6.90. 
 (S)-2-(5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)thiophene-2-carboxamido)pentanedioic acid (181): Compound 181 was 
synthesized as described for 2: yield 96% as a blue powder: mp 141 °C decomposed, Rf  
= 0.06 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  1.59-1.66 (m, 4 H, 2 CH2), 1.88-
1.94 (m, 3 H, CH2), 2.03-2.10 (m, 1 H, CH2), 2.32-2.35 (t, 2 H, CH2, J = 7.5 Hz), 2.57-
2.60 (t, 2 H, CH2, J = 7.5 Hz), 2.79-2.81 (t, 2 H, CH2, J = 7.5 Hz), 4.31-4.35 (m, 1 H, 
CH), 5.95 (s, 2 H, 2-NH2), 6.33-6.34 (d, 1 H, CH,  J = 1.0 Hz), 6.87-6.88 (d, 1 H, CH,  J 
= 2.0 Hz), 7.66-7.67 (d, 1 H, CH,  J = 2.0 Hz), 8.47-8.49 (d, 1 H, CONH, , J = 4.0 Hz), 
10.09 (s, 1 H, 3-NH), 10.60 (s, 1H, 7-NH). Anal. (C20H23N5O6S · 0.55 CH3OH) Cal. C: 
51.52, H: 5.30, N: 14.62, S: 6.69. Found C: 51.57, H: 5.25, N: 14.54, S: 6.70.  
(S)-2-(5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)pentyl)thiophene-2-carboxamido)pentanedioic acid (182): Compound 182 was 
synthesized as described for 2: yield 95% as a pale yellow powder: mp 158 °C 
decomposed,Rf  = 0.07 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ  1.31-1.36 (m, 2 H, 
CH2), 1.59-1.66 (m, 4 H, 2 CH2), 1.88-1.94 (m, 3 H, CH2), 2.03-2.10 (m, 1 H, CH2), 
2.32-2.35 (t, 2 H, CH2, J = 7.5 Hz), 2.52-2.55 (t, 2 H, CH2, J = 7.5 Hz), 2.77-2.80 (t, 2 H, 
CH2, J = 7.5 Hz), 4.31-4.35 (m, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 6.32-6.33 (d, 1 H, CH,  J 
= 1.0 Hz), 6.87-6.88 (d, 1 H, CH,  J = 2.0 Hz), 7.66-7.67 (d, 1 H, CH,  J = 2.0 Hz), 8.48-
8.50 (d, 1 H, CONH, , J = 4.0 Hz), 10.08 (s, 1 H, 3-NH), 10.59 (s, 1H, 7-NH). Anal. 
(C21H25N5O6S · 0.70 H2O) Cal. C: 51.70, H: 5.45, N: 14.36, S: 6.57. Found C: 51.82, H: 
5.39, N: 14.05, S: 6.25. 
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(S)-2-(5-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)hexyl)thiophene-2-carboxamido)pentanedioic acid (183): Compound 183  was 
synthesized as described for 2: yield 89% as a blue powder: mp 126 °C decomposed, Rf  
= 0.07 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ  1.29-1.35 (m, 4 H, 2 CH2), 1.53-
1.64 (m, 4 H, 2 CH2), 1.88-1.94 (m, 3 H, CH2), 2.03-2.10 (m, 1 H, CH2), 2.32-2.35 (t, 2 
H, CH2, J = 7.5 Hz), 2.52-2.55 (t, 2 H, CH2, J = 7.5 Hz), 2.76-2.79 (t, 2 H, CH2, J = 7.5 
Hz), 4.31-4.35 (m, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 6.31-6.32 (d, 1 H, CH,  J = 1.0 Hz), 
6.87-6.88 (d, 1 H, CH,  J = 2.0 Hz), 7.66-7.67 (d, 1 H, CH,  J = 2.0 Hz), 8.48-8.50 (d, 1 
H, CONH, , J = 4.0 Hz), 10.07 (s, 1 H, 3-NH), 10.58 (s, 1H, 7-NH). Anal. (C22H27N5O6S 
· 0.25 H2O) Cal. C: 53.46, H: 5.61, N: 14.17, S: 6.49. Found C: 53.55, H: 5.79, N: 13.92, 
S: 6.38. 
Methyl 9-hydroxynonanoate (333): To a solution of monomethyl azelate 331 (1.0 g, 5 
mmol) in anhydrous THF 5 mL, BH3·THF complex (1M in THF, 5 mL, 5 mmol) was 
added dropwise at -18 °C over 20 minutes. The resulting mixture was stirred at room 
temperature for 4 hours to get a colorless solution. TCL indicated there is no fluorescence 
for both starting material and the product. The reaction was quenched with water and 
K2CO3 (1.15 g, 8.4 mmol) at 0 °C. The organic layer was separated and the aqueous layer 
was extracted with ethyl ether (20 mL x 3). The combined organic layer was dried over 
Na2SO4 and evaporated to dryness under reduced pressure and chromatographed on a 
silica gel column (2 cm x 15 cm) with Hexane/EtOAc ( 3:1) as the eluent. The solvent 
was evaporated to afford 333 0.90 g (yield : 96%)  as a colorless oil. 1H NMR (CDCl3) δ  
1.29-1.34 (m, 8 H, 4 CH2), 1.55-1.57 (m, 2 H, CH2), 1.60-1.63 (m, 2 H, CH2), 2.29-2.32 
(t, 2 H, CH2, J = 7.5 Hz), 3.63-3.65 (t, 2 H, CH2, J = 6.0 Hz), 3.67 (s, 3 H, CH3). 
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Methyl 10-hydroxydecanoate (334): Compound 334 was synthesized as described for 
333: yield 91% as a colorless oil. 1H NMR (CDCl3) δ  1.26-1.34 (m, 10 H, 5 CH2), 1.54-
1.57 (m, 2 H, CH2), 1.60-1.63 (m, 2 H, CH2), 2.28-2.31 (t, 2 H, CH2, J = 7.5 Hz), 3.62-
3.64 (t, 2 H, CH2, J = 6.0 Hz), 3.66 (s, 3 H, CH3). 
Methyl 9-oxononanoate  (335): To a stirring suspension of PCC (1.62 g, 7.5 mmol) and 
silica gel ( 2 g ) in anhydrous CH2Cl2 20 mL, a solution of 333 (0.94g, 5 mmol) in 
anhydrous CH2Cl2 10 mL was added dropwise at 0 °C over 20 minutes. The resulting 
mixture was stirred at room temperature for 4 hours. TCL indicated there is no 
fluorescence for both starting material and the product. The reaction was evaporated to 
dryness under reduced pressure and chromatographed on a silica gel column (2 cm x 15 
cm) with Hexane/EtOAc (2:1) as the eluent. The solvent was evaporated to afford 335 
0.85 g (yield: 90%) as a yellow liquid. 1H NMR (CDCl3) δ  1.30-1.34 (m, 6 H, 3 CH2), 
1.59-1.64 (m, 4 H, 2 CH2), 2.28-2.31 (t, 2 H, CH2, J = 7.5 Hz), 2.40-2.43 (t, 2 H, CH2, J 
= 7.5 Hz), 3.66 (s, 3 H, CH3), 9.75-9.76 (t, 1 H, CHO,  J = 1.0 Hz) 
Methyl 10-oxodecanoate (336): Compound 336 was synthesized as described for 335: 
yield 89% as a yellow liquid. 1H NMR (CDCl3) δ  1.27-1.33 (m, 8 H, 4 CH2), 1.59-1.64 
(m, 4 H, 2 CH2), 2.28-2.31 (t, 2 H, CH2, J = 7.5 Hz), 2.40-2.43 (t, 2 H, CH2, J = 7.5 Hz), 
3.66 (s, 3 H, CH3), 9.75-9.76 (t, 1 H, CHO,  J = 1.0 Hz). 
Methyl 11-oxoundecanoate  (337): A mixture of 338 (2.79 g, 10 mmol) and NaHCO3 ( 
2.0 g, 23 mmol ) in DMSO 20 mL was stirred  at 165 °C for 15 minutes until evolution of 
white fumes was noticed. The resulting mixture was cooled to room temperature. TCL 
indicated there is no fluorescence for both starting material and the product. The reaction 
was quenched with water and extracted with ethyl ether (20 mL x 3). The combined 
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organic layer was dried over Na2SO4 and evaporated to dryness under reduced pressure 
and chromatographed on a silica gel column (2 cm x 15 cm) with Hexane/EtOAc ( 3:1) as 
the eluent. The solvent was evaporated to afford 337 1.88 g (yield : 88%)  as a colorless 
oil. 1H NMR (CDCl3) δ  1.26-1.33 (m, 10 H, 5 CH2), 1.59-1.62 (m, 4 H, 2 CH2), 2.28-
2.31 (t, 2 H, CH2, J = 7.5 Hz), 2.40-2.43 (t, 2 H, CH2, J = 7.5 Hz), 3.66 (s, 3 H, CH3), 
9.75-9.76 (t, 1 H, CHO,  J = 1.0 Hz). 
Methyl 8-bromo-9-oxononanoate (339): To a solution of aldehyde 335 (2.9 mmol, 536 
mg) in 10 mL anhydrous Et2O was added 287 (1.5mmol, 450mg), 2N HCl in Et2O 
solution (0.3mmol, 150µL) and the mixture was stirred at room temperature for 24 hours. 
TCL indicated there is no fluorescence for both starting material and the product. The 
reaction solution was washed with 5% NaHCO3 solution and extracted with H2O (10 mL 
X 3) and dried over Na2SO4. After evaporation of solvent, the residue was loaded on a 
silica gel column (4 X 20 cm) and flash-chromatographed with hexane/EtOAc (4:1) and 
the desired fractions were pooled. After evaporation of solvent the residue was dried in 
vacuo using P2O5 to afford 339 590 mg : yield 77% as a yellow liquid. 
1H NMR (CDCl3) 
δ  1.31-1.36 (m, 4 H, 2 CH2), 1.58-1.66 (m, 4 H, 2 CH2), 1.89-1.94 (m, 1 H, CH2), 2.00-
2.07 (m, 1 H, CH2), 2.29-2.32 (t, 2 H, CH2, J = 7.5 Hz), 3.67 (s, 3 H, CH3), 4.19-4.23 (m, 
1 H, CHBr),  9.42-9.43 (d, 1 H, CHO,  J = 1.5 Hz). 
Methyl 9-bromo-10-oxodecanoate (340): Compound 340 was synthesized as described 
for 339: yield 75% as a yellow liquid. 1H NMR (CDCl3) δ  1.27-1.34 (m, 6 H, 3 CH2), 
1.58-1.64 (m, 4 H, 2 CH2), 1.88-1.94 (m, 1 H, CH2), 1.98-2.03 (m, 1 H, CH2), 2.28-2.32 
(t, 2 H, CH2, J = 7.5 Hz), 3.66 (s, 3 H, CH3), 4.19-4.23 (m, 1 H, CHBr),  9.42-9.43 (d, 1 
H, CHO,  J = 1.5 Hz). 
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Methyl 10-bromo-11-oxoundecanoate (341): Compound 341 was synthesized as 
described for 339: yield 75% as a yellow liquid. 1H NMR (CDCl3) δ  1.25-1.32 (m, 8 H, 
4 CH2), 1.58-1.63 (m, 4 H, 2 CH2), 1.88-1.93 (m, 1 H, CH2), 2.00-2.05 (m, 1 H, CH2), 
2.28-2.31 (t, 2 H, CH2, J = 7.5 Hz), 3.66 (s, 3 H, CH3), 4.19-4.22 (m, 1 H, CHBr),  9.42-
9.43 (d, 1 H, CHO,  J = 1.5 Hz) 
Methyl 7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)heptanoate 
(342): To a solution of 2,4-diamino-6-hydroxypyrimidine 35 (360 mg, 2.8 mmol) and 
sodium acetate (451 mg, 5.5 mmol) in water (3 mL) and methanol (3 mL) was added α-
bromo aldehyde 339 (730 mg, 2.8 mmol)  The reaction mixture was stirred at 45 °C for 5 
hours. TLC showed the disappearance of starting materials and the formation of one 
major spot at Rf  = 0.50 (CHCl3/MeOH, 5:1). After evaporation of solvent, CH3OH (10 
mL) was added followed by silica gel (3 g). Evaporation of the solvent afforded a plug, 
which was loaded onto a silica gel column (3.5 cm x 15 cm) and eluted initially with 
CHCl3 followed by 10% MeOH in CHCl3 and then 15% MeOH in CHCl3. Fractions 
showing Rf  = 0.50 were pooled and evaporated to afford 342 460 mg, yield 56%  as a red 
syrup, Rf  = 0.50 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ 1.25-1.28 (m, 4 H, 2 CH2),  
1.49-1.57 (m, 4 H, 2 CH2), 2.26-2.29 (t, 2 H, CH2, J = 7.5 Hz), 2.52-2.54 (m, 2 H, CH2), 
3.57 (s, 3 H, CH3), 5.94 (s, 2 H, 2-NH2), 6.31-6.32 (d, 1 H, CH,  J = 1.0 Hz), 10.06 (s, 1 
H, 3-NH), 10.58 (s, 1H, 7-NH). 
Methyl 8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)octanoate 
(343): Compound 343 was synthesized as described for 342: yield 58% as a red syrup, Rf  
= 0.48 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ 1.23-1.27 (m, 6 H, 3 CH2),  1.49-
1.57 (m, 4 H, 2 CH2), 2.26-2.29 (t, 2 H, CH2, J = 7.5 Hz), 2.52-2.54 (m, 2 H, CH2), 3.57 
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(s, 3 H, CH3), 5.94 (s, 2 H, 2-NH2), 6.30-6.31 (d, 1 H, CH,  J = 1.0 Hz), 10.06 (s, 1 H, 3-
NH), 10.58 (s, 1H, 7-NH). 
Methyl 9-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)nonanoate 
(344): Compound 344 was synthesized as described for 342: yield 53% as a pink syrup,  
Rf  = 0.50 (CHCl3/MeOH, 5:1).
1H NMR (DMSO-d6) δ 1.20-1.27 (m, 8 H, 4 CH2),  1.48-
1.57 (m, 4 H, 2 CH2), 2.26-2.29 (t, 2 H, CH2, J = 7.5 Hz), 2.52-2.54 (m, 2 H, CH2), 3.57 
(s, 3 H, CH3), 5.95 (s, 2 H, 2-NH2), 6.30-6.31 (d, 1 H, CH,  J = 1.0 Hz), 10.08 (s, 1 H, 3-
NH), 10.57 (s, 1H, 7-NH).  
(S)-diethyl 2-(7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)heptanamido)pentanedioate (345): To a suspension of 342 (56 mg, 0.20 mmol) in 3 
mL CH3OH was added 1 N NaOH (3 mL). The resulting mixture was stirred under N2 at 
room temperature for 2 h. TLC indicated the disappearance of starting material and the 
formation of one major spot at the origin. The resulting solution was passed through 
Celite and washed with a minimum amount of CH3OH. The combined filtrate was 
evaporated under reduced pressure to dryness. To this residue was added distilled water 
(10 mL). The solution was cooled in an ice bath, and the pH was adjusted 3 to 4 using 1 
N HCl. The resulting suspension was chilled in a dry ice/acetone bath and thawed to 4 °C 
overnight in a refrigerator. The precipitate was filtered, washed with cold water, and dried 
in a desiccator under reduced pressure using P2O5 to a brown powder, which was used 
directly for the next step. 
To a solution of this brown powder in anhydrous DMF (5 mL) was added 6-chloro-2,4-
dimethoxy-1,3,5-triazine (50 mg, 0.24 mmol) and N-methylmorpholine (25 mg, 0.24 
mmol). After the mixture was stirred at r.t. for 2 h, N-methylmorpholine (25 mg, 0.24 
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mmol) and dimethyl L-glutamate hydrochloride (72 mg, 0.30 mmol) were added all at 
once. The mixture was stirred at r.t. for 4 h. TLC showed the formation of one major spot 
at Rf  = 0.52 (CHCl3/MeOH, 5:1). The reaction mixture was evaporated to dryness under 
reduced pressure. The residue was dissolved in a minimum amount of CHCl3/MeOH, 5:1, 
and chromatographed on a silica gel column (2 cm x 15 cm) with 4% MeOH in CHCl3 as 
the eluent. Fractions that showed the desired single spot at Rf  = 0.52 were pooled and 
evaporated to dryness to afford 345 50 mg, yield 57% as a pink syrup. 1H NMR (DMSO-
d6) δ 1.14-1.18 (m, 6 H, 2 CH3), 1.24-1.28 (m, 4 H, 2 CH2), 1.46-1.49 (m, 2 H, CH2), 
1.54-1.57 (m, 2 H, CH2), 1.78-1.83 (m, 1 H, CH2), 1.92-1.97 (m, 1 H, CH2), 2.08-2.11 (t, 
2 H, CH2, J = 7.5 Hz), 2.33-2.36 (t, 2 H, CH2, J = 7.5 Hz), 2.52-2.54 (m, 2 H, CH2),  4.02-
4.10 (m, 4 H, 2 CH2), 4.19-4.24 (m, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 6.30-6.31 (d, 1 H, 
CH,  J = 1.0 Hz), 8.14-8.16 (d, 1 H, CONH, , J = 4.0 Hz), 10.06 (s, 1 H, 3-NH), 10.58 (s, 
1H, 7-NH). 
(S)-diethyl 2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)octanamido)pentanedioate (346): Compound 346 was synthesized as described for 
345: yield 68% as a yellow syrup: Rf  = 0.54 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ 
1.15-1.18 (m, 6 H, 2 CH3), 1.22-1.28 (m, 6 H, 3 CH2), 1.46-1.49 (m, 2 H, CH2), 1.54-1.57 
(m, 2 H, CH2), 1.75-1.83 (m, 1 H, CH2), 1.92-1.98 (m, 1 H, CH2), 2.08-2.11 (t, 2 H, CH2, 
J = 7.5 Hz), 2.33-2.36 (t, 2 H, CH2, J = 7.5 Hz), 2.52-2.54 (m, 2 H, CH2),  4.02-4.11 (m, 4 
H, 2 CH2), 4.20-4.24 (m, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 6.30-6.31 (d, 1 H, CH,  J = 1.0 
Hz), 8.14-8.16 (d, 1 H, CONH, , J = 4.0 Hz), 10.06 (s, 1 H, 3-NH), 10.57 (s, 1H, 7-NH). 
 (S)-diethyl 2-(9-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)nonanamido)pentanedioate (347): Compound 347 was synthesized as described for 
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345: yield 64% as a yellow syrup: Rf  = 0.55 (CHCl3/MeOH, 5:1).
1H NMR (DMSO-d6) δ 
1.15-1.18 (m, 6 H, 2 CH3), 1.22-1.28 (m, 8 H, 4 CH2), 1.46-1.49 (m, 2 H, CH2), 1.54-1.57 
(m, 2 H, CH2), 1.76-1.87 (m, 1 H, CH2), 1.93-1.99 (m, 1 H, CH2), 2.08-2.11 (t, 2 H, CH2, 
J = 7.5 Hz), 2.33-2.36 (t, 2 H, CH2, J = 7.5 Hz), 2.52-2.54 (m, 2 H, CH2),  4.02-4.09 (m, 4 
H, 2 CH2), 4.19-4.24 (m, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 6.30-6.31 (d, 1 H, CH,  J = 1.0 
Hz), 8.15-8.16 (d, 1 H, CONH, , J = 4.0 Hz), 10.06 (s, 1 H, 3-NH), 10.57 (s, 1H, 7-NH). 
(S)-2-(7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)heptanamido)pentanedioic acid (184): To a solution of the diester 345 (40 mg, 0.09 
mmol) was added 1 N NaOH (5 mL), and the mixture was stirred under N2 at room 
temperature for 1 h. TLC showed the disappearance of the starting material and formation 
of one major spot at the origin (CHCl3/MeOH, 5:1). The reaction mixture was evaporated 
to dryness under reduced pressure. The residue was dissolved in water (5 mL), the 
resulting solution was cooled in an ice bath, and the pH was adjusted to 3-4 with 
dropwise addition of 1 N HCl. The resulting suspension was frozen in a dry ice/acetone 
bath, thawed in a refrigerator to 4-5 °C, and filtered. The residue was washed with a 
small amount of cold water and ethyl acetate and dried in vacuo using P2O5 to afford 35 
mg (97%) 184 as a yellow powder: mp 133 °C decomposed,Rf  = 0.05 (CHCl3/MeOH, 
5:1). 1H NMR (DMSO-d6) δ 1.24-1.28 (m, 4 H, 2 CH2), 1.46-1.49 (m, 2 H, CH2), 1.54-
1.56 (m, 2 H, CH2), 1.72-1.77 (m, 1 H, CH2), 1.90-1.95 (m, 1 H, CH2), 2.08-2.11 (t, 2 H, 
CH2, J = 7.5 Hz), 2.24-2.28 (t, 2 H, CH2, J = 7.5 Hz), 2.52-2.54 (m, 2 H, CH2), 4.16-4.20 
(m, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 6.30-6.31 (d, 1 H, CH,  J = 1.0 Hz), 8.01-8.03 (d, 1 
H, CONH, , J = 4.0 Hz), 10.07 (s, 1 H, 3-NH), 10.58 (s, 1H, 7-NH). Anal. (C18H25N5O6 · 
0.46 H2O) Cal. C: 52.00, H: 6.28, N: 16.84. Found C: 52.05, H: 6.26, N: 16.68. 
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(S)-2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)octanamido)pentanedioic acid (185): Compound 185 was synthesized from 346 as 
described for 184: yield 98% as a pink powder: mp 147 °C decomposed,  Rf  = 0.05 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ 1.24-1.28 (m, 6 H, 3 CH2), 1.46-1.49 (m, 2 
H, CH2), 1.54-1.57 (m, 2 H, CH2), 1.72-1.77 (m, 1 H, CH2), 1.90-1.95 (m, 1 H, CH2), 
2.08-2.11 (t, 2 H, CH2, J = 7.5 Hz), 2.24-2.28 (t, 2 H, CH2, J = 7.5 Hz), 2.52-2.54 (m, 2 H, 
CH2), 4.16-4.20 (m, 1 H, CH), 5.95 (s, 2 H, 2-NH2), 6.31-6.32 (d, 1 H, CH,  J = 1.0 Hz), 
8.02-8.04 (d, 1 H, CONH, , J = 4.0 Hz), 10.08 (s, 1 H, 3-NH), 10.57 (s, 1H, 7-NH). Anal. 
(C19H27N5O6 · 0.30 CHCl3) Cal. C: 50.66, H: 6.01, N: 15.30. Found C: 50.77, H: 6.15, N: 
14.94. 
(S)-2-(9-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)nonanamido)pentanedioic acid (186): Compound 186 was synthesized from 347 as 
described for 184: yield 97% as a pink powder: mp 119 °C decomposed,Rf  = 0.07 
(CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ 1.20-1.28 (m, 8 H, 4 CH2), 1.46-1.49 (m, 2 
H, CH2), 1.54-1.57 (m, 2 H, CH2), 1.72-1.77 (m, 1 H, CH2), 1.90-1.95 (m, 1 H, CH2), 
2.08-2.11 (t, 2 H, CH2, J = 7.5 Hz), 2.24-2.28 (t, 2 H, CH2, J = 7.5 Hz), 2.52-2.54 (m, 2 H, 
CH2), 4.16-4.20 (m, 1 H, CH), 5.95 (s, 2 H, 2-NH2), 6.31-6.32 (d, 1 H, CH,  J = 1.0 Hz), 
8.02-8.04 (d, 1 H, CONH, , J = 4.0 Hz), 10.08 (s, 1 H, 3-NH), 10.57 (s, 1H, 7-NH). Anal. 
(C20H29N5O6 · 0.45 H2O) Cal. C: 54.16, H: 6.79, N: 15.79. Found C: 54.24, H: 6.72, N: 
15.49. 
Methyl 6-(4-oxo-2-pivalamido-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-yl)hexanoate 
(353): To a solution of 229 (234 mg, 1.0 mmol) in water (3 mL) and anhydrous DMF (5 
mL) cooled at 0 °C was added NaH (26 mg, 1.1 mmol)  The reaction mixture was stirred 
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at 0 °C for 0.5 hour. TLC showed the disappearance of starting materials and the 
formation of one major spot at Rf  = 0.52 (hexane/EtOAc, 1:2 ). Add bromide 348 (230 
mg, 1.1 mmol) to the reaction. The reaction mixture was stirred at room temperature for 5 
hours.  After evaporation of solvent, EtOAc (10 mL) was added followed by silica gel (3 
g). Evaporation of the solvent afforded a plug, which was loaded onto a silica gel column 
(3.5 cm x 15 cm) and eluted hexane/EtOAc, 1:2. Fractions showing Rf  = 0.52 were 
pooled and evaporated to afford 353 230 mg, yield 64%  as a colorless syrup: Rf  = 0.52 
(hexane/EtOAc, 1:2 ). 1H NMR (DMSO-d6) δ 1.06-1.07 (m, 4 H, 2 CH2), 1.25 (s, 9 H, -
C(CH3)3),  1.51-1.57 (m, 2 H, CH2), 1.70-1.76 (m, 2 H, CH2), 2.27-2.30 (t, 2 H, CH2, J = 
7.5 Hz), 3.56 (s, 3 H, CH3), 6.41-6.42 (d, 1 H, CH,  J = 1.5 Hz), 7.04-7.05 (d, 1 H, CH,  J 
= 1.5 Hz), 10.87 (s, 1 H, 3-NH), 11.91 (s, 1H, 2-NHPiv).  
Ethyl 7-(4-oxo-2-pivalamido-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-yl)heptanoate (354): 
Compound 354 was synthesized from 349 as described for 353: yield 53% as a colorless 
syrup: Rf  = 0.56 (hexane/EtOAc, 1:2 ). 
1H NMR (DMSO-d6) δ 1.06-1.07 (m, 4 H, 2 
CH2), 1.16-1.19 (t, 3 H, CH3, J = 7.5 Hz),  1.25 (s, 9 H, -C(CH3)3),  1.49-1.53 (m, 2 H, 
CH2), 1.76-1.80 (m, 2 H, CH2), 2.26-2.29 (t, 2 H, CH2, J = 7.5 Hz), 3.50-3.53 (t, 2 H, 
CH2, J = 7.0 Hz), 4.02-4.07 (m, 2 H, CH2), 6.41-6.42 (d, 1 H, CH,  J = 1.5 Hz), 7.04-7.05 
(d, 1 H, CH,  J = 1.5 Hz), 10.84 (s, 1 H, 3-NH), 11.91 (s, 1H, 2-NHPiv). 
Ethyl 8-(4-oxo-2-pivalamido-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-yl)octanoate (355) 
Compound 355 was synthesized from 350 as described for 353: yield 56% as a colorless 
syrup: Rf  = 0.56 (hexane/EtOAc, 1:2 ). 
1H NMR (DMSO-d6) δ 1.14-1.17 (t, 3 H, CH3, J = 
7.5 Hz), 1.20-1.24 (m, 6 H, 3 CH2),   1.25 (s, 9 H, -C(CH3)3),  1.45-1.51 (m, 2 H, CH2), 
1.70-1.73 (m, 2 H, CH2), 2.23-2.26 (t, 2 H, CH2, J = 7.5 Hz), 4.00-4.07 (m, 2 H, CH2), 
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6.41-6.42 (d, 1 H, CH,  J = 1.5 Hz), 7.04-7.05 (d, 1 H, CH,  J = 1.5 Hz), 10.85 (s, 1 H, 3-
NH), 11.91 (s, 1H, 2-NHPiv).  
Ethyl 9-(4-oxo-2-pivalamido-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-yl)nonanoate (356) 
Compound 356 was synthesized from 351 as described for 353: yield 60% as a colorless 
syrup: Rf  = 0.58 (hexane/EtOAc, 1:2 ). 
1H NMR (DMSO-d6) δ 1.14-1.17 (t, 3 H, CH3, J = 
7.5 Hz), 1.20-1.24 (m, 8 H, 4 CH2),  1.25 (s, 9 H, -C(CH3)3),  1.47-1.50 (m, 2 H, CH2), 
1.71-1.73 (m, 2 H, CH2), 2.22-2.25 (t, 2 H, CH2, J = 7.5 Hz), 4.00-4.07 (m, 2 H, CH2), 
6.41-6.42 (d, 1 H, CH,  J = 1.5 Hz), 7.04-7.05 (d, 1 H, CH,  J = 1.5 Hz), 10.85 (s, 1 H, 3-
NH), 11.91 (s, 1H, 2-NHPiv).  
(S)-diethyl 2-(6-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-
yl)hexanamido)pentanedioate (357) 
To a suspension of 353 (70 mg, 0.27 mmol) in 3 mL CH3OH was added 1 N NaOH (3 
mL). The resulting mixture was stirred under N2 at room temperature for 2 h. TLC 
indicated the disappearance of starting material and the formation of one major spot at the 
origin. The resulting solution was passed through Celite and washed with a minimum 
amount of CH3OH. The combined filtrate was evaporated under reduced pressure to 
dryness. To this residue was added distilled water (10 mL). The solution was cooled in an 
ice bath, and the pH was adjusted 3 to 4 using 1 N HCl. The resulting suspension was 
chilled in a dry ice/acetone bath and thawed to 4 °C overnight in a refrigerator. The 
precipitate was filtered, washed with cold water, and dried in a desiccator under reduced 
pressure using P2O5 to a brown powder, which was used directly for the next step. 
To a solution of this brown powder in anhydrous DMF (5 mL) was added 6-chloro-2,4-
dimethoxy-1,3,5-triazine (70 mg, 0.32 mmol) and N-methylmorpholine (33 mg, 0.32 
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mmol). After the mixture was stirred at r.t. for 2 h, N-methylmorpholine (33 mg, 0.32 
mmol) and dimethyl L-glutamate hydrochloride (96 mg, 0.40 mmol) were added all at 
once. The mixture was stirred at r.t. for 4 h. TLC showed the formation of one major spot 
at Rf  = 0.50 (CHCl3/MeOH, 5:1). The reaction mixture was evaporated to dryness under 
reduced pressure. The residue was dissolved in a minimum amount of CHCl3/MeOH, 5:1, 
and chromatographed on a silica gel column (2 cm x 15 cm) with 4% MeOH in CHCl3 as 
the eluent. Fractions that showed the desired single spot at Rf  = 0.50 were pooled and 
evaporated to dryness to afford 357 70 mg, yield 61% as a white syrup.  1H NMR 
(DMSO-d6) δ 1.15-1.18 (m, 6 H, 2 CH3), 1.19-1.22 (m, 2 H, CH2), 1.49-1.52 (m, 2 H, 
CH2), 1.65-1.68 (m, 2 H, CH2), 1.77-1.82 (m, 1 H, CH2), 1.92-1.99 (m, 1 H, CH2), 2.08-
2.11 (t, 2 H, CH2, J = 7.5 Hz), 2.33-2.36 (t, 2 H, CH2, J = 7.5 Hz), 3.86-3.88 (t, 2 H, CH2, 
J = 7.0 Hz), 4.02-4.07 (m, 4 H, 2 CH2), 4.19-4.23 (m, 1 H, CH), 6.16 (s, 2 H, 2-NH2), 
6.19-6.20 (d, 1 H, CH,  J = 1.8 Hz), 6.69-6.70 (d, 1 H, CH,  J = 1.8 Hz), 8.15-8.17 (d, 1 
H, CONH, , J = 4.0 Hz), 10.21 (s, 1 H, 3-NH). 
(S)-diethyl 2-(7-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-
yl)heptanamido)pentanedioate (358): Compound 358 was synthesized as described for 
357: yield 77% as a colorless syrup: Rf  = 0.51 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-
d6) δ 1.14-1.18 (m, 6 H, 2 CH3), 1.19-1.24 (m, 4 H, 2 CH2), 1.43-1.48 (m, 2 H, CH2), 
1.63-1.66 (m, 2 H, CH2), 1.77-1.82 (m, 1 H, CH2), 1.92-1.98 (m, 1 H, CH2), 2.07-2.10 (t, 
2 H, CH2, J = 7.5 Hz), 2.33-2.36 (t, 2 H, CH2, J = 7.5 Hz), 3.86-3.89 (t, 2 H, CH2, J = 7.0 
Hz), 4.01-4.08 (m, 4 H, 2 CH2), 4.19-4.23 (m, 1 H, CH), 6.16 (s, 2 H, 2-NH2), 6.19-6.20 
(d, 1 H, CH,  J = 1.8 Hz), 6.69-6.70 (d, 1 H, CH,  J = 1.5 Hz), 8.15-8.16 (d, 1 H, CONH, , 
J = 4.0 Hz), 10.21 (s, 1 H, 3-NH). 
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(S)-diethyl 2-(8-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-
yl)octanamido)pentanedioate (359):  
Compound 359 was synthesized as described for 357: yield 81% as a colorless syrup: Rf  
= 0.50 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ 1.14-1.18 (m, 6 H, 2 CH3), 1.19-1.26 
(m, 6 H, 3 CH2), 1.45-1.48 (m, 2 H, CH2), 1.64-1.67 (m, 2 H, CH2), 1.77-1.82 (m, 1 H, 
CH2), 1.92-1.98 (m, 1 H, CH2), 2.07-2.10 (t, 2 H, CH2, J = 7.5 Hz), 2.33-2.36 (t, 2 H, 
CH2, J = 7.5 Hz), 3.86-3.89 (t, 2 H, CH2, J = 7.0 Hz), 4.01-4.08 (m, 4 H, 2 CH2), 4.19-
4.23 (m, 1 H, CH), 6.15 (s, 2 H, 2-NH2), 6.19-6.20 (d, 1 H, CH,  J = 1.8 Hz), 6.69-6.70 
(d, 1 H, CH,  J = 1.5 Hz), 8.13-8.15 (d, 1 H, CONH, , J = 4.0 Hz), 10.21 (s, 1 H, 3-NH). 
(S)-diethyl 2-(9-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-
yl)nonanamido)pentanedioate (360): Compound 360 was synthesized as described for 
357: yield 71% as a colorless syrup: Rf  = 0.52 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-
d6) δ 1.14-1.18 (m, 6 H, 2 CH3), 1.19-1.26 (m, 8 H, 4 CH2), 1.45-1.48 (m, 2 H, CH2), 
1.64-1.67 (m, 2 H, CH2), 1.77-1.82 (m, 1 H, CH2), 1.94-1.99 (m, 1 H, CH2), 2.07-2.10 (t, 
2 H, CH2, J = 7.5 Hz), 2.33-2.36 (t, 2 H, CH2, J = 7.5 Hz), 3.86-3.89 (t, 2 H, CH2, J = 7.0 
Hz), 4.01-4.08 (m, 4 H, 2 CH2), 4.19-4.23 (m, 1 H, CH), 6.15 (s, 2 H, 2-NH2), 6.19-6.20 
(d, 1 H, CH,  J = 1.8 Hz), 6.69-6.70 (d, 1 H, CH,  J = 1.5 Hz), 8.13-8.14 (d, 1 H, CONH, , 
J = 4.0 Hz), 10.21 (s, 1 H, 3-NH). 
(S)-2-(6-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-
yl)hexanamido)pentanedioic acid (187): To a solution of the diester 357 (60 mg, 0.09 
mmol) was added 1 N NaOH (5 mL), and the mixture was stirred under N2 at room 
temperature for 1 h. TLC showed the disappearance of the starting material and formation 
of one major spot at the origin (CHCl3/MeOH, 5:1). The reaction mixture was evaporated 
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to dryness under reduced pressure. The residue was dissolved in water (5 mL), the 
resulting solution was cooled in an ice bath, and the pH was adjusted to 3-4 with 
dropwise addition of 1 N HCl. The resulting suspension was frozen in a dry ice/acetone 
bath, thawed in a refrigerator to 4-5 °C, and filtered. The residue was washed with a 
small amount of cold water and ethyl acetate and dried in vacuo using P2O5 to afford 48 
mg (92%) 187 as as a pink powder: mp 126 °C decomposed, Rf  = 0.05 (CHCl3/MeOH, 
5:1). 1H NMR (DMSO-d6) δ 1.18-1.24 (m, 2 H, CH2), 1.49-1.52 (m, 2 H, CH2), 1.64-1.67 
(m, 2 H, CH2), 1.72-1.78 (m, 1 H, CH2), 1.90-1.96 (m, 1 H, CH2), 2.08-2.11 (t, 2 H, CH2, 
J = 7.5 Hz), 2.24-2.27 (t, 2 H, CH2, J = 7.5 Hz), 3.85-3.90 (t, 2 H, CH2, J = 7.0 Hz), 4.16-
4.21 (m, 1 H, CH), 6.18 (s, 2 H, 2-NH2), 6.19-6.20 (d, 1 H, CH,  J = 1.8 Hz), 6.69-6.70 
(d, 1 H, CH,  J = 1.8 Hz), 8.01-8.02 (d, 1 H, CONH, , J = 4.0 Hz), 10.22 (s, 1 H, 3-NH). 
Anal. (C17H23N5O6 · 0.78 H2O) Cal. C: 50.10, H: 6.08, N: 17.18. Found C: 50.11, H: 
5.89, N: 17.10. 
(S)-2-(7-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-
yl)heptanamido)pentanedioic acid (188): Compound 188 was synthesized as described 
for 187: yield 93% as a pink powder: mp 121 °C decomposed,  Rf  = 0.06 (CHCl3/MeOH, 
5:1). 1H NMR (DMSO-d6) δ 1.18-1.28 (m, 4 H, 2 CH2), 1.45-1.48 (m, 2 H, CH2), 1.63-
1.66 (m, 2 H, CH2), 1.73-1.76 (m, 1 H, CH2), 1.91-1.96 (m, 1 H, CH2), 2.07-2.10 (t, 2 H, 
CH2, J = 7.5 Hz), 2.24-2.27 (t, 2 H, CH2, J = 7.5 Hz), 3.86-3.89 (t, 2 H, CH2, J = 7.0 Hz), 
4.16-4.20 (m, 1 H, CH), 6.17 (s, 2 H, 2-NH2), 6.19-6.20 (d, 1 H, CH,  J = 1.8 Hz), 6.69-
6.70 (d, 1 H, CH,  J = 1.8 Hz), 8.02-8.03 (d, 1 H, CONH, , J = 4.0 Hz), 10.22 (s, 1 H, 3-
NH). Anal. (C18H25N5O6 · 0.46 H2O) Cal. C: 52.01, H: 6.28, N: 16.85. Found C: 52.08, 
H: 6.15, N: 16.60. 
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(S)-2-(8-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-
yl)octanamido)pentanedioic acid (189): Compound 189 was synthesized as described 
for 187: yield 96% as a pink powder: mp 138 °C decomposed, Rf  = 0.06 (CHCl3/MeOH, 
5:1). 1H NMR (DMSO-d6) δ 1.18-1.28 (m, 6 H, 3 CH2), 1.45-1.48 (m, 2 H, CH2), 1.64-
1.67 (m, 2 H, CH2), 1.72-1.78 (m, 1 H, CH2), 1.91-1.96 (m, 1 H, CH2), 2.07-2.10 (t, 2 H, 
CH2, J = 7.5 Hz), 2.24-2.27 (t, 2 H, CH2, J = 7.5 Hz), 3.86-3.89 (t, 2 H, CH2, J = 7.0 Hz), 
4.16-4.20 (m, 1 H, CH), 6.16 (s, 2 H, 2-NH2), 6.19-6.20 (d, 1 H, CH,  J = 1.8 Hz), 6.69-
6.70 (d, 1 H, CH,  J = 1.8 Hz), 8.00-8.02 (d, 1 H, CONH, , J = 4.0 Hz), 10.21 (s, 1 H, 3-
NH). Anal. (C19H27N5O6 ) Cal. C: 54.15, H: 6.46, N: 16.62. Found C: 53.96, H: 6.49, N: 
16.34. 
(S)-2-(9-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7(4H)-
yl)nonanamido)pentanedioic acid (190): Compound 190 was synthesized as described 
for 187: yield 92% as a yellow powder: mp 141 °C decomposed, Rf  = 0.06 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ 1.18-1.28 (m, 8 H, 4 CH2), 1.45-1.48 (m, 2 
H, CH2), 1.64-1.67 (m, 2 H, CH2), 1.72-1.78 (m, 1 H, CH2), 1.91-1.96 (m, 1 H, CH2), 
2.07-2.10 (t, 2 H, CH2, J = 7.5 Hz), 2.24-2.27 (t, 2 H, CH2, J = 7.5 Hz), 3.86-3.89 (t, 2 H, 
CH2, J = 7.0 Hz), 4.16-4.20 (m, 1 H, CH), 6.16 (s, 2 H, 2-NH2), 6.19-6.20 (d, 1 H, CH,  J 
= 1.8 Hz), 6.69-6.70 (d, 1 H, CH,  J = 1.8 Hz), 8.00-8.02 (d, 1 H, CONH, , J = 4.0 Hz), 
10.21 (s, 1 H, 3-NH). Anal. (C20H29N5O6 · 0.43 CH3OH) Cal. C: 54.62, H: 6.89, N: 
15.59. Found C: 54.70, H: 6.78, N: 15.46. 
4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)benzoic 
acid (361): To a suspension of 291 (89 mg, 0.25 mmol) in 1 mL CH3OH was added 3 N 
NaOH (3 mL). The resulting mixture was stirred under N2 at 40-50 °C for 24 h. 
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TLC indicated the disappearance of starting material and the formation of one major spot 
at the origin. The resulting solution was passed through Celite and washed with a 
minimum amount of CH3OH. The combined filtrate was evaporated under reduced 
pressure to dryness. To this residue was added distilled water (10 mL). The solution was 
cooled in an ice bath, and the pH was adjusted 3 to 4 using 3 N HCl. The resulting 
suspension was chilled in a dry ice/acetone bath and thawed to 4 °C overnight in a 
refrigerator. The precipitate was filtered, washed with cold water, and dried in a 
desiccator under reduced pressure using P2O5 to afford 70 mg (82%) of 361 as a brown 
powder:  mp >245 °C decomposed, Rf  = 0.03 (CHCl3/MeOH, 5:1). Put it to next step 
without further purification. 
(S)-dimethyl 2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)-N-methylbenzamido)pentanedioate (363): To a solution of 361 (316 mg, 1.0 
mmol) in anhydrous DMF (10 mL) was added 6-chloro-2,4-dimethoxy-1,3,5-triazine 
(270 mg, 1.2 mmol) and N-methylmorpholine (155 mg, 1.2 mmol). After the mixture was 
stirred at r.t. for 2 h, N-methylmorpholine (155 mg, 1.2 mmol) and N-methyl L-glutamate 
362 (210 mg, 1.2 mmol) were added all at once. The mixture was stirred at r.t. for 4 h. 
TLC showed the formation of one major spot at Rf  = 0.42 (CHCl3/MeOH, 5:1). The 
reaction mixture was evaporated to dryness under reduced pressure. The residue was 
dissolved in a minimum amount of CHCl3/MeOH, 5:1, and chromatographed on a silica 
gel column (2 cm x 15 cm) with 4% MeOH in CHCl3 as the eluent. Fractions that showed 
the desired single spot at Rf  = 0.42 were pooled and evaporated to dryness to afford 363 
320 mg, yield 65% as a colorless syrup, Rf  = 0.42 (CHCl3/MeOH, 5:1). 
1H NMR 
(DMSO-d6) δ  1.52-1.68 (m, 4 H, 2 CH2), 1.97-2.03 (m, 1 H, CH2), 2.06-2.13 (m, 1 H, 
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CH2), 2.42-2.45 (m, 2 H, CH2), 2.57-2.59 (t, 2 H, CH2, J = 7.5 Hz), 2.64-2.67 (t, 2 H, 
CH2, J = 7.5 Hz), 2.83 (s, 3 H, NCH3), 3.60 (s, 3 H, CH3),  3.68 (s, 3 H, CH3), 4.88-4.91 
(m, 1 H, CH), 5.95 (s, 2 H, 2-NH2), 6.32-6.33 (d, 1 H, CH, J = 0.5 Hz), 7.23-7.28 (m, 2 
H, C6H4), 7.29-7.34 (m, 2 H, C6H4), 10.09 (s, 1 H, 3-NH), 10.60 (s, 1H, 7-NH). 
(S)-2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)-N-
methylbenzamido)pentanedioic acid (191): To a solution of the diester 363 (240 mg, 
0.48 mmol) was added 1 N NaOH (5 mL), and the mixture was stirred under N2 at room 
temperature for 1 h. TLC showed the disappearance of the starting material and formation 
of one major spot at the origin (CHCl3/MeOH, 5:1). The reaction mixture was evaporated 
to dryness under reduced pressure. The residue was dissolved in water (5 mL), the 
resulting solution was cooled in an ice bath, and the pH was adjusted to 3-4 with 
dropwise addition of 1 N HCl. The resulting suspension was frozen in a dry ice/acetone 
bath, thawed in a refrigerator to 4-5 °C, and filtered. The residue was washed with a 
small amount of cold water and ethyl acetate and dried in vacuo using P2O5 to afford 240 
mg (89%) 191 as a yellow powder: mp 186 °C decomposed, Rf  = 0.04 (CHCl3/MeOH, 
5:1). 1H NMR (DMSO-d6) δ  1.53-1.68 (m, 4 H, 2 CH2), 1.97-2.03 (m, 1 H, CH2), 2.06-
2.13 (m, 1 H, CH2), 2.42-2.45 (m, 2 H, CH2), 2.57-2.59 (t, 2 H, CH2, J = 7.5 Hz), 2.64-
2.67 (t, 2 H, CH2, J = 7.5 Hz), 2.81 (s, 3 H, NCH3), 4.87-4.90 (m, 1 H, CH), 5.95 (s, 2 H, 
2-NH2), 6.33 (s, 1 H, CH), 7.23-7.28 (m, 2 H, C6H4), 7.29-7.34 (m, 2 H, C6H4), 10.09 (s, 
1 H, 3-NH), 10.60 (s, 1H, 7-NH). Anal. (C23H27N5O6 · 0.44 H2O) Cal. C: 57.86, H: 5.89, 
N: 14.67. Found C: 57.90, H: 6.03, N: 14.58. 
(S)-dimethyl 2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)benzamido)succinate (366): Compound 366 was synthesized from 364 as 
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described for 363: yield 75% as a colorless syrup, Rf  = 0.38 (CHCl3/MeOH, 5:1). 
1H 
NMR (DMSO-d6) δ  1.54-1.63 (m, 4 H, 2 CH2), 2.57-2.59 (t, 2 H, CH2, J = 7.5 Hz), 2.64-
2.67 (t, 2 H, CH2, J = 7.5 Hz), 2.78-2.85 (m, 1 H, CH2), 2.91-2.97 (m, 1 H, CH2), 3.61 (s, 
3 H, CH3),  3.63 (s, 3 H, CH3), 4.80-4.83 (m, 1 H, CH), 5.95 (s, 2 H, 2-NH2), 6.32-6.33 
(d, 1 H, CH, J = 1.0 Hz), 7.28-7.30 (d, 2 H, C6H4, J = 4.0 Hz), 7.73-7.75 (d, 2 H, C6H4, J 
= 4.0 Hz), 8.82-8.84 (d, 1 H, CONH, J = 4.0 Hz), 10.09 (s, 1 H, 3-NH), 10.61 (s, 1H, 7-
NH). 
(S)-dimethyl 2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)benzamido)hexanedioate (367): Compound 367 was synthesized from 365 as 
described for 363: yield 74% as a colorless syrup, Rf  = 0.43 (CHCl3/MeOH, 5:1). 
1H 
NMR (DMSO-d6) δ  1.54-1.63 (m, 6 H, 3 CH2), 1.77-1.81 (m, 2 H, CH2), 2.32-2.35 (t, 2 
H, CH2, J = 7.5 Hz), 2.57-2.60 (t, 2 H, CH2, J = 7.5 Hz), 2.62-2.65 (t, 2 H, CH2, J = 7.5 
Hz), 3.58 (s, 3 H, CH3),  3.63 (s, 3 H, CH3), 4.38-4.43 (m, 1 H, CH), 5.95 (s, 2 H, 2-
NH2), 6.32 (s, 1 H, CH), 7.27-7.29 (d, 2 H, C6H4, J = 4.0 Hz), 7.77-7.79 (d, 2 H, C6H4, J 
= 4.0 Hz), 8.63-8.65 (d, 1 H, CONH, J = 4.0 Hz), 10.09 (s, 1 H, 3-NH), 10.59 (s, 1H, 7-
NH). 
(S)-2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)benzamido)succinic acid (192): Compound 192 was synthesized from 366 as 
described for 191: yield 95% as a light blue powder: mp 139 °C decomposed, Rf  = 0.04 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  1.52-1.66 (m, 4 H, 2 CH2), 2.57-2.59 (t, 2 
H, CH2, J = 7.5 Hz), 2.64-2.67 (t, 2 H, CH2, J = 7.5 Hz), 2.78-2.85 (m, 1 H, CH2), 2.91-
2.97 (m, 1 H, CH2), 4.70-4.76 (m, 1 H, CH), 6.02 (s, 2 H, 2-NH2), 6.33 (s, 1 H, CH), 
7.27-7.29 (d, 2 H, C6H4, J = 4.0 Hz), 7.74-7.76 (d, 2 H, C6H4, J = 4.0 Hz), 8.64-8.66 (d, 1 
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H, CONH, J = 4.0 Hz), 10.16 (s, 1 H, 3-NH), 10.63 (s, 1H, 7-NH). Anal. (C21H23N5O6 · 
1.2 H2O) Cal. C: 54.47, H: 5.53, N: 15.12. Found C: 54.68, H: 5.32, N: 14.78. 
 (S)-2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)benzamido)hexanedioic acid (193): Compound 193 was synthesized from 367 
as described for 191: yield 93% as a blue powder: mp 126 °C decomposed, Rf  = 0.05 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  1.52-1.64 (m, 6 H, 3 CH2), 1.74-1.85 (m, 2 
H, CH2), 2.22-2.25 (t, 2 H, CH2, J = 7.5 Hz), 2.57-2.60 (t, 2 H, CH2, J = 7.5 Hz), 2.62-
2.65 (t, 2 H, CH2, J = 7.5 Hz), 4.32-4.37 (m, 1 H, CH), 6.09 (s, 2 H, 2-NH2), 6.34 (s, 1 H, 
CH), 7.27-7.29 (d, 2 H, C6H4, J = 4.0 Hz), 7.77-7.79 (d, 2 H, C6H4, J = 4.0 Hz), 8.48-8.50 
(d, 1 H, CONH, J = 4.0 Hz), 10.21 (s, 1 H, 3-NH), 10.65 (s, 1H, 7-NH). Anal. 
(C23H27N5O6 · 2.0 H2O) Cal. C: 54.64, H: 6.18, N: 13.85. Found C: 54.86, H: 5.80, N: 
13.81. 
 (S)-dimethyl 2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-N-
methyloctanamido)pentanedioate (369): To a solution of 368 (120 mg, 0.40 mmol) in 
anhydrous DMF (5 mL) was added 6-chloro-2,4-dimethoxy-1,3,5-triazine (100 mg, 0.50 
mmol) and N-methylmorpholine (60 mg, 0.50 mmol). After the mixture was stirred at r.t. 
for 2 h, N-methylmorpholine (60 mg, 0.50 mmol) and N-methyl L-glutamate 362 (90 mg, 
0.50 mmol) were added all at once. The mixture was stirred at r.t. for 4 h. TLC showed 
the formation of one major spot at Rf  = 0.48 (CHCl3/MeOH, 5:1). The reaction mixture 
was evaporated to dryness under reduced pressure. The residue was dissolved in a 
minimum amount of CHCl3/MeOH, 5:1, and chromatographed on a silica gel column (2 
cm x 15 cm) with 4% MeOH in CHCl3 as the eluent. Fractions that showed the desired 
single spot at Rf  = 0.48 were pooled and evaporated to dryness to afford 369 100 mg, 
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yield 56% as a yellow syrup, Rf  = 0.48 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  
1.22-1.32 (m, 6 H,  3 CH2), 1.42-1.57 (m, 4 H, 2 CH2), 1.76-1.82 (m, 1 H,  CH),  1.92-
1.99 (m, 1 H,  CH),  2.26-2.37 (m, 4 H, 2 CH2), 2.45-2.48 (m, 2 H,  CH2), 2.85 (s, 3 H, 
NCH3), 3.56 (s, 3 H, CH3),  3.60 (s, 3 H, CH3), 4.84-4.88 (m, 1 H, CH), 5.83 (s, 1 H, 
CH), 5.95 (s, 2 H, 2-NH2), 10.12 (s, 1 H, 3-NH), 10.78 (s, 1H, 7-NH). 
(S)-2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-N-
methyloctanamido)pentanedioic acid (194): To a solution of the diester 369 (80 mg, 
0.18 mmol) was added 1 N NaOH (5 mL), and the mixture was stirred under N2 at room 
temperature for 1 h. TLC showed the disappearance of the starting material and formation 
of one major spot at the origin (CHCl3/MeOH, 5:1). The reaction mixture was evaporated 
to dryness under reduced pressure. The residue was dissolved in water (5 mL), the 
resulting solution was cooled in an ice bath, and the pH was adjusted to 3-4 with 
dropwise addition of 1 N HCl. The resulting suspension was frozen in a dry ice/acetone 
bath, thawed in a refrigerator to 4-5 °C, and filtered. The residue was washed with a 
small amount of cold water and ethyl acetate and dried in vacuo using P2O5 to afford 65 
mg (87%) 194 as a yellow powder: mp 131-132 °C decomposed, Rf  = 0.06 
(CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  1.22-1.32 (m, 6 H,  3 CH2), 1.42-1.60 (m, 4 
H, 2 CH2), 1.76-1.82 (m, 1 H,  CH),  1.92-1.99 (m, 1 H,  CH),  2.26-2.37 (m, 4 H, 2 
CH2), 2.45-2.48 (m, 2 H,  CH2), 2.84 (s, 3 H, NCH3), 4.86-4.89 (m, 1 H, CH), 5.84 (s, 1 
H, CH), 5.95 (s, 2 H, 2-NH2), 10.12 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH). Anal. 
(C20H29N5O6 · 0.65 CH3OH) Cal. C: 54.36, H: 6.98, N: 15.36. Found C: 54.33, H: 6.85, 
N: 15.35. 
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(S)-dimethyl 2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)octanamido)succinate (370):  
Compound 370 was synthesized from 364 as described for 369: yield 71% as a colorless 
syrup, Rf  = 0.45 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  1.22-1.32 (m, 6 H,  3 
CH2), 1.42-1.60 (m, 4 H, 2 CH2), 2.06-2.10 (t, 2 H, CH2, J = 7.5 Hz), 2.30-2.43 (m, 4 H, 2 
CH2), 2.64-2.70 (m, 1 H, CH2), 2.76-2.82 (m, 1 H, CH2), 3.59 (s, 3 H, CH3),  3.60 (s, 3 H, 
CH3), 4.58-4.63 (m, 1 H, CH), 5.83 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 8.28-8.30 (d, 1 H, 
CONH, J = 4.0 Hz), 10.10 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH). 
(S)-dimethyl 2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)octanamido)hexanedioate (371):  
Compound 371 was synthesized from 365 as described for 369: yield 68% as a colorless 
syrup, Rf  = 0.45 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  1.22-1.32 (m, 8 H,  4 
CH2), 1.42-1.60 (m, 6 H, 3 CH2), 2.06-2.10 (t, 2 H, CH2, J = 7.5 Hz), 2.30-2.43 (m, 4 H, 2 
CH2), 2.64-2.70 (m, 1 H, CH2), 2.76-2.82 (m, 1 H, CH2), 3.59 (s, 3 H, CH3),  3.60 (s, 3 H, 
CH3), 4.58-4.63 (m, 1 H, CH), 5.83 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 8.16-8.18 (d, 1 H, 
CONH, J = 4.0 Hz), 10.11 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH). 
(S)-2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)octanamido)succinic acid (195):  
Compound 195 was synthesized from 370 as described for 194: yield 94% as a yellow 
powder: mp 125 °C decomposed,Rf  = 0.05 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  
1.22-1.32 (m, 6 H,  3 CH2), 1.42-1.60 (m, 4 H, 2 CH2), 2.06-2.10 (t, 2 H, CH2, J = 7.5 
Hz), 2.30-2.43 (m, 4 H, 2 CH2), 2.64-2.70 (m, 1 H, CH2), 2.76-2.82 (m, 1 H, CH2), 4.48-
4.51 (m, 1 H, CH), 5.83 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 8.09-8.11 (d, 1 H, CONH, J = 
229 
 
 
4.0 Hz), 10.12 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH). Anal. (C18H25N5O6 · 0.65 CH3OH) 
Cal. C: 52.30, H: 6.50, N: 16.34. Found C: 52.26, H: 6.31, N: 16.30. 
(S)-2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)octanamido)hexanedioic acid (196):  
Compound 196 was synthesized from 371 as described for 194: yield 92% as a yellow 
powder: mp 153 °C decomposed,Rf  = 0.05 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  
1.22-1.32 (m, 8 H,  4 CH2), 1.42-1.66 (m, 6 H, 3 CH2), 2.06-2.10 (t, 2 H, CH2, J = 7.5 
Hz), 2.30-2.43 (m, 4 H, 2 CH2), 2.64-2.70 (m, 1 H, CH2), 2.76-2.82 (m, 1 H, CH2), 4.48-
4.51 (m, 1 H, CH), 5.83 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH2), 8.09-8.11 (d, 1 H, CONH, J = 
4.0 Hz), 10.11 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH). Anal. (C20H29N5O6 · 1.0 H2O) Cal. C: 
52.97, H: 6.89, N: 15.44. Found C: 53.16, H: 6.81, N: 15.10. 
4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-N-
propylbenzamide (197):  
To a solution of 221 (100 mg, 0.30 mmol) in anhydrous DMF (10 mL) was added 6-
chloro-2,4-dimethoxy-1,3,5-triazine (64 mg, 0.36 mmol) and N-methylmorpholine (41 
mg, 0.36 mmol). After the mixture was stirred at r.t. for 2 h, N-methylmorpholine (41 mg, 
0.36 mmol) and 372 (46 mg, 0.30 mmol) were added all at once. The mixture was stirred 
at r.t. for 4 h. TLC showed the formation of one major spot at Rf  = 0.56 (CHCl3/MeOH, 
5:1). The reaction mixture was evaporated to dryness under reduced pressure. The residue 
was dissolved in a minimum amount of CHCl3/MeOH, 5:1, and chromatographed on a 
silica gel column (2 cm x 15 cm) with 4% MeOH in CHCl3 as the eluent. Fractions that 
showed the desired single spot at Rf  = 0.56 were pooled and evaporated to dryness to 
afford 197 70 mg, yield 64% a colorless syrup, Rf  = 0.56 (CHCl3/MeOH, 5:1). 
1H NMR 
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(DMSO-d6) δ  0.86-0.90 (t, 3 H, CH3, J = 7.0 Hz), 1.49-1.63 (m, 6 H, 3 CH2), 2.50-2.53 
(m, 2 H, CH2), 2.63-2.66 (t, 2 H, CH2, J = 7.5 Hz), 3.17-3.22 (m, 2 H, CH2), 5.83-5.84 (d, 
1 H, CH, J = 1.0 Hz), 5.96 (s, 2 H, 2-NH2), 7.25-7.27 (d, 2 H, C6H4, J = 4.0 Hz), 7.73-
7.75 (d, 2 H, C6H4, J = 4.0 Hz), 8.35-8.38 (t, 1 H, CONH, J = 6.4 Hz), 10.12 (s, 1 H, 3-
NH), 10.80 (s, 1H, 7-NH). 
Methyl 2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)benzamido)butanoate (375):  
Compound 375 was synthesized as described for 197: yield 54% as a colorless syrup, Rf  
= 0.51 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  0.92-0.96 (t, 3 H, CH3, J = 7.0 Hz), 
1.54-1.63 (m, 4 H, 2 CH2), 1.73-1.86 (m, 2 H, CH2), 2.50-2.53 (m, 2 H, CH2), 2.63-2.66 
(t, 2 H, CH2, J = 7.5 Hz), 3.84 (s, 3 H, CH3), 4.30-4.35 (m, 1 H, CH), 5.83-5.84 (d, 1 H, 
CH, J = 1.0 Hz), 5.96 (s, 2 H, 2-NH2), 7.27-7.29 (d, 2 H, C6H4, J = 4.0 Hz), 7.79-7.81 (d, 
2 H, C6H4, J = 4.0 Hz), 8.60-8.62 (d, 1 H, CONH, J = 4.0 Hz), 10.12 (s, 1 H, 3-NH), 
10.80 (s, 1H, 7-NH). 
Ethyl 4-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)benzamido)butanoate (376):  
Compound 376 was synthesized as described for 197: yield 46% a colorless syrup, Rf  = 
0.52 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ  1.14-1.18 (t, 3 H, CH3, J = 7.0 Hz), 
1.52-1.62 (m, 4 H, 2 CH2), 1.74-1.78 (m, 2 H, CH2), 2.31-2.35 (t, 2 H, CH2, J = 7.0 Hz), 
2.59-2.66 (m, 2 H, CH2), 3.23-3.28 (m, 2 H, CH2), 4.01-4.06 (q, 2 H, CH2, J = 7.0 Hz ), 
5.83-5.84 (d, 1 H, CH, J = 1.0 Hz), 5.96 (s, 2 H, 2-NH2), 7.25-7.27 (d, 2 H, C6H4, J = 4.0 
Hz), 7.73-7.75 (d, 2 H, C6H4, J = 4.0 Hz), 8.38-8.41 (t, 1 H, CONH, J = 6.4 Hz), 10.12 (s, 
1 H, 3-NH), 10.79 (s, 1H, 7-NH). 
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2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)benzamido)butanoic acid (198):  
To a solution of the ester 375 (50 mg, 0.09 mmol) was added 1 N NaOH (5 mL), and the 
mixture was stirred under N2 at room temperature for 1 h. TLC showed the disappearance 
of the starting material and formation of one major spot at the origin (CHCl3/MeOH, 5:1). 
The reaction mixture was evaporated to dryness under reduced pressure. The residue was 
dissolved in water (5 mL), the resulting solution was cooled in an ice bath, and the pH 
was adjusted to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was 
frozen in a dry ice/acetone bath, thawed in a refrigerator to 4-5 °C, and filtered. The 
residue was washed with a small amount of cold water and ethyl acetate and dried in 
vacuo using P2O5 to afford 35 mg (86%) 198 as a grey powder: mp 162-163 °C, Rf  = 
0.04 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  0.92-0.96 (t, 3 H, CH3, J = 7.0 Hz), 
1.50-1.63 (m, 4 H, 2 CH2), 1.74-1.87 (m, 2 H, CH2), 2.50-2.53 (m, 2 H, CH2), 2.63-2.66 
(t, 2 H, CH2, J = 7.5 Hz), 4.25-4.32 (m, 1 H, CH), 5.83-5.84 (d, 1 H, CH, J = 1.0 Hz), 
5.96 (s, 2 H, 2-NH2), 7.27-7.29 (d, 2 H, C6H4, J = 4.0 Hz), 7.79-7.81 (d, 2 H, C6H4, J = 
4.0 Hz), 8.44-8.46 (d, 1 H, CONH, J = 4.0 Hz), 10.12 (s, 1 H, 3-NH), 10.79 (s, 1H, 7-
NH). 
4-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)benzamido)butanoic acid (199):  
Compound 199 was synthesized from 376 as described for 198: yield 90% as a grey 
powder: mp 148-149 °C decomposed, Rf  = 0.04 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-
d6) δ  1.52-1.62 (m, 4 H, 2 CH2), 1.74-1.78 (m, 2 H, CH2), 2.31-2.35 (t, 2 H, CH2, J = 7.0 
Hz), 2.59-2.66 (m, 2 H, CH2), 3.23-3.28 (m, 2 H, CH2), 5.83-5.84 (d, 1 H, CH, J = 1.0 
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Hz), 5.96 (s, 2 H, 2-NH2), 7.25-7.27 (d, 2 H, C6H4, J = 4.0 Hz), 7.73-7.75 (d, 2 H, C6H4, J 
= 4.0 Hz), 8.38-8.41 (t, 1 H, CONH, J = 6.4 Hz), 10.12 (s, 1 H, 3-NH), 10.79 (s, 1H, 7-
NH). 
4-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)pentyl)-N-
propylbenzamide (200):  
Compound 200 was synthesized from 222 and 372 as described for 197: yield 67% a 
colorless syrup, Rf  = 0.56 (CHCl3/MeOH, 5:1). 
1H NMR (DMSO-d6) δ  0.85-0.88 (t, 3 H, 
CH3, J = 7.0 Hz), 1.26-1.30 (m, 2 H, CH2), 1.49-1.63 (m, 6 H, 3 CH2), 2.42-2.46 (m, 2 H, 
CH2), 2.57-2.61 (t, 2 H, CH2, J = 7.5 Hz), 3.15-3.20 (m, 2 H, CH2), 5.81-5.82 (d, 1 H, 
CH, J = 1.0 Hz), 5.94 (s, 2 H, 2-NH2), 7.23-7.25 (d, 2 H, C6H4, J = 4.0 Hz), 7.71-7.73 (d, 
2 H, C6H4, J = 4.0 Hz), 8.33-8.35 (t, 1 H, CONH, J = 6.4 Hz), 10.10 (s, 1 H, 3-NH), 
10.77 (s, 1H, 7-NH). 
Ethyl 4-(4-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)pentyl)benzamido)butanoate (377):  
Compound 377 was synthesized from 222 and 374 as described for 197: yield 56% a 
colorless syrup, Rf  = 0.54 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-d6) δ  1.15-1.19 (t, 3 
H, CH3, J = 7.0 Hz), 1.28-1.32 (m, 2 H, CH2), 1.58-1.61 (m, 4 H, 2 CH2), 1.75-1.79 (m, 2 
H, CH2), 2.32-2.36 (t, 2 H, CH2, J = 7.0 Hz), 2.59-2.63 (m, 2 H, CH2), 3.23-3.28 (m, 2 H, 
CH2), 4.01-4.06 (q, 2 H, CH2, J = 7.0 Hz ), 5.83-5.84 (d, 1 H, CH, J = 1.0 Hz), 5.95 (s, 2 
H, 2-NH2), 7.25-7.27 (d, 2 H, C6H4, J = 4.0 Hz), 7.73-7.75 (d, 2 H, C6H4, J = 4.0 Hz), 
8.38-8.41 (t, 1 H, CONH, J = 6.4 Hz), 10.12 (s, 1 H, 3-NH), 10.78 (s, 1H, 7-NH). 
4-(4-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)pentyl)benzamido)butanoic acid (200a):  
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Compound 200a was synthesized from 377 as described for 198: yield 91% as a grey 
powder: mp mp 136 °C decomposed, Rf  = 0.04 (CHCl3/MeOH, 5:1).  
1H NMR (DMSO-
d6) δ 1.28-1.32 (m, 2 H, CH2), 1.58-1.61 (m, 4 H, 2 CH2), 1.75-1.79 (m, 2 H, CH2), 2.32-
2.36 (t, 2 H, CH2, J = 7.0 Hz), 2.59-2.63 (m, 2 H, CH2), 3.23-3.28 (m, 2 H, CH2), 5.83-
5.84 (d, 1 H, CH, J = 1.0 Hz), 5.95 (s, 2 H, 2-NH2), 7.25-7.27 (d, 2 H, C6H4, J = 4.0 Hz), 
7.73-7.75 (d, 2 H, C6H4, J = 4.0 Hz), 8.38-8.41 (t, 1 H, CONH, J = 6.4 Hz), 10.12 (s, 1 H, 
3-NH), 10.79 (s, 1H, 7-NH). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
234 
 
 
VII. BIBLIOGRAPHY 
1. Jae Rin Suh, A. K. H., and Patrick J Stover. New perspectives on folate 
catabolism. . Annu. Rev. Nutr. 2001, 21, 255-282. 
2. Stokstad, E. L. R. Historical perspective on key advances in the biochemistry and 
physiology of folates. Contemp. Issues Clin. Nutr. 1990, 13, 1-21. 
3. Matherly, L. H.; Goldman, I. D. Membrane transport of folates. Vitam. Horm. 
2003, 66, 403-456. 
4. Matherly, L. H.; Hou, Z.; Deng, Y. Human reduced folate carrier: Translation of 
basic biology to cancer etiology and therapy. Cancer Metastasis Rev. 2007, 26, 111-128. 
5. Goldman, I. D.; Chattopadhyay, S.; Zhao, R.; Moran, R. The antifolates: 
evolution, new agents in the clinic, and how targeting delivery via specific membrane 
transporters is driving the development of a next generation of folate analogs. Curr. Opin. 
Invest. Drugs (BioMed Cent.) 2010, 11, 1409-1423. 
6. Hagner, N.; Joerger, M. Cancer chemotherapy: targeting folic acid synthesis. 
Cancer Manage. Res. 2010, 2, 293-301. 
7. Wright, D. L.; Anderson, A. C. Antifolate agents: a patent review (2006 - 2010). 
Expert Opin. Ther. Pat. 2011, 21, 1293-1308. 
8. Gonen, N.; Assaraf, Y. G. Antifolates in cancer therapy: Structure, activity and 
mechanisms of drug resistance. Drug Resist. Updates 2012, 15, 183-210. 
9. Visentin, M.; Zhao, R.; Goldman, I. D. The antifolates. Hematol Oncol Clin North 
Am 2012, 26, 629-48, ix. 
10. Qiu, A.; Jansen, M.; Sakaris, A.; Min, S. H.; Chattopadhyay, S.; Tsai, E.; 
Sandoval, C.; Zhao, R.; Akabas, M. H.; Goldman, I. D. Identification of an intestinal 
235 
 
 
folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006, 
127, 917-928. 
11. Said, H. M.; Chatterjee, N.; Haq, R. U.; Subramanian, V. S.; Ortiz, A.; Matherly, 
L. H.; Sirotnak, F. M.; Halsted, C.; Rubin, S. A. Adaptive regulation of intestinal folate 
uptake: effect of dietary folate deficiency. Am. J. Physiol. 2000, 279, C1889-C1895. 
12. Subramanian, V. S.; Chatterjee, N.; Said, H. M. Folate uptake in the human 
intestine: Promoter activity and effect of folate deficiency. J. Cell. Physiol. 2003, 196, 
403-408. 
13. Ashokkumar, B.; Mohammed, Z. M.; Vaziri, N. D.; Said, H. M. Effect of folate 
oversupplementation on folate uptake by human intestinal and renal epithelial cells. Am. J. 
Clin. Nutr. 2007, 86, 159-166. 
14. Ahmad, S. I.; Kirk, S. H.; Eisenstark, A. Thymine metabolism and thymineless 
death in prokaryotes and eukaryotes. Annu. Rev. Microbiol. 1998, 52, 591-625. 
15. Sangurdekar, D. P.; Hamann, B. L.; Smirnov, D.; Srienc, F.; Hanawalt, P. C.; 
Khodursky, A. B. Thymineless death is associated with loss of essential genetic 
information from the replication origin. Mol. Microbiol. 2010, 75, 1455-1467. 
16. Kompis, I. M.; Islam, K.; Then, R. L. DNA and RNA Synthesis: Antifolates. 
Chem. Rev. (Washington, DC, U. S.) 2005, 105, 593-620. 
17. Berger, F. G.; Berger, S. H. Thymidylate synthase as a chemotherapeutic drug 
target. Where are we after fifty years? Cancer Biol. Ther. 2006, 5, 1238-1241. 
18. Longley, D. B.; Harkin, D. P.; Johnston, P. G. 5-Fluorouracil: mechanisms of 
action and clinical strategies. Nat Rev Cancer 2003, 3, 330-338. 
19. Barner, H. D.; Cohen, S. S. The induction of thymine synthesis by T2 infection of 
236 
 
 
a thymine-requiring mutant of Escherichia coli. J. Bacteriol. 1954, 68, 80-8. 
20. Cohen, S. S.; Barner, H. D. Unbalanced growth in Escherichia coli. Proc. Natl. 
Acad. Sci. U. S. A. 1954, 40, 885-93. 
21. Barner, H. D.; Cohen, S. S. The isolation and properties of amino acid-requiring 
mutants of a thymineless bacterium. J. Bacteriol. 1957, 74, 350-5. 
22. Bazill, G. W. Lethal Unbalanced Growth in Bacteria. Nature 1967, 216, 346-349. 
23. Sangurdekar, D. P.; Hamann, B. L.; Smirnov, D.; Srienc, F.; Hanawalt, P. C.; 
Khodursky, A. B. Thymineless death is associated with loss of essential genetic 
information from the replication origin. Mol. Microbiol. 2010, 75, 1455-67. 
24. Houghton, P. J. In Thymineless death, 1999; Humana: 1999; pp 423-435. 
25. Keszler, G.; Spasokoukotskaja, T.; Csapo, Z.; Virga, S.; Staub, M.; Sasvari-
Szekely, M. Selective Increase of dATP Pools upon Activation of Deoxycytidine Kinase 
in Lymphocytes: Implications in Apoptosis. Nucleosides, Nucleotides Nucleic Acids 2004, 
23, 1335-1342. 
26. Celtikci, B.; Lawrance, A. K.; Wu, Q.; Rozen, R. Methotrexate-induced apoptosis 
is enhanced by altered expression of methylenetetrahydrofolate reductase. Anti-Cancer 
Drugs 2009, 20, 787-793. 
27. Roth, B. Design of dihydrofolate reductase inhibitors from x-ray crystal structures. 
Fed. Proc. 1986, 45, 2765-72. 
28. Costi, M. P.; Ferrari, S. Update on antifolate drugs targets. Curr. Drug Targets 
2001, 2, 135-166. 
29. Carreras, C. W.; Santi, D. V. The catalytic mechanism and structure of 
thymidylate synthase. Annu. Rev. Biochem. 1995, 64, 721-62. 
237 
 
 
30. Warren, M. S.; Mattia, K. M.; Marolewski, A. E.; Benkovic, S. J. The 
transformylase enzymes of de novo purine biosynthesis. Pure Appl. Chem. 1996, 68, 
2029-2036. 
31. Calvert, H. An overview of folate metabolism: features relevant to the action and 
toxicities of antifolate anticancer agents. Semin. Oncol. 1999, 26, 3-10. 
32. Jansen, G. In Receptor- and carrier-mediated transport systems for folates and 
antifolates: exploitation for folate-based chemotherapy and immunotherapy, 1999; 
Humana: 1999; pp 293-321. 
33. Brzezinska, A.; Winska, P.; Balinska, M. Cellular aspects of folate and antifolate 
membrane transport. Acta Biochim. Pol. 2000, 47, 735-749. 
34. Moran, R. G. Roles of folylpoly-γ-glutamate synthetase in therapeutics with 
tetrahydrofolate antimetabolites: an overview. Semin. Oncol. 1999, 26, 24-32. 
35. Yao, R.; Schneider, E.; Ryan, T. J.; Galivan, J. Human γ-glutamyl hydrolase: 
cloning and characterization of the enzyme expressed in vitro. Proc. Natl. Acad. Sci. U. S. 
A. 1996, 93, 10134-10138. 
36. Hooijberg, J. H.; Broxterman, H. J.; Kool, M.; Assaraf, Y. G.; Peters, G. J.; 
Noordhuis, P.; Scheper, R. J.; Borst, P.; Pinedo, H. M.; Jansen, G. Antifolate resistance 
mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999, 59, 
2532-2535. 
37. DeGraw, J. I.; Colwell, W. T.; Piper, J. R.; Sirotnak, F. M.; Smith, R. L. New 
analogs of methotrexate in cancer and arthritis. Curr. Med. Chem. 1995, 2, 630-53. 
38. Huennekens, F. M.; Duffy, T. H.; Vitols, K. S. Folic acid metabolism and its 
disruption by pharmacologic agents. NCI Monogr 1987, 1-8. 
238 
 
 
39. Berman, E. M.; Werbel, L. M. The renewed potential for folate antagonists in 
contemporary cancer chemotherapy. J. Med. Chem. 1991, 34, 479-85. 
40. Weinstein, G. D. Biochemical and pathophysiological rationale for amethopterin 
in psoriasis. Ann. N. Y. Acad. Sci. 1971, 186, 452-66. 
41. Gangjee, A.; Jain, H. D.; Kurup, S. Recent advances in classical and non-classical 
antifolates as antitumor and antiopportunistic infection agents: part I. Anti-Cancer Agents 
Med. Chem. 2007, 7, 524-542. 
42. Gangjee, A.; Jain, H. D.; Kurup, S. Recent advances in classical and non-classical 
antifolates as antitumor and antiopportunistic infection agents: Part II. Anti-Cancer 
Agents Med. Chem. 2008, 8, 205-231. 
43. Gangjee, A.; Dubash, N. P.; Zeng, Y.; McGuire, J. J. Recent advances in the 
chemistry and biology of folypoly-gamma-glutamate synthetase substrates and inhibitors. 
Current medicinal chemistry. Anti-cancer agents 2002, 2, 331-55. 
44. Gangjee, A.; Elzein, E.; Kothare, M.; Vasudevan, A. Classical and nonclassical 
antifolates as potential antitumor, antipneumocystis and antitoxoplasma agents. Curr. 
Pharm. Des. 1996, 2, 263-280. 
45. Jackson, R. C. In Antifolate drugs: past and future perspectives, 1999; Humana: 
1999; pp 1-12. 
46. Matherly, L. H.; Goldman, D. I. Membrane transport of folates. Vitam. Horm. 
2003, 66, 403-56. 
47. Matherly, L. H.; Hou, Z.; Deng, Y. Human reduced folate carrier: translation of 
basic biology to cancer etiology and therapy. Cancer Metastasis Rev. 2007, 26, 111-28. 
48. Zhao, R.; Matherly, L. H.; Goldman, I. D. Membrane transporters and folate 
239 
 
 
homeostasis: intestinal absorption and transport into systemic compartments and tissues. 
Expert Rev Mol Med 2009, 11, e4. 
49. Elnakat, H.; Ratnam, M. Distribution, functionality and gene regulation of folate 
receptor isoforms: implications in targeted therapy. Adv. Drug Delivery Rev. 2004, 56, 
1067-1084. 
50. Zhao, R.; Goldman, I. D. The molecular identity and characterization of a Proton-
Coupled Folate Transporter-PCFT; biological ramifications and impact on the activity of 
pemetrexed-12 06 06. Cancer Metastasis Rev. 2007, 26, 129-139. 
51. Umapathy, N. S.; Gnana-Prakasam, J. P.; Martin, P. M.; Mysona, B.; Dun, Y.; 
Smith, S. B.; Ganapathy, V.; Prasad, P. D. Cloning and functional characterization of the 
proton-coupled electrogenic folate transporter and analysis of its expression in retinal cell 
types. Invest. Ophthalmol. Vis. Sci. 2007, 48, 5299-305. 
52. Nakai, Y.; Inoue, K.; Abe, N.; Hatakeyama, M.; Ohta, K.-y.; Otagiri, M.; Hayashi, 
Y.; Yuasa, H. Functional characterization of human proton-coupled folate 
transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a 
folate transporter. J. Pharmacol. Exp. Ther. 2007, 322, 469-476. 
53. Goldman, I. D.; Matherly, L. H. The cellular pharmacology of methotrexate. 
Pharmacol. Ther. 1985, 28, 77-102. 
54. Goldman, I. D.; Zhao, R. Molecular, biochemical, and cellular pharmacology of 
pemetrexed. Semin. Oncol. 2002, 29, 3-17. 
55. Goldman, I. D.; Lichtenstein, N. S.; Oliverio, V. T. Carrier-mediated transport of 
the folic acid analog, methotrexate, in the L1210 leukemia cell. J. Biol. Chem. 1968, 243, 
5007-17. 
240 
 
 
56. Desmoulin, S. K.; Hou, Z.; Gangjee, A.; Matherly, L. H. The human proton-
coupled folate transporter: Biology and therapeutic applications to cancer. Cancer 
Biology & Therapy 2012, 13, 1355-1373. 
57. Cao, W.; Matherly, L. H. Analysis of the membrane topology for transmembrane 
domains 7-12 of the human reduced folate carrier by scanning cysteine accessibility 
methods. Biochem. J. 2004, 378, 201-206. 
58. Ferguson, P. L.; Flintoff, W. F. Topological and functional analysis of the human 
reduced folate carrier by hemagglutinin epitope insertion. J. Biol. Chem. 1999, 274, 
16269-16278. 
59. Liu, X. Y.; Matherly, L. H. Analysis of membrane topology of the human reduced 
folate carrier protein by hemagglutinin epitope insertion and scanning glycosylation 
insertion mutagenesis. Biochim. Biophys. Acta, Biomembr. 2002, 1564, 333-342. 
60. Wong, S. C.; Zhang, L.; Proefke, S. A.; Matherly, L. H. Effects of the loss of 
capacity for N-glycosylation on the transport activity and cellular localization of the 
human reduced folate carrier. Biochim. Biophys. Acta, Biomembr. 1998, 1375, 6-12. 
61. Liu, X. Y.; Witt, T. L.; Matherly, L. H. Restoration of high-level transport activity 
by human reduced folate carrier/ThTr1 thiamine transporter chimaeras: role of the 
transmembrane domain 6/7 linker region in reduced folate carrier function. Biochem. J. 
2003, 369, 31-37. 
62. Zhao, R.; Diop-Bove, N.; Visentin, M.; Goldman, I. D. Mechanisms of membrane 
transport of folates into cells and across epithelia. Annu. Rev. Nutr. 2011, 31, 177-201, 5 
plates. 
63. Whetstine, J. R.; Flatley, R. M.; Matherly, L. H. The human reduced folate carrier 
241 
 
 
gene is ubiquitously and differentially expressed in normal human tissues: identification 
of seven non-coding exons and characterization of a novel promoter. Biochem. J. 2002, 
367, 629-640. 
64. Zhao, R.; Russell, R. G.; Wang, Y.; Liu, L.; Gao, F.; Kneitz, B.; Edelmann, W.; 
Goldman, I. D. Rescue of embryonic lethality in reduced folate carrier-deficient mice by 
maternal folic acid supplementation reveals early neonatal failure of hematopoietic 
organs. J. Biol. Chem. 2001, 276, 10224-10228. 
65. Liu, M.; Ge, Y.; Cabelof, D. C.; Aboukameel, A.; Heydari, A. R.; Mohammad, R.; 
Matherly, L. H. Structure and Regulation of the Murine Reduced Folate Carrier Gene: 
identification of four noncoding exons and promoters and regulation by dietary folates. J. 
Biol. Chem. 2005, 280, 5588-5597. 
66. Henderson, G. B.; Zevely, E. M. Structural requirements for anion substrates of 
the methotrexate transport system in L1210 cells. Arch. Biochem. Biophys. 1983, 221, 
438-46. 
67. Goldman, I. D. Characteristics of the membrane transportof amethopterin and the 
naturally occurring folates. Ann. N. Y. Acad. Sci. 1971, 186, 400-22. 
68. Goldman, I. D.; Matherly, L. H. The cellular pharmacology of methotrexate. 
Pharmacol. Ther. 1985, 28, 77-102. 
69. Fischer, G. A. Defective transport of amethopterin (methotrexate) as a mechanism 
of resistance to the antimetabolite in L 5178 Y leukemic cells. Biochem. Pharmacol. 
1962, 11, 1233-4. 
70. Zhao, R.; Goldman, I. D. Resistance to antifolates. Oncogene 2003, 22, 7431-
7457. 
242 
 
 
71. Zhao, R.; Chattopadhyay, S.; Hanscom, M.; Goldman, I. D. Antifolate Resistance 
in a HeLa Cell Line Associated With Impaired Transport Independent of the Reduced 
Folate Carrier. Clin. Cancer Res. 2004, 10, 8735-8742. 
72. Ragoussis, J.; Senger, G.; Trowsdale, J.; Campbell, I. G. Genomic organization of 
the human folate receptor genes on chromosome 11q13. Genomics 1992, 14, 423-30. 
73. Salazar, M. D. A.; Ratnam, M. The folate receptor: What does it promise in 
tissue-targeted therapeutics? Cancer Metastasis Rev. 2007, 26, 141-152. 
74. Chancy, C. D.; Kekuda, R.; Huang, W.; Prasad, P. D.; Kuhnel, J.-M.; Sirotnak, F. 
M.; Roon, P.; Ganapathy, V.; Smith, S. B. Expression and differential polarization of the 
reduced-folate transporter-1 and the folate receptor α in mammalian retinal pigment 
epithelium. J. Biol. Chem. 2000, 275, 20676-20684. 
75. Weitman, S. D.; Weinberg, A. G.; Coney, L. R.; Zurawski, V. R.; Jennings, D. S.; 
Kamen, B. A. Cellular localization of the folate receptor: potential role in drug toxicity 
and folate homeostasis. Cancer Res. 1992, 52, 6708-11. 
76. Ratnam, M.; Marquardt, H.; Duhring, J. L.; Freisheim, J. H. Homologous 
membrane folate binding proteins in human placenta: cloning and sequence of a cDNA. 
Biochemistry 1989, 28, 8249-54. 
77. Wang, H.; Zheng, X.; Behm, F. G.; Ratnam, M. Differentiation-independent 
retinoid induction of folate receptor type β, a potential tumor target in myeloid leukemia. 
Blood 2000, 96, 3529-3536. 
78. Reddy, J. A.; Haneline, L. S.; Srour, E. F.; Antony, A. C.; Clapp, D. W.; Low, P. 
S. Expression and functional characterization of the β-isoform of the folate receptor on 
CD34+ cells. Blood 1999, 93, 3940-3948. 
243 
 
 
79. Ross, J. F.; Wang, H.; Behm, F. G.; Mathew, P.; Wu, M.; Booth, R.; Ratnam, M. 
Folate receptor type β is a neutrophilic lineage marker and is differentially expressed in 
myeloid leukemia. Cancer 1999, 85, 348-357. 
80. Pan, X. Q.; Zheng, X.; Shi, G.; Wang, H.; Ratnam, M.; Lee, R. J. Strategy for the 
treatment of acute myelogenous leukemia based on folate receptor β-targeted liposomal 
doxorubicin combined with receptor induction by all-trans-retinoic acid. Blood 2002, 100, 
594-602. 
81. Wu, M.; Gunning, W.; Ratnam, M. Expression of folate receptor type alpha in 
relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer 
Epidemiol Biomarkers Prev 1999, 8, 775-82. 
82. Ross, J. F.; Chaudhuri, P. K.; Ratnam, M. Differential regulation of folate 
receptor isoforms in normal and malignant tissues in vivo and in established cell lines. 
Physiologic and clinical implications. Cancer 1994, 73, 2432-43. 
83. Yang, J.; Vlashi, E.; Low, P. Folate-linked drugs for the treatment of cancer and 
inflammatory diseases. Subcell. Biochem. 2012, 56, 163-179. 
84. Kamen, B. A.; Smith, A. K. A review of folate receptor alpha cycling and 5-
methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv. Drug 
Delivery Rev. 2004, 56, 1085-1097. 
85. Lu, Y.; Low, P. S. Folate-mediated delivery of macromolecular anticancer 
therapeutic agents. Adv. Drug Delivery Rev. 2002, 54, 675-693. 
86. Kamen, B. A.; Wang, M. T.; Streckfuss, A. J.; Peryea, X.; Anderson, R. G. W. 
Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane 
receptor that recycles. J. Biol. Chem. 1988, 263, 13602-9. 
244 
 
 
87. Rothberg, K. G.; Ying, Y.; Kolhouse, J. F.; Kamen, B. A.; Anderson, R. G. W. 
The glycophospholipid-linked folate receptor internalizes folate without entering the 
clathrin-coated pit endocytic pathway. J. Cell Biol. 1990, 110, 637-49. 
88. Yang, J.; Chen, H.; Vlahov, I. R.; Cheng, J.-X.; Low, P. S. Characterization of the 
pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized 
acid-labile folate-drug conjugates. J. Pharmacol. Exp. Ther. 2007, 321, 462-468. 
89. Kamen, B. A.; Smith, A. K.; Anderson, R. G. W. The folate receptor works in 
tandem with a probenecid-sensitive carrier in MA104 cells in vitro. J. Clin. Invest. 1991, 
87, 1442-9. 
90. Prasad, P. D.; Mahesh, V. B.; Leibach, F. H.; Ganapathy, V. Functional coupling 
between a bafilomycin A1-sensitive proton pump and a probenecid-sensitive folate 
transporter in human placental choriocarcinoma cells. Biochim. Biophys. Acta, Mol. Cell 
Res. 1994, 1222, 309-14. 
91. Toffoli, G.; Cernigoi, C.; Russo, A.; Gallo, A.; Bagnoli, M.; Boiocchi, M. 
Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer 1997, 74, 193-
198. 
92. Inoue, K.; Nakai, Y.; Ueda, S.; Kamigaso, S.; Ohta, K.-y.; Hatakeyama, M.; 
Hayashi, Y.; Otagiri, M.; Yuasa, H. Functional characterization of PCFT/HCP1 as the 
molecular entity of the carrier-mediated intestinal folate transport system in the rat model. 
Am. J. Physiol. 2008, 294, G660-G668. 
93. Qiu, A.; Min, S. H.; Jansen, M.; Malhotra, U.; Tsai, E.; Cabelof, D. C.; Matherly, 
L. H.; Zhao, R.; Akabas, M. H.; Goldman, I. D. Rodent intestinal folate transporters 
(SLC46A1): secondary structure, functional properties, and response to dietary folate 
245 
 
 
restriction. Am. J. Physiol. 2007, 293, C1669-C1678. 
94. Unal, E. S.; Zhao, R.; Qiu, A.; Goldman, I. D. N-linked glycosylation and its 
impact on the electrophoretic mobility and function of the human proton-coupled folate 
transporter (HsPCFT). Biochim Biophys Acta 2008, 1778, 1407-14. 
95. Zhao, R.; Unal, E. S.; Shin, D. S.; Goldman, I. D. Membrane Topological 
Analysis of the Proton-Coupled Folate Transporter (PCFT-SLC46A1) by the Substituted 
Cysteine Accessibility Method. Biochemistry 2010, 49, 2925-2931. 
96. Wollack, J. B.; Makori, B.; Ahlawat, S.; Koneru, R.; Picinich, S. C.; Smith, A.; 
Goldman, I. D.; Qiu, A.; Cole, P. D.; Glod, J.; Kamen, B. Characterization of folate 
uptake by choroid plexus epithelial cells in a rat primary culture model. J. Neurochem. 
2008, 104, 1494-1503. 
97. Zhao, R.; Qiu, A.; Tsai, E.; Jansen, M.; Akabas, M. H.; Goldman, I. D. The 
proton-coupled folate transporter: impact on pemetrexed transport and on antifolates 
activities compared with the reduced folate carrier. Mol. Pharmacol. 2008, 74, 854-862. 
98. Qiu, A.; Jansen, M.; Sakaris, A.; Min, S. H.; Chattopadhyay, S.; Tsai, E.; 
Sandoval, C.; Zhao, R.; Akabas, M. H.; Goldman, I. D. Identification of an intestinal 
folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006, 
127, 917-28. 
99. Qiu, A.; Min, S. H.; Jansen, M.; Malhotra, U.; Tsai, E.; Cabelof, D. C.; Matherly, 
L. H.; Zhao, R.; Akabas, M. H.; Goldman, I. D. Rodent intestinal folate transporters 
(SLC46A1): secondary structure, functional properties, and response to dietary folate 
restriction. Am. J. Physiol. Cell Physiol. 2007, 293, C1669-78. 
100. Zhao, R.; Qiu, A.; Tsai, E.; Jansen, M.; Akabas, M. H.; Goldman, I. D. The 
246 
 
 
proton-coupled folate transporter: impact on pemetrexed transport and on antifolates 
activities compared with the reduced folate carrier. Mol. Pharmacol. 2008, 74, 854-62. 
101. Schron, C. M.; Washington, C., Jr.; Blitzer, B. L. The transmembrane pH gradient 
drives uphill folate transport in rabbit jejunum. Direct evidence for folate/hydroxyl 
exchange in brush border membrane vesicles. J. Clin. Invest. 1985, 76, 2030-3. 
102. Helmlinger, G.; Yuan, F.; Dellian, M.; Jain, R. K. Interstitial pH and pO2 
gradients in solid tumors in vivo: High-resolution measurements reveal a lack of 
correlation. Nat. Med. (N. Y.) 1997, 3, 177-182. 
103. Raghunand, N.; Altbach, M. I.; Van, S. R.; Baggett, B.; Taylor, C. W.; Bhujwalla, 
Z. M.; Gillies, R. J. Plasmalemmal pH-gradients in drug-sensitive and drug-resistant 
MCF-7 human breast carcinoma xenografts measured by 31P magnetic resonance 
spectroscopy. Biochem. Pharmacol. 1999, 57, 309-312. 
104. Zhao, R.; Gao, F.; Hanscom, M.; Goldman, I. D. A prominent low-pH 
methotrexate transport activity in human solid tumors: contribution to the preservation of 
methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clin. 
Cancer Res. 2004, 10, 718-727. 
105. Salazar, M. D.; Ratnam, M. The folate receptor: what does it promise in tissue-
targeted therapeutics? Cancer Metastasis Rev. 2007, 26, 141-52. 
106. Hilgenbrink, A. R.; Low, P. S. Folate receptor-mediated drug targeting: from 
therapeutics to diagnostics. J. Pharm. Sci. 2005, 94, 2135-46. 
107. Jansen, G. Receptor- and Carrier-Mediated Transport Systems for Folates and 
Antifolates. Exploitation for Folate Chemotherapy and Immunotherapy. In Anticancer 
Development Guide: Antifolate Drugs in Cancer Therapy, Jackman, A. L., Ed. Humana 
247 
 
 
Press Inc.: Totowa, NJ, 1999; pp 293-321. 
108. Jackman, A. L.; Theti, D. S.; Gibbs, D. D. Antifolates targeted specifically to the 
folate receptor. Adv. Drug Deliv. Rev. 2004, 56, 1111-25. 
109. Deng, Y.; Wang, Y.; Cherian, C.; Hou, Z.; Buck, S. A.; Matherly, L. H.; Gangjee, 
A. Synthesis and Discovery of High Affinity Folate Receptor-Specific Glycinamide 
Ribonucleotide Formyltransferase Inhibitors with Antitumor Activity. J. Med. Chem. 
2008, 51, 5052-5063. 
110. Gibbs, D. D.; Theti, D. S.; Wood, N.; Green, M.; Raynaud, F.; Valenti, M.; 
Forster, M. D.; Mitchell, F.; Bavetsias, V.; Henderson, E.; Jackman, A. L. BGC 945, a 
Novel Tumor-Selective Thymidylate Synthase Inhibitor Targeted to α-Folate Receptor-
Overexpressing Tumors. Cancer Res. 2005, 65, 11721-11728. 
111. Theti, D. S.; Bavetsias, V.; Skelton, L. A.; Titley, J.; Gibbs, D.; Jansen, G.; 
Jackman, A. L. Selective Delivery of CB300638, a Cyclopenta[g]quinazoline-based 
Thymidylate Synthase Inhibitor into Human Tumor Cell Lines Overexpressing the α-
Isoform of the Folate Receptor. Cancer Res. 2003, 63, 3612-3618. 
112. Deng, Y.; Zhou, X.; Desmoulin, S. K.; Wu, J.; Cherian, C.; Hou, Z.; Matherly, L. 
H.; Gangjee, A. Synthesis and Biological Activity of a Novel Series of 6-Substituted 
Thieno[2,3-d]pyrimidine Antifolate Inhibitors of Purine Biosynthesis with Selectivity for 
High Affinity Folate Receptors over the Reduced Folate Carrier and Proton-Coupled 
Folate Transporter for Cellular Entry. J. Med. Chem. 2009, 52, 2940-2951. 
113. Wang, L.; Cherian, C.; Desmoulin, S. K.; Polin, L.; Deng, Y.; Wu, J.; Hou, Z.; 
White, K.; Kushner, J.; Matherly, L. H.; Gangjee, A. Synthesis and Antitumor Activity of 
a Novel Series of 6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Antifolate Inhibitors 
248 
 
 
of Purine Biosynthesis with Selectivity for High Affinity Folate Receptors and the 
Proton-Coupled Folate Transporter over the Reduced Folate Carrier for Cellular Entry. J. 
Med. Chem. 2010, 53, 1306-1318. 
114. Desmoulin, S. K.; Wang, Y.; Wu, J.; Stout, M.; Hou, Z.; Fulterer, A.; Chang, M.-
H.; Romero, M. F.; Cherian, C.; Gangjee, A.; Matherly, L. H. Targeting the proton-
coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine 
antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. 
Mol. Pharmacol. 2010, 78, 577-587. 
115. Wang, L. Ph.D. dissertation. Duquesne University, 2010, 352-353. 
116. Wang, L.; Cherian, C.; Desmoulin, S. K.; Mitchell-Ryan, S.; Hou, Z.; Matherly, L. 
H.; Gangjee, A. Synthesis and biological activity of 6-substituted pyrrolo[2,3-
d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with 
selectivity for cellular uptake by high affinity folate receptors and the proton-coupled 
folate transporter over the reduced folate carrier. J. Med. Chem. 2012, 55, 1758-1770. 
117. Warren, L.; Buchanan, J. M. Biosynthesis of the purines. XIX. 2-Amino-N-
ribosylacetamide 5'-phosphate (glycinamide ribotide) transformylase. J Biol Chem 1957, 
229, 613-26. 
118. Moran, R. G. In Folate antimetabolites inhibitory to de novo purine synthesis, 
1991; Kluwer: 1991; pp 65-87. 
119. Beardsley, G. P.; Moroson, B. A.; Taylor, E. C.; Moran, R. G. A new folate 
antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo 
purine synthesis. J. Biol. Chem. 1989, 264, 328-33. 
120. Shim, J. H.; Benkovic, S. J. Evaluation of the Kinetic Mechanism of Escherichia 
249 
 
 
coli Glycinamide Ribonucleotide Transformylase. Biochemistry 1998, 37, 8776-8782. 
121. Shim, J. H.; Benkovic, S. J. Catalytic Mechanism of Escherichia coli Glycinamide 
Ribonucleotide Transformylase Probed by Site-Directed Mutagenesis and pH-Dependent 
Studies. Biochemistry 1999, 38, 10024-10031. 
122. Poch, M. T.; Qin, W.; Caperelli, C. A. The human trifunctional enzyme of de 
novo purine biosynthesis: heterologous expression, purification, and preliminary 
characterization. Protein Expression Purif. 1998, 12, 17-24. 
123. Klein, C.; Chen, P.; Arevalo, J. H.; Stura, E. A.; Marolewski, A.; Warren, M. S.; 
Benkovic, S. J.; Wilson, I. A. Towards structure-based drug design: crystal structure of a 
multisubstrate adduct complex of glycinamide ribonucleotide transformylase at 1.96 Å 
resolution. J. Mol. Biol. 1995, 249, 153-75. 
124. Almassy, R. J.; Janson, C. A.; Kan, C. C.; Hostomska, Z. Structures of apo and 
complexed Escherichia coli glycinamide ribonucleotide transformylase. Proc. Natl. Acad. 
Sci. U. S. A. 1992, 89, 6114-18. 
125. Greasley, S. E.; Yamashita, M. M.; Cai, H.; Benkovic, S. J.; Boger, D. L.; Wilson, 
I. A. New Insights into Inhibitor Design from the Crystal Structure and NMR Studies of 
Escherichia coli GAR Transformylase in Complex with β-GAR and 10-Formyl-5,8,10-
trideazafolic Acid. Biochemistry 1999, 38, 16783-16793. 
126. Zhang, Y.; Desharnais, J.; Greasley, S. E.; Beardsley, G. P.; Boger, D. L.; Wilson, 
I. A. Crystal Structures of Human GAR Tfase at Low and High pH and with Substrate β-
GAR. Biochemistry 2002, 41, 14206-14215. 
127. Taylor, E. C.; Harrington, P. J.; Fletcher, S. R.; Beardsley, G. P.; Moran, R. G. 
Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-
250 
 
 
tetrahydroaminopterin. J. Med. Chem. 1985, 28, 914-21. 
128. Boger, D. L.; Haynes, N. E.; Kitos, P. A.; Warren, M. S.; Ramcharan, J.; 
Marolewski, A. E.; Benkovic, S. J. 10-Formyl-5,8,10-trideazafolic acid (10-formyl-
TDAF): a potent inhibitor of glycinamide ribonucleotide transformylase. Bioorg. Med. 
Chem. 1997, 5, 1817-30. 
129. Boger, D. L.; Haynes, N. E.; Warren, M. S.; Gooljarsingh, L. T.; Ramcharan, J.; 
Kitos, P. A.; Benkovic, S. J. Functionalized analogues of 5,8,10-trideazafolate as 
potential inhibitors of GAR Tfase or AICAR Tfase. Bioorg. Med. Chem. 1997, 5, 1831-8. 
130. Boger, D. L.; Haynes, N. E.; Warren, M. S.; Ramcharan, J.; Kitos, P. A.; 
Benkovic, S. J. Multisubstrate analogue based on 5,8,10-trideazafolate. Bioorg. Med. 
Chem. 1997, 5, 1853-7. 
131. Boger, D. L.; Haynes, N. E.; Warren, M. S.; Ramcharan, J.; Kitos, P. A.; 
Benkovic, S. J. Functionalized analogues of 5,8,10-trideazafolate: development of an 
enzyme-assembled tight binding inhibitor of GAR Tfase and a potential irreversible 
inhibitor of AICAR Tfase. Bioorg. Med. Chem. 1997, 5, 1839-46. 
132. Boger, D. L.; Haynes, N. E.; Warren, M. S.; Ramcharan, J.; Marolewski, A. E.; 
Kitos, P. A.; Benkovic, S. J. Abenzyl 10-formyl-trideazafolic acid (abenzyl 10-formyl-
TDAF): an effective inhibitor of glycinamide ribonucleotide transformylase. Bioorg. Med. 
Chem. 1997, 5, 1847-52. 
133. Varney, M. D.; Palmer, C. L.; Romines, W. H., 3rd; Boritzki, T.; Margosiak, S. 
A.; Almassy, R.; Janson, C. A.; Bartlett, C.; Howland, E. J.; Ferre, R. Protein structure-
based design, synthesis, and biological evaluation of 5-thia-2,6-diamino-4(3H)-
oxopyrimidines: potent inhibitors of glycinamide ribonucleotide transformylase with 
251 
 
 
potent cell growth inhibition. J. Med. Chem. 1997, 40, 2502-24. 
134. Marsilje, T. H.; Labroli, M. A.; Hedrick, M. P.; Jin, Q.; Desharnais, J.; Baker, S. 
J.; Gooljarsingh, L. T.; Ramcharan, J.; Tavassoli, A.; Zhang, Y.; Wilson, I. A.; Beardsley, 
G. P.; Benkovic, S. J.; Boger, D. L. 10-Formyl-5,10-dideaza-acyclic-5,6,7,8-
tetrahydrofolic acid (10-formyl-DDACTHF): a potent cytotoxic agent acting by selective 
inhibition of human GAR Tfase and the de novo purine biosynthetic pathway. Bioorg. 
Med. Chem. 2002, 10, 2739-49. 
135. Deng, Y.; Wang, Y.; Cherian, C.; Hou, Z.; Buck, S. A.; Matherly, L. H.; Gangjee, 
A. Synthesis and discovery of high affinity folate receptor-specific glycinamide 
ribonucleotide formyltransferase inhibitors with antitumor activity. J. Med. Chem. 2008, 
51, 5052-63. 
136. Deng, Y.; Zhou, X.; Kugel Desmoulin, S.; Wu, J.; Cherian, C.; Hou, Z.; Matherly, 
L. H.; Gangjee, A. Synthesis and biological activity of a novel series of 6-substituted 
thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for 
high affinity folate receptors over the reduced folate carrier and proton-coupled folate 
transporter for cellular entry. J. Med. Chem. 2009, 52, 2940-51. 
137. Wang, L.; Cherian, C.; Desmoulin, S. K.; Polin, L.; Deng, Y.; Wu, J.; Hou, Z.; 
White, K.; Kushner, J.; Matherly, L. H.; Gangjee, A. Synthesis and antitumor activity of 
a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of 
purine biosynthesis with selectivity for high affinity folate receptors and the proton-
coupled folate transporter over the reduced folate carrier for cellular entry. J. Med. Chem. 
2010, 53, 1306-18. 
138. Aimi, J.; Qiu, H.; Williams, J.; Zalkin, H.; Dixon, J. E. De novo purine nucleotide 
252 
 
 
biosynthesis: cloning of human and avian cDNAs encoding the trifunctional glycinamide 
ribonucleotide synthetase-aminoimidazole ribonucleotide synthetase-glycinamide 
ribonucleotide transformylase by functional complementation in E.coli. Nucleic Acids 
Res. 1990, 18, 6665-72. 
139. Zhang, Y.; Desharnais, J.; Marsilje, T. H.; Li, C.; Hedrick, M. P.; Gooljarsingh, L. 
T.; Tavassoli, A.; Benkovic, S. J.; Olson, A. J.; Boger, D. L.; Wilson, I. A. Rational 
Design, Synthesis, Evaluation, and Crystal Structure of a Potent Inhibitor of Human GAR 
Tfase: 10-(Trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic Acid. 
Biochemistry 2003, 42, 6043-6056. 
140. Caperelli, C. A.; Giroux, E. L. The human glycinamide ribonucleotide 
transformylase domain: purification, characterization, and kinetic mechanism. Arch. 
Biochem. Biophys. 1997, 341, 98-103. 
141. Sanghani, S. P.; Moran, R. G. Tight Binding of Folate Substrates and Inhibitors to 
Recombinant Mouse Glycinamide Ribonucleotide Formyltransferase. Biochemistry 1997, 
36, 10506-10516. 
142. Moran, R. G.; Baldwin, S. W.; Taylor, E. C.; Shih, C. The 6S- and 6R-
diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de 
novo purine synthesis. J. Biol. Chem. 1989, 264, 21047-51. 
143. Habeck, L. L.; Leitner, T. A.; Shackelford, K. A.; Gossett, L. S.; Schultz, R. M.; 
Andis, S. L.; Shih, C.; Grindey, G. B.; Mendelsohn, L. G. A novel class of 
monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide 
ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res. 
1994, 54, 1021-6. 
253 
 
 
144. Mendelsohn, L. G.; Shih, C.; Schultz, R. M.; Worzalla, J. F. Biochemistry and 
pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and 
lometrexol. Invest. New Drugs 1996, 14, 287-94. 
145. Boritzki, T. J.; Barlett, C. A.; Zhang, C.; Howland, E. F. AG2034: a novel 
inhibitor of glycinamide ribonucleotide formyltransferase. Invest. New Drugs 1996, 14, 
295-303. 
146. Neuferm, H. B.; Boritzki, T. J. Drug interactions between AG2037 and a panel of 
standard chemotherapeutic agents against cancer cells in vitro. Proc. Am. Assoc. Cancer 
Res. (AACR) 2001, 42, Abst 1579. 
147. Taylor, E. C.; Harrington, P. J.; Fletcher, S. R.; Beardsley, G. P.; Moran, R. G. 
Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-
tetrahydroaminopterin. J. Med. Chem. 1985, 28, 914-21. 
148. Moran, R. G.; Baldwin, S. W.; Taylor, E. C.; Shih, C. The 6S- and 6R-
diastereomers of 5,10-dideaza-5,6,7,8-tetrahydrofolate are equiactive inhibitors of de 
novo purine synthesis. J. Biol. Chem. 1989, 264, 21047-51. 
149. Matherly, L. H.; Angeles, S. M.; McGuire, J. J. Determinants of the disparate 
antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate 
toward human lymphoblastic leukemia cells, characterized by severely impaired 
antifolate membrane transport. Biochem. Pharmacol. 1993, 46, 2185-95. 
150. Ray, M. S.; Muggia, F. M.; Leichman, C. G.; Grunberg, S. M.; Nelson, R. L.; 
Dyke, R. W.; Moran, R. G. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate 
antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst 1993, 85, 1154-
9. 
254 
 
 
151. Grindey, G. B. A., T., Shih, C. Reversal of the toxicity but not the antitumor 
activity of lometrexol by folic acid. Proc. Am. Assoc. Cancer Res. 1991, 32, 324. 
152. Roberts, J. D.; Poplin, E. A.; Tombes, M. B.; Kyle, B.; Spicer, D. V.; Grant, S.; 
Synold, T.; Moran, R. Weekly lometrexol with daily oral folic acid is appropriate for 
phase II evaluation. Cancer Chemother. Pharmacol. 2000, 45, 103-110. 
153. Mendelsohn, L. G.; Worzalla, J. F.; Walling, J. M. In Preclinical and clinical 
evaluation of the glycinamide ribonucleotide formyltransferase inhibitors lometrexol and 
LY309887, 1999; Humana: 1999; pp 261-280. 
154. Aylesworth, C. B., S. D.; Stephenson, J. Phase I and pharmacokinetic study of the 
glycinamide ribonucleotide formyltransferase inhibitor LY309887 as a bolus every 3 
weeks with folic acid (FA). Proc. Am. Soc. Clin. Oncol. (ASCO) 1998, 17, 865. 
155. Budman, D. R. B., B.; Johnson, R. Phase I trial of LY309887: A specific inhibitor 
of purine biosynthesis. Proc. Am. Soc. Clin. Oncol. (ASCO) 1998, 17, 864. 
156. Mader, M. M.; Henry, J. R. In Antimetabolites, 2006; Elsevier Ltd.: 2006; pp 55-
79. 
157. Neuferm, H. B. B., T. J. Drug interactions between AG2037 and a panel of 
standard chemotherapeutic agents against cancer cells in vitro. Proc. Am. Assoc. Cancer 
Res. (AACR) 2001, 42, 1579. 
158. Kisliuk, R. L. Deaza analogs of folic acid as antitumor agents. Curr. Pharm. Des. 
2003, 9, 2615-2625. 
159. Shih, C.; Gossett, L. S.; Worzalla, J. F.; Rinzel, S. M.; Grindey, G. B.; Harrington, 
P. M.; Taylor, E. C. Synthesis and biological activity of acyclic analogues of 5,10-
dideaza-5,6,7,8-tetrahydrofolic acid. J. Med. Chem. 1992, 35, 1109-16. 
255 
 
 
160. Kelley, J. L.; McLean, E. W.; Cohn, N. K.; Edelstein, M. P.; Duch, D. S.; Smith, 
G. K.; Hanlon, M. H.; Ferone, R. Synthesis and biological activity of an acyclic analogue 
of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5- 
pyrimidinyl)propyl]amino]-benzoyl]-L-glutamic acid. J. Med. Chem. 1990, 33, 561-7. 
161. Hodson, S. J.; Bigham, E. C.; Duch, D. S.; Smith, G. K.; Ferone, R. Thienyl and 
thiazolyl acyclic analogues of 5-deazatetrahydrofolic acid. J. Med. Chem. 1994, 37, 
2112-5. 
162. Zhang, Y.; Desharnais, J.; Marsilje, T. H.; Li, C.; Hedrick, M. P.; Gooljarsingh, L. 
T.; Tavassoli, A.; Benkovic, S. J.; Olson, A. J.; Boger, D. L.; Wilson, I. A. Rational 
design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR 
Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid. Biochemistry 
2003, 42, 6043-56. 
163. DeMartino, J. K.; Hwang, I.; Connelly, S.; Wilson, I. A.; Boger, D. L. 
Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase. J. Med. 
Chem. 2008, 51, 5441-8. 
164. Chong, Y.; Hwang, I.; Tavassoli, A.; Zhang, Y.; Wilson, I. A.; Benkovic, S. J.; 
Boger, D. L. Synthesis and biological evaluation of alpha- and gamma-carboxamide 
derivatives of 10-CF3CO-DDACTHF. Bioorg. Med. Chem. 2005, 13, 3587-92. 
165. DeMartino, J. K.; Hwang, I.; Xu, L.; Wilson, I. A.; Boger, D. L. Discovery of a 
potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase. J. 
Med. Chem. 2006, 49, 2998-3002. 
166. Taylor, E. C.; Harrington, P. M.; Shih, C. A facile route to "open chain" analogs 
of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF). Heterocycles 1989, 28, 1169-78. 
256 
 
 
167. Kelley, J. L.; McLean, E. W.; Cohn, N. K.; Edelstein, M. P.; Duch, D. S.; Smith, 
G. K.; Hanlon, M. H.; Ferone, R. Synthesis and biological activity of an acyclic analog of 
5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5-
pyrimidinyl)propyl]amino]benzoyl]-L-glutamic acid. J. Med. Chem. 1990, 33, 561-7. 
168. Marsilje, T. H.; Labroli, M. A.; Hedrick, M. P.; Jin, Q.; Desharnais, J.; Baker, S. 
J.; Gooljarsingh, L. T.; Ramcharan, J.; Tavassoli, A.; Zhang, Y.; Wilson, I. A.; Beardsley, 
G. P.; Benkovic, S. J.; Boger, D. L. 10-Formyl-5,10-dideaza-acyclic-5,6,7,8-
tetrahydrofolic acid (10-Formyl-DDACTHF) A potent cytotoxic agent acting by selective 
inhibition of human GAR Tfase and the de novo purine biosynthetic pathway. Bioorg. 
Med. Chem. 2002, 10, 2739-2749. 
169. Cheng, H.; Chong, Y.; Hwang, I.; Tavassoli, A.; Zhang, Y.; Wilson, I. A.; 
Benkovic, S. J.; Boger, D. L. Design, synthesis, and biological evaluation of 10-
methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-
DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic 
pathway. Bioorg Med Chem 2005, 13, 3577-85. 
170. DeMartino, J. K.; Hwang, I.; Connelly, S.; Wilson, I. A.; Boger, D. L. 
Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase. J. Med. 
Chem. 2008, 51, 5441-5448. 
171. Chong, Y.; Hwang, I.; Tavassoli, A.; Zhang, Y.; Wilson, I. A.; Benkovic, S. J.; 
Boger, D. L. Synthesis and biological evaluation of alpha- and gamma-carboxamide 
derivatives of 10-CF3CO-DDACTHF. Bioorg Med Chem 2005, 13, 3587-92. 
172. DeMartino, J. K.; Hwang, I.; Xu, L.; Wilson, I. A.; Boger, D. L. Discovery of a 
Potent, Nonpolyglutamatable Inhibitor of Glycinamide Ribonucleotide Transformylase. J. 
257 
 
 
Med. Chem. 2006, 49, 2998-3002. 
173. Shim, J. H.; Wall, M.; Benkovic, S. J.; Diaz, N.; Suarez, D.; Merz, K. M., Jr. 
Evaluation of the Catalytic Mechanism of AICAR Transformylase by pH-Dependent 
Kinetics, Mutagenesis, and Quantum Chemical Calculations. J. Am. Chem. Soc. 2001, 
123, 4687-4696. 
174. Greasley, S. E.; Horton, P.; Ramcharan, J.; Beardsley, G. P.; Benkovic, S. J.; 
Wilson, I. A. Crystal structure of a bifunctional transformylase and cyclohydrolase 
enzyme in purine biosynthesis. Nat Struct Biol 2001, 8, 402-6. 
175. Cheong, C. G.; Wolan, D. W.; Greasley, S. E.; Horton, P. A.; Beardsley, G. P.; 
Wilson, I. A. Crystal structures of human bifunctional enzyme aminoimidazole-4-
carboxamide ribonucleotide transformylase/IMP cyclohydrolase in complex with potent 
sulfonyl-containing antifolates. J Biol Chem 2004, 279, 18034-45. 
176. Wolan, D. W.; Greasley, S. E.; Wall, M. J.; Benkovic, S. J.; Wilson, I. A. 
Structure of Avian AICAR Transformylase with a Multisubstrate Adduct Inhibitor β-
DADF Identifies the Folate Binding Site. Biochemistry 2003, 42, 10904-10914. 
177. Erba, E.; Sen, S.; Sessa, C.; Vikhanskaya, F. L.; D'Incalci, M. Mechanism of 
cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in 
vitro and modulation of the drug activity by folic or folinic acid. Br. J. Cancer 1994, 69, 
205-11. 
178. Xu, L.; Chong, Y.; Hwang, I.; D'Onofrio, A.; Amore, K.; Beardsley, G. P.; Li, C.; 
Olson, A. J.; Boger, D. L.; Wilson, I. A. Structure-based Design, Synthesis, Evaluation, 
and Crystal Structures of Transition State Analogue Inhibitors of Inosine Monophosphate 
Cyclohydrolase. J. Biol. Chem. 2007, 282, 13033-13046. 
258 
 
 
179. Wolan, D. W.; Greasley, S. E.; Beardsley, G. P.; Wilson, I. A. Structural Insights 
into the Avian AICAR Transformylase Mechanism. Biochemistry 2002, 41, 15505-15513. 
180. Wolan, D. W.; Cheong, C.-G.; Greasley, S. E.; Wilson, I. A. Structural Insights 
into the Human and Avian IMP Cyclohydrolase Mechanism via Crystal Structures with 
the Bound XMP Inhibitor. Biochemistry 2004, 43, 1171-1183. 
181. Rayl, E. A.; Moroson, B. A.; Beardsley, G. P. The human purH gene product, 5-
aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase. 
Cloning, sequencing, expression, purification, kinetic analysis, and domain mapping. J. 
Biol. Chem. 1996, 271, 2225-33. 
182. Wall, M.; Shim, J. H.; Benkovic, S. J. Human AICAR Transformylase: Role of 
the 4-Carboxamide of AICAR in Binding and Catalysis. Biochemistry 2000, 39, 11303-
11311. 
183. Beardsley, G. P.; Rayl, E. A.; Gunn, K.; Moroson, B. A.; Seow, H.; Anderson, K. 
S.; Vergis, J.; Fleming, K.; Worland, S.; Condon, B.; Davies, J. Structure and functional 
relationships in human pur H. Adv Exp Med Biol 1998, 431, 221-6. 
184. Li, C.; Xu, L.; Wolan, D. W.; Wilson, I. A.; Olson, A. J. Virtual Screening of 
Human 5-Aminoimidazole-4-carboxamide Ribonucleotide Transformylase against the 
NCI Diversity Set by Use of AutoDock to Identify Novel Nonfolate Inhibitors. J. Med. 
Chem. 2004, 47, 6681-6690. 
185. Bulock, K. G.; Beardsley, G. P.; Anderson, K. S. The kinetic mechanism of the 
human bifunctional enzyme ATIC (5-amino-4-imidazolecarboxamide ribonucleotide 
transformylase/inosine 5'-monophosphate cyclohydrolase): A surprising lack of substrate 
channeling. J. Biol. Chem. 2002, 277, 22168-22174. 
259 
 
 
186. Itoh, F.; Russello, O.; Akimoto, H.; Beardsley, G. P. Novel pyrrolo[2,3-
d]pyrimidine antifolate TNP-351: cytotoxic effect on methotrexate-resistant CCRF-CEM 
cells and inhibition of transformylases of de novo purine biosynthesis. Cancer Chemother. 
Pharmacol. 1994, 34, 273-9. 
187. Chattopadhyay, S.; Moran, R. G.; Goldman, I. D. Pemetrexed: Biochemical and 
cellular pharmacology, mechanisms, and clinical applications. Mol. Cancer Ther. 2007, 6, 
404-417. 
188. Ricciardi, S.; Tomao, S.; de, M. F. Pemetrexed as first-line therapy for non-
squamous non-small cell lung cancer. Ther. Clin. Risk Manage. 2009, 5, 781-787. 
189. Taylor, E. C.; Kuhnt, D.; Shih, C.; Rinzel, S. M.; Grindey, G. B.; Barredo, J.; 
Jannatipour, M.; Moran, R. G. A dideazatetrahydrofolate analog lacking a chiral center at 
C-6: N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-
5yl)ethyl[benzoyl]-L-glutamic acid is an inhibitor of thymidylate synthase. J. Med. Chem. 
1992, 35, 4450-4. 
190. Racanelli, A. C.; Rothbart, S. B.; Heyer, C. L.; Moran, R. G. Therapeutics by 
Cytotoxic Metabolite Accumulation: Pemetrexed Causes ZMP Accumulation, AMPK 
Activation, and Mammalian Target of Rapamycin Inhibition. Cancer Res. 2009, 69, 
5467-5474. 
191. Rothbart, S. B.; Racanelli, A. C.; Moran, R. G. Pemetrexed Indirectly Activates 
the Metabolic Kinase AMPK in Human Carcinomas. Cancer Res. 2010, 70, 10299-10309. 
192. Gridelli, C.; Rossi, A.; Morgillo, F.; Bareschino, M. A.; Maione, P.; Di, M. M.; 
Ciardiello, F. A randomized phase II study of pemetrexed or RAD001 as second-line 
treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale 
260 
 
 
and protocol dynamics. Clin. Lung Cancer 2007, 8, 568-571. 
193. Pandya, K. J.; Dahlberg, S.; Hidalgo, M.; Cohen, R. B.; Lee, M. W.; Schiller, J. 
H.; Johnson, D. H. A randomized, phase II trial of two dose levels of temsirolimus (CCI-
779) in patients with extensive-stage small-cell lung cancer who have responding or 
stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology 
Group (E1500). J Thorac Oncol 2007, 2, 1036-41. 
194. Gorlick, R.; Goker, E.; Trippett, T.; Waltham, M.; Banerjee, D.; Bertino, J. R. 
Intrinsic and acquired resistance to methotrexate in acute leukemia. N. Engl. J. Med. 1996, 
335, 1041-8. 
195. Werkheiser, W. C. Specific Binding of 4-Amino Folic Acid Analogs by Folic 
Acid Reductase. J. Biol. Chem. 1961, 236, 888-893. 
196. Trippett, T.; Schlemmer, S.; Elisseyeff, Y.; Goker, E.; Wachter, M.; Steinherz, P.; 
Tan, C.; Berman, E.; Wright, J. E.; Rosowsky, A.; et al. Defective transport as a 
mechanism of acquired resistance to methotrexate in patients with acute lymphocytic 
leukemia. Blood 1992, 80, 1158-62. 
197. Assaraf, Y. G. Characterization by flow cytometry and fluorescein-methotrexate 
labeling of hydrophilic and lipophilic antifolate resistance in cultured mammalian cells. 
Anticancer Drugs 1993, 4, 535-44. 
198. Matherly, L. H.; Taub, J. W.; Ravindranath, Y.; Proefke, S. A.; Wong, S. C.; 
Gimotty, P.; Buck, S.; Wright, J. E.; Rosowsky, A. Elevated dihydrofolate reductase and 
impaired methotrexate transport as elements in methotrexate resistance in childhood 
acute lymphoblastic leukemia. Blood 1995, 85, 500-9. 
199. Goker, E.; Waltham, M.; Kheradpour, A.; Trippett, T.; Mazumdar, M.; Elisseyeff, 
261 
 
 
Y.; Schnieders, B.; Steinherz, P.; Tan, C.; Berman, E.; et al. Amplification of the 
dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in 
patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. 
Blood 1995, 86, 677-84. 
200. Lin, J. T.; Tong, W. P.; Trippett, T. M.; Niedzwiecki, D.; Tao, Y.; Tan, C.; 
Steinherz, P.; Schweitzer, B. I.; Bertino, J. R. Basis for natural resistance to methotrexate 
in human acute non-lymphocytic leukemia. Leuk. Res. 1991, 15, 1191-6. 
201. Hryniuk, W. M.; Bertino, J. R. Treatment of leukemia with large doses of 
methotrexate and folinic acid: clinical-biochemical correlates. J. Clin. Invest. 1969, 48, 
2140-55. 
202. Rodenhuis, S.; McGuire, J. J.; Narayanan, R.; Bertino, J. R. Development of an 
assay system for the detection and classification of methotrexate resistance in fresh 
human leukemic cells. Cancer Res. 1986, 46, 6513-9. 
203. Li, W. W.; Waltham, M.; Tong, W.; Schweitzer, B. I.; Bertino, J. R. Increased 
activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism 
of intrinsic resistance to methotrexate (MTX). Adv. Exp. Med. Biol. 1993, 338, 635-8. 
204. Waltham, M. C.; Li, W. W.; Gritsman, H.; Tong, W. P.; Bertino, J. R. gamma-
Glutamyl hydrolase from human sarcoma HT-1080 cells: characterization and inhibition 
by glutamine antagonists. Mol. Pharmacol. 1997, 51, 825-32. 
205. Matthews, D. A.; Alden, R. A.; Bolin, J. T.; Freer, S. T.; Hamlin, R.; Xuong, N.; 
Kraut, J.; Poe, M.; Williams, M.; Hoogsteen, K. Dihydrofolate reductase: x-ray structure 
of the binary complex with methotrexate. Science 1977, 197, 452-5. 
206. Blakeley, R. L.; Appleman, J. R. Recent Advances in the Study of Dihydrofolate 
262 
 
 
Reductase. In Chemistry and Biology of Pteridines, Walter de Gruyter Berlin N.Y.: 1986; 
pp 769-772. 
207. Freisham, J. H.; Matthews, D. A. The Comparative Biochemistry of DHFR. In 
Folate as Therapeutic Agents, Sirotnak; Burchall; Ensminger; Montgomery, Eds. 
Academic Press, Inc., Orlando: 1984; Vol. 1, pp 69-131. 
208. Davies, J. F., 2nd; Delcamp, T. J.; Prendergast, N. J.; Ashford, V. A.; Freisheim, J. 
H.; Kraut, J. Crystal structures of recombinant human dihydrofolate reductase complexed 
with folate and 5-deazafolate. Biochemistry 1990, 29, 9467-79. 
209. Ferrer, S.; Silla, E.; Tunon, I. Catalytic Mechanism of Dihydrofolate Reductase 
Enzyme. A Combined Quantum-Mechanical/Molecular-Mechanical Characterization of 
the N5 Protonation Step. J. Phys. Chem. B 2003, 107, 14036-14041. 
210. Schnell, J. R.; Dyson, H. J.; Wright, P. E. STRUCTURE, DYNAMICS, AND 
CATALYTIC FUNCTION OF DIHYDROFOLATE REDUCTASE. Annual Review of 
Biophysics and Biomolecular Structure 2004, 33, 119-140. 
211. Oefner, C.; D'Arcy, A.; Winkler, F. K. Crystal structure of human dihydrofolate 
reductase complexed with folate. Eur. J. Biochem. 1988, 174, 377-85. 
212. Gready, J. E. Dihydrofolate reductase: binding of substrates and inhibitors and 
catalytic mechanism. Adv. Pharmacol. Chemother. 1980, 17, 37-102. 
213. Subramanian, S.; Kaufman, B. T. Interaction of methotrexate, folates, and 
pyridine nucleotides with dihydrofolate reductase: calorimetric and spectroscopic binding 
studies. Proc. Natl. Acad. Sci. U S A 1978, 75, 3201-5. 
214. Stockman, B. J.; Nirmala, N. R.; Wagner, G.; Delcamp, T. J.; DeYarman, M. T.; 
Freisheim, J. H. Methotrexate binds in a non-productive orientation to human 
263 
 
 
dihydrofolate reductase in solution, based on NMR spectroscopy. FEBS Lett. 1991, 283, 
267-9. 
215. Fry, D. W.; Jackson, R. C. Biological and biochemical properties of new 
anticancer folate antagonists. Cancer Metastasis Rev. 1987, 5, 251-70. 
216. Roth, B.; Cheng, C. C. Recent progress in the medicinal chemistry of 2,4-
diaminopyrimidines. Prog. Med. Chem. 1982, 19, 269-331. 
217. Seeger, D. R.; Cosulich, D. B.; Smith, J. M., Jr.; Hultquist, M. E. Analogs of 
pteroylglutamic acid. III. 4-Amino derivatives. J. Am. Chem. Soc. 1949, 71, 1753-1758. 
218. Deng, Y.; Hou, Z.; Wang, L.; Cherian, C.; Wu, J.; Gangjee, A.; Matherly, L. H. 
Role of lysine 411 in substrate carboxyl group binding to the human reduced folate 
carrier, as determined by site-directed mutagenesis and affinity inhibition. Mol. 
Pharmacol. 2008, 73, 1274-81. 
219. Jolivet, J.; Cowan, K. H.; Curt, G. A.; Clendeninn, N. J.; Chabner, B. A. The 
pharmacology and clinical use of methotrexate. N. Engl. J. Med. 1983, 309, 1094-104. 
220. Bertino, J. R.; Mini, E.; Sobrero, A.; Moroson, B. A.; Love, T.; Jastreboff, M.; 
Carmen, M.; Srimatkandada, S.; Dube, S. K. In Advances in Enzyme Regulation. 24, 
Weber, G., Ed. Pergamon: New York, 1985; pp 3-12. 
221. Bertino, J. R.; Srimatkandada, S.; Carman, M. D.; Mini, E.; Jastreboff, M.; 
Moroson, B. A.; Dube, S. K. In Modern Trends in Human Leukemia VI, Neth, R.; Gallo, 
R. C.; Greaves, M. F.; Janka, G., Eds. Springer-Verlag: Berlin, 1985. 
222. Flombaum, C. D.; Meyers, P. A. High-dose leucovorin as sole therapy for 
methotrexate toxicity. J. Clin. Oncol. 1999, 17, 1589-1594. 
223. Widemann, B. C.; Adamson, P. C. Understanding and managing methotrexate 
264 
 
 
nephrotoxicity. Oncologist 2006, 11, 694-703. 
224. Zain, J. M.; Marchi, E. Pralatrexate - from bench to bedside. Drugs Today (Barc) 
2010, 46, 91-9. 
225. Malik, S. M.; Liu, K.; Qiang, X.; Sridhara, R.; Tang, S.; McGuinn, W. D., Jr.; 
Verbois, S. L.; Marathe, A.; Williams, G. M.; Bullock, J.; Tornoe, C.; Lin, S. C.; 
Ocheltree, T.; Vialpando, M.; Kacuba, A.; Justice, R.; Pazdur, R. Folotyn (pralatrexate 
injection) for the treatment of patients with relapsed or refractory peripheral T-cell 
lymphoma: u.s. Food and drug administration drug approval summary. Clin. Cancer Res. 
2010, 16, 4921-7. 
226. Harrison, P. T.; Scott, J. E.; Hutchinson, M. J.; Thompson, R. Site-directed 
mutagenesis of varicella-zoster virus thymidylate synthase. Analysis of two highly 
conserved regions of the enzyme. Eur. J. Biochem. 1995, 230, 511-6. 
227. Douglas, K. T. The thymidylate synthesis cycle and anticancer drugs. Med. Res. 
Rev. 1987, 7, 441-75. 
228. Cisneros, R. J.; Silks, L. A.; Dunlap, R. B. Mechanistic aspects of thymidylate 
synthase: molecular basis for drug design. Drugs Fut. 1988, 13, 859. 
229. Pogolotti, A. L., Jr.; Santi, D. V. The Catalytic Activity of Thymidylate Synthase. 
In Bioorganic Chemistry, van Tamelen, E. E., Ed. Academic Press: Orlando, FL, 1977; 
Vol. 1, pp 277-311. 
230. Phan, J.; Koli, S.; Minor, W.; Dunlap, R. B.; Berger, S. H.; Lebioda, L. Human 
thymidylate synthase is in the closed conformation when complexed with dUMP and 
raltitrexed, an antifolate drug. Biochemistry 2001, 40, 1897-902. 
231. Sayre, P. H.; Finer-Moore, J. S.; Fritz, T. A.; Biermann, D.; Gates, S. B.; 
265 
 
 
MacKellar, W. C.; Patel, V. F.; Stroud, R. M. Multi-targeted antifolates aimed at 
avoiding drug resistance form covalent closed inhibitory complexes with human and 
Escherichia coli thymidylate synthases. J. Mol. Biol. 2001, 313, 813-29. 
232. Kamb, A.; Finer-Moore, J. S.; Stroud, R. M. Cofactor triggers the conformational 
change in thymidylate synthase: implications for an ordered binding mechanism. 
Biochemistry 1992, 31, 12876-84. 
233. Kamb, A.; Finer-Moore, J.; Calvert, A. H.; Stroud, R. M. Structural basis for 
recognition of polyglutamyl folates by thymidylate synthase. Biochemistry 1992, 31, 
9883-90. 
234. Matthews, D. A.; Appelt, K.; Oatley, S. J.; Xuong, N. H. Crystal structure of 
Escherichia coli thymidylate synthase containing bound 5-fluoro-2'-deoxyuridylate and 
10-propargyl-5,8-dideazafolate. J. Mol. Biol. 1990, 214, 923-36. 
235. Matthews, D. A.; Villafranca, J. E.; Janson, C. A.; Smith, W. W.; Welsh, K.; 
Freer, S. Stereochemical mechanism of action for thymidylate synthase based on the X-
ray structure of the covalent inhibitory ternary complex with 5-fluoro-2'-deoxyuridylate 
and 5,10-methylenetetrahydrofolate. J. Mol. Biol. 1990, 214, 937-48. 
236. Finer-Moore, J. S.; Montfort, W. R.; Stroud, R. M. Pairwise specificity and 
sequential binding in enzyme catalysis: thymidylate synthase. Biochemistry 1990, 29, 
6977-86. 
237. Carreras, C. W.; Santi, D. V. The catalytic mechanism and structure of 
thymidylate synthase. Annu. Rev. Biochem. 1995, 64, 721-62. 
238. Jackman, A. L.; Calvert, A. H. Folate-based thymidylate synthase inhibitors as 
anticancer drugs. Ann. Oncol. 1995, 6, 871-81. 
266 
 
 
239. Jones, T. R.; Calvert, A. H.; Jackman, A. L.; Brown, S. J.; Jones, M.; Harrap, K. 
R. A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, 
biological properties and therapeutic results in mice. Eur. J. Cancer 1981, 17, 11-9. 
240. Jackman, A. L.; Taylor, G. A.; Gibson, W.; Kimbell, R.; Brown, M.; Calvert, A. 
H.; Judson, I. R.; Hughes, L. R. ICI D1694, a quinazoline antifolate thymidylate synthase 
inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new 
agent for clinical study. Cancer Res. 1991, 51, 5579-86. 
241. Taylor, E. C.; Kuhnt, D.; Shih, C.; Rinzel, S. M.; Grindey, G. B.; Barredo, J.; 
Jannatipour, M.; Moran, R. G. A dideazatetrahydrofolate analogue lacking a chiral center 
at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- 
yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J. Med. Chem. 
1992, 35, 4450-4. 
242. Shih, C.; Thornton, D. E. Preclinical Pharmacology Studies and the Clinical 
Development of a Novel Multitargeted Antifolate, MTA (LY231514). In Antifolate 
Drugs in Cancer Therapy, Jackman, A. L., Ed. Humana Press: Totowa, NJ, 1999; pp 
183-201. 
243. Boyle, F. T.; Stephens, T. C.; Averbuch, S. D.; Jackman, A. L. ZD9331: 
Preclinical and Clinical Studies. In Antifolate Drugs in Cancer Therapy, Jackman, A. L., 
Ed. Humana Press: Totowa, NJ, 1999; pp 243-260. 
244. Paz-Ares, L.; Bezares, S.; Tabernero, J. M.; Castellanos, D.; Cortes-Funes, H. 
Review of a promising new agent - pemetrexed disodium. Cancer 2003, 97, 2056-2063. 
245. Nowak, A. K.; Byrne, M. J.; Millward, M. J.; Alvarez, J. M.; Robinson, B. W. S. 
Current chemotherapeutic treatment of malignant pleural mesothelioma. Expert Opin. 
267 
 
 
Pharmacother. 2004, 5, 2441-2449. 
246. Gangjee, A.; Zaware, N.; Raghavan, S.; Ihnat, M.; Shenoy, S.; Kisliuk, R. L. 
Single agents with designed combination chemotherapy potential: synthesis and 
evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and 
thymidylate synthase inhibitors and as antitumor agents. J. Med. Chem. 2010, 53, 1563-
1578. 
247. Gangjee, A.; Zaware, N.; Raghavan, S.; Yang, J.; Thorpe, J. E.; Ihnat, M. A. N4-
(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple 
receptor tyrosine kinase inhibitors: Design, synthesis, and in vivo evaluation. Bioorg. 
Med. Chem. 2012, 20, 2444-2454. 
248. Gangjee, A.; Qiu, Y.; Li, W.; Kisliuk, R. L. Potent Dual Thymidylate Synthase 
and Dihydrofolate Reductase Inhibitors: Classical and Nonclassical 2-Amino-4-oxo-5-
arylthio-substituted-6-methylthieno[2,3-d]pyrimidine Antifolates. J. Med. Chem. 2008, 
51, 5789-5797. 
249. Zhao, R.; Babani, S.; Gao, F.; Liu, L.; Goldman, I. D. The mechanism of transport 
of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with 
markedly impaired transport of methotrexate. Clin. Cancer Res. 2000, 6, 3687-3695. 
250. Teicher, B. A.; Chen, V.; Shih, C.; Menon, K.; Forler, P. A.; Phares, V. G.; 
Amsrud, T. Treatment Regimens Including the Multitargeted Antifolate LY231514 in 
Human Tumor Xenografts. Clinical Cancer Research 2000, 6, 1016-1023. 
251. Taylor, E. C.; Patel, H. H.; Jun, J. G. A One-Step Ring Transformation/Ring 
Annulation Approach to Pyrrolo[2,3- d]pyrimidines. A New Synthesis of the Potent 
Dihydrofolate Reductase Inhibitor TNP-351. J. Org. Chem. 1995, 60, 6684-6687. 
268 
 
 
252. Noell, C. W.; Robins, R. K. Aromaticity in Heterocyclic Systems. II. The 
Application of NMR in a Study of the Synthesis and Structure of Certain Imidazo[1,2-
c]pyrimidines and Related Pyrrolo[2,3-d]pyrimidines. J. Heterocycl. Chem. 1964, 1, 34-
41. 
253. Gibson, C. L.; Ohta, K.; Paulini, K.; Suckling, C. J. Specific Inhibitors in Vitamin 
Biosynthesis. Part 10. Synthesis of 7- and 8-Substituted 7-Deazaguanines. J. Chem. Soc., 
Perkin Trans. 1 1998, 1998, 3025-3032. 
254. Fumio, Y.; Masatsugu, H.; Keitaro, S.; Michiko, K.; Dadao, N. Synthesis and 
Properties of Some Pyrrolo[2,3-d]pyrimidine Derivatives. Chem. Pharm. Bull. 1973, 21, 
473-477. 
255. Secrist, J. A.; Liu, P. S. Studies directed toward a total synthesis of nucleoside Q. 
Annulation of 2,6-diaminopyrimidin-4-one with .alpha.-halo carbonyls to form 
pyrrolo[2,3-d]pyrimidines and furo[2,3-d]pyrimidines. J. Org. Chem. 1978, 43, 3937-
3941. 
256. Davoll, J. Pyrrolo[2,3-d]pyrimidines. J. Chem. Soc. 1960, 131-138. 
257. Gangjee, A.; Yu, J.; McGuire, J. J.; Cody, V.; Galitsky, N.; Kisliuk, R. L.; 
Queener, S. F. Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of 
thymidylate synthase and dihydrofolate reductase as an antitumor agent. J. Med. Chem. 
2000, 43, 3837-51. 
258. Gangjee, A.; Dubash, N. P.; Kisliuk, R. L. Synthesis of novel, nonclassical 2-
amino-4-oxo-6-(arylthio)ethylpyrrolo[2,3-d]pyrimidines as potential inhibitors of 
thymidylate synthase. J. Heterocycl. Chem. 2001, 38, 349-354. 
259. Gangjee, A.; Vidwans, A.; Elzein, E.; McGuire, J. J.; Queener, S. F.; Kisliuk, R. L. 
269 
 
 
Synthesis, Antifolate, and Antitumor Activities of Classical and Nonclassical 2-Amino-4-
oxo-5-substituted-pyrrolo[2,3-d]pyrimidines. J. Med. Chem. 2001, 44, 1993-2003. 
260. Miwa, T.; Hitaka, T.; Akirnoto, H. A Novel Synthetic Approach to Pyrrolo[2,3-
d]pyrimidine Antifolates. J. Org. Chem. 1993, 58, 1696-1701. 
261. Taylor, E. C.; Liu, B. A Simple and Concise Synthesis of LY231514 (MTA). 
Tetrahedron Lett. 1999, 40, 4023-4026. 
262. Taylor, E. C.; Dowling, J. E.; Schrader, T.; Bhatia, B. Unexpected and Facile 
Bridgehead Substitution in 5,6,7,8,9,10-Hexahydro-5,9-methanopyrimido[4,5-b]azocin-
4(3H)-ones. Tetrahedron Lett. 1998, 54, 9507-9518. 
263. Anderson, G. L. Regioselective Synthesis of Pyrido[2,3-d]pyrimidines. J. 
Heterocycl. Chem. 1985, 22, 1469-1470. 
264. Bennett, G. B.; Mason, R. B. The Regioselective Behavior of Unsaturated Keto 
Esters toward Vinylogous Amides. J. Org. Chem. 1977, 42, 1919-1922. 
265. Broom, A. D.; Shim, J. L.; Anderson, G. L. Pyrido[2,3-d]pyrimidines. IV. 
Synthetic Studies Leading to Various Oxopyrido[2,3-d]pyrimidines. J. Org. Chem. 1976, 
41, 1095-1099. 
266. Koen, M. J.; Gready, J. E. Preparation of 8-Substituted Pyrido[2,3-d]pyrimidines 
(N5-Deazapterins). J. Org. Chem. 1993, 58, 1104-1108. 
267. Taylor, E. C.; Gillespie, P.; Patel, M. Novel 5-Desmethylene Analogs of 5,10-
Dideaza-5,6,7,8-tetrahydrofolic Acid as Potential Anticancer Agents. J. Org. Chem. 1992, 
57, 3218-3225. 
268. Melton, J.; McMurry, J. E. New Method for the Dehydration of Nitro Alcohols. J. 
Org. Chem. 1975, 40, 2138-2319. 
270 
 
 
269. Barnett, C. J.; Wilson, T. M.; Kobierski, M. E. A Practical Synthesis of 
Multitargeted Antifolate LY231514. Organic Process Research & Development 1999, 3, 
184-188. 
270. Legraverend, M.; Ngongo-Tekam, R. M.; Bisagni, E.; Zerial, A. (+/-)-2-Amino-
3,4-dihydro-7-[2,3-dihydroxy-4-(hydroxymethyl)-1- cyclopentyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-ones: new carbocyclic analogues of 7-deazaguanosine with antiviral 
activity. J. Med. Chem. 1985, 28, 1477-80. 
271. Sakamoto, T.; Satoh, C.; Kondo, Y.; Yamanaka, H. Condensed Heteroaromatic 
Ring Systems. XXI. Synthesis of Pyrrolo[2,3-d]pyrimidines and Pyrrolo[3,2-
d]pyrimidines. Chem. Pharm. Bull. 1993, 41, 81-86. 
272. Kondo, Y.; Watanabe, R.; Sakamoto, T.; Yamanaka, H. Condensed 
Heteroaromatic Ring Systems.  XVI. Synthesis of Pyrrolo[2,3-d]pyrimidine Derivatives. 
Chem. Pharm. Bull. 1989, 37, 2933-2936. 
273. Crooks, P. A.; Robinson, B. Thermal Indolization of 4-Pyrimidinylhydrazones 
and 4-Pyridylhydrazones. Chem. Ind. 1967, 547-548. 
274. Senda, S.; Hirota, K. Pyrimidine Derivatives and Related Compounds. XXII. 
Synthesis and Parmacological Properties of 7-Deazaxanthine Derivatives. Chem. Pharm. 
Bull. 1974, 22, 1459-1467. 
275. Senda, S.; Hirota, K. Novel Synthesis of 2,4-Dioxo-1,2,3,4-tetrahydropyrrolo[2,3-
d]pyrimidine Derivatives. Chem. Lett. 1972, 5, 367-368. 
276. Wright, G. E. 9H-Pyrimido[4,5-b]indole-2,4-diones. The Acid-catalyzed 
Cyclization of 6-(Phenylhydrazino)uracils. J. Heterocycl. Chem. 1976, 13, 539-544. 
277. Duffy, T. D.; Wibberley, D. G. Pyrrolo[2,3-d]pyrimidines. Synthesis from 4-
271 
 
 
Pyrimidylhydrazones, A 2-Bis(ethylthio)methyleneaminopyrrolo-3-carbonitrile and a 
Pyrrolo[2,3-d][1,3]thiazine-2(1H)-thione. J. Chem. Soc., Perkin Trans. 1 1974, 16, 1921-
1929. 
278. Taylor, E. C.; Hendess, R. W. Synthesis of Pyrrolo(2,3-D)Pyrimidines. The 
Aglycone of Toyocamycin. J. Am. Chem. Soc. 1965, 87, 1995-2003. 
279. Middleton, W. J.; Engelhardt, V. A.; Fisher, B. S. Cyanocarbon Chemistry. VIII. 
Heterocyclic Compounds from Tetracyanoethylene. J. Am. Chem. Soc. 1958, 80, 2822-
2829. 
280. Tolman, R. L.; Robins, R. K.; Townsend, L. B. Pyrrolopyrimidine nucleosides. 3. 
The total synthesis of toyocamycin, sangivamycin, tubercidin, and related derivatives. J. 
Am. Chem. Soc. 1969, 91, 2102-8. 
281. Ramasamy, K.; Robins, R. K.; Revankar, G. R. Total Synthesis of 2'-
Deoxytoyocamycin, 2'-Deoxysangivamycin and Related 7-(b-D-
Arabinofuranosylpyrrolo[2,3-d]pyrimidines Via Ring Closure of Pyrrole Precursors 
Prepared by the Stereospecific Sodium Salt Glycosylation Procedure. Tetrahedron 1986, 
42, 5869-5878. 
282. Swayze, E. E.; Hinkley, J. M.; Townsend, L. B. 2-Amino-5-bromo-3,4-
dicyanopyrrole. The Improved Preperation of a Versatile Synthon for the Synthesis of 
Pyrrolo[2,3-d]pyrimidines. Nucleic Acid Chem. 1991, 16-18. 
283. Pichler, H.; Folkers, G.; Roth, H. J.; Eger, K. Synthesis of 7-Unsubstituted 7H-
pyrrolo[2,3-d]pyrimidines. Liebigs Ann. Chem. 1986, 9, 1485-1505. 
284. Eger, K.; Pfahl, J. G.; Folkers, G.; Roth, H. J. Selected Reactions on the o-
Aminonitrile System of Substituted Pyrroles. J. Heterocycl. Chem. 1987, 24, 425-430. 
272 
 
 
285. Chen, Y. L.; Mansbach, R. S.; Winter, S. M.; Brooks, E.; Collins, J.; Corman, M. 
L.; Dunaiskis, A. R.; Faraci, W. S.; Gallaschun, R. J.; Schmidt, A.; Schulz, D. W. 
Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally 
active corticotropin-releasing factor1 receptor antagonist. J. Med. Chem. 1997, 40, 1749-
54. 
286. Girgis, N. S.; Joergensen, A.; Pedersen, E. B. Phosphorus Pentoxide in Organic 
Synthesis; XI. A New Synthetic Approach to 7-Deazahypoxanthines. Synthesis 1985, 
101-104. 
287. Wamhoff, H.; Wehling, B. Heterocyclic b-Enamino Esters; 18. Synthesis of 2-
Aminopyrrole-3-carboxylic Acid Derivatives. Synthesis 1976, 51-52. 
288. Yumoto, M.; Kawabuchi, T.; Sato, K.; Takashima, M. 2-Aminopyrrole 
Derivatives and Method for Their Preparation. JP 10316654  A2 19981202  Heisei CAN 
130:66386, 1998. 
289. Taylor, E. C.; Liu, B. A New Route to 7-Substituted Derivatives of N-{4-[2-(2-
Amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-ethyl]benzoyl}-L-glutamic 
Acid [ALIMTA (LY231514, MTA)] J. Org. Chem. 2001, 66, 3726-3738. 
290. Galeazzi, R.; Mobbili, G.; Orena, M. A Convenient Approach to 
Diastereomerically Pure 1,3,4-Trisubstituted Pyrrolidin-2-ones by Intramolecular 
Cyclization of N-(2-Alken-1-yl)amides Mediated by Mn(III). An Entry to Both (R)- and 
(S)-3-Pyrrolidineacetic Acid. Tetrahedron 1996, 52, 1069-1084. 
291. Barnett, C. J.; Wilson, T. M.; Grindley, G. B. Synthesis and Antitumor Activity of 
LY288601, the 5,6 Dihydro analog of LY231514. Adv. Exp. Med Biol. 1993, 338, 409-
412. 
273 
 
 
292. Dave, K. G.; Shishoo, C. J.; Devani, M. B.; Kalyanaraman, R.; Ananthan, S.; 
Ullas, G. V.; Bhadti, V. S. Reaction of nitriles under acidic conditions. Part I. A general 
method of synthesis of condensed pyrimidines. J. Heterocycl. Chem. 1980, 17, 1497-500. 
293. Bookser, B. C.; Ugarkar, B. G.; Matelich, M. C.; Lemus, R. H.; Allan, M.; 
Tsuchiya, M.; Nakane, M.; Nagahisa, A.; Wiesner, J. B.; Erion, M. D. Adenosine Kinase 
Inhibitors. 6. Synthesis, Water Solubility, and Antinociceptive Activity of 5-Phenyl-7-(5-
deoxy-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines Substituted at C4 with Glycinamides 
and Related Compounds. J. Med. Chem. 2005, 48, 7808-7820. 
294. Chinchilla, R.; Najera, C. Recent advances in Sonogashira reactions. Chemical 
Society Reviews 2011, 40, 5084-5121. 
295. Chinchilla, R.; Nájera, C. The Sonogashira Reaction:  A Booming Methodology 
in Synthetic Organic Chemistry†. Chemical Reviews 2007, 107, 874-922. 
296. Sonogashira, K.; Tohda, Y.; Hagihara, N. Convenient synthesis of acetylenes. 
Catalytic substitutions of acetylenic hydrogen with bromo alkenes, iodo arenes, and 
bromopyridines. Tetrahedron Lett. 1975, 4467-70. 
297. Liang, B.; Dai, M.; Chen, J.; Yang, Z. Copper-Free Sonogashira Coupling 
Reaction with PdCl2 in Water under Aerobic Conditions. The Journal of organic 
chemistry 2004, 70, 391-393. 
298. Soheili, A.; Albaneze-Walker, J.; Murry, J. A.; Dormer, P. G.; Hughes, D. L. 
Efficient and General Protocol for the Copper-Free Sonogashira Coupling of Aryl 
Bromides at Room Temperature. Organic letters 2003, 5, 4191-4194. 
299. Chandra, A.; Singh, B.; Khanna, R. S.; Singh, R. M. Copper-Free Palladium-
Catalyzed Sonogashira Coupling−Annulation: Efficient One-Pot Synthesis of 
274 
 
 
Functionalized Pyrano[4,3-b]quinolines from 2-Chloro-3-formylquinolines. The Journal 
of organic chemistry 2009, 74, 5664-5666. 
300. Fukuyama, T.; Shinmen, M.; Nishitani, S.; Sato, M.; Ryu, I. A Copper-Free 
Sonogashira Coupling Reaction in Ionic Liquids and Its Application to a Microflow 
System for Efficient Catalyst Recycling. Organic letters 2002, 4, 1691-1694. 
301. Negishi, E.-i.; Anastasia, L. Palladium-Catalyzed Alkynylation. Chemical 
Reviews 2003, 103, 1979-2018. 
302. Gangjee, A.; Yu, J.; Copper, J. E.; Smith, C. D. Discovery of Novel Antitumor 
Antimitotic Agents That Also Reverse Tumor Resistance. J. Med. Chem. 2007, 50, 3290-
3301. 
303. Heck, R. F.; Nolley, J. P. Palladium-catalyzed vinylic hydrogen substitution 
reactions with aryl, benzyl, and styryl halides. The Journal of organic chemistry 1972, 37, 
2320-2322. 
304. Mizoroki, T.; Mori, K.; Ozaki, A. Arylation of Olefin with Aryl Iodide Catalyzed 
by Palladium. Bulletin of the Chemical Society of Japan 1971, 44, 581-581. 
305. de Meijere, A.; Meyer, F. E. Fine Feathers Make Fine Birds: The Heck Reaction 
in Modern Garb. Angewandte Chemie International Edition in English 1995, 33, 2379-
2411. 
306. Beletskaya, I. P.; Cheprakov, A. V. The Heck Reaction as a Sharpening Stone of 
Palladium Catalysis. Chemical Reviews 2000, 100, 3009-3066. 
307. Muzart, J. Palladium-catalyzed reactions of alcohols. Part B: Formation of C-C 
and C-N bonds from unsaturated alcohols. Tetrahedron 2005, 61, 4179-4212. 
308. Heck, R. F. The arylation of allylic alcohols with organopalladium compounds. A 
275 
 
 
new synthesis of 3-aryl aldehydes and ketones. Journal of the American Chemical 
Society 1968, 90, 5526-5531. 
309. Melpolder, J. B.; Heck, R. F. Palladium-catalyzed arylation of allylic alcohols 
with aryl halides. The Journal of organic chemistry 1976, 41, 265-272. 
310. Chalk, A. J.; Magennis, S. A. Palladium-catalyzed vinyl substitution reactions. I. 
New synthesis of 2- and 3-phenyl-substituted allylic alcohols, aldehydes, and ketones 
from allylic alcohols. The Journal of organic chemistry 1976, 41, 273-278. 
311. Larock, R. C.; Leung, W.-Y.; Stolz-Dunn, S. Synthesis of aryl-substituted 
aldehydes and ketones via palladium-catalyzed coupling of aryl halides and non-allylic 
unsaturated alcohols. Tetrahedron Letters 1989, 30, 6629-6632. 
312. Taylor, E. C.; Wang, Y. Synthesis of 7-methyl derivatives of 5,10-dideaza-
5,6,7,8-tetrahydrofolic acid (DDATHF), 5,10-dideaza-5,6,7,8-tetrahydrohomofolic acid 
(HDDATHF), and LY254155. Heterocycles 1998, 48, 1537-1554. 
313. Belley, M.; Gallant, M.; Roy, B.; Houde, K.; Lachance, N.; Labelle, M.; Trimble, 
L. A.; Chauret, N.; Li, C.; Sawyer, N.; Tremblay, N.; Lamontagne, S.; Carriere, M.-C.; 
Denis, D.; Greig, G. M.; Slipetz, D.; Metters, K. M.; Gordon, R.; Chan, C. C.; Zamboni, 
R. J. Structure-activity relationship studies on ortho-substituted cinnamic acids, a new 
class of selective EP3 antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 527-530. 
314. Kim, H.-Y.; Sohn, J.; Wijewickrama, G. T.; Edirisinghe, P.; Gherezghiher, T.; 
Hemachandra, M.; Lu, P.-Y.; Chandrasena, R. E.; Molloy, M. E.; Tonetti, D. A.; 
Thatcher, G. R. J. Click synthesis of estradiol-cyclodextrin conjugates as cell 
compartment selective estrogens. Bioorg. Med. Chem. 2010, 18, 809-821. 
315. Tamaru, Y.; Yamada, Y.; Yoshida, Z. I. Palladium catalyzed thienylation of 
276 
 
 
allylic alcohols with 3-bromothiophene. Tetrahedron Lett. 1977, 3365-8. 
316. Yoshida, Z.; Yamada, Y.; Tamaru, Y. Palladium-catalyzed thienylation of allylic 
alcohols. Chem. Lett. 1977, 423-4. 
317. Marsham, P. R.; Hughes, L. R.; Jackman, A. L.; Hayter, A. J.; Oldfield, J.; 
Wardleworth, J. M.; Bishop, J. A.; O'Connor, B. M.; Calvert, A. H. Quinazoline 
antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications. J Med 
Chem 1991, 34, 1594-605. 
318. Hilgenbrink, A. R.; Low, P. S. Folate receptor-mediated drug targeting: From 
therapeutics to diagnostics. J. Pharm. Sci. 2005, 94, 2135-2146. 
319. Jackman, A. L.; Theti, D. S.; Gibbs, D. D. Antifolates targeted specifically to the 
folate receptor. Adv. Drug Delivery Rev. 2004, 56, 1111-1125. 
320. Gibbs, D. D.; Theti, D. S.; Wood, N.; Green, M.; Raynaud, F.; Valenti, M.; 
Forster, M. D.; Mitchell, F.; Bavetsias, V.; Henderson, E.; Jackman, A. L. BGC 945, a 
novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-
overexpressing tumors. Cancer Res 2005, 65, 11721-8. 
321. Shih, C.; Grindey, G. B.; Taylor, E. C.; Harrington, P. M. Synthesis and 
biological activity of nor- and homo-5,10-dideazatetrahydrofolic acid. Bioorg. Med. 
Chem. Lett. 1992, 2, 339-42. 
322. Gangjee, A.; Zeng, Y.; McGuire, J. J.; Mehraein, F.; Kisliuk, R. L. Synthesis of 
Classical, Three-Carbon-Bridged 5-Substituted Furo[2,3-d]pyrimidine and 6-Substituted 
Pyrrolo[2,3-d]pyrimidine Analogues as Antifolates. J. Med. Chem. 2004, 47, 6893-6901. 
323. Gangjee, A.; Zeng, Y.; McGuire, J. J.; Kisliuk, R. L. Synthesis of Classical, Four-
Carbon Bridged 5-Substituted Furo[2,3-d]pyrimidine and 6-Substituted Pyrrolo[2,3-
277 
 
 
d]pyrimidine Analogues as Antifolates. J. Med. Chem. 2005, 48, 5329-5336. 
324. Baldwin, S. W.; Tse, A.; Gossett, L. S.; Taylor, E. C.; Rosowsky, A.; Shih, C.; 
Moran, R. G. Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine 
inhibition of mammalian glycinamide ribonucleotide formyltransferase. Biochemistry 
1991, 30, 1997-2006. 
325. Yiqiang Wang, S. R., Larry H. Matherly, Aleem Gangjee  Design, Synthesis and 
Biological Evaluation of 6-Substituted Straight Side Chain Pyrrolo[2,3-d]pyrimidines as 
High Affinity Folate Receptor (FR)-Specific β-Glycinamide Ribonucleotide 
Formyltransferase (GARFTase) Inhibitors with Antitumor Activity. J. Med. Chem. 2013, 
in press. 
326. Habeck, L. L.; Mendelsohn, L. G.; Shih, C.; Taylor, E. C.; Colman, P. D.; Gossett, 
L. S.; Leitner, T. A.; Schultz, R. M.; Andis, S. L.; Moran, R. G. Substrate specificity of 
mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol. 
Pharmacol. 1995, 48, 326-33. 
327. Yiqiang Wang, S. R., Larry H. Matherly, Aleem Gangjee. Design, Synthesis and 
Biological Evaluation of Pemetrexed (PMX) Homologs as Potent Inhibitors of Tumors 
Expressing Folate Receptors via 5-Aminoimidazole-4-carboxamide Ribonucleotide 
Formyl Transferase (AICARFTase) Inhibition. J. Med. Chem. 2013, in press. 
328. Chattopadhyay, S.; Zhao, R.; Krupenko, S. A.; Krupenko, N.; Goldman, I. D. The 
inverse relationship between reduced folate carrier function and Pemetrexed activity in a 
human colon cancer cell line. Mol. Cancer Ther. 2006, 5, 438-449. 
329. Wang, L.; Desmoulin, S. K.; Cherian, C.; Polin, L.; White, K.; Kushner, J.; 
Fulterer, A.; Chang, M.-H.; Mitchell-Ryan, S.; Stout, M.; Romero, M. F.; Hou, Z.-J.; 
278 
 
 
Matherly, L. H.; Gangjee, A. Synthesis, Biological, and Antitumor Activity of a Highly 
Potent 6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Antifolate Inhibitor with Proton-
Coupled Folate Transporter and Folate Receptor Selectivity over the Reduced Folate 
Carrier That Inhibits β-Glycinamide Ribonucleotide Formyltransferase. J. Med. Chem. 
2011, 54, 7150-7164. 
330. Deng, Y.; Hou, Z.; Wang, L.; Cherian, C.; Wu, J.; Gangjee, A.; Matherly, L. H. 
Role of lysine 411 in substrate carboxyl group binding to the human reduced folate 
carrier, as determined by site-directed mutagenesis and affinity inhibition. Mol. 
Pharmacol. 2008, 73, 1274-1281. 
331. Salley, J. J., Jr.; Glennon, R. A. Studies on simplified ergoline derivatives. A 
general six-step synthesis of phenyl-substituted 4-methyl-3,4,4a,5,6,10b-
hexahydrobenzo[f]quinolin-1(2H)-one analogs. J. Heterocycl. Chem. 1982, 19, 545-50. 
332. Gangjee, A.; Yang, J.; Ihnat, M. A.; Kamat, S. Antiangiogenic and antitumor 
agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-
benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases. 
Bioorg. Med. Chem. 2003, 11, 5155-5170. 
333. Taylor, E. C.; Young, W. B.; Chaudhari, R.; Patel, H. H. Syntheses of a 
Regioisomer of N-[4-[2-(2-Amino-4(3H)-Oxo-7h-Pyrrolo[2,3-d]Pyrimidin-5-
Yl)Ethyl]Benzoyl)-L-Glutamic Acid (Ly231514), an Active Thymidylate Synthase 
Inhibitor and Antitumor Agent. Heterocycles 1993, 36, 1897-1908. 
334. Secrist, J. A., III; Liu, P. S. Studies directed toward a total synthesis of nucleoside 
Q. Annulation of 2,6-diaminopyrimidin-4-one with α-halo carbonyls to form pyrrolo[2,3-
d]pyrimidines and furo[2,3-d]pyrimidines. J. Org. Chem. 1978, 43, 3937-41. 
279 
 
 
335. Larock, R. C.; Leung, W. Y.; Stolzdunn, S. Synthesis of Aryl-Substituted 
Aldehydes and Ketones Via Palladium-Catalyzed Coupling of Aryl Halides and Non-
Allylic Unsaturated Alcohols. Tetrahedron Letters 1989, 30, 6629-6632. 
336. Bloch, R. 5,5-Dibromo-2,2-Dimethyl-4,6-Dioxo-1,3-Dioxane - New Brominating 
Agent for Saturated and Alpha,Beta-Unsaturated Carbonyl-Compounds. Synthesis-
Stuttgart 1978, 140-142. 
337. Kisliuk, R. L.; Strumpf, D.; Gaumont, Y.; Leary, R. P.; Plante, L. 
Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-D-glutamic acid. J Med 
Chem 1977, 20, 1531-1533. 
338. Wahba, A. J.; Friedkin, M. Enzymic synthesis of thymidylate. I. Early steps in the 
purification of thymidylate synthetase of Escherichia coli. J. Biol. Chem. 1962, 237, 
3794-3801. 
339. Davisson, V. J.; Sirawaraporn, W.; Santi, D. V. Expression of human thymidylate 
synthase in Escherichia coli. J. Biol. Chem. 1989, 264, 9145-8. 
340. Yiqiang Wang, S. R., Larry H. Matherly, Aleem Gangjee. Design, Synthesis and 
Biological Evaluation of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines with a 
thiophenyl ring in the side chain as Potent Inhibitors of Tumors Expressing Folate 
Receptors via 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyl Transferase 
(AICARFTase) Inhibition J. Med. Chem. 2013 in press. 
 
280 
 
APPENDIX 1 
The biological evaluations of the analogs listed in the following tables were 
performed by Dr. Larry H. Matherly‟s group (Developmental Therapeutics Program, 
Barbara Ann Karmanos Cancer Institute and the Cancer Biology Program and the 
Department of Pharmacology, Wayne State University School of Medicine) against 
GARFTase, RFC-expressing PC43-10 cells, FRα-expressing RT16 cells, FRβ-expressing 
D4 cells and hPCFT-expressing R2/hPCFT4 cells; Dr. Roy L. Kisliuk‟s group 
(Department of Biochemistry, Tufts University School of Medicine) against rhTS, 
rhDHFR, E. coli TS and E. coli DHFR.  
 
Cell Lines and Assays of Antitumor Activities 
          RFC- and FR-null MTXRIIOuaR2-4 (R2) CHO cells were gifts from Dr. Wayne 
Flintoff (University of Western Ontario, London, ON, Canada) and were cultured in R-
minimal essential medium (MEM) supplemented with 10% bovine calf serum 
(Invitrogen, Carlsbad, CA), penicillin- streptomycin solution and L-glutamine at 37 °C 
with 5% CO2. PC43-10 cells are R2 cells transfected with hRFC. RT16 cells are R2 cells 
transfected with human FRα and D4 cells are R2 cells transfected with human FRβ. 
R2/hPCFT4 cells were prepared by transfection of R2 cells with hPCFT cDNA, epitope 
tagged at the C-terminus with Myc-His6 (hPCFTMyc-His6) and cloned in pCDNA3.1. All 
the R2 transfected cells (PC43- 10, RT16, D4 and R2/hPCFT4) were routinely cultured in 
R-MEM plus 1.5 mg/mL G418. Prior to the cytotoxicity assays, RT16 and D4 cells were 
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cultured in complete folate-free RPMI1640 (without added folate) for 3 days. KB human 
cervical cancer cells were purchased from the American Type Culture Collection 
(Manassas, VA) and IGROV1 ovarian carcinoma cells were a gift of Dr. Manohar 
Ratnam (Medical University of Ohio). Cells were routinely cultured in folate-free 
RPMI1640 medium, supplemented with 10% fetal bovine serum, penicillin-streptomycin 
solution, and 2 mM L-glutamine with 5% CO2 at 37 °C.  
           For growth inhibition assays, cells (CHO, KB, and IGROV1) were plated in 96 
well dishes (∼2500-5000 cells/well, total volume of 200 µL medium) with a broad range 
of antifolate concentrations. The medium was RPMI1640 (contains 2.3 µM folic acid) 
with 10% dialyzed serum and antibiotics for experiments with R2 and PC43-10 cell lines. 
For RT16, D4, KB, and IGROV1 cells, they were cultured in folate-free RPMI media 
with 10% dialyzed fetal bovine serum (Invitrogen) and antibiotics supplemented with 2 
nM LCV. The requirement for FR mediated drug uptake in these assays was established 
by a parallel incubation including 200 nM folic acid.  
           For R2/hPCFT4 cells, the medium was folate-free RPMI1640 (pH = 7.2) 
containing 25 nM LCV, supplemented with 10% dialyzed fetal bovine serum (Invitrogen) 
and antibiotics. Cells were routinely incubated for up to 96 h during which the medium 
pH decreased to ∼6.8-6.9 and metabolically active cells (a measure of cell viability) were 
assayed with Cell Titer-blue cell viability assay (Promega, Madison, WI), with 
fluorescence measured (590 nm emission, 560 nm excitation) using a fluorescence plate 
reader. Raw data were exported from Softmax Pro software to an Excel spreadsheet for 
analysis and determinations of IC50 values, corresponding to the drug concentrations that 
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result in 50% loss of cell growth.  
           For some of the in vitro growth inhibition studies, the inhibitory effects of the 
antifolates on de novo thymidylate biosynthesis (i.e., TS) and de novo purine biosynthesis 
(GARFTase and AICARFTase) were tested by coincubations with thymidine (10 µM) 
and adenosine (60 µM), respectively. For de novo purine biosynthesis, additional 
protection experiments used AICA (320 µM) as a way of distinguishing inhibitory effects 
at GARFTase from those at AICARFTase.  
          For assays of colony formation in the presence of the drugs, KB cells were 
harvested and diluted, and 200 cells were plated into 60mmdishes in folate-free 
RPMI1640 medium supplemented with 2 nM LCV, 10% dialyzed fetal bovine serum, 
penicillin-streptomycin, and 2 mM L-glutamine in the presence of antifolate drugs. The 
dishes were incubated with 5% CO2 at 37 °C for 10-14 days. At the end of the 
incubations, the dishes were rinsed with Dulbecco‟s phosphate-buffered saline (DPBS), 
5% trichloroacetic acid and borate buffer (10 mM, pH= 8.8), followed by 30 min 
incubation in 1% methylene blue in the borate buffer. The dishes were rinsed with the 
borate buffer, and colonies were counted for calculating percent colony-forming 
efficiency normalized to control.  
 
Compound solution preparation 
          The compound to be tested was dissolved in DMSO to achieve a final 
concentration of 1 mM and added so that the DMSO concentration in the media with the 
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cells did not exceed 0.5%. The culture conditions are standard media, RPMI1640/10% 
dialyzed fetal bovine serum, penicillin/streptomycin solution and 2mM glutamine. pH 
was adjusted for the RPMI to 7.4 and cells were grown under 5% CO2 to maintain pH 
balance. In spite of this, the pH of the media decreases accompanying cell growth to pH 
6.8-6.9. The cell culture solution composition has been described in the Cell Lines and 
Assays of Antitumor Activities section above. 
 
FR Binding Assay 
          [3H]Folic acid binding was used to assess levels of surface folate receptors (FRs). 
Briefly, cells (e.g., RT16 or D4; ∼1.6 × 106) were rinsed twice with Dulbecco‟s 
phosphate-buffered saline (DPBS) followed by two washes in acidic buffer (10 mM 
sodium acetate, 150 mM NaCl, pH = 3.5) to remove FR-bound folates. Cells were 
washed twice with ice-cold HEPES-buffered saline (20 mM HEPES, 140 mM NaCl, 5 
mM KCl, 2 mM MgCl2, 5 mM glucose, pH = 7.4; HBS), then incubated in HBS with 
[3H]folic acid (50 nM, specific activity 0.5 Ci/mmol) in the presence and absence of a 
range of concentrations of unlabeled folic acid or antifolate for 15 min at 0 °C. The 
dishes were rinsed 3 times with ice-cold HBS, after which the cells were solubilized with 
0.5 N sodium hydroxide and aliquots measured for radioactivity and protein contents. 
Protein concentrations were measured by Folin phenol reagent. Bound [3H]folic acid 
concentration was calculated as pmol/mg protein. Relative binding affinities for tested 
folate/antifolate substrates were calculated as the inverse molar ratios of unlabeled 
ligands required to inhibit [3H]folic acid binding by 50%. By definition, the relative 
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binding affinity of folic acid is 1.  
 
Transport Assays 
          For transport assays, R2/hPCFT4, PC43-10 and R2(VC) CHO cells grown as 
monolayers were used to seed spinner flasks. For experiments to determine the 
inhibitions of transport by antifolate substrates, cells were collected and washed with 
DPBS and resuspended in 2 mL of physiologic Hank‟s balanced salts solution (HBSS) for 
PC43-10 cells and in HBS adjusted to pH = 7.2 or 6.8 or 4-morpholinepropanesulfonic 
acid (MES)-buffered saline (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, and 
5 mM glucose) adjusted to pH 6.5, 6.0, or 5.5 for R2/hPCFT4 cells. In either case, 
uptakes of [3H]MTX (0.5 µM) were measured at 37 °C  over 2 min in the presence and 
absence of unlabeled antifolates (10 µM). Uptakes of [3H]MTX were quenched by ice-
cold DPBS. Cells were washed with ice-cold DPBS 3 times and solubilized with 0.5 N 
NaOH. Intracellular radioactivity Levels were expressed as pmol/mg protein, calculated 
from direct measurements of radioactivity and protein contents of cell homogenates. 
Protein concentrations were measured by Folin phenol reagent. Percentage of MTX 
transport inhibition was calculated by comparing level of [3H]MTX uptake in the 
presence and absence of the inhibitors. Kinetic constants (Kt, Vmax, and Kis) were 
calculated from Lineweaver-Burke and Dixon plots, respectively.  
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In Vitro GARFTase Enzyme Inhibition Assay 
          Purified recombinant mouse GARFTase enzyme was a gift of Dr. Richard Moran 
(Virginia Commonwealth University, Richmond, VA). Briefly, enzyme activity was 
assayed spectrophotometrically at 37 °C using GARFTase (0.75 nM), α,β-GAR (11 µM) 
and coenzyme 10-formyl-5,8-dideazafolic acid (10 µM) in HEPES buffer (75 mM, pH = 
7.5) with or without antifolate inhibitor (10-30 000 nM). The absorbance of the reaction 
product, 5,8-dideazafolic acid, was monitored at 295 nM by UV over the first minute as a 
measure of the initial rate of enzyme activity. IC50 values were calculated as the 
concentrations of inhibitors that resulted in a 50% decrease in the initial velocity of the 
GARFTase reaction.  
 
In Situ GARFT Enzyme Inhibition Assay 
          Incorporation of [14C]glycine into [14C]FGAR was used as an in situ measure of 
endogenous GARFTase activity. For these experiments, KB cells were seeded in 4 mL of 
complete folate acid-free RPMI1640 plus 2 nM LCVin 60 mm dishes at a density of 2 × 
106 cells per dish. On the next day, the medium was replaced with 2 mL of fresh 
complete folate acid-free RPMI1640 plus 2 nM LCV (without supplementing glutamine). 
Azaserine (4 µM) was added in the presence and absence of the antifolate inhibitors (0.1, 
1, 10, 100, or 1000 nM). After 30 min, L-glutamine (2 mM) and [14C]glycine (tracer 
amounts; final specific activity 0.1 mCi/L) were added. Incubations were at 37 °C for 15 
h, at which time cells were washed with ice-cold folate-free RPMI1640 plus serum. Cell 
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pellets were dissolved at 0 °C in 2mL of 5% trichloroacetic acid. Cell debris was 
removed by centrifugation (the cell protein contents in the pellets were measured) and the 
supernatants were extracted with 2 mL of ice-cold ether twice. The aqueous layer was 
passed through a 1 cm column of AG1 × 8 (chloride form), 100-200 mesh (Bio-Rad), 
washed with 10 mL of 0.5 N formic acid and then 10 mL of 4 N formic acid, and eluted 
with 8 mL of 1 N HCl. The elutants were collected and measured for radioactivity. The 
accumulation of radioactive FGAR was calculated as pmol per mg protein over a range of 
inhibitor concentrations. IC50 values were calculated as the concentrations of inhibitors 
that resulted in a 50% decrease in FGAR synthesis. 
 
Dihydrofolate Reductase (DHFR) Assay246, 337  
       Human DHFR enzyme was kindly provided by Dr. Andre Rosowsky, Dana-Farber 
Cancer Institute, Harvard Medical School, Boston, MA. All enzymes were assayed 
spectrophotometrically in a solution containing 80 μM NADPH, 50 μM dihydrofolate, 50 
mM Tris-HCl, 0.001 M 2-mercaptoethanol, and 0.001 M EDTA at pH 7.4 at 30 °C.The 
reaction was initiated by an amount of enzymes yielding a change in optical density at 
340 nm of 0.015 units/min. 
 
Thymidylate Synthase (TS) Assay.  
        Human TS enzyme was kindly provided by Dr. Andre Rosowsky, Dana-Farber 
Cancer Institute, Harvard Medical School, Boston, MA. TS was assayed 
spectrophotometrically at pH 7.4 at 30 °C in a mixture containing 0.1 M 2-
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mercaptoethanol, 0.0003 M( 6R,S)-tetrahydrofolate, 0.012 M formaldehyde, 0.02 M 
MgCl2, 0.001 M dUMP, 0.04 M Tris-HCl, and 0.00075 M NaEDTA. This was the assay 
described by Wahba and coworkers338  except that the dUMP concentration was increased 
25-fold according to the method of Davisson and coworkers.339 The reaction was initiated 
with the addition of an amount of enzyme yielding a change in absorbance at 340 nm of 
0.016 units/min in the absence of inhibitor. 
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APPENDIX 2 
          The molecular modeling and computational studies of the analogs listed in 
dissertation were performed by Dr. Sudhir Raghavan in Dr. Aleem Gangjee‟s group with 
hGARFTase and hAICARFTase. 
 
Molecular Modeling and Computational Studies 
        The X-ray crystal structures of hGARFTase at 1.98Å resolution (PDB ID: 1NJS)139 
and AICARFTase at 2.55 Å resolution (PDB ID: 1P4R)175 were obtained from the protein 
database. The hGARFTase crystal structure contains hGARFTase complexed with the 
hydrolyzed form of 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid 
(10-CF3CO-DDACTHF) while the AICARFTase crystal structure contains human 
AICARFTase with the sulfamido-bridged 5,8-dideazafolate analog BW1540. 
 
General docking procedure:  
          Docking studies were performed using Lead IT 1.3 (BioSolveIT GmbH Sankt 
Augustin, Germany, 2011). The protonation state of the proteins and the ligands were 
calculated using the default settings. Water molecules in the active site were permitted to 
rotate freely. The active site was defined by a sphere of 6.5 Å from the native ligand in 
the crystal structure. Ligands for docking were prepared using MOE 2010.10 (Chemical 
Computing Group: Montreal, Quebec, Canada) and energy minimized using the 
MMF94X forcefield to a constant of 0.05 kcal/mol. Triangle matching was used as the 
placement method and the docked poses were scored using default settings. The docked 
poses were exported and visualized in MOE.  
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Validation of docking software:  
Molecules used for the docking experiments were constructed in MOE 2010.11 and 
minimized using the MMFF94x forcefield to a constant of 0.05 kcal/mol.In order to 
validate the docking software for docking the proposed compounds, the native ligands, 
10-CF3CO-DDACTHF for hGARFTase and BW1540 for AICARFTase were built using 
the molecule builder function in MOE, energy minimized and docked as described above. 
RMSD of the docked poses were calculated using an SVL code obtained from the MOE 
website (www.chemcomp.com) and compared to the conformation of the crystal structure 
ligands. 
         The best docked pose for 10-CF3CO-DDACTHF in the hGARFTase crystal 
structure had an RMSD of 1.0368 Å and the best docked pose for BW1540 had an 
RMSD of 1.0995 Å in the AICARFTase crystal structure. Thus LeadIT 1.3. was validated 
for our docking purposes in hGARFTase and AICARFTase.  
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APPENDIX 3 
1. SAR of 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines with a phenyl ring 
in the side chain in whole cell assay as GARFTase inhibitors with selectivity for FRs 
and/or PCFT over RFC (carbon bridge optimization).109 
 
Figure A1 Structures of 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidines.109 
         The series of 6-substituted pyrrolo[2,3-d]pyrimidine antifolates with a phenyl ring 
in the side chain (Figure A1) was screened in the CHO cell sublines by in vitro drug 
sensitivity assays as measures of their capacities for cellular uptake by RFC versus FRs 
(Table 1).109 Only analog 1 showed significant (low level) growth inhibitory activity (IC50 
= 304 nM) toward RFC-expressing PC43-10 cells; however, the level was nearly 
identical for R2 cells which do not express RFC or FRs, suggesting the additional 
involvement of an unidentified non-RFC mechanism of cellular uptake. All the 
compounds in this series (3- to 6-carbon bridge, respectively) showed potent inhibition 
against the FR-expressing sublines (RT-16 and D4) with IC50s in the low to moderate nM 
range. Analogs 1 and 2 with 3- and 4-methylene groups in the bridge, respectively, were 
the most potent of this series and there were no obvious differences in their activities 
toward FRα (RT16) versus FRβ (D4) -expressing cells. For both RT-16 and D4 cells, the 
growth inhibitory effects of all these compounds were completely abolished in the 
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presence of excess (200 nM) folic acid, indicating the specific utilization of FRs by these 
analogs. 
Table A1 IC50s (nM) for compounds 6-substituted-pyrrolo[2,3-d]pyrimidines with a 
phenyl ring in cell proliferation inhibition of RFC- and FR-expressing cell lines.109 
 
Antifolate 
hRFC hFRα hFRβ hRFC/ FRα  hRFC/ FRα  
PC43-
10 
R2 RT16  
RT16 
(+FA) 
D4 D4  (+FA) KB 
KB  
(+FA) 
IGROV1 
IGROV
1 (+FA) 
1  304(89) 448(78) 4.1(1.6) >1000 5.6(1.2) >1000 1.7(0.4) >1000 2.2(0.8) >1000 
2  >1000 >1000 6.3(1.6) >1000 10(2.0) >1000 1.9(0.7) >1000 3.6(0.9) >1000 
161 >1000 >1000 54(21) >1000 80(9) >1000 13(7.2) >1000 40(12) >1000 
162  >1000 >1000 162(18) >1000 198(34) >1000 23(12) >1000 309(77) >1000 
Methotrexate 12(1.1) 216(8.7) 114(31) 461(62) 106(11) 211(43) 6.0(0.6) 20(2.4) 21(3.4) 22(2.1) 
Pemetrexed 14(2.5) 258(44) 42(9) 388(68) 60(8) 254(78) 68(12) 327(103) 102(25) 200(18) 
Raltitrexed 6.3(1.3) >1000 15(5) >1000 22(10) 746(138) 5.9(2.2) 22(5) 12.6(3.3) 20(4.3) 
Lometrexol 12(2.3) >1000 12(8) 188(41) 2.6(1.0) 275(101) 1.2(0.6) 31(7) 3.1(0.9) 16(6) 
Trimetrexate 25(7.3) 6.7(1.3) 13(1) 4.1(1) 11(4.2) 6.1(1.9) 58(18) 155(38) 12(4) 8.6(1.9) 
GW1843U89 11(3.3) >1000 277(81) >1000 52(12) >1000 5.8(3.5) 32(15) 5.2(1.7) 6.9(1.6) 
       
a)For the FR experiments, cytotoxicity assays were performed in the absence and presence of 200 nM folic 
acid (FA). The data shown are mean values from three experiments (plus/minus SEM in parentheses).b) 
Compound 1 was synthesized by Dr. Yibin Zeng.  
 
        Analogous patterns of drug sensitivity and protection by folic acid were seen with 
KB and IGROV1 human tumor cells (Table A1). In order to assess the effects of 
increasing levels of extracellular reduced folate on the activity of 2, KB cells were treated 
in complete folate-free media including 2-100 nM leucovorin (LCV).   
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Table A2 IC50s for 6-substituted pyrrolo[2,3-d]pyrimidine compounds in in vitro 
(mouse GARFTase) and in situ GARFTase inhibition assays.109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    The IC50 data shown are mean values from 3 (in vitro; SEM in parentheses) or 2 (in situ; range  
    in parentheses) experiments. 
 
 
          The compounds were also evaluated as inhibitors of isolated mouse GARFTase and 
compared with in situ assay (KB cells) against GARFTase (Table 2). The most potent 
compound in isolated mouse GARFTase was 2 and compounds 1, 161 and 162 were 
equipotent. However this difference in potency is absent in the in situ assays and all of 
the analogs are almost equipotent nanomolar inhibitors. The equalization and increased 
inhibition in situ of GARFTase could reflect the result of polyglutamylation in situ that 
would be absent in the isolated GARFTase assays. 
 
 
 
 
 
Antifolate  
IC50 
In vitro (µM) In situ (nM) 
1  2.44 (0.12) 18(2.0) 
2  0.15 (0.01) 6.8(0.9) 
161  2.26 (0.16) 7.2(1.8) 
162  2.51 (0.25) 8.6(0.7) 
Pemetrexed >20 30(7.7) 
Lometrexol 0.78 (0.08) 14(5.6) 
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2. SAR of 6-substituted straight chain compounds as folate receptor transport and 
GARFTase enzyme Inhibition325  
 
Figure A2 Structures of 2-amino-4-oxo-6-substituted straight chain pyrrolo[2,3-
d]pyrimidines.325 
       No compound in the new straight chain series showed any growth inhibitory activity 
toward RFC-expressing PC43-10 cells, which is similar to the lead compound 2 
indicating absolute selectivity for FR transport and hence tumor selectivity. 
         Table A3 IC50s (nM) for compound 164-167 (n=5-8) in cell proliferation inhibition of 
         RFC-, FR- and PCFT-expressing cell lines.325  
Antifolate 
hRFC hFRα hPCFT  hRFC/ FRα/hPCFT  
PC43-10 R2 RT16  R2/hPCFT4 KB 
164 (n=5) >1000 >1000 >1000 >1000 181.1 (49.9) 
165 (n=6) >1000 >1000 153.7 (79.8) >1000 6.8 (0.7) 
166 (n=7) >1000 >1000 9.32 (2.69) >1000 1.3 (0.58) 
167 (n=8) >1000 >1000 12.31 (3.14) >1000 1.48 (0.04) 
Pemetrexed (n=2)  138(13) 894(93) 42(9) 13.2(2.4) 68(12) 
Raltitrexed 6.3(1.3) >1000 15(5) 99.5(11.4) 5.9(2.2) 
Methotrexate 12(1.1) 216(8.7) 114(31) 120.5( 16.8) 6.0(0.6) 
Lometrexol 12(2.3) >1000 12(8) 38.0(5.3) 1.2(0.6) 
GW1843U 11(3.3) >1000 277(81) >1000 5.8(3.5) 
   The data shown are mean values from three experiments (plus/minus SEM in parentheses). 
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         While the analogue with a five-carbon bridge (164, n=5) was also inactive toward 
both FRα-expressing RT-16, compounds 165-167 (six- to eight-carbon bridge, 
respectively) showed potent inhibition against RT-16 with IC50 values in the moderate to 
low nanomolar range. Analogues 166-167 with 7- and 8-methylene groups in the bridge, 
respectively, were the most potent of this series, and there were no obvious differences in 
their activities toward FRα (RT16) expressing cells. For RT-16 cells, the growth 
inhibitory effects of compounds 165-167 were completely abolished in the presence of 
excess (200 nM) folic acid, indicating the specific utilization of FRs by these analogues. 
Analogous patterns of drug sensitivity and protection by folic acid were seen with KB 
and IGROV1 human tumor cells (Table A2). Compared with lead compound 2 showed 
moderate inhibition toward PCFT-expressing cells, it is very interesting to note that there 
is no growth inhibitory activity toward PCFT-expressing cells for any of the new straight 
chain series. Thus, the in vitro cytotoxicity results establish that the growth inhibitory 
effects of compounds 165-167 are dependent on their cellular accumulation via FRs 
rather than RFC and/or PCFT indicating the FR targeted specificity of these straight chain 
compounds. Against KB tumor cells in culture,  the 7-carbon atom chain analog (166) 
showed an IC50 value of 1.3 nM, similar to the most potent phenyl analog 2 (1.9 nM).  In 
the CHO sublines, both 166 and 2 inhibited growth of RT-16 cells (IC50 = 9.3 nM and 6.3 
nM respectively). The most potent compound 166 (n=7) has been selected for antitumor 
activity in tumor xenograft models in animals.   
        The present work is, to our knowledge, the first study on the impact of a modulation 
(replacement of the aromatic ring by methylene units) on the side chain of classical 
antifolates for transport specificity to FRs. A novel series of classical 6-substituted 
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straight chain pyrrolo[2,3-d]pyrimidine antifolate 164-167 (n=5-8) were designed and 
synthesized as 2 analogs with the replacement of the phenyl ring by methylene units.  We 
have identified distinct structure-activity relationship for this series involving the length 
of the methylene “bridge” region between the pyrrolo[2,3-d]pyrimidine and the L-
glutamate with corresponding FR binding and optimal inhibition of  GARFTase. 
Compounds with 7- and 8-carbon chain lengths, 166 and 167 (n=7-8),   proved to be the 
most potent for the KB tumor cell inhibition (IC50=1.3 nM and IC50=1.48 nM, 
respectively).   Compounds had excellent FR specificity over RFC and PCFT. In 
conclusion, the aromatic ring in the side chain of the lead 2 was demonstrated not 
necessary for either FR specificity or potent tumor cell inhibition.  It was also concluded 
that the spatial requirements for the bridge region/phenyl ring region are highly 
compatible that analogs with a more flexible side chain 164-167 (n=5-8) were equal or 
more potent to GARFTase and selective to FRs than their rigid analogs. The structure 
simplicity and extraordinary antitumor activities of these 6-substituted straight chain 
compounds provide a good starting point for further study including in vivo antitumor 
activities and the design of additional analogs to optimize cellular folate uptake by FRs 
and GARFTase inhibition to discover potent antitumor agents with high tumor-targeting 
capability. 
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3. SAR of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines with a phenyl ring 
in the side chain as GARFTase inhibitors with selectivity for FRs and/or PCFT over 
RFC.327 
 
Figure A3 Structures of 2-amino-4-oxo-5-substituted pyrrolo[2,3-d]pyrimidines 172-177 
(n=1-6).327 
          Table A4 IC50s (nM) for compound 172-177 (n=1-6) in cell proliferation inhibition 
          of RFC-, FR- and PCFT-expressing cell lines.327  
Antifolate 
hRFC hFRα hPCFT  hRFC/ FRα/hPCFT  
PC43-10 R2 RT16  R2/hPCFT4 KB 
172 (n=1) >1000 >1000 N >1000 N 
174 (n=3) 81.6 >1000 54.67 328.5 38.5 
175 (n=4) 53.9 >1000 8.2 733 3.6 
176 (n=5) 194.6 >1000 33.5 >1000 20.1 
177 (n=6) >1000 >1000 >1000 >1000 N 
Pemetrexed (n=2)  138(13) 894(93) 42(9) 13.2(2.4) 68(12) 
Raltitrexed 6.3(1.3) >1000 15(5) 99.5(11.4) 5.9(2.2) 
Methotrexate 12(1.1) 216(8.7) 114(31) 120.5( 16.8) 6.0(0.6) 
Lometrexol 12(2.3) >1000 12(8) 38.0(5.3) 1.2(0.6) 
GW1843U 11(3.3) >1000 277(81) >1000 5.8(3.5) 
The data shown are mean values from three experiments (plus/minus SEM in parentheses). N = No activity 
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          Compound 174-176, the 3-5 carbon chain homologs of PMX, could be transported 
by all three folate uptake systems just like PMX.  More importantly, 174-176 have better 
KB cell inhibition potency than PMX. Compound 175 inhibits KB cells at 3.6 nM, about 
20-fold greater than PMX. Thus increasing the side chain length of PMX improves tumor 
cell inhibitory activity. It is also interesting to note that this series of compounds 172-177 
(n=1-6) do not have selectivity for FR or PCFT over RFC as we have reported for their 6-
substituted regioisomers.  
  
 
 
 
 
 
 
 
Figure A4  3 (AG71) and 175 (AG127) KB Protections.327   
 
        The 3 and 175 KB tumor cell nucleoside protection assays were employed to 
determine the targeted pathway and folate-dependent enzyme (Figure A4).  These data 
show that KB cells treated with 3 are completely protected from the growth inhibitory 
effects by adenosine but not thymidine, establishing de novo as the targeted pathway. 5-
Amino-4-imidazolecarboxamide (AICA), a precursor of 5-amino-4-
imidazolecarboxamide ribonucleotide (ZMP) is also protective, establishing that 
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Nucleoside Protection From Growth Inhibition of Novel Antifolates. Cell proliferation inhibition was 
measured on 96-well plates with 4000 KB cells per well initially and a range of antifolate concentrations 
(1-1000 nM), in the presence or absence of: adenosine (60 μM), thymidine (10 μM), or AICA (320 µM).  
Cell densities were measured with CellTiter BlueTM fluorescence dye and a fluorescence plate reader. 
Results were normalized to cell density in the absence of drug. Results shown are representative data 
of experiments performed in triplicate. 
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GARFTase is the major intracellular target.11 Inhibition of KB cell proliferation by 175 
was abolished by excess adenosine, but not thymidine or AICA, suggesting that 
AICARFTase was the principle intracellular target. Collectively, our results show that the 
side chain two carbon homologated analog of PMX, 175, exhibits nanomolar inhibition 
of proliferation of KB tumor cells in culture. The unique and specific AICARFTase 
inhibition of 175 makes it a promising lead for further preclinical development as an 
agent for cancer chemotherapy. 
           It was also determined that 172-177 (n=1-6), like PMX, inhibit human TS and 
DHFR at 1-20 µM range (Table A5). The GARFTase inhibitory effects are currently 
being evaluated. It is highly probable that 172-177 (n=1-6) have multiple enzyme 
inhibition including TS, DHFR and GARFTase similar to PMX.     
Table A5 hDHFR and hTS inhibitory activity of 172-177 (n=1-6).327 
Antifolate IC50 (μM, hDHFR) IC50 (μM, hTS) 
MTX 0.022 - 
PDDF - 0.037 
PMX(n=2) 2.2 11 
172 (n=1) 0.45 7.6 
            174 (n=3) 3.3 9 
175 (n=4) 21 15 
176 (n=5) 20 15 
177 (n=6) 3 14 
 
The most potent compound 175 (n=4) was further selected by NCI (National Cancer 
Institute ) for evaluation in their preclinical 60 tumor cell line panel. Compound 175 
shows excellent growth inhibition (GI50 < 100 nM  ) on 16 different cancer cell 
lines(Table A6). 
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Table A6    Tumor cell inhibitory activity (NCI) GI50 (M) of 175 (n=4).
327
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel/ Cell line GI50 (M) Panel/ Cell line GI50 (M) 
Panel/ Cell 
line 
GI50 (M) 
Leukemia  Colon Cancer  Melanoma  
CCRF-CEM   6.51×10-8 COLO 205 >1.00×10-4 LOX IMVI    5.58×10-5 
HL-60(TB) - HCT-116    3.76×10-8 MALME-3M >1.00×10-4 
K-562 < 1.00×10-8 HCT-15 >1.00×10-4 M14 >1.00×10-4 
MOLT-4    8.10×10-8 HT29    3.84×10-8 MDA-MB-435    6.98×10-8 
SR    5.23×10-7 KM12    8.60×10-7 SK-MEL-2 >1.00×10-4 
  SW-620    2.96×10-8 SK-MEL-28    9.27×10-5 
Prostate Cancer    SK-MEL-5 >1.00×10
-4 
PC-3    6.37×10-8 NSCLC  UACC-257 >1.00×10
-4 
DU-145 >1.00×10-4 A549/ATCC    2.19×10-7 UACC-62 >1.00×10-4 
  EKVX    3.25×10-7   
CNS Cancer  HOP-62 >1.00×10
-4 Breast Cancer  
SF-268   8.84×10-5 HOP-92 >1.00×10-4 MCF7    4.24×10-8 
SF-295   5.28×10-8 NCI-H226 >1.00×10-4 
MDA-MB-
231/ATCC 
>1.00×10-4 
SF-539 >1.00×10-4 NCI-H23 >1.00×10-4 HS 578T >1.00×10-4 
SNB-19 >1.00×10-4 NCI-H322M >1.00×10-4 BT-549 >1.00×10-4 
SNB-75 >1.00×10-4 NCI-H460    6.16×10-8 T-47D >1.00×10-4 
U251   6.15×10-8 NCI-H522 >1.00×10-4 MDA-MB-468 >1.00×10-4 
      
Renal Cancer  Ovarian cancer    
786 - 0   1.60×10-8 IGROVI   1.60×10-6   
A498 >1.00×10-4 OVCAR-3 >1.00×10-4   
ACHN   1.78×10-6 OVCAR-4 >1.00×10-4   
CAKI-1   5.75×10-8 OVCAR-5 >1.00×10-4   
RXF 393 >1.00×10-4 OVCAR-8 >1.00×10-4   
SN12C    7.87×10-7 NCI/ADR-RES >1.00×10-4   
TK10 >1.00×10-4 SK-OV-3    9.00×10-5   
UO-31    3.60×10-7     
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4. SAR of 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines with a thiophenyl 
ring in the side chain as GARFTase inhibitors with selectivity for FRs and/or PCFT 
over RFC.340 
 
Figure A5 Structures of 2-amino-4-oxo-5-substituted pyrrolo[2,3-d]pyrimidines 178-183 
(n=1-6).340 
 
Table A7 IC50s (nM) for compound 178-183 in cell proliferation inhibition of RFC-, 
FR- and PCFT-expressing cell lines.340  
Antifolate 
hRFC hFRα hPCFT  hRFC/ FRα/hPCFT  
PC43-10 R2 RT16  R2/hPCFT4 KB 
178 (n=1) >1000 >1000 >1000 552 N 
179 (n=2) 43.1 >1000 500 86.7 500 
180 (n=3) 110 >1000 109 396 215 
181  (n=4) 26.15 >1000 25 103 17.1 
182 (n=5) 220 >1000 46 362 32.4 
183 (n=6) >1000 >1000 >1000 >1000 >1000 
3 (n=4) >1000 >1000 2 43.4 0.25 
Pemetrexed (n=2)  138(13) 894(93) 42(9) 13.2(2.4) 68(12) 
Raltitrexed 6.3(1.3) >1000 15(5) 99.5(11.4) 5.9(2.2) 
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Methotrexate 12(1.1) 216(8.7) 114(31) 120.5( 16.8) 6.0(0.6) 
Lometrexol 12(2.3) >1000 12(8) 38.0(5.3) 1.2(0.6) 
GW1843U 11(3.3) >1000 277(81) >1000 5.8(3.5) 
The data shown are mean values from three experiments (plus/minus SEM in parentheses). N = No activity 
 
        Analogs with 4 and 5-carbon atom chains (181 and 182) showed IC50 values of 17.9 
nM and 16.4 nM, respectively, against KB tumor cells in culture; other analogs of this 
series were 13- to >58-fold less active. Drug effects were completely abolished by excess 
folic acid establishing FR-mediated uptake. In the CHO sublines, 181 and 182 were 
growth inhibitory in the order RT-16 = PC43-10 > R2/PCFT4 and RT-16 >> PC43-10 = 
R2/PCFT4, respectively. Thus, at least for 181 unlike 3, significant RFC activity is 
preserved. Whereas PMX is a multi-targeted agent with inhibitory effects on both de novo 
thymidylate and purine nucleotide biosynthetic pathways, the anti-proliferative effects of 
181 and 182 were abolished by adenosine but not thymidine, establishing exclusive 
inhibition of purine biosynthesis. Our results suggest that 6-subtitution of the pyrrolo[2,3-
d]pyrimidine scaffold is  more effective in conferring selective transport of FRα over 
RFC, although inhibition of de novo purine biosynthesis is preserved in the 5-substituted 
compounds. 
 
 
 
 
Figure A6  3 (G71) and 181 (G136) KB Protections.340        
 
G71 KB Protection
0.01 0.1 1 10 100
0
25
50
75
100
125
No additions
60 uM Adenosine
10 uM Thymidine
Adenosine and Thymidine
320 uM AICA
Conc. nM
%
 C
e
ll
 G
ro
w
th
G136 KB Protection
0.01 0.1 1 10 100 1000 10000
0
25
50
75
100
125
No additions
60 uM Adenosine
10 uM Thymidine
Adenosine and Thymidine
320 uM AICA
Conc. nM
%
 C
e
ll
 G
ro
w
th
302 
 
         These data (Figure A6) show that KB cells treated with 3 are completely protected 
from the growth inhibitory effects by adenosine but not thymidine. 
Aminoimidazolecarboxamide a precursor of aminoimidazolecarboxamide ribonucleotide 
is also protective, establishing that GARFTase is the major intracellular target. These 
results were previously reported.113           
          For 181, adenosine was again protective whereas thymidine is not. AICA is 
protective at G136 concentrations up to 32 uM but not at higher concentrations 
suggesting an alternate enzyme target, likely 5-amino-4-imidazolecarboxamide 
ribonucleotide formyltransferase (AICARFTase). 
 
Table A8 hDHFR and hTS inhibitory activity of 178-183.340 
Antifolate IC50 (μM, hDHFR) IC50 (μM, hTS) 
MTX 0.022 - 
PDDF - 0.037 
PMX(n=2) 2.2 11 
  178  (n=1) 11 0.36 
 179 (n=2) 23 3.8 
  180 (n=3) 11 2.7 
  181 (n=4) 19 16 
  182 (n=5) 22 1.9 
  183 (n=6) 18 2.6 
 
          It was also determined that 178-183, like PMX, inhibit human TS and DHFR at 1-
23 µM range (Table A8). The GARFTase inhibitory effects are currently being evaluated. 
It is highly probable that 178-183 have multiple enzyme inhibition including TS, DHFR 
and GARFTase similar to PMX.  
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Table A9 Tumor cell inhibitory activity (NCI) GI50 (M) of 181 (n=4).
340
 
 
 
          One of the most potent compounds against KB tumor cells in culture, 181 (n=4), 
was further selected by NCI (National Cancer Institute) for evaluation in their preclinical 
60 tumor cell line panel. Compound 181 shows excellent growth inhibition against 12 
different cancer cell lines (Table A9). It is important to note that 181 was not a general 
tumor poison but showed GI50 values in a range of 10,000-fold demonstrating selectivity 
for certain tumor types. 
 
Panel/ Cell line GI50 (M) Panel/Cell line GI50 (M) Panel/ Cell line GI50 (M) 
Leukemia  Colon Cancer  Melanoma  
CCRF-CEM   8.96×10-8 COLO 205    7.20×10
-5 LOX IMVI    1.50×10-8 
HL-60(TB) - HCT-116 
   < 
1.00×10-8 
MALME-3M >1.00×10-4 
K-562 < 1.00×10-8 HCT-15 >1.00×10
-4 M14 >1.00×10-4 
MOLT-4    1.22×10-7 HT29    3.10×10-8 MDA-MB-435    7.09×10-8 
SR    2.86×10-7 KM12    5.10×10-5 SK-MEL-2 >1.00×10-4 
  SW-620    1.91×10-8 SK-MEL-28 >1.00×10
-4 
Prostate Cancer    SK-MEL-5 >1.00×10
-4 
PC-3    1.88×10-7 NSCLC  UACC-257 >1.00×10
-4 
DU-145 >1.00×10-4 A549/ATCC    1.38×10-7 UACC-62 >1.00×10-4 
  EKVX    2.14×10-7   
CNS Cancer  HOP-62 >1.00×10
-4 Breast Cancer  
SF-268   >1.00×10-4 HOP-92 >1.00×10-4 MCF7    5.87×10-8 
SF-295   2.56×10-8 NCI-H226 - 
MDA-MB-
231/ATCC 
>1.00×10-4 
SF-539 >1.00×10-4 NCI-H23 >1.00×10-4 HS 578T >1.00×10-4 
SNB-19 >1.00×10-4 NCI-H322M >1.00×10-4 BT-549 >1.00×10-4 
SNB-75 >1.00×10-4 NCI-H460    8.82×10-8 T-47D >1.00×10
-4 
U251   4.02×10-8 NCI-H522 >1.00×10
-4 MDA-MB-468 >1.00×10-4 
      
Renal Cancer  Ovarian cancer    
786 - 0   2.56×10-8 IGROVI  >1.00×10
-4   
A498 >1.00×10-4 OVCAR-3 >1.00×10-4   
ACHN   - OVCAR-4 >1.00×10-4   
CAKI-1   2.09×10-8 OVCAR-5 >1.00×10
-4   
RXF 393 >1.00×10-4 OVCAR-8 >1.00×10-4   
SN12C - NCI/ADR-RES >1.00×10-4   
TK10 >1.00×10-4 SK-OV-3 >1.00×10-4   
UO-31 -     
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APPENDIX 4 
GARFTase inhibitors 2, 161, 166 and 194 had showed potent antitumor activity in 
the nanomolar range against KB and IGROV1 tumor cells. For further evaluation in 
animal models, gram quantities of these analogs were synthesized using the same 
synthetic procedures as described in the experimental section.  
 
 
Figure A7  Bulk synthesis for animal study. 
AICARFTase inhibitors 175 had showed potent antitumor activity in the 
nanomolar range against KB and IGROV1 tumor cells. For further evaluation of this 
analog in animal models, gram quantities were synthesized. 
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APPENDIX 5 
The physico-chemical properties of the market drug, pemetrexed (PMX) and the 
most potent compound 2, 161, 166, 175 and 194 were predicted by calculating the tPSA 
and ClogP values with ChemBioDraw Ultra 12.0.2.  
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Figure A8  Calculated tPSA and ClogP values of PMX and selected compounds by 
ChemBioDraw Ultra 12.0.2.. 
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